0001156039-22-000084.txt : 20221019 0001156039-22-000084.hdr.sgml : 20221019 20221019123821 ACCESSION NUMBER: 0001156039-22-000084 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 97 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221019 DATE AS OF CHANGE: 20221019 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elevance Health, Inc. CENTRAL INDEX KEY: 0001156039 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 352145715 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-16751 FILM NUMBER: 221317913 BUSINESS ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 BUSINESS PHONE: 8003311476 MAIL ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 FORMER COMPANY: FORMER CONFORMED NAME: Anthem, Inc. DATE OF NAME CHANGE: 20141202 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT, INC DATE OF NAME CHANGE: 20100105 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT INC DATE OF NAME CHANGE: 20041130 10-Q 1 elv-20220930.htm FORM 10-Q elv-20220930
false2022Q3000115603912/3128,30625,641106671616————100,000,000100,000,000————0.010.01900,000,000900,000,000238,974,624241,770,746238,974,624241,770,746http://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent00011560392022-01-012022-09-3000011560392022-10-12xbrli:shares00011560392022-09-30iso4217:USD00011560392021-12-31iso4217:USDxbrli:shares00011560392022-07-012022-09-3000011560392021-07-012021-09-3000011560392021-01-012021-09-3000011560392020-12-3100011560392021-09-300001156039us-gaap:CommonStockMember2021-12-310001156039us-gaap:AdditionalPaidInCapitalMember2021-12-310001156039us-gaap:RetainedEarningsMember2021-12-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001156039us-gaap:NoncontrollingInterestMember2021-12-310001156039us-gaap:RetainedEarningsMemberus-gaap:AccountingStandardsUpdate202006Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001156039us-gaap:AccountingStandardsUpdate202006Membersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001156039us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2021-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2021-12-310001156039us-gaap:RetainedEarningsMember2022-01-012022-03-310001156039us-gaap:NoncontrollingInterestMember2022-01-012022-03-3100011560392022-01-012022-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001156039us-gaap:CommonStockMember2022-01-012022-03-310001156039us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001156039us-gaap:CommonStockMember2022-03-310001156039us-gaap:AdditionalPaidInCapitalMember2022-03-310001156039us-gaap:RetainedEarningsMember2022-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001156039us-gaap:NoncontrollingInterestMember2022-03-3100011560392022-03-310001156039us-gaap:RetainedEarningsMember2022-04-012022-06-300001156039us-gaap:NoncontrollingInterestMember2022-04-012022-06-3000011560392022-04-012022-06-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001156039us-gaap:CommonStockMember2022-04-012022-06-300001156039us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001156039us-gaap:CommonStockMember2022-06-300001156039us-gaap:AdditionalPaidInCapitalMember2022-06-300001156039us-gaap:RetainedEarningsMember2022-06-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001156039us-gaap:NoncontrollingInterestMember2022-06-3000011560392022-06-300001156039us-gaap:RetainedEarningsMember2022-07-012022-09-300001156039us-gaap:NoncontrollingInterestMember2022-07-012022-09-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001156039us-gaap:CommonStockMember2022-07-012022-09-300001156039us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001156039us-gaap:CommonStockMember2022-09-300001156039us-gaap:AdditionalPaidInCapitalMember2022-09-300001156039us-gaap:RetainedEarningsMember2022-09-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001156039us-gaap:NoncontrollingInterestMember2022-09-300001156039us-gaap:CommonStockMember2020-12-310001156039us-gaap:AdditionalPaidInCapitalMember2020-12-310001156039us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2020-12-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001156039us-gaap:NoncontrollingInterestMember2020-12-310001156039srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2020-12-310001156039us-gaap:RetainedEarningsMember2021-01-012021-03-310001156039us-gaap:NoncontrollingInterestMember2021-01-012021-03-3100011560392021-01-012021-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001156039us-gaap:CommonStockMember2021-01-012021-03-310001156039us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001156039us-gaap:CommonStockMember2021-03-310001156039us-gaap:AdditionalPaidInCapitalMember2021-03-310001156039us-gaap:RetainedEarningsMember2021-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001156039us-gaap:NoncontrollingInterestMember2021-03-3100011560392021-03-310001156039us-gaap:RetainedEarningsMember2021-04-012021-06-300001156039us-gaap:NoncontrollingInterestMember2021-04-012021-06-3000011560392021-04-012021-06-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001156039us-gaap:CommonStockMember2021-04-012021-06-300001156039us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001156039us-gaap:CommonStockMember2021-06-300001156039us-gaap:AdditionalPaidInCapitalMember2021-06-300001156039us-gaap:RetainedEarningsMember2021-06-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001156039us-gaap:NoncontrollingInterestMember2021-06-3000011560392021-06-300001156039us-gaap:RetainedEarningsMember2021-07-012021-09-300001156039us-gaap:NoncontrollingInterestMember2021-07-012021-09-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001156039us-gaap:CommonStockMember2021-07-012021-09-300001156039us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001156039us-gaap:CommonStockMember2021-09-300001156039us-gaap:AdditionalPaidInCapitalMember2021-09-300001156039us-gaap:RetainedEarningsMember2021-09-300001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001156039us-gaap:NoncontrollingInterestMember2021-09-30elv:medical_memberelv:countyelv:statesxbrli:pure0001156039elv:IntegraManagedCareMember2022-01-012022-09-300001156039elv:IntegraManagedCareMember2022-09-300001156039elv:CommercialSpecialtyBusinessSegmentMemberus-gaap:EmployeeSeveranceMember2021-12-310001156039us-gaap:EmployeeSeveranceMemberelv:GovernmentBusinessSegmentMember2021-12-310001156039us-gaap:EmployeeSeveranceMemberelv:IngenioRxSegmentMember2021-12-310001156039elv:OtherSegmentMemberus-gaap:EmployeeSeveranceMember2021-12-310001156039us-gaap:EmployeeSeveranceMember2021-12-310001156039elv:CommercialSpecialtyBusinessSegmentMemberus-gaap:EmployeeSeveranceMember2022-01-012022-09-300001156039us-gaap:EmployeeSeveranceMemberelv:GovernmentBusinessSegmentMember2022-01-012022-09-300001156039us-gaap:EmployeeSeveranceMemberelv:IngenioRxSegmentMember2022-01-012022-09-300001156039elv:OtherSegmentMemberus-gaap:EmployeeSeveranceMember2022-01-012022-09-300001156039us-gaap:EmployeeSeveranceMember2022-01-012022-09-300001156039elv:CommercialSpecialtyBusinessSegmentMemberus-gaap:EmployeeSeveranceMember2022-09-300001156039us-gaap:EmployeeSeveranceMemberelv:GovernmentBusinessSegmentMember2022-09-300001156039us-gaap:EmployeeSeveranceMemberelv:IngenioRxSegmentMember2022-09-300001156039elv:OtherSegmentMemberus-gaap:EmployeeSeveranceMember2022-09-300001156039us-gaap:EmployeeSeveranceMember2022-09-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-09-300001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-09-300001156039us-gaap:ForeignGovernmentDebtMember2022-09-300001156039us-gaap:USStatesAndPoliticalSubdivisionsMember2022-09-300001156039us-gaap:CorporateDebtSecuritiesMember2022-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2022-09-300001156039us-gaap:CommercialMortgageBackedSecuritiesMember2022-09-300001156039us-gaap:OtherAggregatedInvestmentsMember2022-09-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310001156039us-gaap:ForeignGovernmentDebtMember2021-12-310001156039us-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310001156039us-gaap:CorporateDebtSecuritiesMember2021-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMember2021-12-310001156039us-gaap:OtherAggregatedInvestmentsMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-09-30elv:securities0001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2022-09-300001156039us-gaap:FixedMaturitiesMemberus-gaap:ForeignGovernmentDebtMember2022-09-300001156039us-gaap:FixedMaturitiesMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2022-09-300001156039us-gaap:FixedMaturitiesMemberus-gaap:CorporateDebtSecuritiesMember2022-09-300001156039us-gaap:FixedMaturitiesMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2022-09-300001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMember2022-09-300001156039us-gaap:FixedMaturitiesMemberus-gaap:OtherAggregatedInvestmentsMember2022-09-300001156039us-gaap:FixedMaturitiesMember2022-09-300001156039us-gaap:FixedMaturitiesMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FixedMaturitiesMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:ForeignGovernmentDebtMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FixedMaturitiesMember2021-12-310001156039us-gaap:FixedMaturitiesMemberus-gaap:OtherAggregatedInvestmentsMember2021-12-310001156039us-gaap:FixedMaturitiesMember2021-12-310001156039us-gaap:FixedMaturitiesMember2022-07-012022-09-300001156039us-gaap:FixedMaturitiesMember2022-01-012022-09-300001156039us-gaap:FixedMaturitiesMember2021-07-012021-09-300001156039us-gaap:FixedMaturitiesMember2021-01-012021-09-300001156039us-gaap:ExchangeTradedFundsMember2022-09-300001156039us-gaap:ExchangeTradedFundsMember2021-12-310001156039elv:CommonEquitySecuritiesMember2022-09-300001156039elv:CommonEquitySecuritiesMember2021-12-310001156039us-gaap:PrivateEquityFundsMember2022-09-300001156039us-gaap:PrivateEquityFundsMember2021-12-310001156039us-gaap:EquitySecuritiesMember2022-07-012022-09-300001156039us-gaap:EquitySecuritiesMember2021-07-012021-09-300001156039us-gaap:EquitySecuritiesMember2022-01-012022-09-300001156039us-gaap:EquitySecuritiesMember2021-01-012021-09-300001156039us-gaap:OtherInvestmentsMember2022-07-012022-09-300001156039us-gaap:OtherInvestmentsMember2021-07-012021-09-300001156039us-gaap:OtherInvestmentsMember2022-01-012022-09-300001156039us-gaap:OtherInvestmentsMember2021-01-012021-09-300001156039us-gaap:CashMemberus-gaap:MaturityOvernightMember2022-09-300001156039us-gaap:CashMemberus-gaap:MaturityOvernightMember2021-12-310001156039us-gaap:MaturityOvernightMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-09-300001156039us-gaap:MaturityOvernightMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001156039us-gaap:MaturityOvernightMemberus-gaap:OtherAggregatedInvestmentsMember2022-09-300001156039us-gaap:MaturityOvernightMemberus-gaap:OtherAggregatedInvestmentsMember2021-12-310001156039us-gaap:CashFlowHedgingMember2022-09-300001156039us-gaap:CashFlowHedgingMember2021-12-310001156039us-gaap:FairValueInputsLevel1Member2022-09-300001156039us-gaap:FairValueInputsLevel2Member2022-09-300001156039us-gaap:FairValueInputsLevel3Member2022-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-09-300001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-09-300001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-09-300001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-09-300001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignGovernmentDebtMember2022-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtMember2022-09-300001156039us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignGovernmentDebtMember2022-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2022-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2022-09-300001156039us-gaap:FairValueInputsLevel3Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2022-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2022-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2022-09-300001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:ResidentialMortgageBackedSecuritiesMember2022-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:ResidentialMortgageBackedSecuritiesMember2022-09-300001156039us-gaap:FairValueInputsLevel3Memberus-gaap:ResidentialMortgageBackedSecuritiesMember2022-09-300001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-09-300001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-09-300001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:OtherDebtSecuritiesMember2022-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:OtherDebtSecuritiesMember2022-09-300001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-09-300001156039us-gaap:OtherDebtSecuritiesMember2022-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2022-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2022-09-300001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ExchangeTradedFundsMember2022-09-300001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2022-09-300001156039us-gaap:FairValueInputsLevel1Memberelv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMember2022-09-300001156039us-gaap:FairValueInputsLevel2Memberelv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMember2022-09-300001156039elv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-09-300001156039elv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMember2022-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMember2022-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMember2022-09-300001156039us-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMemberus-gaap:FairValueInputsLevel3Member2022-09-300001156039us-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMember2022-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2022-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2022-09-300001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-09-300001156039us-gaap:EquitySecuritiesMember2022-09-300001156039us-gaap:FairValueInputsLevel1Memberelv:CommonEquitySecuritiesMemberus-gaap:OtherInvestmentsMember2022-09-300001156039us-gaap:FairValueInputsLevel2Memberelv:CommonEquitySecuritiesMemberus-gaap:OtherInvestmentsMember2022-09-300001156039elv:CommonEquitySecuritiesMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel3Member2022-09-300001156039elv:CommonEquitySecuritiesMemberus-gaap:OtherInvestmentsMember2022-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:DerivativeMember2022-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:DerivativeMember2022-09-300001156039us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeMember2022-09-300001156039us-gaap:DerivativeMember2022-09-300001156039us-gaap:FairValueInputsLevel1Member2021-12-310001156039us-gaap:FairValueInputsLevel2Member2021-12-310001156039us-gaap:FairValueInputsLevel3Member2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignGovernmentDebtMember2021-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtMember2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignGovernmentDebtMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2021-12-310001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:OtherDebtSecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:OtherDebtSecuritiesMember2021-12-310001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001156039us-gaap:OtherDebtSecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2021-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2021-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ExchangeTradedFundsMember2021-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberelv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel2Memberelv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMember2021-12-310001156039elv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001156039elv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMember2021-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMember2021-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMemberus-gaap:FairValueInputsLevel3Member2021-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2021-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310001156039us-gaap:EquitySecuritiesMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberelv:CommonEquitySecuritiesMemberus-gaap:OtherInvestmentsMember2021-12-310001156039us-gaap:FairValueInputsLevel2Memberelv:CommonEquitySecuritiesMemberus-gaap:OtherInvestmentsMember2021-12-310001156039elv:CommonEquitySecuritiesMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel3Member2021-12-310001156039elv:CommonEquitySecuritiesMemberus-gaap:OtherInvestmentsMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:DerivativeMember2021-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:DerivativeMember2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeMember2021-12-310001156039us-gaap:DerivativeMember2021-12-310001156039us-gaap:CorporateDebtSecuritiesMember2022-06-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2022-06-300001156039us-gaap:OtherDebtSecuritiesMember2022-06-300001156039us-gaap:EquitySecuritiesMember2022-06-300001156039us-gaap:CorporateDebtSecuritiesMember2022-07-012022-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2022-07-012022-09-300001156039us-gaap:OtherDebtSecuritiesMember2022-07-012022-09-300001156039us-gaap:EquitySecuritiesMember2022-07-012022-09-300001156039us-gaap:EquitySecuritiesMember2022-09-300001156039us-gaap:CorporateDebtSecuritiesMember2021-06-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2021-06-300001156039us-gaap:OtherDebtSecuritiesMember2021-06-300001156039us-gaap:EquitySecuritiesMember2021-06-300001156039us-gaap:CorporateDebtSecuritiesMember2021-07-012021-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2021-07-012021-09-300001156039us-gaap:OtherDebtSecuritiesMember2021-07-012021-09-300001156039us-gaap:EquitySecuritiesMember2021-07-012021-09-300001156039us-gaap:CorporateDebtSecuritiesMember2021-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2021-09-300001156039us-gaap:OtherDebtSecuritiesMember2021-09-300001156039us-gaap:EquitySecuritiesMember2021-09-300001156039us-gaap:EquitySecuritiesMember2021-12-310001156039us-gaap:CorporateDebtSecuritiesMember2022-01-012022-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2022-01-012022-09-300001156039us-gaap:OtherDebtSecuritiesMember2022-01-012022-09-300001156039us-gaap:EquitySecuritiesMember2022-01-012022-09-300001156039us-gaap:CorporateDebtSecuritiesMember2020-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2020-12-310001156039us-gaap:OtherDebtSecuritiesMember2020-12-310001156039us-gaap:EquitySecuritiesMember2020-12-310001156039us-gaap:CorporateDebtSecuritiesMember2021-01-012021-09-300001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2021-01-012021-09-300001156039us-gaap:OtherDebtSecuritiesMember2021-01-012021-09-300001156039us-gaap:EquitySecuritiesMember2021-01-012021-09-300001156039us-gaap:FairValueMeasurementsNonrecurringMember2022-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001156039us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001156039us-gaap:OtherInvestmentsMember2022-09-300001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001156039us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001156039us-gaap:FairValueMeasurementsNonrecurringMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001156039us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001156039us-gaap:OtherInvestmentsMember2021-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001156039elv:CommercialSpecialtyBusinessSegmentMember2021-12-310001156039elv:GovernmentBusinessSegmentMember2021-12-310001156039elv:OtherSegmentMember2021-12-310001156039elv:CommercialSpecialtyBusinessSegmentMember2022-09-300001156039elv:GovernmentBusinessSegmentMember2022-09-300001156039elv:OtherSegmentMember2022-09-300001156039elv:CommercialSpecialtyBusinessSegmentMember2022-01-012022-09-300001156039elv:GovernmentBusinessSegmentMember2022-01-012022-09-300001156039elv:OtherSegmentMember2022-01-012022-09-300001156039us-gaap:ShortDurationInsuranceContractAccidentYear2020Memberelv:CommercialSpecialtyBusinessSegmentMember2022-09-300001156039us-gaap:ShortDurationInsuranceContractAccidentYear2021Memberelv:CommercialSpecialtyBusinessSegmentMember2022-09-300001156039us-gaap:ShortDurationInsuranceContractAccidentYear2022Memberelv:CommercialSpecialtyBusinessSegmentMember2022-09-300001156039us-gaap:ShortDurationInsuranceContractAccidentYear2020Memberelv:GovernmentBusinessSegmentMember2022-09-300001156039us-gaap:ShortDurationInsuranceContractAccidentYear2021Memberelv:GovernmentBusinessSegmentMember2022-09-300001156039us-gaap:ShortDurationInsuranceContractAccidentYear2022Memberelv:GovernmentBusinessSegmentMember2022-09-300001156039us-gaap:ShortDurationInsuranceContractAccidentYear2020Memberelv:OtherSegmentMember2022-09-300001156039us-gaap:ShortDurationInsuranceContractAccidentYear2021Memberelv:OtherSegmentMember2022-09-300001156039us-gaap:ShortDurationInsuranceContractAccidentYear2022Memberelv:OtherSegmentMember2022-09-300001156039elv:CommercialSpecialtyBusinessSegmentMember2020-12-310001156039elv:GovernmentBusinessSegmentMember2020-12-310001156039elv:OtherSegmentMember2020-12-310001156039elv:CommercialSpecialtyBusinessSegmentMember2021-09-300001156039elv:GovernmentBusinessSegmentMember2021-09-300001156039elv:OtherSegmentMember2021-09-300001156039elv:CommercialSpecialtyBusinessSegmentMember2021-01-012021-09-300001156039elv:GovernmentBusinessSegmentMember2021-01-012021-09-300001156039elv:OtherSegmentMember2021-01-012021-09-300001156039elv:CommercialSpecialtyBusinessSegmentMember2022-01-012022-03-310001156039elv:CommercialSpecialtyBusinessSegmentMember2022-04-012022-06-300001156039elv:CommercialSpecialtyBusinessSegmentMember2022-07-012022-09-300001156039elv:GovernmentBusinessSegmentMember2022-01-012022-03-310001156039elv:GovernmentBusinessSegmentMember2022-04-012022-06-300001156039elv:GovernmentBusinessSegmentMember2022-07-012022-09-300001156039elv:OtherSegmentMember2022-01-012022-03-310001156039elv:OtherSegmentMember2022-04-012022-06-300001156039elv:OtherSegmentMember2022-07-012022-09-300001156039elv:CommercialSpecialtyBusinessSegmentMember2021-01-012021-03-310001156039elv:CommercialSpecialtyBusinessSegmentMember2021-04-012021-06-300001156039elv:CommercialSpecialtyBusinessSegmentMember2021-07-012021-09-300001156039elv:GovernmentBusinessSegmentMember2021-01-012021-03-310001156039elv:GovernmentBusinessSegmentMember2021-04-012021-06-300001156039elv:GovernmentBusinessSegmentMember2021-07-012021-09-300001156039elv:OtherSegmentMember2021-01-012021-03-310001156039elv:OtherSegmentMember2021-04-012021-06-300001156039elv:OtherSegmentMember2021-07-012021-09-300001156039elv:SeniorUnsecuredNotesMember2022-09-300001156039elv:SeniorUnsecuredNotesMember2021-12-310001156039elv:ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMemberelv:SeniorUnsecuredNotesMember2022-05-160001156039elv:FourPointOneZeroPercentDueTwoThousandThirtyTwoMemberelv:SeniorUnsecuredNotesMember2022-04-290001156039elv:FourPointFiveFiveZeroDueTwoThousandFiftyTwoMemberelv:SeniorUnsecuredNotesMember2022-04-290001156039elv:SurplusNotesMember2021-12-310001156039elv:SurplusNotesMember2022-09-300001156039us-gaap:RevolvingCreditFacilityMemberelv:A5YearFacilityMember2022-03-310001156039us-gaap:RevolvingCreditFacilityMemberelv:A5YearFacilityMember2022-04-180001156039elv:A2021364DayFacilityMember2022-04-182022-04-180001156039us-gaap:RevolvingCreditFacilityMemberelv:A2021364DayFacilityMember2022-03-310001156039us-gaap:RevolvingCreditFacilityMember2022-01-012022-09-300001156039us-gaap:LineOfCreditMember2022-09-300001156039us-gaap:CommercialPaperMember2022-09-300001156039us-gaap:CommercialPaperMember2022-06-300001156039us-gaap:CommercialPaperMember2021-12-310001156039us-gaap:ConvertibleDebtMember2022-07-012022-09-300001156039us-gaap:ConvertibleDebtMember2022-01-012022-09-300001156039us-gaap:ConvertibleDebtMember2022-09-300001156039us-gaap:FederalHomeLoanBankAdvancesMember2022-09-300001156039us-gaap:FederalHomeLoanBankAdvancesMember2021-12-310001156039srt:MinimumMember2022-09-300001156039srt:MaximumMember2022-09-300001156039elv:BCBSAntitrustLitigationMember2022-09-300001156039elv:PharmacypricingMemberelv:AnthemInc.v.ExpressScriptsInc.Member2022-01-012022-09-300001156039elv:OperationalMemberelv:AnthemInc.v.ExpressScriptsInc.Member2022-01-012022-09-300001156039elv:AnthemInc.v.ExpressScriptsInc.Member2022-01-012022-09-300001156039us-gaap:SubsequentEventMember2022-10-180001156039us-gaap:SubsequentEventMember2022-10-182022-10-1800011560392021-01-260001156039elv:A2022To2024Memberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2021-06-300001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-07-012022-09-300001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2021-07-012021-09-300001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-09-300001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-09-300001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-09-300001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2021-09-300001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2022-06-300001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2021-06-300001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2021-12-310001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2020-12-310001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2022-07-012022-09-300001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2021-07-012021-09-300001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2022-01-012022-09-300001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2021-01-012021-09-300001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2022-09-300001156039elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember2021-09-300001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-06-300001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-06-300001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-12-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2020-12-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-07-012022-09-300001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-07-012021-09-300001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-01-012022-09-300001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-01-012021-09-300001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-09-300001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-09-300001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-06-300001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-07-012022-09-300001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-07-012021-09-300001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-09-300001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-09-300001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-09-300001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-09-300001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-06-300001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-07-012022-09-300001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-07-012021-09-300001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-09-300001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-01-012021-09-300001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-09-300001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2021-09-300001156039elv:A2022To2024Member2022-07-012022-09-300001156039elv:A2022To2024Member2022-01-012022-09-300001156039elv:A2021To2023Member2021-07-012021-09-300001156039elv:A2021To2023Member2021-01-012021-09-30elv:segment0001156039elv:CommercialSpecialtyMemberelv:UnaffiliatedMember2022-07-012022-09-300001156039elv:GovernmentBusinessSegmentMemberelv:UnaffiliatedMember2022-07-012022-09-300001156039elv:IngenioRxSegmentMemberelv:UnaffiliatedMember2022-07-012022-09-300001156039elv:OtherSegmentMemberelv:UnaffiliatedMember2022-07-012022-09-300001156039elv:UnaffiliatedMember2022-07-012022-09-300001156039elv:IngenioRxSegmentMemberelv:AffiliatedMember2022-07-012022-09-300001156039elv:OtherSegmentMemberelv:AffiliatedMember2022-07-012022-09-300001156039us-gaap:IntersegmentEliminationMember2022-07-012022-09-300001156039elv:AffiliatedMember2022-07-012022-09-300001156039elv:CommercialSpecialtyMember2022-07-012022-09-300001156039elv:GovernmentBusinessSegmentMember2022-07-012022-09-300001156039elv:IngenioRxSegmentMember2022-07-012022-09-300001156039elv:OtherSegmentMember2022-07-012022-09-300001156039elv:CommercialSpecialtyMemberelv:UnaffiliatedMember2021-07-012021-09-300001156039elv:GovernmentBusinessSegmentMemberelv:UnaffiliatedMember2021-07-012021-09-300001156039elv:IngenioRxSegmentMemberelv:UnaffiliatedMember2021-07-012021-09-300001156039elv:OtherSegmentMemberelv:UnaffiliatedMember2021-07-012021-09-300001156039elv:UnaffiliatedMember2021-07-012021-09-300001156039elv:CommercialSpecialtyMemberelv:AffiliatedMember2021-07-012021-09-300001156039elv:GovernmentBusinessSegmentMemberelv:AffiliatedMember2021-07-012021-09-300001156039elv:IngenioRxSegmentMemberelv:AffiliatedMember2021-07-012021-09-300001156039elv:OtherSegmentMemberelv:AffiliatedMember2021-07-012021-09-300001156039us-gaap:IntersegmentEliminationMember2021-07-012021-09-300001156039elv:AffiliatedMember2021-07-012021-09-300001156039elv:CommercialSpecialtyMember2021-07-012021-09-300001156039elv:GovernmentBusinessSegmentMember2021-07-012021-09-300001156039elv:IngenioRxSegmentMember2021-07-012021-09-300001156039elv:OtherSegmentMember2021-07-012021-09-300001156039elv:CommercialSpecialtyMemberelv:UnaffiliatedMember2022-01-012022-09-300001156039elv:GovernmentBusinessSegmentMemberelv:UnaffiliatedMember2022-01-012022-09-300001156039elv:IngenioRxSegmentMemberelv:UnaffiliatedMember2022-01-012022-09-300001156039elv:OtherSegmentMemberelv:UnaffiliatedMember2022-01-012022-09-300001156039elv:UnaffiliatedMember2022-01-012022-09-300001156039elv:CommercialSpecialtyMemberelv:AffiliatedMember2022-01-012022-09-300001156039elv:GovernmentBusinessSegmentMemberelv:AffiliatedMember2022-01-012022-09-300001156039elv:IngenioRxSegmentMemberelv:AffiliatedMember2022-01-012022-09-300001156039elv:OtherSegmentMemberelv:AffiliatedMember2022-01-012022-09-300001156039us-gaap:IntersegmentEliminationMember2022-01-012022-09-300001156039elv:AffiliatedMember2022-01-012022-09-300001156039elv:CommercialSpecialtyMember2022-01-012022-09-300001156039elv:GovernmentBusinessSegmentMember2022-01-012022-09-300001156039elv:IngenioRxSegmentMember2022-01-012022-09-300001156039elv:OtherSegmentMember2022-01-012022-09-300001156039elv:CommercialSpecialtyMemberelv:UnaffiliatedMember2021-01-012021-09-300001156039elv:GovernmentBusinessSegmentMemberelv:UnaffiliatedMember2021-01-012021-09-300001156039elv:IngenioRxSegmentMemberelv:UnaffiliatedMember2021-01-012021-09-300001156039elv:OtherSegmentMemberelv:UnaffiliatedMember2021-01-012021-09-300001156039elv:UnaffiliatedMember2021-01-012021-09-300001156039elv:CommercialSpecialtyMemberelv:AffiliatedMember2021-01-012021-09-300001156039elv:GovernmentBusinessSegmentMemberelv:AffiliatedMember2021-01-012021-09-300001156039elv:IngenioRxSegmentMemberelv:AffiliatedMember2021-01-012021-09-300001156039elv:OtherSegmentMemberelv:AffiliatedMember2021-01-012021-09-300001156039us-gaap:IntersegmentEliminationMember2021-01-012021-09-300001156039elv:AffiliatedMember2021-01-012021-09-300001156039elv:CommercialSpecialtyMember2021-01-012021-09-300001156039elv:GovernmentBusinessSegmentMember2021-01-012021-09-300001156039elv:IngenioRxSegmentMember2021-01-012021-09-300001156039elv:OtherSegmentMember2021-01-012021-09-300001156039elv:CommercialSpecialtyBusinessSegmentMemberelv:ManagedCareProductsMember2022-07-012022-09-300001156039elv:CommercialSpecialtyBusinessSegmentMemberelv:ManagedCareProductsMember2021-07-012021-09-300001156039elv:CommercialSpecialtyBusinessSegmentMemberelv:ManagedCareProductsMember2022-01-012022-09-300001156039elv:CommercialSpecialtyBusinessSegmentMemberelv:ManagedCareProductsMember2021-01-012021-09-300001156039elv:ManagedCareServicesMemberelv:CommercialSpecialtyBusinessSegmentMember2022-07-012022-09-300001156039elv:ManagedCareServicesMemberelv:CommercialSpecialtyBusinessSegmentMember2021-07-012021-09-300001156039elv:ManagedCareServicesMemberelv:CommercialSpecialtyBusinessSegmentMember2022-01-012022-09-300001156039elv:ManagedCareServicesMemberelv:CommercialSpecialtyBusinessSegmentMember2021-01-012021-09-300001156039elv:CommercialSpecialtyBusinessSegmentMemberelv:DentalVisionProductsAndServicesMember2022-07-012022-09-300001156039elv:CommercialSpecialtyBusinessSegmentMemberelv:DentalVisionProductsAndServicesMember2021-07-012021-09-300001156039elv:CommercialSpecialtyBusinessSegmentMemberelv:DentalVisionProductsAndServicesMember2022-01-012022-09-300001156039elv:CommercialSpecialtyBusinessSegmentMemberelv:DentalVisionProductsAndServicesMember2021-01-012021-09-300001156039elv:OtherProductsMemberelv:CommercialSpecialtyBusinessSegmentMember2022-07-012022-09-300001156039elv:OtherProductsMemberelv:CommercialSpecialtyBusinessSegmentMember2021-07-012021-09-300001156039elv:OtherProductsMemberelv:CommercialSpecialtyBusinessSegmentMember2022-01-012022-09-300001156039elv:OtherProductsMemberelv:CommercialSpecialtyBusinessSegmentMember2021-01-012021-09-300001156039elv:ManagedCareProductsMemberelv:GovernmentBusinessSegmentMember2022-07-012022-09-300001156039elv:ManagedCareProductsMemberelv:GovernmentBusinessSegmentMember2021-07-012021-09-300001156039elv:ManagedCareProductsMemberelv:GovernmentBusinessSegmentMember2022-01-012022-09-300001156039elv:ManagedCareProductsMemberelv:GovernmentBusinessSegmentMember2021-01-012021-09-300001156039elv:ManagedCareServicesMemberelv:GovernmentBusinessSegmentMember2022-07-012022-09-300001156039elv:ManagedCareServicesMemberelv:GovernmentBusinessSegmentMember2021-07-012021-09-300001156039elv:ManagedCareServicesMemberelv:GovernmentBusinessSegmentMember2022-01-012022-09-300001156039elv:ManagedCareServicesMemberelv:GovernmentBusinessSegmentMember2021-01-012021-09-300001156039elv:PharmacyproductsandservicesMemberelv:IngenioRxSegmentMember2022-07-012022-09-300001156039elv:PharmacyproductsandservicesMemberelv:IngenioRxSegmentMember2021-07-012021-09-300001156039elv:PharmacyproductsandservicesMemberelv:IngenioRxSegmentMember2022-01-012022-09-300001156039elv:PharmacyproductsandservicesMemberelv:IngenioRxSegmentMember2021-01-012021-09-300001156039elv:IntegratedHealthServicesMemberelv:OtherSegmentMember2022-07-012022-09-300001156039elv:IntegratedHealthServicesMemberelv:OtherSegmentMember2021-07-012021-09-300001156039elv:IntegratedHealthServicesMemberelv:OtherSegmentMember2022-01-012022-09-300001156039elv:IntegratedHealthServicesMemberelv:OtherSegmentMember2021-01-012021-09-300001156039elv:OtherProductsMemberelv:OtherSegmentMember2022-07-012022-09-300001156039elv:OtherProductsMemberelv:OtherSegmentMember2021-07-012021-09-300001156039elv:OtherProductsMemberelv:OtherSegmentMember2022-01-012022-09-300001156039elv:OtherProductsMemberelv:OtherSegmentMember2021-01-012021-09-300001156039elv:SegmentEliminationsMember2022-07-012022-09-300001156039elv:SegmentEliminationsMember2021-07-012021-09-300001156039elv:SegmentEliminationsMember2022-01-012022-09-300001156039elv:SegmentEliminationsMember2021-01-012021-09-300001156039elv:IngenioRxSegmentMember2020-12-310001156039elv:GovernmentBusinessSegmentMember2021-01-012021-12-310001156039elv:IngenioRxSegmentMember2021-01-012021-12-310001156039elv:OtherSegmentMember2021-01-012021-12-3100011560392021-01-012021-12-310001156039elv:IngenioRxSegmentMember2021-12-310001156039elv:IngenioRxSegmentMember2022-01-012022-09-300001156039elv:IngenioRxSegmentMember2022-09-300001156039us-gaap:CustomerRelationshipsMember2022-09-300001156039us-gaap:CustomerRelationshipsMember2021-12-310001156039us-gaap:ContractualRightsMember2022-09-300001156039us-gaap:ContractualRightsMember2021-12-310001156039us-gaap:OtherIntangibleAssetsMember2022-09-300001156039us-gaap:OtherIntangibleAssetsMember2021-12-310001156039us-gaap:TrademarksMember2022-09-300001156039us-gaap:TrademarksMember2021-12-310001156039us-gaap:LicensingAgreementsMember2022-09-300001156039us-gaap:LicensingAgreementsMember2021-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended September 30, 2022
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                     to                     
Commission file number: 001-16751
elv-20220930_g1.jpg
ELEVANCE HEALTH, INC.
(Exact name of registrant as specified in its charter)
Indiana 35-2145715
(State or other jurisdiction of
incorporation or organization)		 (I.R.S. Employer
Identification Number)
220 Virginia Avenue
Indianapolis, Indiana 46204
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (833) 401-1577
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par valueELVNew York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒ No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer☒  Accelerated filer☐
Non-accelerated filer☐  Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
As of October 12, 2022, 238,827,582 shares of the Registrant’s Common Stock were outstanding.


Elevance Health, Inc.
Quarterly Report on Form 10-Q
For the Period Ended September 30, 2022
Table of Contents
 
  Page
PART I. FINANCIAL INFORMATION
ITEM 1.
ITEM 2.
ITEM 3.
ITEM 4.
PART II. OTHER INFORMATION
ITEM 1.
ITEM 1A.
ITEM 2.
ITEM 3.
ITEM 4.
ITEM 5.
ITEM 6.
-1-

PART I. FINANCIAL INFORMATION
ITEM 1.    FINANCIAL STATEMENTS
Elevance Health, Inc.
Consolidated Balance Sheets
September 30,
2022		December 31,
2021
(In millions, except share data)(Unaudited) 
Assets
Current assets:
Cash and cash equivalents$8,872 $4,880 
Fixed maturity securities (amortized cost of $28,306 and $25,641; allowance for credit losses of $10 and $6)
25,526 26,267 
Equity securities1,503 1,881 
Premium receivables6,682 5,681 
Self-funded receivables3,873 4,010 
Other receivables3,651 3,749 
Other current assets5,496 4,654 
Total current assets55,603 51,122 
Long-term investments:
Fixed maturity securities (amortized cost of $671 and $616; allowance for credit losses of $0 and $0)
622 632 
Other invested assets5,516 5,225 
Property and equipment, net4,197 3,919 
Goodwill24,381 24,228 
Other intangible assets10,536 10,615 
Other noncurrent assets2,171 1,719 
Total assets$103,026 $97,460 
Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable$15,242 $13,518 
Other policyholder liabilities5,482 5,521 
Unearned income3,702 1,153 
Accounts payable and accrued expenses4,963 4,970 
Short-term borrowings265 275 
Current portion of long-term debt2,249 1,599 
Other current liabilities9,384 7,849 
Total current liabilities41,287 34,885 
Long-term debt, less current portion21,258 21,157 
Reserves for future policy benefits825 802 
Deferred tax liabilities, net1,825 2,805 
Other noncurrent liabilities1,788 1,683 
Total liabilities66,983 61,332 
Commitments and contingencies – Note 11
Shareholders’ equity
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none
— — 
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding –
238,974,624 and 241,770,746
2 2 
Additional paid-in capital9,169 9,148 
Retained earnings29,604 27,088 
Accumulated other comprehensive loss(2,784)(178)
Total shareholders’ equity35,991 36,060 
Noncontrolling interests52 68 
Total equity36,043 36,128 
Total liabilities and equity$103,026 $97,460 


See accompanying notes.
-2-

Elevance Health, Inc.
Consolidated Statements of Income
(Unaudited) 
 Three Months Ended 
 September 30		Nine Months Ended 
 September 30
(In millions, except per share data)2022202120222021
Revenues
Premiums$33,722 $30,395 $99,583 $86,604 
Product revenue3,972 3,353 10,841 9,132 
Administrative fees and other revenue1,931 1,800 5,569 5,189 
Total operating revenue39,625 35,548 115,993 100,925 
Net investment income371 335 1,112 1,026 
Net (losses) gains on financial instruments(57)(61)(439)107 
Total revenues39,939 35,822 116,666 102,058 
Expenses
Benefit expense29,404 26,645 86,396 75,107 
Cost of products sold3,437 2,898 9,389 7,825 
Selling, general and administrative expense4,514 3,946 13,124 11,692 
Interest expense213 201 622 598 
Amortization of other intangible assets225 136 520 306 
Loss on extinguishment of debt— — — 5 
Total expenses37,793 33,826 110,051 95,533 
Income before income tax expense
2,146 1,996 6,615 6,525 
Income tax expense533 494 1,557 1,555 
Net income1,613 1,502 5,058 4,970 
Net loss (income) attributable to noncontrolling interests5 7 18 (3)
Shareholders’ net income$1,618 $1,509 $5,076 $4,967 
Shareholders’ net income per share
Basic $6.75 $6.20 $21.11 $20.33 
Diluted $6.68 $6.13 $20.86 $20.09 
Dividends per share$1.28 $1.13 $3.84 $3.39 
















See accompanying notes.
-3-

Elevance Health, Inc.
Consolidated Statements of Comprehensive Income
(Unaudited) 
 Three Months Ended 
 September 30		Nine Months Ended 
 September 30
(In millions)2022202120222021
Net income$1,613 $1,502 $5,058 $4,970 
Other comprehensive (loss) income, net of tax:
Change in net unrealized losses/gains on investments(639)(97)(2,630)(284)
Change in non-credit component of impairment losses on investments
(1)(1)(3)1 
Change in net unrealized gains/losses on cash flow hedges2 4 8 10 
Change in net periodic pension and postretirement costs7 8 23 26 
Foreign currency translation adjustments(7)(1)(15)(7)
Other comprehensive loss(638)(87)(2,617)(254)
Net loss (income) attributable to noncontrolling interests5 7 18 (3)
Other comprehensive loss attributable to noncontrolling interests3 1 11 1 
Total shareholders’ comprehensive income$983 $1,423 $2,470 $4,714 































See accompanying notes.
-4-

Elevance Health, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
 Nine Months Ended 
 September 30
(In millions)20222021
Operating activities
Net income$5,058 $4,970 
Adjustments to reconcile net income to net cash provided by operating activities:
Net losses (gains) on financial instruments439 (107)
Equity in net earnings of other invested assets(304)(437)
Depreciation and amortization1,202 942 
Deferred income taxes(170)114 
Share-based compensation191 196 
Changes in operating assets and liabilities:
Receivables, net(678)(1,751)
Other invested assets46 (56)
Other assets(474)(470)
Policy liabilities1,537 2,328 
Unearned income2,548 (308)
Accounts payable and other liabilities598 1,093 
Income taxes(41)168 
Other, net(35)10 
Net cash provided by operating activities9,917 6,692 
Investing activities
Purchases of investments(19,612)(15,130)
Proceeds from sale of investments9,402 8,339 
Maturities, calls and redemptions from investments7,606 3,388 
Changes in securities lending collateral(677)(1,030)
Purchases of subsidiaries, net of cash acquired(623)(3,442)
Purchases of property and equipment(854)(747)
Other, net(91)(50)
Net cash used in investing activities(4,849)(8,672)
Financing activities
Net proceeds from (repayments of) commercial paper borrowings375 (150)
Proceeds from long-term borrowings1,286 3,462 
Repayments of long-term borrowings(982)(954)
Proceeds from short-term borrowings1,365 175 
Repayments of short-term borrowings(1,375)— 
Changes in securities lending payable685 1,030 
Changes in bank overdrafts181 316 
Repurchase and retirement of common stock(1,748)(1,378)
Cash dividends(924)(831)
Proceeds from issuance of common stock under employee stock plans152 161 
Taxes paid through withholding of common stock under employee stock plans(91)(101)
Other, net16 8 
Net cash (used in) provided by financing activities(1,060)1,738 
Effect of foreign exchange rates on cash and cash equivalents(16)(9)
Change in cash and cash equivalents3,992 (251)
Cash and cash equivalents at beginning of period4,880 5,741 
Cash and cash equivalents at end of period$8,872 $5,490 








See accompanying notes.
-5-

Elevance Health, Inc.
Consolidated Statements of Changes in Equity
(Unaudited)
Total Shareholders’ Equity
 Common StockAdditional
Paid-in
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss		Noncontrolling
Interests		Total
Equity
(In millions)Number of
Shares		Par
Value
December 31, 2021 (audited)241.8 $2 $9,148 $27,088 $(178)$68 $36,128 
Adoption of Accounting Standards Update 2020-06 (Note 2)— — — (23)— — (23)
January 1, 2022241.8 2 9,148 27,065 (178)68 36,105 
Net income (loss)— — — 1,805 — (10)1,795 
Other comprehensive loss— — — — (1,058)(5)(1,063)
Noncontrolling interests adjustment— — — — — 3 3 
Repurchase and retirement of common stock(1.2)— (45)(500)— — (545)
Dividends and dividend equivalents— — — (312)— — (312)
Issuance of common stock under employee stock plans, net of related tax benefits0.5 — 39 — — — 39 
Convertible debenture repurchases, conversions and tax adjustments— — 9 — — — 9 
March 31, 2022241.1 2 9,151 28,058 (1,236)56 36,031 
Net income (loss)— — — 1,653 — (3)1,650 
Other comprehensive loss— — — — (913)(3)(916)
Noncontrolling interests adjustment— — — — — 5 5 
Repurchase and retirement of common stock(1.3)— (48)(576)— — (624)
Dividends and dividend equivalents— — — (310)— — (310)
Issuance of common stock under employee stock plans, net of related tax benefits0.2 — 111 — — — 111 
Convertible debenture repurchases and conversions— — (80)— — — (80)
June 30, 2022240.0 2 9,134 28,825 (2,149)55 35,867 
Net income (loss)— — — 1,618 — (5)1,613 
Other comprehensive loss— — — — (635)(3)(638)
Noncontrolling interest adjustment— — — — — 5 5 
Repurchase and retirement of common stock(1.2)— (47)(532)— — (579)
Dividends and dividend equivalents— — — (307)— — (307)
Issuance of common stock under employee stock plans, net of related tax benefits0.2 — 103 — — — 103 
Convertible debenture repurchases and conversions— — (21)— — — (21)
September 30, 2022239.0 $2 $9,169 $29,604 $(2,784)$52 $36,043 

See accompanying notes.
-6-

Elevance Health, Inc.
Consolidated Statements of Changes in Equity (continued)
(Unaudited)
Total Shareholders’ Equity
 Common StockAdditional
Paid-in
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Income (Loss) 		Noncontrolling
Interests		Total
Equity
(In millions)Number of
Shares		Par
Value
January 1, 2021245.4 $3 $9,244 $23,802 $150 $— $33,199 
Net income— — — 1,665 — 2 1,667 
Other comprehensive loss— — — — (345)(2)(347)
Accumulated noncontrolling interests— — — — — 65 65 
Repurchase and retirement of common stock(1.4)(1)(53)(393)— — (447)
Dividends and dividend equivalents— — — (281)— — (281)
Issuance of common stock under employee stock plans, net of related tax benefits
0.9 — 62 — — — 62 
March 31, 2021244.9 2 9,253 24,793 (195)65 33,918 
Net income— — — 1,793 — 8 1,801 
Other comprehensive income— — — — 178 2 180 
Noncontrolling interests adjustment— — — — — 3 3 
Repurchase and retirement of common stock
(1.3)— (47)(433)— — (480)
Dividends and dividend equivalents— — — (279)— — (279)
Issuance of common stock under employee stock plans, net of related tax benefits
0.3 — 119 — — — 119 
Convertible debenture repurchases and conversions
— — (216)— — — (216)
June 30, 2021243.9 2 9,109 25,874 (17)78 35,046 
Net income (loss)— — — 1,509 — (7)1,502 
Other comprehensive loss— — — — (86)(1)(87)
Noncontrolling interests adjustment— — — — — 1 1 
Repurchase and retirement of common stock
(1.2)— (44)(407)— — (451)
Dividends and dividend equivalents
— — — (276)— — (276)
Issuance of common stock under employee stock plans, net of related tax benefits
0.1 — 75 — — — 75 
Convertible debenture repurchases and conversions
— — (2)— — — (2)
September 30, 2021242.8 $2 $9,138 $26,700 $(103)$71 $35,808 





See accompanying notes.
-7-

Elevance Health, Inc.
Notes to Consolidated Financial Statements
(Unaudited)
September 30, 2022
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
 
1.     Organization
On May 18, 2022, our shareholders approved a proposal to amend our amended and restated articles of incorporation to change our name from Anthem, Inc. to Elevance Health, Inc. This amendment and name change went into effect on June 27, 2022. We began operating as Elevance Health, Inc. and trading under our new ticker symbol “ELV” on June 28, 2022. References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context otherwise requires.
Elevance Health is a health company with the purpose of improving the health of humanity. We are the largest health insurer in the United States in terms of medical membership, serving over 47 million medical members through our affiliated health plans as of September 30, 2022. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management and wellness programs, actuarial services and other administrative services. We also provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to our subsidiary health plans and also unaffiliated health plans, including pharmacy benefits management (“PBM”) services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. In addition, we conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, Integra Managed Care, MMM, Optimum HealthCare, Simply Healthcare, and/or UniCare. We offer PBM services through our IngenioRx, Inc. (“IngenioRx”) subsidiary. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.
As part of our name change to Elevance Health, on June 15, 2022 we announced that over the next several years we will organize our brand portfolio into the following core go-to-market brands:
•Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;
•Wellpoint — we intend to unite select non-BCBSA licensed Medicare, Medicaid and Commercial plans under the Wellpoint name; and
•Carelon — this brand will bring together our healthcare brands and capabilities, including our Diversified Business Group and IngenioRx business under a single brand name. We now refer to our Diversified Business Group as Carelon. In January 2023, IngenioRx will become CarelonRx.
There are currently no segment changes associated with this branding strategy. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner, and given this evolution we are in the process of reviewing and modifying how we will manage our businesses in the future.
-8-

2.     Basis of Presentation and Significant Accounting Policies
Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our 2021 Annual Report on Form 10-K, unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and nine months ended September 30, 2022 and 2021 have been recorded. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2022, or any other period. The seasonal nature of portions of our health care and related benefits business, competitive and other market conditions, as well as COVID-19 related impacts, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $291 and $173 at September 30, 2022 and December 31, 2021, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the
-9-

securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption “Other invested assets” in our consolidated balance sheets.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” in our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities” in our consolidated balance sheets. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $140 and $142 at September 30, 2022 and December 31, 2021, respectively.
Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $82 and $50 at September 30, 2022 and December 31, 2021, respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income, and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $709 and $648 at September 30, 2022 and December 31, 2021, respectively.
Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at September 30, 2022. For the three and nine months ended September 30, 2022 and 2021, revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
-10-

Recently Adopted Accounting Guidance: In January 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2021-01, Reference Rate Reform (Topic 848) (“ASU 2021-01”). The amendments in ASU 2021-01 provide optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of the reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
In October 2020, the FASB issued Accounting Standards Update No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other Costs (“ASU 2020-08”). The amendments in ASU 2020-08 clarify when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting periods beginning after December 15, 2020. The amendments were to be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted earnings per share calculation and expand disclosure requirements. The amendments became effective for our annual and interim reporting periods beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease to our deferred tax liabilities of $8, and a corresponding cumulative-effect reduction to our opening retained earnings of $23; these amounts are not material to our overall consolidated financial position. The adoption of ASU 2020-06 did not have an impact on our results of operations or our consolidated cash flows. Use of the if-converted method did not have an impact on our overall earnings per share calculation.
In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
Recent Accounting Guidance Not Yet Adopted: In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments
-11-

for market risk benefits are to be applied retrospectively. We do not believe the adoption of ASU 2020-11 and ASU 2018-12 will have a material impact on our consolidated financial position, results of operations, cash flows, and related disclosures.
There were no other new accounting pronouncements that were issued or became effective since the issuance of our 2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.
3.    Business Acquisitions
Completed Acquisitions
On May 5, 2022, we completed our acquisition of Integra Managed Care (“Integra”) from Personal Touch Holding Corporation. Integra is a managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in their own homes. The purchase price was allocated to the tangible and intangible net assets acquired based on management’s initial estimates of their fair values, of which $89 has been allocated to finite-lived intangible assets, $250 to indefinite-lived intangible assets, and $123 to goodwill, including measurement period adjustments to goodwill of $13 during the quarter ended September 30, 2022. The majority of goodwill is deductible for income tax purposes. As of September 30, 2022, the initial accounting for the acquisition had not been finalized. Any subsequent adjustments made to the assets acquired or liabilities assumed during the measurement period will be recorded as an adjustment to goodwill. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.
Acquisitions completed during the year ended December 31, 2021, for which the initial accounting was finalized during the three months ended June 30, 2022 included myNEXUS, Inc. (“myNEXUS”), a comprehensive home-based nursing management company for payors, and MMM Holdings, LLC (“MMM”), including its Medicare Advantage plan, Medicaid plan and other affiliated companies. As of September 30, 2022, the purchase price of each transaction was allocated to the tangible and intangible net assets acquired based on management’s final estimates of their fair values, of which $1,577 has been allocated to finite-lived intangible assets, $20 to indefinite-lived intangible assets, and $2,531 to goodwill. The majority of goodwill is not deductible for income tax purposes.
4.    Business Optimization Initiatives
Provided below is a summary of the activity, by reportable segment, related to the liability for employee termination costs previously incurred in connection with our enterprise-wide business optimization initiatives introduced in 2020.
Commercial & Specialty BusinessGovernment BusinessIngenioRxOtherTotal
2020 Business Optimization Initiatives
Employee termination costs:
Liability for employee termination costs at January 1, 2022$61 $57 $1 $3 $122 
Payments(16)(14)— — (30)
Liability for employee termination costs at September 30, 2022
$45 $43 $1 $3 $92 
5.     Investments
Fixed Maturity Securities
We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. We have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value may occur and additional material impairment losses for credit losses on investments may be recorded in future periods.
-12-

A summary of current and long-term fixed maturity securities, available-for-sale, at September 30, 2022 and December 31, 2021 is as follows:
Cost or Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Allowance
For Credit
Losses		Estimated
Fair Value
 
September 30, 2022
Fixed maturity securities:
United States Government securities$1,673 $— $(125)$— $1,548 
Government sponsored securities65 — (4)— 61 
Foreign government securities322 — (70)(1)251 
States, municipalities and political subdivisions4,431 5 (355)— 4,081 
Corporate securities13,766 9 (1,560)(7)12,208 
Residential mortgage-backed securities4,748 7 (506)(2)4,247 
Commercial mortgage-backed securities77 — (7)— 70 
Other securities3,895 37 (250)— 3,682 
Total fixed maturity securities$28,977 $58 $(2,877)$(10)$26,148 
December 31, 2021
Fixed maturity securities:
United States Government securities$1,443 $7 $(18)$— $1,432 
Government sponsored securities65 4 (1)— 68 
Foreign government securities353 7 (13)— 347 
States, municipalities and political subdivisions5,321 310 (10)— 5,621 
Corporate securities12,044 401 (78)(4)12,363 
Residential mortgage-backed securities4,059 75 (35)(2)4,097 
Commercial mortgage-backed securities65 2 (3)— 64 
Other securities2,907 24 (24)— 2,907 
Total fixed maturity securities$26,257 $830 $(182)$(6)$26,899 

-13-

For fixed maturity securities in an unrealized loss position at September 30, 2022 and December 31, 2021, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position: 
 Less than 12 Months12 Months or Greater
(Securities are whole amounts)Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss		Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss
September 30, 2022
Fixed maturity securities:
United States Government securities65 $911 $(77)29 $303 $(48)
Government sponsored securities40 61 (4)1 — — 
Foreign government securities
225 169 (34)151 81 (36)
States, municipalities and political subdivisions
1,964 3,602 (314)139 200 (41)
Corporate securities4,322 10,228 (1,165)1,318 1,679 (395)
Residential mortgage-backed securities2,035 2,949 (294)530 1,182 (212)
Commercial mortgage-backed securities34 56 (3)7 13 (4)
Other securities921 2,535 (165)269 670 (85)
Total fixed maturity securities9,606 $20,511 $(2,056)2,444 $4,128 $(821)
December 31, 2021
Fixed maturity securities:
United States Government securities
51 $990 $(11)27 $176 $(7)
Government sponsored securities
— — — 1 1 (1)
Foreign government securities
188 143 (8)68 41 (5)
States, municipalities and political subdivisions
281 634 (9)8 16 (1)
Corporate securities
1,846 3,310 (57)403 485 (21)
Residential mortgage-backed securities
692 1,967 (26)125 173 (9)
Commercial mortgage-backed securities
2 4 (1)4 8 (2)
Other securities
511 1,707 (19)50 85 (5)
Total fixed maturity securities3,571 $8,755 $(131)686 $985 $(51)
Although not material to our consolidated results of operations, during the nine months ended September 30, 2022, we recorded a combination of credit losses, losses on sales of fixed maturity securities and impairments related to our exposure resulting from investments in Russia and Ukraine. At September 30, 2022, our remaining holdings of Russia and Ukraine fixed maturity securities were not material.
Unrealized losses on our securities shown in the table above have not been recognized into income because, as of September 30, 2022, we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior to their maturity or anticipated recovery. The declines in fair values are largely due to increasing interest rates driven by the high rate of inflation and other market conditions and not by unfavorable changes in the credit quality characteristics that impact our assessment on collectability of principal and interest. We have evaluated qualitative and quantitative factors for indications of credit losses on our securities, including factors such as credit rating, foreign political conflicts, uncertainties around future ability to collect payment, significant declines in fair value and industry conditions, market data, and notifications of maturity and coupon default, and have recorded an allowance for credit losses in the amount of $10 and $6 at September 30, 2022 and December 31, 2021, respectively.

-14-


The amortized cost and fair value of fixed maturity securities at September 30, 2022, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.
Amortized
Cost		Estimated
Fair Value
Due in one year or less$911 $901 
Due after one year through five years7,364 6,871 
Due after five years through ten years9,535 8,467 
Due after ten years6,342 5,592 
Mortgage-backed securities4,825 4,317 
Total fixed maturity securities$28,977 $26,148 
During the three and nine months ended September 30, 2022, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $5,281 and $15,953, respectively. During the three and nine months ended September 30, 2021, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $2,620 and $8,570, respectively.
In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.
All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
Equity Securities
A summary of marketable equity securities at September 30, 2022 and December 31, 2021 is as follows:
 September 30, 2022December 31, 2021
Equity securities:
Exchange traded funds$1,403 $1,750 
Common equity securities5 42 
Private equity securities95 89 
Total$1,503 $1,881 
Other Invested Assets
Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, mortgage loans and the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Financial information for certain of these investments are reported on a one or three month lag due to the timing of when we receive financial information from the companies.
-15-

Investment Gains and Losses
Net investment (losses) gains for the three and nine months ended September 30, 2022 and 2021 are as follows:
Three Months Ended
September 30		Nine Months Ended
September 30
2022202120222021
Net (losses) gains:
Fixed maturity securities:
Gross realized gains from sales$8 $30 $44 $133 
Gross realized losses from sales(99)(8)(353)(32)
Impairment (losses) recoveries recognized in income(5)— (25)1 
Net realized (losses) gains from sales of fixed maturity securities(96)22 (334)102 
Equity securities:
Unrealized (losses) gains recognized on equity securities still held at the end of the period(43)(4)(192)4 
Net realized gains (losses) recognized on equity securities sold during the period4 (1)(20)(57)
Net losses on equity securities(39)(5)(212)(53)
Other investments:
Gross gains95 2 126 9 
Gross losses(2)(93)(45)(5)
Impairment (losses) recoveries recognized in income(12)1 (17)(5)
Net losses (gains) on other investments81 (90)64 (1)
Net (losses) gains on investments$(54)$(73)$(482)$48 
Accrued Investment Income
At September 30, 2022 and December 31, 2021, accrued investment income totaled $228 and $205, respectively. We recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets.
Securities Lending Programs
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. The fair value of the collateral received at the time of the transactions amounted to $2,841 and $2,155 at September 30, 2022 and December 31, 2021, respectively. The value of the collateral represented 102% of the market value of the securities on loan at each of September 30, 2022 and December 31, 2021. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets.
At September 30, 2022 and December 31, 2021, the remaining contractual maturity of our securities lending agreements included overnight and continuous transactions of cash for $2,636 and $1,874, respectively, of United States Government securities for $180 and $281, respectively, and of Other securities for $25 and $0, respectively.
6.    Derivative Financial Instruments
We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions.
We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to
-16-

LIBOR or the Secured Overnight Financing Rate (“SOFR”). Any amounts recognized for changes in fair value of these derivatives are included in the captions “Other current assets,” “Other noncurrent assets,” “Other current liabilities” or “Other noncurrent liabilities” in our consolidated balance sheets.
The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $231 and $239 at September 30, 2022 and December 31, 2021, respectively.
During the three and nine months ended September 30, 2022, we recognized net (losses) gains on non-hedging derivatives of $(3) and $43, respectively. During the three and nine months ended September 30, 2021, we recognized net gains on non-hedging derivatives of $12 and $59, respectively.
For additional information relating to the fair value of our derivative assets and liabilities, see Note 7, “Fair Value,” of this Form 10-Q.
7.    Fair Value
Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:
Level InputInput Definition
Level IInputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level IIInputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.
Level IIIUnobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in our consolidated balance sheets:
Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.
Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities, United States government securities, foreign government securities, and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily corporate debt securities, which are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.
Equity securities: Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions
-17-

for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.
Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures.
Derivatives: Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate observable market inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by counterparty.
-18-

A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at September 30, 2022 and December 31, 2021 is as follows:
Level ILevel IILevel IIITotal
September 30, 2022
Assets:
Cash equivalents$5,794 $— $— $5,794 
Fixed maturity securities, available-for-sale:
United States Government securities— 1,548 — 1,548 
Government sponsored securities— 61 — 61 
Foreign government securities— 251 — 251 
States, municipalities and political subdivisions, tax-exempt— 4,081 — 4,081 
Corporate securities— 12,079 129 12,208 
Residential mortgage-backed securities— 4,247 — 4,247 
Commercial mortgage-backed securities— 70 — 70 
Other securities— 3,371 311 3,682 
Total fixed maturity securities, available-for-sale— 25,708 440 26,148 
Equity securities:
Exchange traded funds1,403 — — 1,403 
Common equity securities6 (1)— 5 
Private equity securities— — 95 95 
Total equity securities1,409 (1)95 1,503 
Other invested assets - common equity securities149 — — 149 
Securities lending collateral— 2,841 — 2,841 
Derivatives - other assets— 25 — 25 
Total assets$7,352 $28,573 $535 $36,460 
Liabilities:
Derivatives - other liabilities$— $(70)$— $(70)
Total liabilities$— $(70)$— $(70)
December 31, 2021
Assets:
Cash equivalents$2,415 $— $— $2,415 
Fixed maturity securities, available-for-sale:
United States Government securities— 1,432 — 1,432 
Government sponsored securities— 68 — 68 
Foreign government securities— 347 — 347 
States, municipalities and political subdivisions, tax-exempt— 5,621 — 5,621 
Corporate securities— 12,027 336 12,363 
Residential mortgage-backed securities— 4,092 5 4,097 
Commercial mortgage-backed securities— 64 — 64 
Other securities— 2,888 19 2,907 
Total fixed maturity securities, available-for-sale— 26,539 360 26,899 
Equity securities:
Exchange traded funds1,750 — — 1,750 
Common equity securities8 34 — 42 
Private equity securities— — 89 89 
Total equity securities1,758 34 89 1,881 
Other invested assets - common equity securities138 — — 138 
Securities lending collateral— 2,155 — 2,155 
Derivatives - other assets— 19 — 19 
Total assets$4,311 $28,747 $449 $33,507 
Liabilities:
Derivatives - other liabilities$— $(1)$— $(1)
Total liabilities$— $(1)$— $(1)
-19-

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended September 30, 2022 and 2021 is as follows:
Corporate
Securities		Residential
Mortgage-
backed
Securities		Other 
Securities		Equity
Securities		Total
Three Months Ended September 30, 2022
Beginning balance at July 1, 2022$155 $— $218 $94 $467 
Total losses:
Recognized in net income— — — — — 
Recognized in accumulated other comprehensive loss1 — 17 — 18 
Purchases15 — 77 3 95 
Sales(26)— (1)(2)(29)
Settlements(10)— — — (10)
Transfers out of Level III(6)— — — (6)
Ending balance at September 30, 2022$129 $— $311 $95 $535 
Change in unrealized losses included in net income related to assets still held at September 30, 2022$— $— $— $— $— 
Three Months Ended September 30, 2021
Beginning balance at July 1, 2021$351 $2 $7 $77 $437 
Total gains:
Recognized in net income1 — — 5 6 
Recognized in accumulated other comprehensive loss(1)— — — (1)
Purchases34 — — 3 37 
Sales— — — (1)(1)
Settlements(47)— — — (47)
Transfers out of Level III(4)(1)(5)— (10)
Ending balance at September 30, 2021$334 $1 $2 $84 $421 
Change in unrealized gains included in net income related to assets still held at September 30, 2021$— $— $— $5 $5 
















-20-

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the nine months ended September 30, 2022 and 2021 is as follows:
Corporate
Securities		Residential
Mortgage-
backed
Securities		Other 
Securities		Equity
Securities		Total
Nine Months Ended September 30, 2022
Beginning balance at January 1, 2022$336 $5 $19 $89 $449 
Total losses:
Recognized in net income— — — 1 1 
Recognized in accumulated other comprehensive loss(1)— 17 — 16 
Purchases40 — 281 24 345 
Sales(201)— (1)(19)(221)
Settlements(42)— — — (42)
Transfers into Level III9 — — — 9 
Transfers out of Level III(12)(5)(5)— (22)
Ending balance at September 30, 2022$129 $— $311 $95 $535 
Change in unrealized gains included in net income related to assets still held at September 30, 2022$— $— $— $1 $1 
Nine Months Ended September 30, 2021
Beginning balance at January 1, 2021$325 $2 $5 $60 $392 
Total gains:
Recognized in net income2 — — 17 19 
Recognized in accumulated other comprehensive loss4 — — — 4 
Purchases135 — — 11 146 
Sales(12)— — (4)(16)
Settlements(118)— (1)— (119)
Transfers out of Level III(2)(1)(2)— (5)
Ending balance at September 30, 2021$334 $1 $2 $84 $421 
Change in unrealized gains included in net income related to assets still held at September 30, 2021$— $— $— $17 $17 
There were no individually material transfers into or out of Level III during the three and nine months ended September 30, 2022 or 2021.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions,” we completed our acquisition of Integra in the second quarter of 2022 and the acquisitions of myNEXUS and MMM during the second quarter of 2021. The net assets acquired in our acquisitions of Integra, myNEXUS and MMM and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of assets acquired and liabilities assumed were recorded at their carrying values as of the respective date of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of Integra, myNEXUS and MMM were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisitions of Integra, myNEXUS and MMM described above, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the three and nine months ended September 30, 2022 or 2021.
-21-

Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows.
Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the three and nine months ended September 30, 2022 or 2021.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in our consolidated balance sheets.
Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.
The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.
The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value in our consolidated balance sheets:
Other invested assets: Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations and mortgage loans, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.
Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or, if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt—commercial paper: The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest rates at market value.
Long-term debt—senior unsecured notes and surplus notes: The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt—convertible debentures: The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade.
-22-

A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at September 30, 2022 and December 31, 2021 is as follows:
 Carrying
Value		Estimated Fair Value
 Level ILevel IILevel IIITotal
September 30, 2022
Assets:
Other invested assets$5,367 $— $— $5,367 $5,367 
Liabilities:
Debt:
Short-term borrowings265 — 265 — 265 
Commercial paper675 — 675 — 675 
Notes22,747 — 20,163 — 20,163 
Convertible debentures86 — 554 — 554 
December 31, 2021
Assets:
Other invested assets$5,087 $— $— $5,087 $5,087 
Liabilities:
Debt:
Short-term borrowings275 — 275 — 275 
Commercial paper300 — 300 — 300 
Notes22,384 — 25,150 — 25,150 
Convertible debentures72 — 687 — 687 
8.     Income Taxes
During the three months ended September 30, 2022 and 2021, we recognized income tax expense of $533 and $494, respectively, which represent effective income tax rates of 24.8% and 24.7%, respectively.
During the nine months ended September 30, 2022 and 2021, we recognized income tax expense of $1,557 and $1,555, respectively, which represent effective income tax rates of 23.5% and 23.8%, respectively. The decrease in our effective tax rate from the nine months ended September 30, 2021 was primarily related to the tax impact of expected geographic changes in our mix of 2022 earnings.
Income taxes receivable totaled $214 and $173 at September 30, 2022 and December 31, 2021, respectively. We recognized the income taxes receivable as an asset under the caption “Other current assets” in our consolidated balance sheets.
-23-

9. Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2022 is as follows:
Commercial
& Specialty
Business		Government
Business		OtherTotal
Gross medical claims payable, beginning of period$3,847 $9,157 $278 $13,282 
Ceded medical claims payable, beginning of period(13)(8)— (21)
Net medical claims payable, beginning of period3,834 9,149 278 13,261 
Business combinations and purchase adjustments3 130 — 133 
Net incurred medical claims:
Current period22,049 60,971 1,157 84,177 
Prior periods redundancies(183)(639)(79)(901)
Total net incurred medical claims21,866 60,332 1,078 83,276 
Net payments attributable to:
Current period medical claims18,604 50,950 899 70,453 
Prior periods medical claims3,181 7,854 184 11,219 
Total net payments21,785 58,804 1,083 81,672 
Net medical claims payable, end of period3,918 10,807 273 14,998 
Ceded medical claims payable, end of period3 — — 3 
Gross medical claims payable, end of period$3,921 $10,807 $273 $15,001 
At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Commercial & Specialty Business was $81, $388 and $3,449 for the claim years 2020 and prior, 2021 and 2022, respectively.
At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Government Business was $148, $508 and $10,151 for the claim years 2020 and prior, 2021 and 2022, respectively.
At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for Other was $2, $14 and $257 for the claim years 2020 and prior, 2021 and 2022, respectively.
-24-

A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2021 is as follows:
Commercial
& Specialty
Business		Government
Business		OtherTotal
Gross medical claims payable, beginning of period$3,294 $7,646 $195 $11,135 
Ceded medical claims payable, beginning of period(13)(33)— (46)
Net medical claims payable, beginning of period3,281 7,613 195 11,089 
Business combinations and purchase adjustments— 375 45 420 
Net incurred medical claims:
Current period20,499 52,422 1,176 74,097 
Prior periods redundancies(496)(1,309)(17)(1,822)
Total net incurred medical claims20,003 51,113 1,159 72,275 
Net payments attributable to:
Current period medical claims16,985 44,160 978 62,123 
Prior periods medical claims2,450 5,781 169 8,400 
Total net payments19,435 49,941 1,147 70,523 
Net medical claims payable, end of period3,849 9,160 252 13,261 
Ceded medical claims payable, end of period15 23 — 38 
Gross medical claims payable, end of period$3,864 $9,183 $252 $13,299 
The favorable development recognized in the nine months ended September 30, 2022 and 2021 resulted primarily from trend factors in late 2021 and late 2020, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter parts of 2020 developing faster than expected also contributed to the favorable development in the nine months ended September 30, 2021. The impact from COVID-19 on healthcare utilization and medical claims submission patterns continues to provide increased estimation uncertainty on our incurred but not reported liability at September 30, 2022.
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2022 is as follows:
Three Months EndedNine Months Ended September 30, 2022
March 31, 2022June 30, 2022September 30, 2022
Net incurred medical claims:
Commercial & Specialty Business$6,834 $7,522 $7,510 $21,866 
Government Business19,943 19,788 20,601 60,332 
Other354 324 400 1,078 
Total net incurred medical claims27,131 27,634 28,511 83,276 
Quality improvement and other claims expense1,084 1,143 893 3,120 
Benefit expense$28,215 $28,777 $29,404 $86,396 
During the three months ended September 30, 2022, based on recent regulatory clarification, we realigned certain quality improvement costs from benefit expense to administrative expense that were previously allocated to benefit expense during the three months ended March 31, 2022 and the three months ended June 30, 2022.
-25-

The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2021 is as follows:
Three Months EndedNine Months Ended September 30, 2021
March 31, 2021June 30, 2021September 30, 2021
Net incurred medical claims:
Commercial & Specialty Business$6,072 $6,718 $7,213 $20,003 
Government Business16,319 16,723 18,071 51,113 
Other336 403 420 1,159 
Total net incurred medical claims22,727 23,844 25,704 72,275 
Quality improvement and other claims expense972 919 941 2,832 
Benefit expense$23,699 $24,763 $26,645 $75,107 
The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of September 30, 2022, is as follows:
Commercial
& Specialty
Business		Government
Business		OtherTotal
Net medical claims payable, end of period$3,918 $10,807 $273 $14,998 
Ceded medical claims payable, end of period3 — — 3 
Insurance lines other than short duration— 241 — 241 
Gross medical claims payable, end of period$3,921 $11,048 $273 $15,242 
10.     Debt
We generally issue senior unsecured notes for long-term borrowing purposes. At September 30, 2022 and December 31, 2021, we had $22,722 and $22,359, respectively, outstanding under these notes.
On May 16, 2022, we repaid, at maturity, the $850 outstanding balance of our 3.125% senior unsecured notes.
On April 29, 2022, we issued $600 aggregate principal amount of 4.100% Notes due 2032 (the “2032 Notes”) and $700 aggregate principal amount of 4.550% Notes due 2052 (the “2052 Notes”) under our shelf registration statement. Interest on the 2032 Notes and 2052 Notes is payable semi-annually in arrears on May 15 and November 15 of each year, commencing November 15, 2022. We used the net proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.
We have an unsecured surplus note with an outstanding principal balance of $25 at both September 30, 2022 and December 31, 2021.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. On April 18, 2022, we amended and restated the credit agreement for the 5-Year Facility to, among other things, extend the maturity date of the 5-Year Facility from June 2024 to April 2027 and increase the amount of credit available under the 5-Year Facility from $2,500 to $4,000. Also on April 18, 2022, concurrently with the amendment and restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which was scheduled to mature in June 2022 (the “2021 364-Day Facility”). In June 2021, we terminated our 364-day senior revolving credit facility (the “prior 364-Day Facility”), which was scheduled to mature in June 2021, and entered into the 2021 364-Day Facility with a group of lenders for general corporate purposes. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. As of September 30, 2022, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.7%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As
-26-

of September 30, 2022, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility, the 2021 364-Day Facility or the prior 364-Day Facility at any time during the nine months ended September 30, 2022 or the year ended December 31, 2021.
Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit of up to $200. At September 30, 2022 and December 31, 2021, there were no amounts outstanding under our Subsidiary Credit Facilities.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. In July 2022, we increased the amount available under the commercial paper program from $3,500 to $4,000. At September 30, 2022 and December 31, 2021, we had $675 and $300, respectively, outstanding under this program.
We have outstanding senior unsecured convertible debentures due 2042 (the “Debentures”), which are governed by an indenture (the “indenture”) between us and The Bank of New York Mellon Trust Company, N.A., as trustee. We accounted for the Debentures in accordance with the FASB cash conversion guidance for debt with conversion and other options at the time of issue. As a result, the value of the embedded conversion option (net of deferred taxes and equity issuance costs) was bifurcated from its debt host and recorded as a component of additional paid-in capital in our consolidated balance sheets. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease of our deferred tax liabilities of $8 and a corresponding cumulative-effect reduction to our opening retained earnings of $23, eliminating the bifurcation of the embedded conversion option. During the three and nine months ended September 30, 2022, $4 and $19 of aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of the indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments during the three and nine months ended September 30, 2022 of $25 and $132, respectively.
The following table summarizes at September 30, 2022 the related balances, conversion rate and conversion price of the Debentures:
Outstanding principal amount$86 
Net debt carrying amount$86 
Conversion rate (shares of common stock per $1,000 of principal amount)14.2967 
Effective conversion price (per $1,000 of principal amount)$69.9462 
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $265 and $275 of outstanding short-term borrowings from the FHLBs at September 30, 2022 and December 31, 2021, respectively.
All debt is a direct obligation of Elevance Health, Inc., except for the surplus note, the FHLB borrowings, and the Subsidiary Credit Facilities.
11.     Commitments and Contingencies
Litigation and Regulatory Proceedings
In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to
-27-

income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss.
With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves is, in the aggregate, from $0 to approximately $250 at September 30, 2022. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.
Blue Cross Blue Shield Antitrust Litigation
We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the “Blue plans”) across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation that is pending in the U.S. District Court for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard® and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.

In April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, determining that the defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.
The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the “Subscriber Settlement Agreement”), which agreement required the Court’s approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-monetary obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan.
In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the July 2021 opt-out deadline. In excess of eight thousand claims were submitted by the November 2021 claims submission deadline. A fairness hearing was held in October 2021 and the Court took the request for final approval under advisement and requested supplemental briefing that was submitted. In February 2022, the Court ordered the issuance of a supplemental notice to self-funded account class members, which notice process was completed in March 2022. The deadline for objections to the supplemental notice along with opt-outs was in May 2022.
In August 2022, the Court issued a final approval order for the Subscriber Settlement Agreement. The Court amended its final approval order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In September 2022, an objector filed a motion to amend the final approval order, which the Court
-28-

denied. In compliance with the Subscriber Settlement Agreement, the Company paid its remaining $506 portion of the settlement fund into an escrow account in September 2022, for an aggregate settlement payment by the Company of $596.
Four notices of appeal of the final approval order were filed by the September 2022 deadline. Those appeals will proceed in the United States Court of Appeals for the Eleventh Circuit. In October 2022, the subscriber plaintiffs filed a motion to consolidate and expedite the four appeals. After all appellate rights have been exhausted in a manner that affirms the Court’s final order and judgment, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective.
In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determines the standard of review applicable to providers’ claims. In May 2021, the defendants and provider plaintiffs filed renewed standard of review motions. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued (i) an order granting certain defendants’ motion for partial summary judgment against provider plaintiffs who had previously released claims against such defendants, and (ii) an order granting provider plaintiffs’ motion for partial summary judgment, holding that Ohio v. American Express Co. does not affect the standard of review in this case. In August 2022, the Court issued (i) an order granting in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the “national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation conspiracy claims, and (ii) an order denying the provider plaintiffs’ motion for partial summary judgment on the standard of review, reaffirming its prior holding that the providers’ group boycott claims are subject to the rule of reason. We intend to continue to vigorously defend the provider litigation, which we believe is without merit; however, its ultimate outcome cannot be presently determined.
A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are: Alaska Air Group, Inc., et al. v. Anthem, Inc., et al., No. 2:21-cv-01209-AMM (N.D. Ala.); JetBlue Airways Corp., et al. v. Anthem, Inc., et al., No. 2:22-cv-00558-GMB (N.D. Ala.); Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al., No. 2:22-cv-00265-RDP (N.D. Ala.); Bed Bath & Beyond Inc. v. Anthem, Inc., No. 2:22-cv-01256-SGC (N.D. Ala.); Hoover, et al. v. Blue Cross Blue Shield Association, et al., No. 2:22-cv-00261-RDP (N.D. Ala.); and VHS Liquidating Trust v. Blue Cross of California, et al., No. RG21106600 (Cal. Super.). We intend to continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined.

Blue Cross of California Taxation Litigation
In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (“BCC”) was named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court (the “Superior Court”) captioned Michael D. Myers v. State Board of Equalization, et al. This action was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an “insurer” for purposes of taxation despite acknowledging it is not an “insurer” under regulatory law. At the time, under California law, “insurers” were required to pay a gross premiums tax (“GPT”) calculated as 2.35% on gross premiums. As a licensed Health Care Service Plan, BCC has paid the California Corporate Franchise Tax (“CFT”), the tax paid by California businesses generally. Plaintiff contends that BCC must pay the GPT rather than the CFT, and seeks a writ of mandate directing the taxing agencies to collect the GPT and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the complaint.
Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax periods at issue in the litigation.
In March 2018, the Superior Court denied BCC’s motion for judgment on the pleadings and similar motions brought by other entities. BCC filed a motion for summary judgment with the Superior Court, which was heard in October 2020. In December 2020, the Superior Court granted BCC’s motion for summary judgment, dismissing the plaintiff’s lawsuit. In
-29-

November 2021, the plaintiff appealed the order granting BCC's motion for summary judgment. BCC’s responding brief was filed in March 2022. Plaintiff’s reply was filed in May 2022. We estimate that the appeal will be heard in the winter of 2022. We intend to vigorously defend the appeal of this lawsuit.
Express Scripts, Inc. Pharmacy Benefit Management Litigation
In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for PBM services, captioned Anthem, Inc. v. Express Scripts, Inc., in the U.S. District Court for the Southern District of New York (the “District Court”). The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the “ESI PBM Agreement”), over $158 in damages related to operational breaches, as well as various declarations under the ESI PBM Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to us through the term of the ESI PBM Agreement; (iii) has breached the ESI PBM Agreement; and (iv) is required under the ESI PBM Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination.
Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI PBM Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI PBM Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have been unjustly enriched by its payment of $4,675 at the time we entered into the ESI PBM Agreement. In March 2017, the District Court granted our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such action, the only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In March 2022, the District Court granted in part and denied in part Express Scripts’ motion for summary judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Quarterly Report on Form 10-Q are (i) our operational breach claim based on Express Scripts’ prior authorization processes and (ii) Express Scripts’ counterclaim for breach of the market check provision of the ESI PBM Agreement. Express Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims, which we opposed in July 2022. We intend to appeal the earlier summary judgment decision at the appropriate time, vigorously pursue our claims and defend against counterclaims, which we believe are without merit; however, the ultimate outcome of this litigation cannot be presently determined.
Medicare Risk Adjustment Litigation
In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. (f/k/a Anthem, Inc.) in the U.S. District Court for the Southern District of New York (the “New York District Court”) in a case captioned United States v. Anthem, Inc. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint. In an opinion and order issued October 3, 2022, the New York District Court denied our motions, and the case will now proceed in such court. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.

Investigations of CareMore and HealthSun
With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data submitted to CMS (unrelated to our retrospective chart review program) at CareMore Health Plans, Inc. (“CareMore”), one of our California subsidiaries, and HealthSun Health Plans, Inc. (“HealthSun”), one of our Florida subsidiaries. Our CareMore investigation has resulted in the termination of CareMore’s relationship with one contracted provider in California. Our
-30-

HealthSun investigation has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to CMS and the Criminal and Civil Divisions of the DOJ. We are cooperating with the ongoing investigations of the Criminal and Civil Divisions of the DOJ related to these risk adjustment practices, and have entered into a tolling agreement with the Civil Division of the DOJ related to its investigation. We are analyzing the scope of potential data corrections to be submitted to CMS and have begun to submit data corrections to CMS. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for, among other things, breach of healthcare and financial representation provisions, based on the conduct discovered during our investigation. While certain elements of the escrow claims were resolved in the fourth quarter of 2021, litigation in the Delaware Court of Chancery related to the remaining indemnity claims for escrowed funds remains ongoing.
Other Contingencies
From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (“HMOs”) and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.
In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.
Contractual Obligations and Commitments
In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through June 2025. The new agreement supersedes certain prior agreements for such services and includes provisions for additional services not provided under those agreements. Our remaining commitment under this agreement at September 30, 2022 is approximately $830. We will have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination fees.
In the second quarter of 2019, we began using our pharmacy benefits manager IngenioRx to market and offer PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. The comprehensive PBM services portfolio includes, but is not limited to, formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities. IngenioRx delegates certain PBM administrative functions, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement. With IngenioRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy.
12.     Capital Stock
Use of Capital – Dividends and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
-31-

A summary of our cash dividend activity for the nine months ended September 30, 2022 and 2021 is as follows: 
Declaration DateRecord DatePayment Date
Cash
Dividend
per Share
Total
Nine Months Ended September 30, 2022
January 25, 2022March 10, 2022March 25, 2022$1.28$309 
April 19, 2022June 10, 2022June 24, 2022$1.28$309 
July 19, 2022September 9, 2022September 23, 2022$1.28$306 
Nine Months Ended September 30, 2021
January 26, 2021March 10, 2021March 25, 2021$1.13$277 
April 20, 2021June 10, 2021June 25, 2021$1.13$278 
July 20, 2021September 10, 2021September 24, 2021$1.13$276 
On October 18, 2022, our Audit Committee declared a fourth quarter 2022 dividend to shareholders of $1.28 per share, payable on December 21, 2022 to shareholders of record at the close of business on December 5, 2022.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 26, 2021, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to the common stock repurchase program. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are effected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.
A summary of common stock repurchases for the nine months ended September 30, 2022 and 2021 is as follows:
Nine Months Ended September 30
 20222021
Shares repurchased3.7 3.9 
Average price per share$473.36 $356.43 
Aggregate cost$1,748 $1,378 
Authorization remaining at the end of the period$2,444 $4,714 
For additional information regarding the use of capital for debt security repurchases, see Note 10, “Debt,” included in this Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K.
-32-

Stock Incentive Plans
A summary of stock option activity for the nine months ended September 30, 2022 is as follows:
Number of
Shares		Weighted-
Average
Option Price
per Share		Weighted-
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding at January 1, 20222.9 $255.50 
Granted0.5 452.34 
Exercised(0.4)243.39 
Forfeited or expired(0.1)339.52 
Outstanding at September 30, 20222.9 291.95 6.56$477 
Exercisable at September 30, 20221.7 239.27 5.35$370 
A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the nine months ended September 30, 2022 is as follows:
Restricted
Stock Shares
and Units		Weighted-
Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 20221.3 $299.65 
Granted0.6 453.16 
Vested(0.6)301.44 
Forfeited(0.1)345.25 
Nonvested at September 30, 20221.2 356.33 
During the nine months ended September 30, 2022, we granted approximately 0.2 restricted stock units that are contingent upon us achieving earnings targets over the three year period from 2022 to 2024. These grants have been included in the activity shown above, but will be subject to adjustment at the end of 2024 based on results in the three year period.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed discussion of our stock incentive plan fair value methodology, see Note 15, “Capital Stock,” to our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K.
The following weighted-average assumptions were used to estimate the fair values of options granted during the nine months ended September 30, 2022 and 2021:
Nine Months Ended September 30
20222021
Risk-free interest rate1.97 %1.44 %
Volatility factor29.00 %30.00 %
Quarterly dividend yield0.282 %0.360 %
Weighted-average expected life (years)5.105.50
-33-

The following weighted-average fair values per option or share were determined for the nine months ended September 30, 2022 and 2021: 
Nine Months Ended September 30
20222021
Options granted during the period$116.85 $79.51 
Restricted stock awards granted during the period453.16 315.54 
-34-

13.     Accumulated Other Comprehensive Loss
A reconciliation of the components of accumulated other comprehensive loss at September 30, 2022 and 2021 is as follows:
Three Months Ended
September 30		Nine Months Ended
September 30
2022202120222021
Net unrealized investment (losses) gains:
Beginning of period balance$(1,489)$762 $494 $949 
Other comprehensive loss before reclassifications, net of tax benefit of $220, $25, $896 and $71, respectively
(719)(80)(2,914)(203)
Amounts reclassified from accumulated other comprehensive loss, net of tax (expense) benefit of $(21), $5, $(75) and $21, respectively
80 (17)284 (81)
Other comprehensive loss(639)(97)(2,630)(284)
Other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(1), $0, $(4) and $(1), respectively
3 1 11 1 
End of period balance(2,125)666 (2,125)666 
Non-credit components of impairments on investments:
Beginning of period balance(2)— — (2)
Other comprehensive (loss) income, net of tax benefit (expense) of $0, $0, $1 and $(1), respectively
(1)(1)(3)1 
End of period balance(3)(1)(3)(1)
Net cash flow hedges:
Beginning of period balance(233)(244)(239)(250)
Other comprehensive income, net of tax expense of $0, $0, $(2) and $(2), respectively
2 4 8 10 
End of period balance(231)(240)(231)(240)
Pension and other postretirement benefits:
Beginning of period balance(413)(534)(429)(552)
Other comprehensive income, net of tax expense of $(3), $(4), $(9) and $(10), respectively
7 8 23 26 
End of period balance(406)(526)(406)(526)
Foreign currency translation adjustments:
Beginning of period balance(12)(1)(4)5 
Other comprehensive loss, net of tax benefit of $2, $1, $4 and $2, respectively
(7)(1)(15)(7)
End of period balance(19)(2)(19)(2)
Total:
Total beginning of period accumulated other comprehensive (loss)(2,149)(17)(178)150 
Total other comprehensive loss, net of tax benefit of $198, $27, $815 and $81, respectively
(638)(87)(2,617)(254)
Total other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(1), $0, $(4) and $(1), respectively
3 1 11 1 
Total end of period accumulated other comprehensive loss$(2,784)$(103)$(2,784)$(103)
-35-

14.     Earnings per Share
The denominator for basic and diluted earnings per share for the three and nine months ended September 30, 2022 and 2021 is as follows:
 Three Months Ended 
 September 30		Nine Months Ended 
 September 30
 2022202120222021
Denominator for basic earnings per share – weighted-average shares
239.6 243.4 240.5 244.3 
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures
2.6 2.6 2.8 2.9 
Denominator for diluted earnings per share
242.2 246.0 243.3 247.2 
During the three months ended September 30, 2022 and 2021, weighted-average shares related to certain stock options of 0.5 and 0.0, respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive. During the nine months ended September 30, 2022 and 2021, weighted-average shares related to certain stock options of 0.4 and 0.3, respectively, were excluded from each of the denominators for diluted earnings per share because the stock options were anti-dilutive.
During the three and nine months ended September 30, 2022, we issued approximately 0.0 and 0.6 restricted stock units under our stock incentive plans, 0.0 and 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three year period of 2022 through 2024. During the three and nine months ended September 30, 2021, we issued approximately 0.1 and 1.0 restricted stock units under our stock incentive plans, 0.0 and 0.3 of which vesting is contingent upon us meeting specified annual earnings targets for the three year period of 2021 through 2023. The contingent restricted stock units have been excluded from the denominators for diluted earnings per share and will be included only if and when the contingency is met.
15.     Segment Information
As discussed in Note 1 “Organization”, we will be organizing our brand portfolio into three core go-to-market brands over the next several years. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner, and given this evolution we are in the process of reviewing and modifying how we will manage our businesses in the future. Currently, there are no changes to our segments associated with this branding strategy. The results of our operations continue to be described through four reportable segments: Commercial & Specialty Business, Government Business, IngenioRx and Other.
Our Commercial & Specialty Business segment offers plans and services to our Individual, Group risk-based, Group fee-based and BlueCard® members. The Commercial & Specialty Business segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as dental, vision, life, disability and supplemental health insurance benefits.
Our Government Business segment includes our Medicare and Medicaid businesses, National Government Services, and services provided to the federal government in connection with the FEHB program.
Our IngenioRx segment includes our PBM business. IngenioRx markets and offers PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. IngenioRx has a comprehensive PBM services portfolio, which includes services such as formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities.
Our Other segment includes our Diversified Business Group, now known as Carelon, which is our health services business focused on lowering the cost and improving the quality of healthcare by enabling and creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic conditions. This segment also includes certain eliminations and corporate expenses not allocated to our other reportable segments.
-36-

We define operating revenues to include premium income, product revenue and administrative fees and other revenues. Operating revenues are derived from premiums and fees received, primarily from the sale and administration of health benefits and pharmacy products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative expense.
Affiliated revenues represent revenues or cost for services provided to our subsidiaries by IngenioRx and Carelon, formerly known as our Diversified Business Group, as well as certain back-office services provided by our international businesses, and are recorded at cost or management’s estimate of fair market value. These affiliated revenues are eliminated in consolidation.
Financial data by reportable segment for the three and nine months ended September 30, 2022 and 2021 is as follows:
Commercial
& Specialty
Business		Government
Business		IngenioRxOtherEliminationsTotal
Three Months Ended September 30, 2022
Operating revenue - unaffiliated$10,494 $24,571 $3,971 $589 $— $39,625 
Operating revenue - affiliated— — 3,278 2,776 (6,054)— 
Operating gain785 868 516 101 — 2,270 
Three Months Ended September 30, 2021
Operating revenue - unaffiliated$9,863 $21,658 $3,369 $658 $— $35,548 
Operating revenue - affiliated— — 3,180 2,012 (5,192)— 
Operating gain620 967 445 27 — 2,059 
Nine Months Ended September 30, 2022
Operating revenue - unaffiliated$31,324 $72,164 $10,838 $1,667 $— $115,993 
Operating revenue - affiliated— — 10,165 8,217 (18,382)— 
Operating gain2,673 2,653 1,393 365 — 7,084 
Nine Months Ended September 30, 2021
Operating revenue - unaffiliated$28,904 $61,007 $9,131 $1,883 $— $100,925 
Operating revenue - affiliated— — 9,499 5,674 (15,173)— 
Operating gain2,679 2,313 1,257 52 — 6,301 
-37-

The major product revenues for each of the reportable segments for the three and nine months ended September 30, 2022 and 2021 are as follows:
Three Months Ended 
 September 30		Nine Months Ended 
 September 30
2022202120222021
Commercial & Specialty Business
Managed care products
$8,478 $8,005 $25,500 $23,481 
Managed care services
1,610 1,489 4,618 4,291 
Dental/Vision products and services
360 342 1,075 1,013 
Other
46 27 131 119 
Total Commercial & Specialty Business
10,494 9,863 31,324 28,904 
Government Business
Managed care products
24,456 21,565 71,823 60,711 
Managed care services
115 93 341 296 
Total Government Business
24,571 21,658 72,164 61,007 
IngenioRx
Pharmacy products and services7,249 6,549 21,003 18,630 
Other
Integrated health services3,153 2,506 9,083 7,121 
Other
212 164 801 436 
Total Other3,365 2,670 9,884 7,557 
Eliminations
Eliminations
(6,054)(5,192)(18,382)(15,173)
Total product revenues
$39,625 $35,548 $115,993 $100,925 
The classification between managed care products and managed care services in the above table primarily distinguishes between the levels of risk assumed. Managed care products represent insurance products where we bear the insurance risk, whereas managed care services represent product offerings where we provide claims adjudication and other administrative services to the customer, but the customer principally bears the insurance risk. 
A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and nine months ended September 30, 2022 and 2021 is as follows:
 Three Months Ended 
 September 30		Nine Months Ended 
 September 30
 2022202120222021
Reportable segments’ operating revenue$39,625 $35,548 $115,993 $100,925 
Net investment income371 335 1,112 1,026 
Net (losses) gains on financial instruments(57)(61)(439)107 
Total revenues$39,939 $35,822 $116,666 $102,058 
-38-

A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three and nine months ended September 30, 2022 and 2021 is as follows:
 Three Months Ended 
 September 30		Nine Months Ended 
 September 30
 2022202120222021
Income before income tax expense$2,146 $1,996 $6,615 $6,525 
Net investment income(371)(335)(1,112)(1,026)
Net losses (gains) on financial instruments57 61 439 (107)
Interest expense213 201 622 598 
Amortization of other intangible assets225 136 520 306 
Loss on extinguishment of debt— — — 5 
Reportable segments’ operating gain$2,270 $2,059 $7,084 $6,301 
16.     Leases
We lease office space and certain computer and related equipment using noncancellable operating leases. Our leases have remaining lease terms of 1 year to 12 years.
The information related to our leases is as follows:
Balance Sheet LocationSeptember 30, 2022December 31, 2021
Operating Leases
Right-of-use assetsOther noncurrent assets$600 $628 
Lease liabilities, currentOther current liabilities182 133 
Lease liabilities, noncurrentOther noncurrent liabilities739 864 
Three Months Ended 
 September 30		Nine Months Ended 
 September 30
2022202120222021
Lease Expense
Operating lease expense$35 $37 $100 $100 
Short-term lease expense11 10 35 34 
Sublease income(1)(1)(3)(3)
Total lease expense$45 $46 $132 $131 
Other information
 Operating cash paid for amounts included in the measurement of lease liabilities, operating leases$53 $53 $158 $141 
Right-of-use assets obtained in exchange for new lease liabilities, operating leases$23 $32 $62 $192 
As of September 30, 2022 and December 31, 2021, the weighted average remaining lease term of our operating leases was 7 years for each period. The lease liabilities reflect a weighted average discount rate of 2.79% at September 30, 2022 and 2.69% at December 31, 2021.
-39-

Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows:
2022 (excluding the nine months ended September 30, 2022)$54 
2023207 
2024179 
2025142 
2026105 
Thereafter345 
Total future minimum payments 1,032 
Less imputed interest(111)
Total lease liabilities$921 
As of September 30, 2022, we have no new leases which will commence during the fourth quarter of 2022.
17. Goodwill and Other Intangible Assets
A summary of the change in the carrying amount of goodwill for our segments (see Note 15, “Segment Information”) for 2022 and 2021 is as follows:
Commercial
& Specialty
Business		Government
Business		IngenioRxOtherTotal
Balance as of January 1, 2021$11,593 $8,331 $48 $1,719 $21,691 
Acquisitions and adjustments— 2,018 11 508 2,537 
Balance as of December 31, 202111,593 10,349 59 2,227 24,228 
Acquisitions and adjustments18 126 — 9 153 
Balance as of September 30, 2022$11,611 $10,475 $59 $2,236 $24,381 
Accumulated impairment as of September 30, 2022$— $— $— $— $— 
The components of other intangible assets as of September 30, 2022 and December 31, 2021 are as follows:
 September 30, 2022December 31, 2021
Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount
Intangible assets with finite lives:
Customer relationships$5,791 $(3,580)$2,211 $5,598 $(3,236)$2,362 
Provider and hospital relationships326 (142)184 324 (129)195 
Other920 (310)610 610 (141)469 
Total7,037 (4,032)3,005 6,532 (3,506)3,026 
Intangible assets with indefinite lives:
Blue Cross and Blue Shield and other trademarks5,991 — 5,991 6,299 — 6,299 
State Medicaid licenses1,540 — 1,540 1,290 — 1,290 
Total7,531 — 7,531 7,589 — 7,589 
Other intangible assets$14,568 $(4,032)$10,536 $14,121 $(3,506)$10,615 
-40-

During the nine months ended September 30, 2022, we recorded intangible assets related to Integra and also reclassified $308 of trademarks with indefinite lives to intangible assets with finite lives - Other, which relates to our new branding strategy. In addition, the amortization period of certain intangible assets was shortened to align with the anticipated dates the new branding will take place.
Intangible assets, along with the related accumulated amortization, are removed from the table above at the end of the fiscal year in which they become fully amortized.
As of September 30, 2022, the estimated amortization expense for the year ending December 31, 2022 and each of the five succeeding years is as follows: 2022, $748; 2023, $735; 2024, $370; 2025, $311; 2026, $258; and 2027, $219.
-41-


ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
(In Millions, Except Per Share Data or as Otherwise Stated Herein)
On May 18, 2022, our shareholders approved a proposal to amend our amended and restated articles of incorporation to change our name from Anthem, Inc. to Elevance Health, Inc. This amendment and name change went into effect on June 27, 2022. We began operating as Elevance Health, Inc. and trading under our new ticker symbol “ELV” on June 28, 2022. References to the terms “we,” “our,” “us,” or “Elevance Health” used throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context otherwise requires.
This MD&A should be read in conjunction with the accompanying consolidated financial statements and notes, our consolidated financial statements and notes as of and for the year ended December 31, 2021 and the MD&A included in our 2021 Annual Report on Form 10-K.
Results of operations, cost of care trends, investment yields and other measures for the three and nine months ended September 30, 2022 are not necessarily indicative of the results and trends that may be expected for the full year ending December 31, 2022, or any other period.
Overview
Elevance Health is a health company with the purpose of improving the health of humanity. We are the largest health insurer in the United States in terms of medical membership, serving over 47 million medical members through our affiliated health plans as of September 30, 2022. We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. In addition, we conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, Integra Managed Care, MMM, Optimum HealthCare, Simply Healthcare, and/or UniCare. We offer pharmacy benefits management (“PBM”) services through our IngenioRx, Inc. (“IngenioRx”) subsidiary. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.
As part of our name change to Elevance Health, on June 15, 2022 we announced that over the next several years we will organize our brand portfolio into the following core go-to-market brands:
•Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;
•Wellpoint — we intend to unite select non-BCBSA licensed Medicare, Medicaid and Commercial plans under the Wellpoint name; and
•Carelon — this brand will bring together our healthcare brands and capabilities, including our Diversified Business Group and IngenioRx business under a single brand name. We now refer to our Diversified Business Group as Carelon. In January 2023, IngenioRx will become CarelonRx.
There are currently no segment changes associated with this branding strategy. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner, and given this evolution we are in the process of reviewing and modifying how we will manage our businesses in the future.
For additional information about our organization, see Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in our 2021 Annual Report on Form 10-
-42-

K. Additional information on our segments can be found in this MD&A and in Note 15, “Segment Information” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
COVID-19
The COVID-19 pandemic continues to evolve, impacting the global economy, causing market instability and uncertainty in the labor market and putting pressure on the healthcare system, and it has impacted, and will likely continue to impact, our membership, benefit expense and member behavior, including how members access healthcare services. The full extent of the impact of the COVID-19 pandemic will depend on future developments, which are highly uncertain and cannot be predicted at this time. We will continue to monitor the COVID-19 pandemic as well as resulting legislative and regulatory changes to manage our response and assess and mitigate potential adverse impacts to our business. For additional discussion regarding our risks related to the COVID-19 pandemic and our other risk factors, see Part I, Item 1A, “Risk Factors” included in our 2021 Annual Report on Form 10-K.
Business Trends
We made the decision to modestly expand our participation in the Individual on-exchange products through state- or federally-facilitated marketplaces (the “Public Exchange”) for 2022 after also expanding in 2021. As a result, for 2022 we are offering Public Exchange products in 122 of the 143 rating regions in which we operate, in comparison to 103 of 143 rating regions in 2021. Our strategy has been, and will continue to be, to only participate in rating regions where we have an appropriate level of confidence that these markets are sustainable, given consideration to factors including, but not limited to, expected financial performance, regulatory environment and underlying market characteristics. Changes to our business environment are likely to continue as elected officials at the national and state levels continue to enact, and both elected officials and candidates for election continue to propose, significant modifications to existing laws and regulations, including changes to taxes and fees. In addition, the continuing growth in our government-sponsored business exposes us to increased regulatory oversight.
Our IngenioRx subsidiary markets and offers PBM services to our affiliated health plan customers throughout the country, as well as to customers outside of the health plans we own. Our comprehensive PBM services portfolio includes features such as formulary management, pharmacy networks, a prescription drug database, member services and mail order capabilities. IngenioRx delegates certain PBM administrative functions, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement. With IngenioRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy.
Pricing Trends: We strive to price our health benefit products consistent with anticipated underlying medical cost trends. We continue to closely monitor the COVID-19 pandemic (including new COVID-19 variants, which may be more contagious or severe, or less responsive to treatment or vaccines) and the impacts it may have on our pricing, such as surges in COVID-19 related hospitalizations, infection rates, the cost of COVID-19 vaccines, testing and treatment and the return of non-COVID-19 healthcare utilization to historical utilization patterns. We frequently make adjustments to respond to legislative and regulatory changes as well as pricing and other actions taken by existing competitors and new market entrants. Product pricing in our Commercial & Specialty Business segment, including our Individual and small group lines of business, remains competitive. Revenues from the Medicare and Medicaid programs are dependent, in whole or in part, upon annual funding from the federal government and/or applicable state governments.
Medical Cost Trends: Our medical cost trends are primarily driven by increases in the utilization of services across all provider types and the unit cost increases of these services. We work to mitigate these trends through various medical management programs such as care and condition management, program integrity and specialty pharmacy management and utilization management, as well as benefit design changes. There are many drivers of medical cost trends that can cause variance from our estimates, such as changes in the level and mix of services utilized, regulatory changes, aging of the population, health status and other demographic characteristics of our members, epidemics, pandemics, advances in medical technology, new high-cost prescription drugs, provider contracting inflation and healthcare provider or member fraud.
At its onset, the COVID-19 pandemic caused a decrease in utilization of non-COVID-19 health services, which decreased our claim costs in 2020. As the pandemic continued through 2021, our non-COVID-19 healthcare utilization
-43-

experience gradually increased and largely normalized. Our COVID-19 related healthcare expenses increased during 2021 as new variants (Delta and Omicron) emerged and vaccinations and boosters became available.
The COVID-19 surge quickly declined during the first quarter of 2022, with COVID-19 inpatient authorizations, provider-based tests, visits and vaccinations all decreasing to lower levels by the end of the first nine months of 2022; concurrently, non-COVID-19 healthcare utilization throughout the first nine months of 2022 recovered from lower levels earlier in the year. We expect the fourth quarter of 2022 will have higher claim costs related to a more normal flu season as well as incremental COVID-19 related healthcare expenses compared to the second and third quarters of 2022. The ongoing cost and volume of covered services related to the COVID-19 pandemic may have a material adverse effect on our future claim costs. We continue to closely monitor the COVID-19 pandemic and its impacts on our business, financial condition, results of operations and medical cost trends.
For additional discussion regarding business trends, see Part I, Item 1, “Business” included in our 2021 Annual Report on Form 10-K.
Regulatory Trends and Uncertainties
Federal and state governments have enacted, and may continue to enact, legislation and regulations in response to the COVID-19 pandemic that have had, and we expect will continue to have, a significant impact on health benefits, consumer eligibility for public programs and our cash flows for all lines of business and which have introduced increased uncertainty around our cost structure. These actions, which are or have been in effect for various durations, provide, among other things: mandates to waive cost-sharing for COVID-19 testing, vaccines and related services; financial support to healthcare providers; and mandates related to prior authorizations, payment levels to providers, consumer enrollment windows and telehealth services.
The current public health emergency (“PHE”) has been extended to January 2023. Medicaid eligibility recertification will resume when the PHE ends, meaning that if the PHE ends in January 2023, recertifications could begin as early as February 2023, but may not occur until later in certain states. When recertifications resume, we expect a decline in our Medicaid membership. At the same time, we expect growth in our Commercial risk-based and fee-based plans, including through the Public Exchange, as members exiting Medicaid in our fourteen Commercial states seek coverage elsewhere.
The Inflation Reduction Act of 2022 (the “Inflation Reduction Act”), which was signed into law in August 2022, contains a variety of provisions that impact our business including an extension of the American Rescue Plan Act of 2021’s enhanced Premium Tax Credits (“PTC”) through 2025; providing a one percent excise tax on repurchases of stock made after December 31, 2022; allowing the Centers for Medicare and Medicaid Services (“CMS”) to negotiate prices on a limited set of prescription drugs in Medicare Parts B and D beginning in 2026; instituting caps on insulin cost sharing in Medicare Parts B and D; redesigning of the Medicare Part D benefit; adding a requirement that drug manufacturers pay rebates if prices increase beyond inflation; and delaying implementation of the Trump Administration Medicare drug rebate rule to 2032. The extension of the enhanced PTC will likely allow for growth in Individual exchange market enrollment, as Medicaid eligibility recertifications resume, supporting continuity of coverage for more people.

The health plan price transparency regulations issued in October 2020 by the U.S. Departments of Health and Human Services, Labor and Treasury required us to begin disclosing in July 2022, on a monthly basis, detailed pricing information regarding negotiated rates for all covered items and services between the plan or issuer and in-network providers and historical payments to, and billed charges from, out-of-network providers. Additionally, beginning in 2023, we will be required to make available to members personalized out-of-pocket cost information and the underlying negotiated rates for 500 covered healthcare items and services, including prescription drugs. In 2024, this requirement will expand to all items and services.
The Consolidated Appropriations Act of 2021 (the “Appropriations Act”) has impacted and in the future may have a material effect upon our business, including procedures and coverage requirements related to surprise medical bills and new mandates for continuity of care for certain patients, price comparison tools, disclosure of broker compensation, mental health parity reporting, and reporting on pharmacy benefits and drug costs. The requirements of the Appropriations Act applicable to us have varying effective dates, some of which were effective in December 2021 and others that have been extended since the enactment of the Appropriations Act.
-44-

Since its enactment in 2010, the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively, the “ACA”), has introduced new risks, regulatory challenges and uncertainties, has impacted our business model and strategy and has required changes in the way our products are designed, underwritten, priced, distributed and administered. We expect the ACA will continue to significantly impact our business and results of operations, including pricing, minimum medical loss ratios and the geographies in which our products are available, and as a result of future modifications of, and guidance by federal regulatory agencies related to, the ACA and our businesses more broadly. We will continue to evaluate the impact of the ACA as any further developments occur.

For additional discussion regarding regulatory trends and uncertainties and risk factors, see Part I, Item 1, “Business – Regulation”, Part I, Item 1A, “Risk Factors”, and the “Regulatory Trends and Uncertainties” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2021 Annual Report on Form 10-K.
Other Significant Items
Business and Operational Matters
As mentioned above, we began operating as Elevance Health on June 28, 2022. This name change is intended to better reflect our business and our journey from a traditional health benefits organization to a lifetime, trusted health partner. Elevance Health supports health at every stage, offering health plans and clinical, behavioral, pharmacy and complex-care solutions that promote whole health.
On May 5, 2022, we completed our acquisition of Integra Managed Care (“Integra”). Integra is a managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in their own homes.
On June 29, 2021, we completed our acquisition of MMM Holdings, LLC (“MMM”) and its Medicare Advantage plan, Medicaid plan and other affiliated companies. MMM is a Puerto Rico-based integrated healthcare organization and seeks to provide its Medicare Advantage and Medicaid members with a whole health experience through its network of specialized clinics and wholly owned independent physician associations. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve.
On April 28, 2021, we completed our acquisition of myNEXUS, Inc. (“myNEXUS”). myNEXUS is a comprehensive home-based nursing management company for payors and, at the time of acquisition, delivered integrated clinical support services for Medicare Advantage members across twenty states. This acquisition aligns with our strategy to manage integrated, whole person multi-site care and support by providing national, large-scale expertise to manage nursing services in the home and facilitate transitions of care.
For additional information, see Note 3, “Business Acquisitions,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
In 2020, we introduced enterprise-wide initiatives to optimize our business and as a result, recorded a charge of $653 in selling, general and administrative expenses. We believe these initiatives largely represent the next step forward in our progression towards becoming a more agile organization, including process automation and a reduction in our office space footprint. In the fourth quarter of 2021, we identified additional office space reductions and related fixed asset impairments due to the continuing COVID-19 pandemic and recorded a charge of $202 in selling, general and administrative expenses. For additional information, see Note 4, “Business Optimization Initiatives,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Litigation Matters
In the consolidated multi-district proceeding in the United States District Court for the Northern District of Alabama (the “Court”) captioned In re Blue Cross Blue Shield Antitrust Litigation (“BCBSA Litigation”), the BCBSA and Blue Cross and/or Blue Shield licensees, including us (the “Blue plans”) previously approved a settlement agreement and release with the plaintiffs representing a putative nationwide class of health plan subscribers (the “Subscriber Settlement Agreement”), which
-45-

agreement required the Court’s approval to become effective. Generally, the lawsuits in the BCBSA Litigation challenge elements of the licensing agreements between the BCBSA and the independently owned and operated Blue plans. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers. The Subscriber Settlement Agreement applies only to the putative subscriber class. No settlement agreement has been reached with the provider plaintiffs at this time, and the defendants continue to contest the consolidated cases brought by the provider plaintiffs.

In August 2022, the Court approved the Subscriber Settlement Agreement. In compliance with the Subscriber Settlement Agreement, in September 2022 the Company paid its remaining $506 portion of the settlement fund into an escrow account, for an aggregate settlement payment by the Company of $596. Four notices of appeal of the final approval order were filed by the September 2022 deadline. After all appellate rights have been exhausted in a manner that affirms the Court’s final order and judgment, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective. For additional information regarding the BCBSA Litigation, see Note 11, “Commitments and Contingencies – Litigation and Regulatory Proceedings – Blue Cross Blue Shield Antitrust Litigation,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Selected Operating Performance
For the twelve months ended September 30, 2022, total medical membership increased by 2.2 million, or 4.9%. Our membership increase was primarily driven by organic growth in our Commercial & Specialty Business segment, and in particular in our Group fee-based membership, and organic growth in our Government Business segment primarily driven by the continued temporary suspension of Medicaid eligibility recertification during the COVID-19 pandemic.

Operating revenue for the three months ended September 30, 2022 was $39,625, an increase of $4,077, or 11.5%, from the three months ended September 30, 2021. Operating revenue increased primarily as a result of higher premium revenue in our Medicaid business, including due to membership growth from the continued temporary suspension of Medicaid eligibility recertification during the COVID-19 pandemic, the acquisition of Integra in the second quarter of 2022 and the acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022. Premium rate increases to cover medical cost trends and membership growth in our Medicare Advantage and Commercial & Specialty Business risk-based businesses also generated higher premium revenue. Finally, the increase in operating revenue was further attributable to increased pharmacy product revenue in our IngenioRx segment, resulting from growth in membership and higher script volume.
Operating revenue for the nine months ended September 30, 2022 was $115,993, an increase of $15,068, or 14.9%, from the nine months ended September 30, 2021. This increase in operating revenue was primarily driven by higher premium revenue in our Medicaid business, as noted above, the acquisition of MMM in the second quarter of 2021 and the retroactive reinstatement of a Medicaid directed payment program. Membership growth and premium rate increases to cover medical cost trends in our Medicare Advantage and Commercial & Specialty Business risk-based businesses also generated higher premium revenue. Finally, the increase in operating revenue was further attributable to increased pharmacy product revenue in our IngenioRx segment resulting from higher script volume, the acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022 and the acquisition of Integra in the second quarter of 2022.
Net income for the three months ended September 30, 2022 was $1,613, an increase of $111, or 7.4%, from the three months ended September 30, 2021. The increase in net income was primarily due to operating gain increases in our Commercial & Specialty Business, Other and IngenioRx segments, partially offset by increased intangible amortization in 2022 related to recent acquisitions and the rebranding of our products, as we expect to retire certain trade names in the future, and a decline in our Government Business segment operating results.
Net income for the nine months ended September 30, 2022 was $5,058, an increase of $88, or 1.8%, from the nine months ended September 30, 2021. The increase in net income was primarily due to operating gain increases in our Government Business, Other and IngenioRx segments, partially offset by losses on financial instruments in 2022 as compared to gains in 2021 and increased intangible amortization in 2022 related to recent acquisitions and the rebranding of our products, as we expect to retire certain trade names in the future. Our Commercial & Specialty Business segment had a slight decline year over year.
-46-

Our fully-diluted shareholders’ earnings per share (“EPS”) was $6.68 for the three months ended September 30, 2022, which represented a 9.0% increase from EPS of $6.13 for the three months ended September 30, 2021. Our diluted shares for the three months ended September 30, 2022 were 242.2, a decrease of 3.8, or 1.5%, compared to the three months ended September 30, 2021. The increase in EPS for the three months ended September 30, 2022 resulted primarily from increased shareholders’ income, as well as from the impact of fewer diluted shares outstanding.
Our fully-diluted shareholders’ EPS was $20.86 for the nine months ended September 30, 2022, which represented a 3.8% increase from fully-diluted EPS of $20.09 for the nine months ended September 30, 2021. Our diluted shares for the nine months ended September 30, 2022 were 243.3, a decrease of 3.9, or 1.6%, compared to the nine months ended September 30, 2021. The increase in EPS for the nine months ended September 30, 2022 resulted primarily from increased shareholders’ income, as well as from the impact of fewer diluted shares outstanding.
Operating cash flow for the nine months ended September 30, 2022 and 2021 was $9,917 and $6,692, respectively. The increase was primarily due to the timing of CMS payments received in the current year, partially offset by the Subscriber Settlement Agreement payment made in September 2022.
Membership
The following table presents our medical membership by reportable segment and customer type as of September 30, 2022 and 2021. Also included below is other membership by product. The medical membership and other membership data presented are unaudited and in certain instances include estimates of the number of members represented by each contract at the end of the period. For a more detailed description of our medical membership, see the “Membership” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2021 Annual Report on Form 10-K.
  
September 30  
(In thousands)20222021Change% Change
Medical Membership
Commercial & Specialty Business:
Individual800 769 314.0 %
Group Risk-Based3,988 3,946 421.1 %
Commercial Risk-Based4,788 4,715 731.5 %
BlueCard®
6,453 6,166 2874.7 %
Group Fee-Based20,184 19,370 8144.2 %
Commercial Fee-Based26,637 25,536 1,101 4.3 %
Total Commercial & Specialty Business31,425 30,251 1,174 3.9 %
Government Business:
Medicare Advantage1,969 1,853 1166.3 %
Medicare Supplement945 947 (2)(0.2)%
Total Medicare2,914 2,800 114 4.1 %
Medicaid11,319 10,391 9288.9 %
Federal Employees Health Benefits1,625 1,629 (4)(0.2)%
Total Government Business15,858 14,820 1,0387.0 %
Total Medical Membership47,283 45,071 2,2124.9 %
Other Membership
Life and Disability Members4,796 4,695 101 2.2 %
Dental Members6,655 6,637 18 0.3 %
Dental Administration Members1,577 1,486 91 6.1 %
Vision Members9,628 7,974 1,654 20.7 %
Medicare Part D Standalone Members274 438 (164)(37.4)%
-47-

Medical Membership
Medical membership increased in both our Commercial & Specialty Business and Government Business segments primarily due to organic growth. Our Commercial & Specialty Business segment experienced organic growth in our Group fee-based and risk-based membership as sales exceeded lapses. BlueCard® membership increased due to favorable membership activity at other BCBSA plans whose members reside in or travel to our licensed areas. Individual membership increased due to our Public Exchange expansion in 2022. Our Government Business segment organic growth was primarily driven by the continued temporary suspension of Medicaid eligibility recertification during the COVID-19 pandemic. In addition, Medicaid membership was positively impacted by the acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022 and the acquisition of Integra in the second quarter of 2022. Medicare Advantage organic growth due to sales exceeding lapses also contributed to the overall Government Business segment growth.
Other Membership
Our other membership can be impacted by changes in our medical membership, as our medical members often purchase our other products that are ancillary to our health business. Life and disability membership increased primarily due to new sales of disability products, partially offset by lapses and negative in-group change of life membership. Dental membership increased primarily due to sales exceeding lapses in our Group risk-based accounts and penetration increases in our Federal Employees Health Benefits (“FEHB”) program, partially offset by the loss of a significant Group fee-based account. Dental administration membership increased primarily due to increased sales to other BCBS plans associated with the FEHB program. Vision membership increased primarily due to the launch of a new entry level vision product in our Group markets. Medicare Part D Standalone membership declined as we discontinued certain legacy products.
-48-

Consolidated Results of Operations
Our consolidated summarized results of operations and other financial information for the three and nine months ended September 30, 2022 and 2021 are as follows: 
Three Months Ended 
 September 30		Nine Months Ended 
 September 30		Change
Three Months Ended 
 September 30		Nine Months Ended 
 September 30
2022 vs. 20212022 vs. 2021
2022202120222021$%$%
Total operating revenue$39,625$35,548$115,993$100,925$4,077 11.5 %$15,068 14.9 %
Net investment income3713351,1121,02636 10.7 %86 8.4 %
Net (losses) gains on financial instruments(57)(61)(439)1074 NM(546)NM
Total revenues39,93935,822116,666102,0584,117 11.5 %14,608 14.3 %
Benefit expense29,40426,64586,39675,1072,759 10.4 %11,289 15.0 %
Cost of products sold3,4372,8989,3897,825539 18.6 %1,564 20.0 %
Selling, general and administrative expense4,5143,94613,12411,692568 14.4 %1,432 12.2 %
Other expense1 
4383371,142909101 30.0 %233 25.6 %
Total expenses37,79333,826110,05195,5333,967 11.7 %14,518 15.2 %
Income before income tax expense2,1461,9966,6156,525150 7.5 %90 1.4 %
Income tax expense5334941,5571,55539 7.9 %2 0.1 %
Net income$1,613$1,502$5,058$4,970$111 7.4 %$88 1.8 %
Net loss (income) attributable to noncontrolling interests5718(3)(2)NM21 NM
Shareholders’ net income$1,618$1,509$5,076$4,967$109 7.2 %$109 2.2 %
Average diluted shares outstanding242.2246.0243.3247.2(3.8)(1.5)%(3.9)(1.6)%
Diluted shareholders’ net income per share$6.68$6.13$20.86$20.09$0.55 9.0 %$0.77 3.8 %
Effective tax rate24.8 %24.7 %23.5 %23.8 %
10 bp3
(30) bp3
Benefit expense ratio2
87.2 %87.7 %86.8 %86.7 %
(50) bp3
10 bp3
Selling, general and administrative expense ratio4
11.4 %11.1 %11.3 %11.6 %
30 bp3
(30) bp3
Income before income tax expense as a percentage of total revenues5.4 %5.6 %5.7 %6.4 %
(20) bp3
(70) bp3
Shareholders’ net income as a percentage of total revenues4.0 %4.2 %4.3 %4.9 %
(20) bp3
(60) bp3
Certain of the following definitions are also applicable to all other results of operations tables in this discussion:
NM    Not meaningful.
1    Includes interest expense, amortization of other intangible assets and loss on extinguishment of debt.
2    Benefit expense ratio represents benefit expense as a percentage of premium revenue. Premiums for the three months ended September 30, 2022 and 2021 were $33,722 and $30,395, respectively. Premiums for the nine months ended September 30, 2022 and 2021 were $99,583 and $86,604, respectively.
3    bp = basis point; one hundred basis points = 1%.
4    Selling, general and administrative expense ratio represents selling, general and administrative expense as a percentage of total operating revenue.
Three Months Ended September 30, 2022 Compared to the Three Months Ended September 30, 2021
Total operating revenue increased primarily as a result of higher premium revenue in our Medicaid business due to membership growth from the continued temporary suspension of Medicaid eligibility recertification during the COVID-19 pandemic, the acquisition of Integra in the second quarter of 2022 and the acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022. Membership growth in our Medicare Advantage and Commercial & Specialty Business risk-based businesses, as well as premium rate increases to cover medical cost trends also generated higher premium revenue. Finally, the increase in operating revenue was further attributable to increased pharmacy product revenue in our IngenioRx segment, resulting from growth in membership and higher script volume.
-49-

Net investment income increased primarily due to higher income from fixed maturity securities, partially offset by reduced investment income from alternative investments.
Benefit expense increased primarily due to healthcare costs associated with organic membership growth in our Medicaid and Medicare businesses, the acquisition of Integra in the second quarter of 2022 and the acquisition of Ohio Medicaid members in the first quarter of 2022 through the purchase of a Medicaid contract. Membership growth in our Commercial risk-based business also contributed to the increased benefit expense.
Our benefit expense ratio decreased and was driven by the realignment of certain quality improvement costs from benefit expense to administrative expense. Excluding the realignment, our benefit expense ratio would have been approximately flat year-over-year.
Cost of products sold reflects the cost of pharmaceuticals dispensed by IngenioRx for our unaffiliated PBM customers. Cost of products sold increased as the corresponding pharmacy product revenues increased.
Selling, general and administrative expense increased primarily due to increased costs to support growth and the prior period realignment of certain quality improvement costs from benefit expense to administrative expense described above.
Our selling, general and administrative expense ratio increased primarily due to increased costs to support membership growth and the prior period realignment of certain quality improvement costs from benefit expense to administrative expense, partially offset by the impact of operating revenue growth in 2022.
Other expense increased primarily due to additional amortization of intangible assets related to recent acquisitions and the rebranding of our products. The amortization period of certain intangible assets was shortened to align with anticipated dates the new branding will take place. In addition, certain indefinite-lived intangible assets have been reclassified as definite-lived, and therefore, are now being amortized. For additional information regarding intangible asset amortization, see Note 17, “Goodwill and Other Intangible Assets,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Our shareholders’ net income as a percentage of total revenues decreased in 2022 as compared to 2021 as a result of all factors discussed above.
Nine Months Ended September 30, 2022 Compared to the Nine Months Ended September 30, 2021
Total operating revenue increased primarily as a result of higher premium revenue in our Medicaid business due to membership growth from the continued temporary suspension of Medicaid eligibility recertification during the COVID-19 pandemic, the acquisition of MMM in the second quarter of 2021 and the retroactive reinstatement of a Medicaid directed payment program. Membership growth and premium rate increases to cover medical cost trends in our Medicare Advantage and Commercial & Specialty Business risk-based businesses also contributed to higher premium revenue. Finally, the increase in operating revenue was further attributable to increased pharmacy product revenue in our IngenioRx segment resulting from higher script volume, the acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022 and the acquisition of Integra in the second quarter of 2022.
Net investment income increased primarily due to higher income from fixed maturity securities, partially offset by reduced investment income from alternative investments.
We had net losses on financial instruments in the first nine months of 2022, as compared to net gains in the first nine months of 2021, as a result of increased net losses on fixed maturity securities, reduced gains on sales of equity securities and increased mark-to-market losses on equity securities still held, partially offset by increased net gains in other investments.
Benefit expense increased primarily due to healthcare costs associated with organic membership growth in our Medicaid and Medicare businesses, the acquisition of MMM in the second quarter of 2021 and the retroactive reinstatement of a Medicaid directed payment program. Membership growth and higher healthcare costs in our Commercial risk-based business also contributed to the higher benefit expense. The increase in benefit expense was also attributable to the acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022 and the acquisition of Integra in the second quarter of 2022.
-50-

Our benefit expense ratio increased slightly primarily due to the impact of continued membership increases in our Government Business segment, which has a higher benefit expense ratio than our Commercial & Specialty Business segment.
Cost of products sold reflects the cost of pharmaceuticals dispensed by IngenioRx for our unaffiliated PBM customers. Cost of products sold increased as the corresponding pharmacy product revenues increased.
Selling, general and administrative expense increased primarily due to increased costs to support membership growth and from our acquisitions.
Our selling, general and administrative expense ratio decreased primarily due to operating revenue growth in 2022, partially offset by increased costs to support membership growth.
Other expense increased primarily due to additional amortization of intangible assets related to recent acquisitions and the rebranding of our products. The amortization period of certain intangible assets was shortened to align with anticipated dates the new branding will take place. In addition, certain indefinite-lived intangible assets have been reclassified as definite-lived, and therefore, are now being amortized. For additional information regarding intangible asset amortization, see Note 17, “Goodwill and Other Intangible Assets,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Our shareholders’ net income as a percentage of total revenues decreased in 2022 as compared to 2021 as a result of all factors discussed above.
Reportable Segments Results of Operations
Our results of operations discussed throughout this MD&A are determined in accordance with U.S. generally accepted accounting principles (“GAAP”). We also calculate operating gain and operating margin to further aid investors in understanding and analyzing our core operating results and comparing them among periods. We define operating revenue as premium income, product revenue and administrative fees and other revenue. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative expense. It does not include net investment income, net (losses) gains on financial instruments, interest expense, amortization of other intangible assets, loss on extinguishment of debt or income taxes, as these items are managed in our corporate shared service environment and are not the responsibility of operating segment management. Operating margin is calculated as operating gain divided by operating revenue. We use these measures as a basis for evaluating segment performance, allocating resources, forecasting future operating periods and setting incentive compensation targets. This information is not intended to be considered in isolation or as a substitute for income before income tax expense, shareholders’ net income or EPS prepared in accordance with GAAP, and may not be comparable to similarly titled measures reported by other companies. For a reconciliation of reportable segments’ operating revenue to the amounts of total revenue included in the consolidated statements of income and a reconciliation of income before income tax expense to reportable segments’ operating gain, see Note 15, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
As previously discussed, we will be organizing our brand portfolio into three core go-to-market brands over the next several years. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner, and given this evolution we are in the process of reviewing and modifying how we will manage our businesses in the future. There are currently no changes to our segments associated with this branding strategy. The results of our operations continue to be described through four reportable segments: Commercial & Specialty Business,
-51-

Government Business, IngenioRx and Other. For additional information, see Note 15, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
The following table presents a summary of the reportable segment financial information for the three and nine months ended September 30, 2022 and 2021:
 Three Months Ended 
 September 30		Nine Months Ended 
 September 30		Change
 Three Months Ended 
 September 30		Nine Months Ended 
 September 30
 2022 vs. 20212022 vs. 2021
 2022202120222021$%$%
Operating Revenue
Commercial & Specialty Business$10,494$9,863$31,324$28,904$631 6.4 %$2,420 8.4 %
Government Business24,57121,65872,16461,0072,913 13.4 %11,157 18.3 %
IngenioRx7,2496,54921,00318,630700 10.7 %2,373 12.7 %
Other3,3652,6709,8847,557695 26.0 %2,327 30.8 %
Eliminations (6,054)(5,192)(18,382)(15,173)(862)NM(3,209)NM
Total operating revenue$39,625$35,548$115,993$100,925$4,077 11.5 %$15,068 14.9 %
Operating Gain
Commercial & Specialty Business$785$620$2,673$2,679$165 26.6 %$(6)(0.2)%
Government Business8689672,6532,313(99)(10.2)%340 14.7 %
IngenioRx5164451,3931,25771 16.0 %136 10.8 %
Other101273655274 NM313 NM
Operating Margin
Commercial & Specialty Business7.5 %6.3 %8.5 %9.3 %120 bp(80) bp
Government Business3.5 %4.5 %3.7 %3.8 %(100) bp(10) bp
IngenioRx7.1 %6.8 %6.6 %6.7 %30 bp(10) bp
Three Months Ended September 30, 2022 Compared to the Three Months Ended September 30, 2021
Commercial & Specialty Business
Operating revenue increased primarily due to premium rate increases in our Commercial risk-based business designed to cover medical cost trends, higher premiums in our Commercial risk-based business due to membership growth and increased administrative fees in our Commercial fee-based business due to increased membership.
Operating gain increased primarily due to improved medical underwriting performance in our Commercial risk-based business, partially offset by increased costs to support membership growth.
Government Business
Operating revenue increased primarily as a result of higher premium revenue in our Medicaid business, including due to membership growth from the continued temporary suspension of Medicaid eligibility recertification during the COVID-19 pandemic, the acquisition of Integra during the second quarter of 2022 and the acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022. Membership growth and premium rate increases to cover medical cost trends in our Medicare Advantage business also increased premium revenue.
The decrease in operating gain was primarily driven by increased administrative costs to support growth in our Government Business, partially offset by increased gross profit in the period.
-52-

IngenioRx
Operating revenue increased primarily due to higher prescription volume, driven by growth in integrated medical and pharmacy members in 2022. Operating revenue also increased due to a favorable out of period adjustment to fee-based revenue in the third quarter of 2022.
The increase in operating gain was primarily driven by a favorable out of period adjustment to fee-based revenue in the third quarter of 2022 as well as the impact of higher prescription volume associated with growth in integrated medical and pharmacy members in 2022.
Other
Operating revenue increased primarily due to higher revenue for expanded services performed by Carelon for our Commercial & Specialty Business segment in 2022. These increases were partially offset by the reduction of external revenue due to the loss of a behavioral health contract.
Operating gain increased primarily due to improved performance in Carelon.
Nine Months Ended September 30, 2022 Compared to the Nine Months Ended September 30, 2021
Commercial & Specialty Business
Operating revenue increased primarily due to higher premiums in our Commercial risk-based business due to membership growth, premium rate increases in our Commercial risk-based business to cover medical cost trends and increased administrative fees in our Commercial fee-based business.
Operating gain decreased primarily due to the net unfavorable effect of COVID-19 in the first nine months of 2022 and increased spend to support growth. These impacts were partially offset by improved medical underwriting performance in our Commercial risk-based membership.
Government Business
Operating revenue increased primarily as a result of higher premium revenue in our Medicaid business, including due to membership growth from the continued temporary suspension of Medicaid eligibility recertification during the COVID-19 pandemic and the retroactive reinstatement of a Medicaid directed payment program. Membership growth and premium rate increases to cover medical cost trends in our Medicare Advantage business also contributed to premium revenue, as did the acquisition of MMM at the end of the second quarter of 2021, the acquisition of Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022 and the acquisition of Integra during the second quarter of 2022.
The increase in operating gain was primarily driven by premium rate increases to cover medical cost trends in our Medicare business, the acquisition of MMM in the second quarter of 2021 and organic membership growth in our Medicaid membership from the continued suspension of eligibility recertifications during the COVID-19 pandemic. These increases were partially offset by additional administrative spend to support the growth in our Government Business.
IngenioRx
Operating revenue increased as a result of higher prescription volume, driven by growth in integrated medical and pharmacy members in 2022.
The increase in operating gain was primarily a result of higher prescription volume, driven by growth in integrated medical and pharmacy members in 2022 and a favorable out of period adjustment to fee-based revenue in the third quarter of 2022. These increases were partially offset by the non-recurrence of a favorable out of period adjustment recorded in the first quarter of 2021 related to 2020.
-53-

Other
Operating revenue increased primarily due to higher revenue for expanded services performed by Carelon for our Commercial & Specialty Business segment in 2022. In addition, results in 2022 included revenue from myNEXUS for the full nine months of 2022, which was acquired in the second quarter of 2021. These increases were partially offset by the reduction of external revenue due to the loss of a behavioral health contract.
Operating gain increased primarily due to improved performance in Carelon and the acquisition of myNEXUS in 2021.
Critical Accounting Policies and Estimates
We prepare our consolidated financial statements in conformity with GAAP. Application of GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes and within this MD&A. We consider our most important accounting policies that require significant estimates and management judgment to be those policies with respect to liabilities for medical claims payable, income taxes, goodwill and other intangible assets, investments and retirement benefits. Our accounting policies related to these items are discussed in our 2021 Annual Report on Form 10-K in Note 2, “Basis of Presentation and Significant Accounting Policies,” to our audited consolidated financial statements as of and for the year ended December 31, 2021, as well as in the “Critical Accounting Policies and Estimates” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” As of September 30, 2022, our critical accounting policies and estimates have not changed from those described in our 2021 Annual Report on Form 10-K.
Medical Claims Payable
The most subjective accounting estimate in our consolidated financial statements is our liability for medical claims payable. Our accounting policies related to medical claims payable are discussed in the references cited above. As of September 30, 2022, our critical accounting policies and estimates related to medical claims payable have not changed from those described in our 2021 Annual Report on Form 10-K. For a reconciliation of the beginning and ending balance for medical claims payable for the nine months ended September 30, 2022 and 2021, see Note 9, “Medical Claims Payable,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the nine months ended September 30, 2022 and 2021, which are the trend and completion factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations. The impact from COVID-19 on healthcare utilization and medical claims submission patterns continues to provide increased estimation uncertainty on our incurred but not reported liability at September 30, 2022.
Favorable Developments by 
Changes in Key Assumptions
Nine Months Ended 
 September 30
20222021
Assumed trend factors$850 $1,443 
Assumed completion factors51 379 
Total$901 $1,822 
The favorable development recognized in the nine months ended September 30, 2022 and 2021 resulted primarily from trend factors in late 2021 and late 2020, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter part of 2020 developing faster than expected also contributed to the favorable development for the nine months ended September 30, 2021.
The ratio of current year medical claims paid as a percent of current year net medical claims incurred was 83.7% and 83.8% for the nine months ended September 30, 2022 and 2021, respectively. This ratio serves as an indicator of claims
-54-

processing speed whereby speed for claims payments was similar during the nine months ended September 30, 2022 as compared to the nine months ended September 30, 2021.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net medical claims payable less prior year redundancies in the current period in order to demonstrate the development of prior year reserves. For the nine months ended September 30, 2022, this metric was 7.3%, largely driven by favorable trend factor development at the end of 2021. For the nine months ended September 30, 2021, this metric was 19.7%, largely driven by favorable trend factor development at the end of 2020 as well as favorable completion factor development from 2020.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net incurred medical claims to indicate the percentage of redundancy included in the preceding year calculation of current year net incurred medical claims. We believe this calculation supports the reasonableness of our prior year estimate of incurred medical claims and the consistency in our methodology. For the nine months ended September 30, 2022, this metric was 0.9%, which was calculated using the redundancy of $901. For the nine months ended September 30, 2021, the comparable metric was 2.2%, which was calculated using the redundancy of $1,822. We believe these metrics demonstrate an appropriate level of reserve conservatism.
New Accounting Pronouncements
For information regarding new accounting pronouncements that were adopted and new accounting pronouncements that were issued during the nine months ended September 30, 2022, see the “Recently Adopted Accounting Guidance” and “Recent Accounting Guidance Not Yet Adopted” sections of Note 2, “Basis of Presentation and Significant Accounting Policies,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Liquidity and Capital Resources
Sources and Uses of Capital
Our cash receipts result primarily from premiums, product revenue, administrative fees and other revenue, investment income, proceeds from the sale or maturity of our investment securities, proceeds from borrowings, and proceeds from the issuance of common stock under our employee stock plans. Cash disbursements result mainly from claims payments, administrative expenses, taxes, purchases of investment securities, interest expense, payments on borrowings, acquisitions, capital expenditures, repurchases of our debt securities and common stock and the payment of cash dividends. Cash outflows fluctuate with the amount and timing of settlement of these transactions. Any future decline in our profitability would likely have an unfavorable impact on our liquidity.
For a more detailed overview of our liquidity and capital resources management, see the “Introduction” section included in the “Liquidity and Capital Resources” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2021 Annual Report on Form 10-K.
For additional information regarding our sources and uses of capital during the three and nine months ended September 30, 2022, see Note 6, “Derivative Financial Instruments,” Note 10, “Debt,” and Note 12, “Capital Stock – Use of Capital – Dividends and Stock Repurchase Program,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
-55-

Liquidity
A summary of our major sources and uses of cash and cash equivalents for the nine months ended September 30, 2022 and 2021 is as follows:
 Nine Months Ended 
 September 30		2022 vs. 2021
 20222021Change
Sources of Cash:
Net cash provided by operating activities$9,917 $6,692 $3,225 
Issuances of commercial paper and short- and long-term debt, net of repayments669 2,533 (1,864)
Proceeds from issuance of common stock under employee stock plans152 161 (9)
Other sources of cash, net23 173 (150)
Total sources of cash10,761 9,559 1,202 
Uses of Cash:
Purchases of investments, net of proceeds from sales, maturities, calls and redemptions(2,604)(3,403)799 
Purchases of subsidiaries, net of cash acquired(623)(3,442)2,819 
Repurchase and retirement of common stock(1,748)(1,378)(370)
Purchases of property and equipment(854)(747)(107)
Cash dividends(924)(831)(93)
Total uses of cash(6,753)(9,801)3,048 
Effect of foreign exchange rates on cash and cash equivalents(16)(9)(7)
Net increase (decrease) in cash and cash equivalents$3,992 $(251)$4,243 
The increase in net cash provided by operating activities was primarily due to the timing of CMS payments received in the current year, partially offset by the Subscriber Settlement Agreement payment made in September 2022.
Other significant changes in sources or uses of cash year-over-year included lower amounts for purchases of subsidiaries, net of cash acquired and reduced purchases of investments, net of proceeds from sales, maturities, calls and redemptions, partially offset by reduced proceeds from commercial paper and short- and long-term debt, net of repayments.
Financial Condition
We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and investments in fixed maturity and equity securities of $36,523 at September 30, 2022. Since December 31, 2021, total cash, cash equivalents and investments in fixed maturity and equity securities increased by $2,863, primarily due to cash generated from operations. This increase was partially offset by a decline in market value of our fixed maturity securities as well as cash used for common stock repurchases, dividends paid to shareholders, the purchase of property and equipment and acquisitions.
Many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends and other distributions that may be paid to their respective parent companies. Certain accounting practices prescribed by insurance regulatory authorities, or statutory accounting practices, differ from GAAP. Changes that occur in statutory accounting practices, if any, could impact our subsidiaries’ future dividend capacity. In addition, we have agreed to certain undertakings to regulatory authorities, including the requirement to maintain certain capital levels in certain of our subsidiaries.
At September 30, 2022, we held $1,045 of cash, cash equivalents and investments at the parent company, which are available for general corporate use, including investment in our businesses, acquisitions, potential future common stock repurchases and dividends to shareholders, repurchases of debt securities and debt and interest payments.
Periodically, we access capital markets and issue debt (“Notes”) for long-term borrowing purposes, for example, to refinance debt, to finance acquisitions or for share repurchases. Certain of these Notes may have a call feature that allows us to redeem the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the
-56-

occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. For more information on our debt, including redemptions and issuances, see Note 10, “Debt,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
We calculate our consolidated debt-to-capital ratio, a non-GAAP measure, from the amounts presented on our consolidated balance sheets included in Part I, Item 1 of this Form 10-Q. Our debt-to-capital ratio is calculated as total debt divided by total debt plus total shareholders’ equity. Total debt is the sum of short-term borrowings, current portion of long-term debt and long-term debt, less current portion. We believe our debt-to-capital ratio assists investors and rating agencies in measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants include a maximum debt-to-capital ratio that we cannot and did not exceed. Our debt-to-capital ratio may not be comparable to similarly titled measures reported by other companies. Our consolidated debt-to-capital ratio was 39.7% and 38.9% as of September 30, 2022 and December 31, 2021, respectively.
Our senior debt is rated “A” by S&P Global Ratings, “BBB” by Fitch Ratings, Inc., “Baa2” by Moody’s Investor Service, Inc. and “bbb+” by AM Best Company, Inc. We intend to maintain our senior debt investment grade ratings. If our credit ratings are downgraded, our business, liquidity, financial condition and results of operations could be adversely impacted by limitations on future borrowings and a potential increase in our borrowing costs.
Capital Resources
We have a shelf registration statement on file with the U.S. Securities and Exchange Commission to register an unlimited amount of any combination of debt or equity securities in one or more offerings. Specific information regarding terms and securities being offered will be provided at the time of an offering. Proceeds from future offerings are expected to be used for general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of credit to our subsidiaries, the financing of possible acquisitions or business expansions.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. In April 2022, we amended and restated the credit agreement for the 5-Year Facility to, among other things, extend the maturity date of the 5-Year Facility from June 2024 to April 2027 and increase the amount of credit available under the 5-Year Facility from $2,500 to $4,000. Also in April 2022, concurrently with the amendment and restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which was scheduled to mature in June 2022. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. We do not believe the restrictions contained in our 5-Year Credit Facility covenants materially affect our financial or operating flexibility. As of September 30, 2022, we were in compliance with all of the debt covenants under the 5-Year Facility.
Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit up to $200. Our ability to borrow under the Subsidiary Credit Facilities is subject to compliance with certain covenants. At September 30, 2022 and December 31, 2021, we had no outstanding borrowings under the Subsidiary Credit Facilities.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. In July 2022, we increased the amount available under the commercial paper program from $3,500 to $4,000. Should commercial paper issuance become unavailable, we have the ability to use a combination of cash on hand and/or our 5-Year Facility, which provides for credit in the amount of $4,000, to redeem any outstanding commercial paper upon maturity. At September 30, 2022, we had $675 outstanding under our commercial paper program.
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York, collectively (the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $265 and $275 of outstanding short-term borrowings from the FHLBs at September 30, 2022 and December 31, 2021, respectively.
-57-

While there is no assurance in the current economic environment, we believe the lenders participating in our 5-Year Facility and Subsidiary Credit Facilities, if market conditions allow, would be willing to provide financing in accordance with their legal obligations.
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
For additional information regarding our sources and uses of capital at September 30, 2022, see Note 5, “Investments,” Note 6, “Derivative Financial Instruments,” Note 10, “Debt,” and Note 12, “Capital Stock – Use of Capital – Dividends and Stock Repurchase Program,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
In addition to regulations regarding the timing and amount of dividends, our regulated subsidiaries’ states of domicile have statutory risk-based capital (“RBC”) requirements for health and other insurance companies and health maintenance organizations largely based on the National Association of Insurance Commissioners (“NAIC”) Risk-Based Capital (RBC) for Health Organizations Model Act (the “RBC Model Act”). These RBC requirements are intended to measure capital adequacy, taking into account the risk characteristics of an insurer’s investments and products. The NAIC sets forth the formula for calculating the RBC requirements, which are designed to take into account asset risks, insurance risks, interest rate risks and other relevant risks with respect to an individual insurance company’s business. In general, under the RBC Model Act, an insurance company must submit a report of its RBC level to the state insurance department or insurance commissioner, as appropriate, at the end of each calendar year. Our regulated subsidiaries’ respective RBC levels as of December 31, 2021, which was the most recent date for which reporting was required, were in excess of all applicable mandatory RBC requirements. In addition to exceeding these RBC requirements, we are in compliance with the liquidity and capital requirements for a licensee of the BCBSA and with the tangible net worth requirements applicable to certain of our California subsidiaries. For additional information, see Note 22, “Statutory Information,” in our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K.
Future Sources and Uses of Liquidity
We believe that funds from cash on hand, future operating cash receipts, investments and funds available under our commercial paper program, our 5-Year Facility, our Subsidiary Credit Facilities and the FHLBs will be adequate to fund our expected cash disbursements over the next twelve months.
There have been no material changes to our long-term liquidity requirements as disclosed in our 2021 Annual Report on Form 10-K. For additional updates regarding our estimated long-term liquidity requirements, see Note 6, “Derivative Financial Instruments,” Note 10, “Debt,” and the “Other Contingencies” and “Contractual Obligations and Commitments” sections of Note 11 “Commitments and Contingencies,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q. We believe that funds from future operating cash flows, cash and investments and funds available under our 5-Year Facility and/or from public or private financing sources will be sufficient for future operations and commitments, and for capital acquisitions and other strategic transactions.
-58-

FORWARD-LOOKING STATEMENTS
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent otherwise required by federal securities laws, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof. These risks and uncertainties include, but are not limited to: the impact of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19, and catastrophes; trends in healthcare costs and utilization rates; our ability to secure sufficient premium rates, including regulatory approval for and implementation of such rates; the impact of federal, state and international law and regulation, including changes in the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; our ability to contract with providers on cost-effective and competitive terms; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; reduced enrollment; the impact of a cyber-attack or other cyber security breach resulting in unauthorized disclosure of member or employee sensitive or confidential information, including the impact and outcome of any investigations, inquiries, claims and litigation related thereto; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; risks and uncertainties related to our pharmacy benefit management (“PBM”) business, including non-compliance by any party with the PBM services agreement between us and CaremarkPCS Health, L.L.C.; medical malpractice or professional liability claims or other risks related to healthcare and PBM services provided by our subsidiaries; general risks associated with mergers, acquisitions, joint ventures and strategic alliances; changes in tax laws; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; failure to effectively maintain and modernize our information systems; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.
-59-

ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
For a discussion of our market risks, refer to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” included in our 2021 Annual Report on Form 10-K. There have been no material changes to any of these risks since December 31, 2021.

ITEM 4.    CONTROLS AND PROCEDURES
We carried out an evaluation as of September 30, 2022, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to us (including our consolidated subsidiaries) required to be disclosed in our reports under the Exchange Act. In addition, based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.
There have been no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.    LEGAL PROCEEDINGS
For information regarding legal proceedings at September 30, 2022, see the “Litigation and Regulatory Proceedings,” and “Other Contingencies” sections of Note 11, “Commitments and Contingencies” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q, which information is incorporated herein by reference.

ITEM 1A.    RISK FACTORS
There have been no material changes to the risk factors disclosed in our 2021 Annual Report on Form 10-K.
-60-

ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities
The following table presents information related to our repurchases of common stock for the periods indicated:
Period
Total Number
of Shares
Purchased1 
Average
Price Paid
per Share
Total Number
of Shares
Purchased
as Part
of Publicly
Announced
Programs2
Approximate
Dollar Value
of Shares
that May Yet
Be Purchased
Under the
Programs
(in millions, except share and per share data)    
July 1, 2022 to July 31, 2022396,275 $473.54 394,162 $2,836 
August 1, 2022 to August 31, 2022367,089 485.27 364,850 2,659 
September 1, 2022 to September 30, 2022455,898 472.59 454,779 2,444 
1,219,262 1,213,791 
1    Total number of shares purchased includes 5,471 shares delivered to or withheld by us in connection with employee payroll tax withholding upon the exercise or vesting of stock awards. Stock grants to employees and directors and stock issued for stock option plans and stock purchase plans in the consolidated statements of shareholders’ equity are shown net of these shares purchased.
2    Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of Directors, which the Board of Directors evaluates periodically. During the three months ended September 30, 2022, we repurchased 1,213,791 shares at a total cost of $579 under the program, including the cost of options to purchase shares. The Board of Directors has authorized our common stock repurchase program since 2003. The most recent authorized increase to the program was $5,000 on January 26, 2021 by our Audit Committee, pursuant to authorization granted by the Board of Directors. No duration has been placed on our common stock repurchase program, and we reserve the right to discontinue the program at any time.

ITEM 3.    DEFAULTS UPON SENIOR SECURITIES
None.

ITEM 4.    MINE SAFETY DISCLOSURES
None.

ITEM 5.    OTHER INFORMATION
None.

-61-

ITEM 6.    EXHIBITS
Exhibit
Number
 Exhibit
3.1 
3.2 
4.7 Upon the request of the U.S. Securities and Exchange Commission, the Company will furnish copies of any other instruments defining the rights of holders of long-term debt of the Company or its subsidiaries.
31.1 
31.2 
32.1 
32.2 
101 The following material from Elevance Health, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Inline XBRL (Inline Extensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Income; (iii) the Consolidated Statements of Comprehensive Income; (iv) the Consolidated Statements of Cash Flows; (v) the Consolidated Statements of Changes in Equity; and (vi) Notes to Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104 Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.

-62-

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
ELEVANCE HEALTH, INC.
Registrant
October 19, 2022By: 
/S/  JOHN E. GALLINA
 John E. Gallina
Executive Vice President and Chief Financial Officer
(Duly Authorized Officer and Principal Financial Officer)
October 19, 2022By: 
/S/  RONALD W. PENCZEK
 Ronald W. Penczek
Chief Accounting Officer and Controller
(Principal Accounting Officer)
-63-
 EX-31.1 2 exhibit311-20220930q32022.htm EX-31.1 Document

Exhibit 31.1

CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Gail K. Boudreaux, certify that:
1.I have reviewed this report on Form 10-Q of Elevance Health, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
October 19, 2022 /s/ GAIL K. BOUDREAUX
 President and Chief Executive Officer


 EX-31.2 3 exhibit312-20220930q32022.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, John E. Gallina, certify that:
1.I have reviewed this report on Form 10-Q of Elevance Health, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
October 19, 2022 /s/ JOHN E. GALLINA
      Executive Vice President and
     Chief Financial Officer


 EX-32.1 4 exhibit321-20220930q32022.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Elevance Health, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gail K. Boudreaux, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ GAIL K. BOUDREAUX
Gail K. Boudreaux
President and Chief Executive Officer
October 19, 2022


 EX-32.2 5 exhibit322-20220930q32022.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Elevance Health, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John E. Gallina, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ JOHN E. GALLINA
John E. Gallina
Executive Vice President and Chief Financial Officer
October 19, 2022


 EX-101.SCH 6 elv-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document And Entity Information Document link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Consolidated Statements Of Income link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Consolidated Statements Of Changes in Equity link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Basis Of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Basis of Presentation and Signficant Accounting Policies Basis of Presentation and Significant Acconting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2106103 - Disclosure - Business Acquisitions link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Business Acquisitions Business Acquisition (Assets Liabilities Acquired) (Details) link:presentationLink link:calculationLink link:definitionLink 2108104 - Disclosure - Business Optimization Initiatives link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Business Optimization Initiatives (Tables) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Business Optimization Initiatives (Employee Termination Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 2111105 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2312302 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Investments (Current And Long-Term Fixed Maturity Securities, Available-For-Sale) (Details) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details) link:presentationLink link:calculationLink link:definitionLink 2415407 - Disclosure - Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details) link:presentationLink link:calculationLink link:definitionLink 2416408 - Disclosure - Investments (Current Equity Securities) (Details) link:presentationLink link:calculationLink link:definitionLink 2417409 - Disclosure - Investments (Net Investment Gains/Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 2418410 - Disclosure - Investments (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2119106 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2420411 - Disclosure - Derivative Financial Instruments (Financial Statement Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2121107 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 2322303 - Disclosure - Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 2423412 - Disclosure - Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details) link:presentationLink link:calculationLink link:definitionLink 2424413 - Disclosure - Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details) link:presentationLink link:calculationLink link:definitionLink 2425414 - Disclosure - Fair Value (Carrying And Estimated Fair Values by Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details) link:presentationLink link:calculationLink link:definitionLink 2426415 - Disclosure - Fair Value (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2127108 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2428416 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2129109 - Disclosure - Medical Claims Payable link:presentationLink link:calculationLink link:definitionLink 2330304 - Disclosure - Medical Claims Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 2431417 - Disclosure - Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable By Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 2432418 - Disclosure - Medical Claims Payable (Reconciliation Of Net Incurred Medical Claims To Benefit Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 2433419 - Disclosure - Medical Claims Payable Medical Claims Payable (Reconciliation of the Claims Development to the Claims Liability) (Details) link:presentationLink link:calculationLink link:definitionLink 2434420 - Disclosure - Medical Claims Payable (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2135110 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2336305 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2437421 - Disclosure - Debt (Convertible Debenture Details) (Details) link:presentationLink link:calculationLink link:definitionLink 2438422 - Disclosure - Debt (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2139111 - Disclosure - Commitments And Contingencies link:presentationLink link:calculationLink link:definitionLink 2440423 - Disclosure - Commitments And Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2141112 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 2342306 - Disclosure - Capital Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 2443424 - Disclosure - Capital Stock (Summary of Cash Dividend Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2444425 - Disclosure - Capital Stock (Summary of Share Repurchases) (Details) link:presentationLink link:calculationLink link:definitionLink 2445426 - Disclosure - Capital Stock (Summary of Stock Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2446427 - Disclosure - Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details) link:presentationLink link:calculationLink link:definitionLink 2447428 - Disclosure - Capital Stock (Fair Values of Options Granted During The Period Estimated Using Weighted-Average Assumptions) (Details) link:presentationLink link:calculationLink link:definitionLink 2448429 - Disclosure - Capital Stock (Schedule Of Weighted-Average Fair Values Determined For The Periods) (Details) link:presentationLink link:calculationLink link:definitionLink 2449430 - Disclosure - Capital Stock (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2150113 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 2351307 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 2452431 - Disclosure - Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2153114 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2354308 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2455432 - Disclosure - Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 2456433 - Disclosure - Earnings Per Share (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2157115 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2358309 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2459434 - Disclosure - Segment Information (Financial Data By Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 2460435 - Disclosure - Segment Information Segment Information (Major Product Revenues for Each Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 2461436 - Disclosure - Segment Information (Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income) (Details) link:presentationLink link:calculationLink link:definitionLink 2462437 - Disclosure - Segment Information (Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income) (Details) link:presentationLink link:calculationLink link:definitionLink 2463438 - Disclosure - Segment Information Segment Information (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2164116 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2365310 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2466439 - Disclosure - Leases (Lease and Other Information) (Details) link:presentationLink link:calculationLink link:definitionLink 2467440 - Disclosure - Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2468441 - Disclosure - Leases (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2169117 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2370311 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2471442 - Disclosure - Goodwill And Other Intangible Assets (Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 2472443 - Disclosure - Goodwill And Other Intangible Assets (Components Of Other Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2473444 - Disclosure - Goodwill And Other Intangible Assets (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 elv-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 elv-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 elv-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Due in one year or less, Estimated Fair Value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Business Acquisition [Axis] Business Acquisition [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total future minimum payments Lessee, Operating Lease, Liability, to be Paid Liability for Claims and Claims Adjustment Expense [Abstract] Liability for Claims and Claims Adjustment Expense [Abstract] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Net income Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Loss Contingency, Pending Claims, Number Loss Contingency, Pending Claims, Number Insurance lines other than short duration Short-Duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Other Reconciling Item Benefit expense Policyholder Benefits and Claims Incurred, Net Outstanding principal amount Long-Term Debt, Gross Covenant description Debt Instrument, Covenant Description Entity Address, Postal Zip Code Entity Address, Postal Zip Code Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Debt Securities AOCI, Other than Temporary Impairment, Not Credit Loss, Ending Balance Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Debt Securities Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Commercial paper authorized Commercial Paper Maximum Borrowing Capacity Commercial Paper, Maximum Borrowing Capacity Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Senior Unsecured Notes [Member] Senior Unsecured Notes [Member] Senior Unsecured Notes [Member] Liability for employee terminations costs, beginning Liability for employee terminations costs, ending Restructuring Reserve Components Of Other Intangible Assets Present Value of Future Insurance Profits [Table Text Block] Expenses Benefits, Losses and Expenses [Abstract] Additional paid-in capital Additional Paid in Capital Medical claims payable Gross medical claims payable, end of period Liability for Claims and Claims Adjustment Expense Due after five years through ten years, Estimated Fair Value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Financial Instruments [Domain] Financial Instruments [Domain] Federal Home Loan Bank, advances, short-term Federal Home Loan Bank, Advances, Maturities Summary, Due in Next Rolling 12 Months Other, net Payments for (Proceeds from) Other Investing Activities Statistical Measurement [Domain] Statistical Measurement [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Exercised, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Debt instrument interest rate Debt Instrument, Interest Rate, Stated Percentage Equity Securities Equity Securities Fair value of investments in equity securities. Number of Medical Members Number Of Medical Members Served Number of medical members served Self-funded receivables Self-Funded Receivables, Net The carrying amount as of the balance sheet date due the entity from self-insured customers, net of the allowance for doubtful accounts. Medical Claims Payable Liability for Claims and Claims Adjustment Expense [Table] Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, tax expense Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense -- None. No documentation exists for this element. -- Option Indexed to Issuer's Equity [Axis] Option Indexed to Issuer's Equity [Axis] Shareholders’ net income Shareholders' net income Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Four Point One Zero Percent Due Two Thousand Thirty Two [Member] Four Point One Zero Percent Due Two Thousand Thirty Two [Member] Four Point One Zero Percent Due Two Thousand Thirty Two Weighted average shares excluded from denominator for diluted earnings per share because the stock options were anti-dilutive Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Due after one year through five years, Estimated Fair Value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Other [Member] Other Intangible Assets [Member] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Fixed maturities, allowance for credit loss, current Debt Securities, Available-for-Sale, Allowance for Credit Loss, Current Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Share Repurchase Program [Domain] Share Repurchase Program [Domain] Operating lease payments, Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Number of states in which the Company is licensed to conduct insurance operations Number of States in which Entity Operates Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest Net investment income Net investment income Net Investment Income Number of counties in the Kansas City area the Company does not serve Number Of Counties In State Of Kansas Company Does Not Serve Number Of Counties In The State Of Kansas Company Does Not Serve Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Fair Value, Nonrecurring [Member] Fair Value, Nonrecurring [Member] AOCI, Debt Securities, Beginning Balance AOCI, Debt Securities, Ending Balance AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax Total assets Assets, Fair Value Disclosure Leases Lessee, Operating Leases [Text Block] Indefinite-Lived Intangible Assets, Period Decrease Indefinite-Lived Intangible Assets, Period Increase (Decrease) Aggregate settlement amount Loss Contingency, Estimate of Possible Loss States, Municipalities And Political Subdivisions [Member] US States and Political Subdivisions Debt Securities [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] AOCI, Foreign Currency Translation Adjustment, Net of Tax, Beginning Balance Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax, Ending Balance Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Integra Managed Care [Member] Integra Managed Care [Member] Integra Managed Care AOCI, Defined Benefit Plan, Beginning Balance AOCI, Defined Benefit Plan, Ending Balance Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Available-for-sale Securities Available-for-sale securities, Estimated Fair Value Debt Securities, Available-for-Sale Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Balance sheet location of current operating lease liabilities Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Gross medical claims payable, beginning of period Gross medical claims payable, end of period Short Duration Contract Liability For Claims Adjustment Expense The amount needed to reflect the estimated ultimate cost of settling short duration contract claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date for short duration. Damages for Pharmacy Pricing [Member] Pharmacy pricing [Member] Pharmacy pricing [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] IngenioRx Segment [Member] IngenioRx Segment [Member] IngenioRx Segment [Member] Goodwill [Line Items] Goodwill [Line Items] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Other Products [Member] Other Products [Member] Other Products [Member] Transfers out of Level III Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Level I [Member] Fair Value, Inputs, Level 1 [Member] Sales Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales Other comprehensive (loss) income, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Outstanding at end of period, Weighted-Average Remaining Contractual Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Pension and other postretirement benefits Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Award Type [Axis] Award Type [Axis] Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Operating Lease, Liability, Current Operating Lease, Liability, Current Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Summary of Nonvested Restricted Stock Activity Including Restricted Stock Units Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Proceeds originally received at time of divestiture Proceeds from Divestiture of Businesses Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Legal Entity [Axis] Legal Entity [Axis] Long-term debt, less current portion Long-Term Debt, Excluding Current Maturities Net losses (gains) on other investments Gain (Loss) on Sale of Other Investments Total liabilities Liabilities Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Goodwill, Purchase Accounting Adjustments Goodwill, Purchase Accounting Adjustments Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Position [Axis] Position [Axis] Net payments attributable to prior periods medical claims Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Debt Instruments [Abstract] Debt Instruments [Abstract] Short-duration Insurance Contracts, Claims Development [Table] Short-Duration Insurance Contracts, Claims Development [Table] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Fixed maturities, amortized cost, current Debt Securities, Available-for-Sale, Amortized Cost, Current Senior Revolving Credit Facility [Member] Revolving Credit Facility [Member] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fixed maturities, current Debt Securities, Available-for-Sale, Current Preferred stock, shares issued Preferred Stock, Shares Issued Document Type Document Type Net holding gain (loss) on investment securities arising during the period, tax (expense) benefit OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax Weighted-Average Option Price Per Share [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Debt Securities, Available-for-sale, Realized Gain (Loss) Debt Securities, Available-for-Sale, Realized Gain (Loss) Restricted Stock Shares and Units [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Forfeited or expired, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Business Optimization Initiatives by Type [Axis] Restructuring Type [Axis] Nonvested at Beginning Balance, Weighted-Average Grant Date Fair Value per Share Nonvested at Ending Balance, Weighted-Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Debt Debt Disclosure [Text Block] Segments [Axis] Segments [Axis] Other Segment [Member] Other [Member] Other Segment [Member] Other segment Product and Service [Domain] Product and Service [Domain] Change in non-credit component of impairment losses on investments Change in non-credit component of impairment losses on investments net of tax Change in non-credit component of impairment losses on investments, net of tax effect. Net cash flow hedges Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Entity Shell Company Entity Shell Company Investments [Abstract] Investments [Abstract] Deferred income taxes Deferred Income Tax Expense (Benefit) Damages for Operational Breaches [Member] Operational [Member] Operational [Member] Unearned income Increase (Decrease) in Deferred Revenue Investment [Line Items] Gain (Loss) on Securities [Line Items] Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract] Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract] Operating lease payments, 2022; excluding the nine months ended September 30, 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Dental Vision Products And Services [Member] Dental Vision Products And Services [Member] Dental Vision Products And Services [Member] Financial Instrument [Axis] Financial Instrument [Axis] Balance sheet location of noncurrent operating lease liabilities Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Total gains (losses) recognized in net income Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Foreign Government Securities [Member] Foreign Government Debt [Member] Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Document Period End Date Document Period End Date Other Investments [Member] Other Investments [Member] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Accounting Standards Update 2020-06 [Member] Accounting Standards Update 2020-06 [Member] Reconciliation Of Components Of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total assets Assets Total net payments Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid Overnight and Continuous [Member] Maturity Overnight [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Shareholders’ net income per share Earnings Per Share [Abstract] Earnings Per Share [Abstract] Federal Home Loan Bank Advances [Member] Federal Home Loan Bank Advances [Member] Changes in securities lending collateral Increase (Decrease) in Collateral Held under Securities Lending Equity securities Equity Securities, FV-NI, Current Other Comprehensive Income (Loss), Tax (Expense) Benefit, Portion Attributable to Parent Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Schedule of Business Optimization Initiatives [Table] Schedule of Restructuring and Related Costs [Table] Current portion of long-term debt Long-Term Debt, Current Maturities Intangible Assets [Line Items] Intangible Assets [Line Items] Intangible Assets Operating lease payments, 2026 Lessee, Operating Lease, Liability, to be Paid, Year Five Exercised, Weighted-Average Option Price per Share Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Finite-lived Intangible Assets Acquired Finite-Lived Intangible Assets Acquired Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Product revenue Product Revenue Amount of revenue recognized from goods sold. Subsidiary Credit Facilities [Member] Line of Credit [Member] Income before income tax expense Income before income tax expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shareholders' equity Stockholders' Equity Attributable to Parent [Abstract] Segments [Domain] Segments [Domain] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Earnings Per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Summary of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted During the Periods Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Private Equity Funds [Member] Private Equity Securities [Member] Private Equity Funds [Member] Due after one year through five years, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Ceded medical claims payable, beginning of period Ceded medical claims payable, end of period Ceded medical claims payable end of period Reinsurance Recoverable for Unpaid Claims and Claims Adjustments Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities Schedule of Investments [Line Items] Schedule of Investments [Line Items] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Award Type [Domain] Award Type [Domain] Residential Mortgage-Backed Securities [Member] Residential Mortgage-Backed Securities [Member] Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Exercisable at end of period, Weighted-Average Remaining Contractual Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Net medical claims payable, end of period Short duration contract liability for unpaid claims and adjustment expense, Net Short duration contract liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for short duration contract claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid short duration contract claims. Receivable Receivable [Policy Text Block] Income taxes receivable Income Taxes Receivable, Current Derivative Contract [Domain] Derivative Contract [Domain] Increase In Stock Repurchase Program Authorization Increase In Stock Repurchase Program Authorization The amount of an increase authorized by an entity's Board of Directors to a previously authorized stock repurchase program. Other invested assets Increase (Decrease) in Debt Securities, Trading, and Equity Securities, FV-NI Entity Registrant Name Entity Registrant Name Changes in bank overdrafts Increase (Decrease) in Outstanding Checks, Financing Activities Lessee, Operating Lease, Not yet Commenced, Description [Abstract] Lessee, Operating Lease, Not yet Commenced, Description [Abstract] Debt instruments, repurchased face amount Debt Instrument, Repurchased Face Amount AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax AOCI, Cash Flow Hedge, Beginning Balance AOCI, Cash Flow Hedge, Ending Balance AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax Insurance [Abstract] Insurance [Abstract] Commercial & Specialty [Member] Commercial Specialty [Member] Commercial & Specialty [Member] Quarterly dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Short-Duration Insurance Contract, Accident Year 2022 [Member] Short-Duration Insurance Contract, Accident Year 2022 [Member] Customer Relationships [Member] Customer Relationships [Member] Entity Address, City or Town Entity Address, City or Town Mortgage-backed securities, Estimated Fair Value Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value Leases [Abstract] Leases [Abstract] Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net Short-Duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net Total equity Total equity, Beginning Balance Total equity, Ending Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Intersegment Eliminations [Member] Intersegment Eliminations [Member] Minimum [Member] Minimum [Member] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies [Table]. Conversion rate (shares of common stock per $1,000 of principal) Debt Instrument, Convertible, Conversion Ratio Noncontrolling interests Noncontrolling interests, Beginning Balance Noncontrolling interests, Ending Balance Stockholders' Equity Attributable to Noncontrolling Interest Due in one year or less, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Securities lending transactions ratio of fair value of collateral held to fair value of securities loaned Securities Lending Transactions Ratio of Fair Value of Collateral Held To Securities On Loan Ratio of fair value of collateral held to fair value of securities loaned in securities lending transactions. Common stock, par value Common Stock, Par or Stated Value Per Share Claims Development [Line Items] Claims Development [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Fair Value Fair Value Disclosures [Text Block] Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Trading Symbol Trading Symbol Entity File Number Entity File Number Finite-Lived Intangible Asset, Expected Amortization, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Four Reconciliation Of The Claims Development To The Claims Liability [Abstract] Reconciliation Of The Claims Development To The Claims Liability [Abstract] Reconciliation Of The Claims Development To The Claims Liability [Abstract] Fixed maturities, allowance for credit Loss, noncurrent Debt Securities, Available-for-Sale, Allowance for Credit Loss, Noncurrent 2022 to 2024 2022 to 2024 [Member] 2022 to 2024 [Member] 2022 to 2024 Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Investment Income [Table] Investment Income [Table] Equity Securities [Line Items] Marketable Securities [Line Items] Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) [Member] Granted, Restricted Stock Shares and Units Restricted stock units issued under stock incentive plan Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Entity Information [Line Items] Entity Information [Line Items] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Performance measurement period [Domain] Performance measurement period [Domain] Performance measurement period [Domain] Gross losses Gross Losses From Other Investments Gross Losses From Other Investments Total revenues Revenues Change in net unrealized gains/losses on cash flow hedges Cash flow hedges, holding gain (loss), net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Number of securities, 12 months or greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Income Taxes Income Tax Disclosure [Text Block] Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) [Abstract] Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) [Abstract] Reconciliation of future lease payments to total lease liabilities. Credit Facility [Domain] Credit Facility [Domain] Estimated fair value, 12 months or greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Gross Carrying Amount, Total Intangible Assets Intangible Assets, Gross (Excluding Goodwill) Record date Dividends Payable, Date of Record Dividends Payable, Date of Record Amortization of other intangible assets Amortization of Intangible Assets Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment Schedule of Goodwill [Table Text Block] Basic net income per share Earnings Per Share, Basic Operating lease payments, 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Net proceeds from (repayments of) commercial paper borrowings Proceeds from (Repayments of) Commercial Paper Indefinite-Lived Intangible Assets by Major Class [Axis] Indefinite-Lived Intangible Assets [Axis] Approximate amount of damages sought for breaches Loss Contingency, Damages Sought, Value Total shareholders' equity Total shareholders' equity, Beginning Balance Total shareholders' equity, Ending Balance Stockholders' equity attributable to parent Stockholders' Equity Attributable to Parent Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Common Equity Securities [Member] Common Equity Securities [Member] Common Equity Securities [Member] Forfeited, Weighted-Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Due after five years through ten years, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Dividends and dividend equivalents Dividends, Common Stock Fixed maturities, allowance for credit loss Fixed maturities, allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Gain Contingency, Nature [Domain] Gain Contingency, Nature [Domain] Entity Interactive Data Current Entity Interactive Data Current Commercial Mortgage-Backed Securities [Member] Commercial Mortgage-Backed Securities [Member] Accumulated Amortization, Finite-Lived Intangible Assets Finite-Lived Intangible Assets, Accumulated Amortization Government Sponsored Securities [Member] US Government-sponsored Enterprises Debt Securities [Member] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Finite-Lived Intangible Asset, Expected Amortization, 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Three Short-Duration Insurance Contract, Accident Year 2021 [Member] Short-Duration Insurance Contract, Accident Year 2021 [Member] Proceeds from Sale of Available-for-sale Securities Proceeds from Sale of Debt Securities, Available-for-Sale Retained Earnings [Member] Retained Earnings [Member] Retained Earnings [Member] Cash dividends Total payment Payments of Dividends Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Lease, Cost Lease, Cost 5-Year Facility [Member] 5-Year Facility [Member] 5-Year Facility [Member] Common Stock [Member] Common Stock [Member] Shareholders' other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Integrated health services Integrated health services [Member] Integrated health services Quality improvement and other claims expense SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Other Operating Expense Premium receivables Premiums Receivable, Net Lessee, Operating Lease, Disclosure [Table Text Block] Lease, Cost [Table Text Block] Number of Reportable Segments Number of Reportable Segments Repurchase and retirement of common stock Payments for Repurchase of Common Stock Class of Stock [Axis] Class of Stock [Axis] Commercial paper Commercial Paper Revenue Recognition Revenue [Policy Text Block] Statement [Table] Statement [Table] Vested, Weighted-Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Intangible Assets [Table] Intangible Assets [Table] Intangible Assets 2021 364-Day Facility [Member] 2021 364-Day Facility [Member] 2021 364-Day Facility [Member] Document Quarterly Report Document Quarterly Report Derivative liabilities Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement Allowance for doubtful accounts, other receivables Allowance for Credit Loss, Receivable, Other, Current Current assets: Assets, Current [Abstract] Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Summary of Share Repurchases Class of Treasury Stock [Table Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Net realized gains (losses) recognized on equity securities sold during the period Equity Securities, FV-NI, Realized Gain (Loss) Unrealized (losses) gains recognized on equity securities still held at the end of the period Equity Securities, FV-NI, Realized Gain Gross Carrying Amount, Indefinite-Lived Intangible Assets Net Carrying Amount, Indefinite-Lived Intangible Assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Retained earnings Retained Earnings (Accumulated Deficit) Transfers into Level III Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Due after ten years, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 Government Business Segment [Member] Government Business [Member] Government Business Segment [Member] Government Business Segment Statement, Equity Components [Axis] Equity Components [Axis] Blue Cross And Blue Shield And Other Trademarks [Member] Trademarks [Member] Change in unrealized gains (losses) included in net income related to assets still held Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss) Short-duration Insurance Contracts, Claim Year [Domain] Short-Duration Insurance Contracts, Accident Year [Domain] Fair Value, Recurring [Member] Fair Value, Recurring [Member] Litigation Case [Domain] Litigation Case [Domain] Exercisable at end of period, Weighted-Average Option Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Reclassification adjustment for net realized loss (gain) on investment securities, tax (benefit) expense Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax Estimated fair value, less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Document Fiscal Year Focus Document Fiscal Year Focus Accounting Policies [Line Items] Accounting Policies [Line Items] Accounting Policies [Line Items] Four Point Five Five Zero Due Two Thousand Fifty Two [Member] Four Point Five Five Zero Due Two Thousand Fifty Two [Member] Four Point Five Five Zero Due Two Thousand Fifty Two Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Nonvested at Beginning Balance, Restricted Stock Shares and Units Nonvested at Ending Balance, Restricted Stock Shares and Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Goodwill, Period Increase (Decrease) Goodwill, Period Increase (Decrease) Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Variable Rate [Domain] Variable Rate [Domain] Gross Carrying Amount, Finite Lived Intangibles Finite-Lived Intangible Assets, Gross Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general and administrative expense Selling, General and Administrative Expense Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Investments In Equity Securities Investments in equity securities [Table Text Block] Investments in equity securities [Table Text Block] Accumulated Other Comprehensive (Loss) Income [Member] AOCI Attributable to Parent [Member] Reportable segments operating revenues Insurance Services Revenue Insurance Services Revenue Accumulated Other Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Business Optimization Initiatives by Type [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Operating gain (loss) Reportable segments operating gain Operating Income (Loss) Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Business combinations and purchase adjustments Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Other policyholder liabilities Other Policyholder Funds Position [Domain] Position [Domain] Common stock, shares outstanding Common Stock, Shares, Outstanding Goodwill Goodwill, Beginning Balance Goodwill, Ending Balance Goodwill Affiliated [Member] Affiliated [Member] Affiliated [Member] Major Product Revenue by Segment Major Product Revenue By Segment [Table Text Block] [Table Text Block] for Major Product Revenue By Segment [Table] Notes Notes Payable Net unrealized investment (losses) gains AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member] Indefinite-lived Intangible Assets Acquired Indefinite-Lived Intangible Assets Acquired Noncontrolling interests adjustment Noncontrolling Interest, Increase from Subsidiary Equity Issuance Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Text Block] Income tax expense Income Tax Expense (Benefit) Collateral received for securities loaned, at carrying value Deposits Received for Securities Loaned, at Carrying Value Deferred tax liabilities, net Deferred Income Tax Liabilities, Net Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Operating lease payments, 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Proceeds from short-term borrowings Proceeds from Short-Term Debt Income Statement [Abstract] Income Statement [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Hedging Relationship [Axis] Hedging Relationship [Axis] Additional Paid-In Capital [Member] Additional Paid-in Capital [Member] State Medicaid Licenses [Member] Licensing Agreements [Member] Document Fiscal Period Focus Document Fiscal Period Focus Cumulative Effect, Period of Adoption, Adjusted Balance Cumulative Effect, Period of Adoption, Adjusted Balance [Member] Cost of products sold Cost of Goods and Services Sold Net realized gains (losses) recognized on equity securities sold during the period Equity Securities, FV-NI, Realized Loss Denominator for diluted earnings per share Weighted Average Number of Shares Outstanding, Diluted Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Weighted-average expected life (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Convertible debentures Net debt carrying amount Convertible Debt, Noncurrent Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Current and Long-Term Investments, Available-For-Sale Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Cash dividends per share Common Stock, Dividends, Per Share, Cash Paid Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Covenant compliance Debt Instrument, Covenant Compliance Reconciliation of Net Incurred Medical Claims to Benefit Expense Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table Text Block] Tabular Disclosure For Reconciliation of Net Incurred Medical Claims to Benefit Expense. Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding – 238,974,624 and 241,770,746 Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Granted, Weighted-Average Grant Date Fair Value per Share Restricted stock awards granted during the period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Effective conversion price (per $1,000 of principal amount) per share Debt Instrument, Convertible, Conversion Price Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Convertible Debt [Member] Convertible Debt [Member] Short-term Lease, Cost Short-Term Lease, Cost Administrative fees and other revenue Other Income Line of Credit Facility, Description Line of Credit Facility, Description Preferred stock, shares authorized Preferred Stock, Shares Authorized Restricted stock units excluded from the denominator for diluted earnings per share Potentially Dilutive Restricted Stock Units Contingent On Operating Results Potentially Dilutive Restricted Stock Units Contingent On Operating Results Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign currency translation adjustments Foreign currency translation adjustment, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Net loss (income) attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Noncontrolling Interest Commitments And Contingencies Commitments and Contingencies Disclosure [Text Block] Goodwill, Impaired, Accumulated Impairment Loss as of September 30, 2022 Goodwill, Impaired, Accumulated Impairment Loss Current Liabilities: Liabilities, Current [Abstract] Proceeds from issuance of common stock under employee stock plans Proceeds from Stock Options Exercised Proceeds from long-term borrowings Proceeds from Issuance of Long-Term Debt Common stock, shares issued Common Stock, Shares, Issued Debt Conversion Debt Principal Amount Debt Conversion Debt Principal Amount The aggregate principal amount of the original debt instrument that was surrendered for conversion. Cash Flow Hedging [Member] Cash Flow Hedging [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating Lease, Cost Operating Lease, Cost Debt Instrument, Face Amount Debt Instrument, Face Amount Anthem, Inc. v. Express Scripts, Inc. [Member] Anthem, Inc. v. Express Scripts, Inc. [Member] Anthem, Inc. v. Express Scripts, Inc. [Member] Investment Type [Axis] Investment Type [Axis] Investment, Policy Investment, Policy [Policy Text Block] Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax Total shareholders’ comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Short-Duration Insurance Contract, Accident Year 2020 [Member] Short-Duration Insurance Contract, Accident Year 2020 [Member] Reconciliation of Short Duration Medical Claims Payable to the Consolidated Medical Claims Payable Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block] Goodwill, Acquired During Period Goodwill, Acquired During Period Business Acquisitions Mergers, Acquisitions and Dispositions Disclosures [Text Block] Financial Data By Reportable Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Goodwill and Intangible Assets Disclosure [Abstract] Other current liabilities Other Liabilities, Current Other noncurrent assets Other Assets, Noncurrent Payments Payments for Restructuring Exercisable at end of period, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Employee Severance [Member] Employee Severance [Member] Medical Claims Payable [Line Items] Liability for Claims and Claims Adjustment Expense [Line Items] Dividends Payable, Amount Per Share Dividends Payable, Amount Per Share 2021 to 2023 [Member] 2021 to 2023 [Member] 2021 to 2023 Lessee, Operating Lease, Term of Contract Lessee, Operating Lease, Term of Contract Outstanding at beginning of period, Number of Shares Outstanding at end of period, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Unaffiliated Unaffiliated [Member] Unaffiliated [Member] Gross premium tax rate, state of California Gross Premium Tax Rate Gross premium tax rate Securities lending transactions, initial collateral percentage value Securities Lending Transactions Initial Collateral Percentage Value Initial minimum percentage of cash and/or securities collateral accepted as compared to the value of securities on loan in a securities lending transaction. Policy liabilities Increase (Decrease) in Insurance Liabilities Reconciliation of net incurred medical claims to benefit expense [Line Items] reconciliation of net incurred medical claims to benefit expense [Line Items] [Line Items] for Reconciliation of net incurred medical claims to benefit expense [Table] Number of securities, less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of foreign exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net Property, Plant and Equipment, Net Operating Lease, Payments Operating Lease, Payments Non-credit components of impairments on investments [Member] Non-credit components of impairments on investments [Member] Non-credit components of impairments on investments Performance measurement period [Axis] Performance measurement period [Axis] Performance measurement period [Axis] Depreciation and amortization Depreciation, Amortization and Accretion, Net Entities [Table] Entities [Table] Repayments of long-term borrowings Repayments of Long-term Debt Repayments of Long-Term Debt Finite-Lived Intangible Assets, Period Increase Finite-Lived Intangible Assets, Period Increase (Decrease) Summary of Cash Dividend Activity Dividends Declared [Table Text Block] Change in net periodic pension and postretirement costs Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Volatility factor Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Three Point One Two Five Percent Due Two Thousand Twenty Two [Member] Three Point One Two Five Percent Due Two Thousand Twenty Two [Member] Three Point One Two Five Percent Due Two Thousand Twenty Two Issuance of common stock under employee stock plans, net of related tax benefits Stock Issued During Period, Value, Stock Options Exercised Forfeited, Restricted Stock Shares And Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Long-term Debt Senior revolving credit facility Long-Term Debt Change in net unrealized losses/gains on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Business Optimization Initiatives Restructuring and Related Activities Disclosure [Text Block] Common stock, shares authorized Common Stock, Shares Authorized Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Maximum [Member] Maximum [Member] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Accumulated other comprehensive loss Accumulated Other Comprehensive Loss, Beginning Balance Accumulated Other Comprehensive Loss, Ending Balance Accumulated Other Comprehensive Income (Loss), Net of Tax BCBS Antitrust Litigation [Member] BCBS Antitrust Litigation [Member] BCBS Antitrust Litigation [Member] Business Acquisitions [Table] Schedule of Business Acquisitions, by Acquisition [Table] Repurchase and retirement of common stock Aggregate cost Stock Repurchased and Retired During Period, Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Repurchase Agreements and Similar Transactions, Maturity Periods [Axis] Repurchase Agreements and Similar Transactions, Maturity Periods [Axis] Net losses on equity securities Equity Securities, FV-NI, Gain (Loss) Total current assets Assets, Current Cash flow hedges, holding gain (loss), tax (expense) benefit Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Finite-Lived Intangible Asset, Expected Amortization, 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Six Finite-Lived Intangible Asset, Expected Amortization, Year Six Balance sheet location of operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Small Business Entity Small Business Major Product Revenue By Segment [Table] Major Product Revenue By Segment [Table] Major Product Revenue By Segment [Table] Balance (in shares), Beginning Balance (in shares), Ending Shares, Outstanding Capital Stock Stockholders' Equity Note Disclosure [Text Block] Measurement Frequency [Domain] Measurement Frequency [Domain] Dividends per share Common Stock, Dividends, Per Share, Declared Revenues Revenues [Abstract] Net Carrying Amount, Finite-Lived Intangible Assets Finite-Lived Intangible Assets, Net Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet [Table Text Block] -- None. No documentation exists for this element. -- Reserves for future policy benefits, noncurrent Liability for Future Policy Benefit, before Reinsurance Business Optimization Initiatives [Abstract] Business Optimization Initiatives Premiums Premiums Earned, Net Number of Shares [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Other invested assets Other invested assets Other Long-Term Investments Accumulated Amortization, Total Intangible Assets Intangible Assets Accumulated Amortization Excluding Goodwill Intangible Assets Accumulated Amortization Excluding Goodwill Mortgage-backed securities, Amortized Cost Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost Sublease Income Sublease Income Outstanding at end of period, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Repurchase and retirement of common stock, shares Shares repurchased Stock Repurchased and Retired During Period, Shares Short-term borrowings Short-term borrowings Short-Term Debt Title of 12(b) Security Title of 12(b) Security Proceeds from sale of investments Proceeds from sale of equity and fixed maturity securities Proceeds from sale of equity and fixed maturity securities. Consolidated Entities [Axis] Consolidated Entities [Axis] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Granted, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Debt Instrument [Line Items] Debt Instrument [Line Items] Impairment (losses) recoveries recognized in income Impairment (losses) reversals on investments Total impairment (losses) reversals on investments, before considering whether or not such amount is recognized in earnings or other comprehensive income. Gross unrealized loss, less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Issuance of common stock under employee stock plans, net of related tax benefits, Shares Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Self-funded receivables, allowance for doubtful accounts Self-funded Receivables, Allowance For Doubtful Accounts The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross self-funded receivable to net realizable value. Operating Lease Liabilities Operating Lease, Liability United States Government Securities [Member] US Government Agencies Debt Securities [Member] Segment Information Segment Reporting Disclosure [Text Block] Segment Eliminations [Member] Segment Eliminations [Member] Segment Eliminations [Member] Managed Care Products [Member] Managed Care Products [Member] Managed Care Products [Member] Other receivables Other Receivables Finite-Lived Intangible Asset, Expected Amortization, 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Two Derivative, Gain (Loss) Recognized Derivative, Gain (Loss) on Derivative, Net Gross unrealized loss, 12 months or greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Liabilities and shareholders' equity Liabilities and Equity [Abstract] Granted, Weighted-Average Option Price per Share Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Cost or Amortized Cost Available-for-sale securities, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Forfeited or expired, Weighted-Average Option Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Current period net incurred medical claims Current Year Claims and Claims Adjustment Expense Managed Care Services [Member] Managed Care Services [Member] Managed Care Services [Member] Provider And Hospital Relationships [Member] Contractual Rights [Member] Repurchase Agreements and Similar Transactions, Maturity Periods [Domain] Repurchase Agreements and Similar Transactions, Maturity Periods [Domain] Other assets Increase (Decrease) in Other Operating Assets Tax (expense) benefit of non credit impairment on available-for-sale securities recognized in other comprehensive income (loss) Tax (expense) benefit of non credit impairment on available-for-sale securities recognized in other comprehensive income (loss) Tax (expense) benefit of non-credit component of impairment loss on available-for-sale securities recognized in other comprehensive income Hedging Relationship [Domain] Hedging Relationship [Domain] Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity Investments Classified by Contractual Maturity Date [Table Text Block] Organization Nature of Operations [Text Block] Entity Filer Category Entity Filer Category Denominator for basic earnings per share - weighted-average shares Weighted Average Number of Shares Outstanding, Basic Investment [Table] Schedule of Gain (Loss) on Securities [Table] Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items] Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items] Derivative assets Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement Prior periods redundancies Prior Year Claims and Claims Adjustment Expense Commitments and contingencies – Note 11 Commitments and Contingencies Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Available-for-sale Securities Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Available-for-Sale Securities Security Exchange Name Security Exchange Name Outstanding at beginning of period, Weighted-Average Option Price per Share Outstanding at end of period, Weighted-Average Option Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Changes in securities lending payable Increase (Decrease) in Securities Lending Payable Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none Preferred Stock, Value, Issued Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Net (losses) gains on investments Investment Gains (Losses) Investment Gains (Losses) Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Payment date Dividends Payable, Date to be Paid Dividends Payable, Date to be Paid Total gains (losses) recognized in accumulated other comprehensive loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) Declaration date Dividends Payable, Date Declared Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Cover [Abstract] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Level III [Member] Fair Value, Inputs, Level 3 [Member] Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract] Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract] Surplus Notes [Member] Surplus Notes [Member] Surplus Notes [Member] Net (losses) gains on financial instruments Net losses (gains) on financial instruments Net losses (gains) on financial instruments Net (losses) gains on financial instruments Net (losses) gains on financial instruments Fixed maturities, long-term Debt Securities, Available-for-Sale, Noncurrent Derivatives [Member] Derivative [Member] Fixed Maturities [Member] Fixed Maturities [Member] Business Combinations [Abstract] Business Combinations [Abstract] Segment Reporting [Abstract] Segment Reporting [Abstract] Investments [Domain] Investments [Domain] Premium receivable, allowance for doubtful accounts Premium Receivable, Allowance for Credit Loss Noncontrolling Interest [Member] Noncontrolling Interest [Member] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Taxes paid through withholding of common stock under employee stock plans Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and shareholders' equity Liabilities and Equity Net payments attributable to current period medical claims Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year Goodwill [Roll Forward] Goodwill [Roll Forward] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Authorization remaining at the end of the period Stock Repurchase Program, Remaining Authorized Repurchase Amount Receivables, net Increase (Decrease) in Receivables Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Average price per share Stock Repurchased and Retired During Period Average Price Stock Repurchased and Retired During Period Average Price Noncontrolling interests adjustment Noncontrolling Interest, Period Increase (Decrease) Noncontrolling Interest, Period Increase (Decrease) Purchases of subsidiaries, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Convertible debenture repurchases, conversions and tax adjustments Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Level II [Member] Fair Value, Inputs, Level 2 [Member] Purchases of investments Payments to Acquire Investments Current Fiscal Year End Date Current Fiscal Year End Date Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Debt Securities, Available-for-sale, Realized Gain Debt Securities, Available-for-Sale, Realized Gain Imputed Interest, Leases Lessee, Operating Lease, Liability, Undiscounted Excess Amount Diluted net income per share Earnings Per Share, Diluted Other intangible assets Net Carrying Amount, Total Intangible Assets Intangible Assets, Net (Excluding Goodwill) Gross gains Gains From Other Investments Gains From Other Investments Fixed Maturities, long-term, amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Total current liabilities Liabilities, Current Operating lease payments, 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Long-term investments: Long-Term Investments [Abstract] Other current assets Other Assets, Current Due after ten years, Estimated Fair Value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Customer funds and cash and cash equivalents on deposit for regulatory requirements Restricted Cash and Investments, Current Schedule of Available-for-sale Securities [Table] Schedule of Available-for-Sale Securities [Table] Net medical claims payable, beginning of period Net medical claims payable, end of period Liability for Unpaid Claims and Claims Adjustment Expense, Net Equity Securities [Table] Marketable Securities [Table] Equity Securities [Member] Equity Securities [Member] Business Optimization Initiatives [Line Items] Restructuring Cost and Reserve [Line Items] Pharmacy products and services [Member] Pharmacy products and services [Member] Pharmacy products and services [Member] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Corporate Securities [Member] Corporate Debt Securities [Member] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Unrealized (losses) gains recognized on equity securities still held at the end of the period Equity Securities, FV-NI, Unrealized Gain (Loss) Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Lessee, Operating Lease, Liability, Maturity [Table Text Block] Income taxes Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable Entity Address, Address Line One Entity Address, Address Line One Total expenses Benefits, Losses and Expenses Other, net Proceeds from (Payments for) Other Financing Activities Product and Service [Axis] Product and Service [Axis] Class of Stock [Domain] Class of Stock [Domain] Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table] Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table] Reconciliation of net incurred medical claims to benefit expense [Table] Commercial & Specialty Business Segment [Member] Commercial & Specialty Business Segment [Member] Commercial and Specialty Business Segment Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Total net incurred medical claims Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims Interest expense Interest Expense Exercisable at end of period, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Credit Facility [Axis] Credit Facility [Axis] Accounting Policies [Table] Accounting Policies [Table] Accounting Policies Vested, Restricted Stock Shares And Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Tax Identification Number Entity Tax Identification Number Fair value of collateral received at time of securities lending transactions Securities Loaned, Fair Value of Collateral Schedule of Weighted-Average Fair Values Determined for the Periods Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Medical Claims payable Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block] Capital [Abstract] Banking Regulation, Total Capital [Abstract] Other Securities [Member] Other Security Investments [Member] Deferred Tax and Other Liabilities, Noncurrent Deferred Tax and Other Liabilities, Noncurrent Exchange Traded Funds [Member] Exchange Traded Funds [Member] Securities lending collateral Securities Held as Collateral, at Fair Value Consolidated Entities [Domain] Consolidated Entities [Domain] Cash [Member] Cash [Member] Change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Accrued investment income receivable Accrued Investment Income Receivable Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures Weighted Average Number of Shares Outstanding, Diluted, Adjustment Business Optimization Initiatives Restructuring and Related Costs [Table Text Block] Commercial Paper Commercial Paper Program Commercial Paper [Member] Finite-Lived Intangible Asset, Expected Amortization, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Five Entity Central Index Key Entity Central Index Key Short-duration Insurance Contracts, Claim Year [Axis] Short-Duration Insurance Contracts, Accident Year [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Major Product Revenue By Segment [Line Items] Major Product Revenue By Segment [Line Items] [Line Items] for Major Product Revenue By Segment [Table] Weighted-Average Grant Date Fair Value Per Share [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Entity [Domain] Entity [Domain] Type of Adoption [Domain] Accounting Standards Update [Domain] City Area Code City Area Code Assets Assets [Abstract] Other, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Other Securities [Member] Other Debt Obligations [Member] Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position Schedule of Unrealized Loss on Investments [Table Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table] Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Maturities, calls and redemptions from investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Net Investment Gains (Losses) Gain (Loss) on Securities [Table Text Block] Other comprehensive loss attributable to noncontrolling interests Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Total liabilities Financial Liabilities Fair Value Disclosure Repayments of short-term borrowings Repayments of Short-Term Debt Share-based compensation Share-Based Payment Arrangement, Noncash Expense Options granted during the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Total operating revenue Operating Revenue Revenue from insurance services and products sold. Variable Rate [Axis] Variable Rate [Axis] Other noncurrent liabilities Other Liabilities, Noncurrent Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) [Abstract] Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) [Abstract] Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) [Abstract] Equity in net earnings of other invested assets Income (Loss) from Equity Method Investments Gain Contingency, Nature [Axis] Gain Contingencies, Nature [Axis] Loss Contingency Accrual, Payments Loss Contingency Accrual, Payments Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Long-term purchase commitment, amount Long-Term Purchase Commitment, Amount Finite-Lived Intangible Asset, Expected Amortization, 2022 Finite-Lived Intangible Asset, Expected Amortization, Year One Denominator for Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax (Expense) Benefit Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Debt Securities, Available-for-sale, Realized Loss Debt Securities, Available-for-Sale, Realized Loss Unearned income Unearned Premiums Convertible Debenture Terms Convertible Debt [Table Text Block] Customer [Domain] Customer [Domain] EX-101.PRE 10 elv-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 elv-20220930_g1.jpg ELEVANCE HEALTH LOGO begin 644 elv-20220930_g1.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document And Entity Information Document - shares
 9 Months Ended
Sep. 30, 2022
Oct. 12, 2022
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Amendment Flag false  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Current Fiscal Year End Date --12-31  
Entity Central Index Key 0001156039  
Entity File Number 001-16751  
Entity Registrant Name ELEVANCE HEALTH, INC.  
Entity Incorporation, State or Country Code IN  
Entity Tax Identification Number 35-2145715  
Entity Address, Address Line One 220 Virginia Avenue  
Entity Address, City or Town Indianapolis  
Entity Address, State or Province IN  
Entity Address, Postal Zip Code 46204  
City Area Code 833  
Local Phone Number 401-1577  
Title of 12(b) Security Common Stock, $0.01 par value  
Trading Symbol ELV  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   238,827,582
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 8,872 $ 4,880
Fixed maturities, current 25,526 26,267
Equity securities 1,503 1,881
Premium receivables 6,682 5,681
Self-funded receivables 3,873 4,010
Other receivables 3,651 3,749
Other current assets 5,496 4,654
Total current assets 55,603 51,122
Long-term investments:    
Fixed maturities, long-term 622 632
Other invested assets 5,516 5,225
Property and equipment, net 4,197 3,919
Goodwill 24,381 24,228
Other intangible assets 10,536 10,615
Other noncurrent assets 2,171 1,719
Total assets 103,026 97,460
Current Liabilities:    
Medical claims payable 15,242 13,518
Other policyholder liabilities 5,482 5,521
Unearned income 3,702 1,153
Accounts payable and accrued expenses 4,963 4,970
Short-term borrowings 265 275
Current portion of long-term debt 2,249 1,599
Other current liabilities 9,384 7,849
Total current liabilities 41,287 34,885
Long-term debt, less current portion 21,258 21,157
Reserves for future policy benefits, noncurrent 825 802
Deferred tax liabilities, net 1,825 2,805
Other noncurrent liabilities 1,788 1,683
Total liabilities 66,983 61,332
Commitments and contingencies – Note 11
Shareholders' equity    
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none 0 0
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding – 238,974,624 and 241,770,746 2 2
Additional paid-in capital 9,169 9,148
Retained earnings 29,604 27,088
Accumulated other comprehensive loss (2,784) (178)
Total shareholders' equity 35,991 36,060
Noncontrolling interests 52 68
Total equity 36,043 36,128
Total liabilities and shareholders' equity $ 103,026 $ 97,460
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Fixed maturities, amortized cost, current $ 28,306 $ 25,641
Fixed maturities, allowance for credit loss, current 10 6
Fixed Maturities, long-term, amortized cost 671 616
Fixed maturities, allowance for credit Loss, noncurrent $ 0 $ 0
Preferred stock, par value $ 0 $ 0
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 900,000,000 900,000,000
Common stock, shares issued 238,974,624 241,770,746
Common stock, shares outstanding 238,974,624 241,770,746
Preferred stock, shares authorized 100,000,000 100,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements Of Income - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues        
Premiums $ 33,722 $ 30,395 $ 99,583 $ 86,604
Product revenue 3,972 3,353 10,841 9,132
Administrative fees and other revenue 1,931 1,800 5,569 5,189
Total operating revenue 39,625 35,548 115,993 100,925
Net investment income 371 335 1,112 1,026
Net (losses) gains on financial instruments (57) (61) (439) 107
Total revenues 39,939 35,822 116,666 102,058
Expenses        
Benefit expense 29,404 26,645 86,396 75,107
Cost of products sold 3,437 2,898 9,389 7,825
Selling, general and administrative expense 4,514 3,946 13,124 11,692
Interest expense 213 201 622 598
Amortization of other intangible assets 225 136 520 306
Loss on extinguishment of debt 0 0 0 5
Total expenses 37,793 33,826 110,051 95,533
Income before income tax expense 2,146 1,996 6,615 6,525
Income tax expense 533 494 1,557 1,555
Net income 1,613 1,502 5,058 4,970
Net loss (income) attributable to noncontrolling interests 5 7 18 (3)
Shareholders’ net income $ 1,618 $ 1,509 $ 5,076 $ 4,967
Shareholders’ net income per share        
Basic net income per share $ 6.75 $ 6.20 $ 21.11 $ 20.33
Diluted net income per share 6.68 6.13 20.86 20.09
Dividends per share $ 1.28 $ 1.13 $ 3.84 $ 3.39
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]        
Net income $ 1,613 $ 1,502 $ 5,058 $ 4,970
Other comprehensive (loss) income, net of tax:        
Change in net unrealized losses/gains on investments (639) (97) (2,630) (284)
Change in non-credit component of impairment losses on investments (1) (1) (3) 1
Change in net unrealized gains/losses on cash flow hedges 2 4 8 10
Change in net periodic pension and postretirement costs 7 8 23 26
Foreign currency translation adjustments (7) (1) (15) (7)
Other comprehensive loss (638) (87) (2,617) (254)
Net loss (income) attributable to noncontrolling interests 5 7 18 (3)
Other comprehensive loss attributable to noncontrolling interests 3 1 11 1
Total shareholders’ comprehensive income $ 983 $ 1,423 $ 2,470 $ 4,714
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements Of Cash Flows - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Operating activities    
Net income $ 5,058 $ 4,970
Adjustments to reconcile net income to net cash provided by operating activities:    
Net losses (gains) on financial instruments 439 (107)
Equity in net earnings of other invested assets (304) (437)
Depreciation and amortization 1,202 942
Deferred income taxes (170) 114
Share-based compensation 191 196
Changes in operating assets and liabilities:    
Receivables, net (678) (1,751)
Other invested assets 46 (56)
Other assets (474) (470)
Policy liabilities 1,537 2,328
Unearned income 2,548 (308)
Accounts payable and other liabilities 598 1,093
Income taxes (41) 168
Other, net (35) 10
Net cash provided by operating activities 9,917 6,692
Investing activities    
Purchases of investments (19,612) (15,130)
Proceeds from sale of investments 9,402 8,339
Maturities, calls and redemptions from investments 7,606 3,388
Changes in securities lending collateral (677) (1,030)
Purchases of subsidiaries, net of cash acquired (623) (3,442)
Purchases of property and equipment (854) (747)
Other, net (91) (50)
Net cash used in investing activities (4,849) (8,672)
Financing activities    
Net proceeds from (repayments of) commercial paper borrowings 375 (150)
Proceeds from long-term borrowings 1,286 3,462
Repayments of long-term borrowings (982) (954)
Proceeds from short-term borrowings 1,365 175
Repayments of short-term borrowings (1,375) 0
Changes in securities lending payable 685 1,030
Changes in bank overdrafts 181 316
Repurchase and retirement of common stock (1,748) (1,378)
Cash dividends (924) (831)
Proceeds from issuance of common stock under employee stock plans 152 161
Taxes paid through withholding of common stock under employee stock plans (91) (101)
Other, net 16 8
Net cash (used in) provided by financing activities (1,060) 1,738
Effect of foreign exchange rates on cash and cash equivalents (16) (9)
Change in cash and cash equivalents 3,992 (251)
Cash and cash equivalents at beginning of period 4,880 5,741
Cash and cash equivalents at end of period $ 8,872 $ 5,490
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements Of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Cumulative Effect, Period of Adoption, Adjustment
Cumulative Effect, Period of Adoption, Adjusted Balance
Common Stock [Member]
Additional Paid-In Capital [Member]
Retained Earnings [Member]
Retained Earnings [Member]
Cumulative Effect, Period of Adoption, Adjustment
Retained Earnings [Member]
Cumulative Effect, Period of Adoption, Adjusted Balance
Accumulated Other Comprehensive (Loss) Income [Member]
Noncontrolling Interest [Member]
Balance (in shares), Beginning at Dec. 31, 2020       245.4            
Total shareholders' equity, Beginning Balance at Dec. 31, 2020       $ 3 $ 9,244     $ 23,802 $ 150  
Noncontrolling interests, Beginning Balance at Dec. 31, 2020                   $ 0
Total equity, Beginning Balance at Dec. 31, 2020     $ 33,199              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Shareholders' net income           $ 1,665        
Net Income (Loss) Attributable to Noncontrolling Interest                   2
Net income $ 1,667                  
Shareholders' other comprehensive income (loss)                 (345)  
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest                   (2)
Other Comprehensive Income (Loss), Net of Tax (347)                  
Noncontrolling interests adjustment 65                 65
Repurchase and retirement of common stock, shares       (1.4)            
Repurchase and retirement of common stock (447)     $ (1) (53) (393)        
Dividends and dividend equivalents (281)         (281)        
Issuance of common stock under employee stock plans, net of related tax benefits, Shares       0.9            
Issuance of common stock under employee stock plans, net of related tax benefits 62       62          
Balance (in shares), Ending at Mar. 31, 2021       244.9            
Total shareholders' equity, Ending Balance at Mar. 31, 2021       $ 2 9,253 24,793     (195)  
Noncontrolling interests, Ending Balance at Mar. 31, 2021                   65
Total equity, Ending Balance at Mar. 31, 2021 33,918                  
Balance (in shares), Beginning at Dec. 31, 2020       245.4            
Total shareholders' equity, Beginning Balance at Dec. 31, 2020       $ 3 9,244     23,802 150  
Noncontrolling interests, Beginning Balance at Dec. 31, 2020                   0
Total equity, Beginning Balance at Dec. 31, 2020     33,199              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Shareholders' net income 4,967                  
Net Income (Loss) Attributable to Noncontrolling Interest 3                  
Net income 4,970                  
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest (1)                  
Other Comprehensive Income (Loss), Net of Tax $ (254)                  
Repurchase and retirement of common stock, shares (3.9)                  
Repurchase and retirement of common stock $ (1,378)                  
Balance (in shares), Ending at Sep. 30, 2021       242.8            
Total shareholders' equity, Ending Balance at Sep. 30, 2021 35,808     $ 2 9,138 26,700     (103)  
Noncontrolling interests, Ending Balance at Sep. 30, 2021                   71
Balance (in shares), Beginning at Mar. 31, 2021       244.9            
Total shareholders' equity, Beginning Balance at Mar. 31, 2021       $ 2 9,253 24,793     (195)  
Noncontrolling interests, Beginning Balance at Mar. 31, 2021                   65
Total equity, Beginning Balance at Mar. 31, 2021 33,918                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Shareholders' net income           1,793        
Net Income (Loss) Attributable to Noncontrolling Interest                   8
Net income 1,801                  
Shareholders' other comprehensive income (loss)                 178  
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest                   2
Other Comprehensive Income (Loss), Net of Tax 180                  
Noncontrolling interests adjustment 3                 3
Repurchase and retirement of common stock, shares       (1.3)            
Repurchase and retirement of common stock (480)     $ 0 (47) (433)        
Dividends and dividend equivalents (279)         (279)        
Issuance of common stock under employee stock plans, net of related tax benefits, Shares       0.3            
Issuance of common stock under employee stock plans, net of related tax benefits 119       119          
Convertible debenture repurchases, conversions and tax adjustments (216)       (216)          
Balance (in shares), Ending at Jun. 30, 2021       243.9            
Total shareholders' equity, Ending Balance at Jun. 30, 2021       $ 2 9,109 25,874     (17)  
Noncontrolling interests, Ending Balance at Jun. 30, 2021                   78
Total equity, Ending Balance at Jun. 30, 2021 35,046                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Shareholders' net income 1,509         1,509        
Net Income (Loss) Attributable to Noncontrolling Interest (7)                 (7)
Net income 1,502                  
Shareholders' other comprehensive income (loss)                 (86)  
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest (1)                 (1)
Other Comprehensive Income (Loss), Net of Tax (87)                  
Noncontrolling interests adjustment 1                 1
Repurchase and retirement of common stock, shares       (1.2)            
Repurchase and retirement of common stock (451)     $ 0 (44) (407)        
Dividends and dividend equivalents (276)         (276)        
Issuance of common stock under employee stock plans, net of related tax benefits, Shares       0.1            
Issuance of common stock under employee stock plans, net of related tax benefits 75       75          
Convertible debenture repurchases, conversions and tax adjustments (2)       (2)          
Balance (in shares), Ending at Sep. 30, 2021       242.8            
Total shareholders' equity, Ending Balance at Sep. 30, 2021 35,808     $ 2 9,138 26,700     (103)  
Noncontrolling interests, Ending Balance at Sep. 30, 2021                   71
Balance (in shares), Beginning at Dec. 31, 2021       241.8            
Total shareholders' equity, Beginning Balance at Dec. 31, 2021 36,060     $ 2 9,148 27,088   27,065 (178)  
Total shareholders' equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021             $ (23)      
Noncontrolling interests, Beginning Balance at Dec. 31, 2021 68                 68
Total equity, Beginning Balance at Dec. 31, 2021 36,128   36,105              
Total equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021   $ (23)                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Shareholders' net income           1,805        
Net Income (Loss) Attributable to Noncontrolling Interest                   (10)
Net income 1,795                  
Shareholders' other comprehensive income (loss)                 (1,058)  
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest                   (5)
Other Comprehensive Income (Loss), Net of Tax (1,063)                  
Noncontrolling interests adjustment 3                 3
Repurchase and retirement of common stock, shares       (1.2)            
Repurchase and retirement of common stock (545)       (45) (500)        
Dividends and dividend equivalents (312)         (312)        
Issuance of common stock under employee stock plans, net of related tax benefits, Shares       0.5            
Issuance of common stock under employee stock plans, net of related tax benefits 39       39          
Convertible debenture repurchases, conversions and tax adjustments 9       9          
Balance (in shares), Ending at Mar. 31, 2022       241.1            
Total shareholders' equity, Ending Balance at Mar. 31, 2022       $ 2 9,151 28,058     (1,236)  
Noncontrolling interests, Ending Balance at Mar. 31, 2022                   56
Total equity, Ending Balance at Mar. 31, 2022 36,031                  
Balance (in shares), Beginning at Dec. 31, 2021       241.8            
Total shareholders' equity, Beginning Balance at Dec. 31, 2021 36,060     $ 2 9,148 27,088   $ 27,065 (178)  
Total shareholders' equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021             $ (23)      
Noncontrolling interests, Beginning Balance at Dec. 31, 2021 68                 68
Total equity, Beginning Balance at Dec. 31, 2021 36,128   $ 36,105              
Total equity, Beginning Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021   $ (23)                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Shareholders' net income 5,076                  
Net Income (Loss) Attributable to Noncontrolling Interest (18)                  
Net income 5,058                  
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest (11)                  
Other Comprehensive Income (Loss), Net of Tax $ (2,617)                  
Repurchase and retirement of common stock, shares (3.7)                  
Repurchase and retirement of common stock $ (1,748)                  
Balance (in shares), Ending at Sep. 30, 2022       239.0            
Total shareholders' equity, Ending Balance at Sep. 30, 2022 35,991     $ 2 9,169 29,604     (2,784)  
Noncontrolling interests, Ending Balance at Sep. 30, 2022 52                 52
Total equity, Ending Balance at Sep. 30, 2022 36,043                  
Balance (in shares), Beginning at Mar. 31, 2022       241.1            
Total shareholders' equity, Beginning Balance at Mar. 31, 2022       $ 2 9,151 28,058     (1,236)  
Noncontrolling interests, Beginning Balance at Mar. 31, 2022                   56
Total equity, Beginning Balance at Mar. 31, 2022 36,031                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Shareholders' net income           1,653        
Net Income (Loss) Attributable to Noncontrolling Interest                   (3)
Net income 1,650                  
Shareholders' other comprehensive income (loss)                 (913)  
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest                   (3)
Other Comprehensive Income (Loss), Net of Tax (916)                  
Noncontrolling interests adjustment 5                 5
Repurchase and retirement of common stock, shares       (1.3)            
Repurchase and retirement of common stock (624)       (48) (576)        
Dividends and dividend equivalents (310)         (310)        
Issuance of common stock under employee stock plans, net of related tax benefits, Shares       0.2            
Issuance of common stock under employee stock plans, net of related tax benefits 111       111          
Convertible debenture repurchases, conversions and tax adjustments (80)       (80)          
Balance (in shares), Ending at Jun. 30, 2022       240.0            
Total shareholders' equity, Ending Balance at Jun. 30, 2022       $ 2 9,134 28,825     (2,149)  
Noncontrolling interests, Ending Balance at Jun. 30, 2022                   55
Total equity, Ending Balance at Jun. 30, 2022 35,867                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Shareholders' net income 1,618         1,618        
Net Income (Loss) Attributable to Noncontrolling Interest (5)                 (5)
Net income 1,613                  
Shareholders' other comprehensive income (loss)                 (635)  
Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest (3)                 (3)
Other Comprehensive Income (Loss), Net of Tax (638)                  
Noncontrolling interests adjustment 5                  
Noncontrolling interests adjustment                   5
Repurchase and retirement of common stock, shares       (1.2)            
Repurchase and retirement of common stock (579)       (47) (532)        
Dividends and dividend equivalents (307)         (307)        
Issuance of common stock under employee stock plans, net of related tax benefits, Shares       0.2            
Issuance of common stock under employee stock plans, net of related tax benefits 103       103          
Convertible debenture repurchases, conversions and tax adjustments (21)       (21)          
Balance (in shares), Ending at Sep. 30, 2022       239.0            
Total shareholders' equity, Ending Balance at Sep. 30, 2022 35,991     $ 2 $ 9,169 $ 29,604     $ (2,784)  
Noncontrolling interests, Ending Balance at Sep. 30, 2022 52                 $ 52
Total equity, Ending Balance at Sep. 30, 2022 $ 36,043                  
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization
On May 18, 2022, our shareholders approved a proposal to amend our amended and restated articles of incorporation to change our name from Anthem, Inc. to Elevance Health, Inc. This amendment and name change went into effect on June 27, 2022. We began operating as Elevance Health, Inc. and trading under our new ticker symbol “ELV” on June 28, 2022. References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context otherwise requires.
Elevance Health is a health company with the purpose of improving the health of humanity. We are the largest health insurer in the United States in terms of medical membership, serving over 47 million medical members through our affiliated health plans as of September 30, 2022. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management and wellness programs, actuarial services and other administrative services. We also provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to our subsidiary health plans and also unaffiliated health plans, including pharmacy benefits management (“PBM”) services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. In addition, we conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, Integra Managed Care, MMM, Optimum HealthCare, Simply Healthcare, and/or UniCare. We offer PBM services through our IngenioRx, Inc. (“IngenioRx”) subsidiary. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.
As part of our name change to Elevance Health, on June 15, 2022 we announced that over the next several years we will organize our brand portfolio into the following core go-to-market brands:
•Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;
•Wellpoint — we intend to unite select non-BCBSA licensed Medicare, Medicaid and Commercial plans under the Wellpoint name; and
•Carelon — this brand will bring together our healthcare brands and capabilities, including our Diversified Business Group and IngenioRx business under a single brand name. We now refer to our Diversified Business Group as Carelon. In January 2023, IngenioRx will become CarelonRx.
There are currently no segment changes associated with this branding strategy. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner, and given this evolution we are in the process of reviewing and modifying how we will manage our businesses in the future.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis Of Presentation and Significant Accounting Policies
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies
Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our 2021 Annual Report on Form 10-K, unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and nine months ended September 30, 2022 and 2021 have been recorded. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2022, or any other period. The seasonal nature of portions of our health care and related benefits business, competitive and other market conditions, as well as COVID-19 related impacts, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $291 and $173 at September 30, 2022 and December 31, 2021, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the
securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption “Other invested assets” in our consolidated balance sheets.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” in our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities” in our consolidated balance sheets. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $140 and $142 at September 30, 2022 and December 31, 2021, respectively.
Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $82 and $50 at September 30, 2022 and December 31, 2021, respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income, and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $709 and $648 at September 30, 2022 and December 31, 2021, respectively.
Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at September 30, 2022. For the three and nine months ended September 30, 2022 and 2021, revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
Recently Adopted Accounting Guidance: In January 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2021-01, Reference Rate Reform (Topic 848) (“ASU 2021-01”). The amendments in ASU 2021-01 provide optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of the reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
In October 2020, the FASB issued Accounting Standards Update No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other Costs (“ASU 2020-08”). The amendments in ASU 2020-08 clarify when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting periods beginning after December 15, 2020. The amendments were to be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted earnings per share calculation and expand disclosure requirements. The amendments became effective for our annual and interim reporting periods beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease to our deferred tax liabilities of $8, and a corresponding cumulative-effect reduction to our opening retained earnings of $23; these amounts are not material to our overall consolidated financial position. The adoption of ASU 2020-06 did not have an impact on our results of operations or our consolidated cash flows. Use of the if-converted method did not have an impact on our overall earnings per share calculation.
In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
Recent Accounting Guidance Not Yet Adopted: In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments
for market risk benefits are to be applied retrospectively. We do not believe the adoption of ASU 2020-11 and ASU 2018-12 will have a material impact on our consolidated financial position, results of operations, cash flows, and related disclosures.
There were no other new accounting pronouncements that were issued or became effective since the issuance of our 2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Acquisitions
 9 Months Ended
Sep. 30, 2022
Business Combinations [Abstract]  
Business Acquisitions Business Acquisitions
Completed Acquisitions
On May 5, 2022, we completed our acquisition of Integra Managed Care (“Integra”) from Personal Touch Holding Corporation. Integra is a managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in their own homes. The purchase price was allocated to the tangible and intangible net assets acquired based on management’s initial estimates of their fair values, of which $89 has been allocated to finite-lived intangible assets, $250 to indefinite-lived intangible assets, and $123 to goodwill, including measurement period adjustments to goodwill of $13 during the quarter ended September 30, 2022. The majority of goodwill is deductible for income tax purposes. As of September 30, 2022, the initial accounting for the acquisition had not been finalized. Any subsequent adjustments made to the assets acquired or liabilities assumed during the measurement period will be recorded as an adjustment to goodwill. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.
Acquisitions completed during the year ended December 31, 2021, for which the initial accounting was finalized during the three months ended June 30, 2022 included myNEXUS, Inc. (“myNEXUS”), a comprehensive home-based nursing management company for payors, and MMM Holdings, LLC (“MMM”), including its Medicare Advantage plan, Medicaid plan and other affiliated companies. As of September 30, 2022, the purchase price of each transaction was allocated to the tangible and intangible net assets acquired based on management’s final estimates of their fair values, of which $1,577 has been allocated to finite-lived intangible assets, $20 to indefinite-lived intangible assets, and $2,531 to goodwill. The majority of goodwill is not deductible for income tax purposes.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Optimization Initiatives
 9 Months Ended
Sep. 30, 2022
Business Optimization Initiatives [Abstract]  
Business Optimization Initiatives Business Optimization Initiatives
Provided below is a summary of the activity, by reportable segment, related to the liability for employee termination costs previously incurred in connection with our enterprise-wide business optimization initiatives introduced in 2020.
Commercial & Specialty BusinessGovernment BusinessIngenioRxOtherTotal
2020 Business Optimization Initiatives
Employee termination costs:
Liability for employee termination costs at January 1, 2022$61 $57 $1 $3 $122 
Payments(16)(14)— — (30)
Liability for employee termination costs at September 30, 2022
$45 $43 $1 $3 $92 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments
 9 Months Ended
Sep. 30, 2022
Investments [Abstract]  
Investments Investments
Fixed Maturity Securities
We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. We have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value may occur and additional material impairment losses for credit losses on investments may be recorded in future periods.
A summary of current and long-term fixed maturity securities, available-for-sale, at September 30, 2022 and December 31, 2021 is as follows:
Cost or Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Allowance
For Credit
Losses		Estimated
Fair Value
 
September 30, 2022
Fixed maturity securities:
United States Government securities$1,673 $— $(125)$— $1,548 
Government sponsored securities65 — (4)— 61 
Foreign government securities322 — (70)(1)251 
States, municipalities and political subdivisions4,431 5 (355)— 4,081 
Corporate securities13,766 9 (1,560)(7)12,208 
Residential mortgage-backed securities4,748 7 (506)(2)4,247 
Commercial mortgage-backed securities77 — (7)— 70 
Other securities3,895 37 (250)— 3,682 
Total fixed maturity securities$28,977 $58 $(2,877)$(10)$26,148 
December 31, 2021
Fixed maturity securities:
United States Government securities$1,443 $7 $(18)$— $1,432 
Government sponsored securities65 4 (1)— 68 
Foreign government securities353 7 (13)— 347 
States, municipalities and political subdivisions5,321 310 (10)— 5,621 
Corporate securities12,044 401 (78)(4)12,363 
Residential mortgage-backed securities4,059 75 (35)(2)4,097 
Commercial mortgage-backed securities65 2 (3)— 64 
Other securities2,907 24 (24)— 2,907 
Total fixed maturity securities$26,257 $830 $(182)$(6)$26,899 
For fixed maturity securities in an unrealized loss position at September 30, 2022 and December 31, 2021, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position: 
 Less than 12 Months12 Months or Greater
(Securities are whole amounts)Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss		Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss
September 30, 2022
Fixed maturity securities:
United States Government securities65 $911 $(77)29 $303 $(48)
Government sponsored securities40 61 (4)1 — — 
Foreign government securities
225 169 (34)151 81 (36)
States, municipalities and political subdivisions
1,964 3,602 (314)139 200 (41)
Corporate securities4,322 10,228 (1,165)1,318 1,679 (395)
Residential mortgage-backed securities2,035 2,949 (294)530 1,182 (212)
Commercial mortgage-backed securities34 56 (3)7 13 (4)
Other securities921 2,535 (165)269 670 (85)
Total fixed maturity securities9,606 $20,511 $(2,056)2,444 $4,128 $(821)
December 31, 2021
Fixed maturity securities:
United States Government securities
51 $990 $(11)27 $176 $(7)
Government sponsored securities
— — — 1 1 (1)
Foreign government securities
188 143 (8)68 41 (5)
States, municipalities and political subdivisions
281 634 (9)8 16 (1)
Corporate securities
1,846 3,310 (57)403 485 (21)
Residential mortgage-backed securities
692 1,967 (26)125 173 (9)
Commercial mortgage-backed securities
2 4 (1)4 8 (2)
Other securities
511 1,707 (19)50 85 (5)
Total fixed maturity securities3,571 $8,755 $(131)686 $985 $(51)
Although not material to our consolidated results of operations, during the nine months ended September 30, 2022, we recorded a combination of credit losses, losses on sales of fixed maturity securities and impairments related to our exposure resulting from investments in Russia and Ukraine. At September 30, 2022, our remaining holdings of Russia and Ukraine fixed maturity securities were not material.
Unrealized losses on our securities shown in the table above have not been recognized into income because, as of September 30, 2022, we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior to their maturity or anticipated recovery. The declines in fair values are largely due to increasing interest rates driven by the high rate of inflation and other market conditions and not by unfavorable changes in the credit quality characteristics that impact our assessment on collectability of principal and interest. We have evaluated qualitative and quantitative factors for indications of credit losses on our securities, including factors such as credit rating, foreign political conflicts, uncertainties around future ability to collect payment, significant declines in fair value and industry conditions, market data, and notifications of maturity and coupon default, and have recorded an allowance for credit losses in the amount of $10 and $6 at September 30, 2022 and December 31, 2021, respectively.
The amortized cost and fair value of fixed maturity securities at September 30, 2022, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.
Amortized
Cost		Estimated
Fair Value
Due in one year or less$911 $901 
Due after one year through five years7,364 6,871 
Due after five years through ten years9,535 8,467 
Due after ten years6,342 5,592 
Mortgage-backed securities4,825 4,317 
Total fixed maturity securities$28,977 $26,148 
During the three and nine months ended September 30, 2022, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $5,281 and $15,953, respectively. During the three and nine months ended September 30, 2021, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $2,620 and $8,570, respectively.
In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.
All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
Equity Securities
A summary of marketable equity securities at September 30, 2022 and December 31, 2021 is as follows:
 September 30, 2022December 31, 2021
Equity securities:
Exchange traded funds$1,403 $1,750 
Common equity securities5 42 
Private equity securities95 89 
Total$1,503 $1,881 
Other Invested Assets
Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, mortgage loans and the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Financial information for certain of these investments are reported on a one or three month lag due to the timing of when we receive financial information from the companies.
Investment Gains and Losses
Net investment (losses) gains for the three and nine months ended September 30, 2022 and 2021 are as follows:
Three Months Ended
September 30		Nine Months Ended
September 30
2022202120222021
Net (losses) gains:
Fixed maturity securities:
Gross realized gains from sales$8 $30 $44 $133 
Gross realized losses from sales(99)(8)(353)(32)
Impairment (losses) recoveries recognized in income(5)— (25)1 
Net realized (losses) gains from sales of fixed maturity securities(96)22 (334)102 
Equity securities:
Unrealized (losses) gains recognized on equity securities still held at the end of the period(43)(4)(192)4 
Net realized gains (losses) recognized on equity securities sold during the period4 (1)(20)(57)
Net losses on equity securities(39)(5)(212)(53)
Other investments:
Gross gains95 2 126 9 
Gross losses(2)(93)(45)(5)
Impairment (losses) recoveries recognized in income(12)1 (17)(5)
Net losses (gains) on other investments81 (90)64 (1)
Net (losses) gains on investments$(54)$(73)$(482)$48 
Accrued Investment Income
At September 30, 2022 and December 31, 2021, accrued investment income totaled $228 and $205, respectively. We recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets.
Securities Lending Programs
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. The fair value of the collateral received at the time of the transactions amounted to $2,841 and $2,155 at September 30, 2022 and December 31, 2021, respectively. The value of the collateral represented 102% of the market value of the securities on loan at each of September 30, 2022 and December 31, 2021. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets.
At September 30, 2022 and December 31, 2021, the remaining contractual maturity of our securities lending agreements included overnight and continuous transactions of cash for $2,636 and $1,874, respectively, of United States Government securities for $180 and $281, respectively, and of Other securities for $25 and $0, respectively.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Derivative Financial Instruments
 9 Months Ended
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments Derivative Financial Instruments
We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions.
We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to
LIBOR or the Secured Overnight Financing Rate (“SOFR”). Any amounts recognized for changes in fair value of these derivatives are included in the captions “Other current assets,” “Other noncurrent assets,” “Other current liabilities” or “Other noncurrent liabilities” in our consolidated balance sheets.
The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $231 and $239 at September 30, 2022 and December 31, 2021, respectively.
During the three and nine months ended September 30, 2022, we recognized net (losses) gains on non-hedging derivatives of $(3) and $43, respectively. During the three and nine months ended September 30, 2021, we recognized net gains on non-hedging derivatives of $12 and $59, respectively.
For additional information relating to the fair value of our derivative assets and liabilities, see Note 7, “Fair Value,” of this Form 10-Q.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Fair Value
Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:
Level InputInput Definition
Level IInputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level IIInputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.
Level IIIUnobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in our consolidated balance sheets:
Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.
Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities, United States government securities, foreign government securities, and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily corporate debt securities, which are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.
Equity securities: Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions
for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.
Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures.
Derivatives: Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate observable market inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by counterparty.
A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at September 30, 2022 and December 31, 2021 is as follows:
Level ILevel IILevel IIITotal
September 30, 2022
Assets:
Cash equivalents$5,794 $— $— $5,794 
Fixed maturity securities, available-for-sale:
United States Government securities— 1,548 — 1,548 
Government sponsored securities— 61 — 61 
Foreign government securities— 251 — 251 
States, municipalities and political subdivisions, tax-exempt— 4,081 — 4,081 
Corporate securities— 12,079 129 12,208 
Residential mortgage-backed securities— 4,247 — 4,247 
Commercial mortgage-backed securities— 70 — 70 
Other securities— 3,371 311 3,682 
Total fixed maturity securities, available-for-sale— 25,708 440 26,148 
Equity securities:
Exchange traded funds1,403 — — 1,403 
Common equity securities6 (1)— 5 
Private equity securities— — 95 95 
Total equity securities1,409 (1)95 1,503 
Other invested assets - common equity securities149 — — 149 
Securities lending collateral— 2,841 — 2,841 
Derivatives - other assets— 25 — 25 
Total assets$7,352 $28,573 $535 $36,460 
Liabilities:
Derivatives - other liabilities$— $(70)$— $(70)
Total liabilities$— $(70)$— $(70)
December 31, 2021
Assets:
Cash equivalents$2,415 $— $— $2,415 
Fixed maturity securities, available-for-sale:
United States Government securities— 1,432 — 1,432 
Government sponsored securities— 68 — 68 
Foreign government securities— 347 — 347 
States, municipalities and political subdivisions, tax-exempt— 5,621 — 5,621 
Corporate securities— 12,027 336 12,363 
Residential mortgage-backed securities— 4,092 5 4,097 
Commercial mortgage-backed securities— 64 — 64 
Other securities— 2,888 19 2,907 
Total fixed maturity securities, available-for-sale— 26,539 360 26,899 
Equity securities:
Exchange traded funds1,750 — — 1,750 
Common equity securities8 34 — 42 
Private equity securities— — 89 89 
Total equity securities1,758 34 89 1,881 
Other invested assets - common equity securities138 — — 138 
Securities lending collateral— 2,155 — 2,155 
Derivatives - other assets— 19 — 19 
Total assets$4,311 $28,747 $449 $33,507 
Liabilities:
Derivatives - other liabilities$— $(1)$— $(1)
Total liabilities$— $(1)$— $(1)
A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended September 30, 2022 and 2021 is as follows:
Corporate
Securities		Residential
Mortgage-
backed
Securities		Other 
Securities		Equity
Securities		Total
Three Months Ended September 30, 2022
Beginning balance at July 1, 2022$155 $— $218 $94 $467 
Total losses:
Recognized in net income— — — — — 
Recognized in accumulated other comprehensive loss1 — 17 — 18 
Purchases15 — 77 3 95 
Sales(26)— (1)(2)(29)
Settlements(10)— — — (10)
Transfers out of Level III(6)— — — (6)
Ending balance at September 30, 2022$129 $— $311 $95 $535 
Change in unrealized losses included in net income related to assets still held at September 30, 2022$— $— $— $— $— 
Three Months Ended September 30, 2021
Beginning balance at July 1, 2021$351 $2 $7 $77 $437 
Total gains:
Recognized in net income1 — — 5 6 
Recognized in accumulated other comprehensive loss(1)— — — (1)
Purchases34 — — 3 37 
Sales— — — (1)(1)
Settlements(47)— — — (47)
Transfers out of Level III(4)(1)(5)— (10)
Ending balance at September 30, 2021$334 $1 $2 $84 $421 
Change in unrealized gains included in net income related to assets still held at September 30, 2021$— $— $— $5 $5 
A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the nine months ended September 30, 2022 and 2021 is as follows:
Corporate
Securities		Residential
Mortgage-
backed
Securities		Other 
Securities		Equity
Securities		Total
Nine Months Ended September 30, 2022
Beginning balance at January 1, 2022$336 $5 $19 $89 $449 
Total losses:
Recognized in net income— — — 1 1 
Recognized in accumulated other comprehensive loss(1)— 17 — 16 
Purchases40 — 281 24 345 
Sales(201)— (1)(19)(221)
Settlements(42)— — — (42)
Transfers into Level III9 — — — 9 
Transfers out of Level III(12)(5)(5)— (22)
Ending balance at September 30, 2022$129 $— $311 $95 $535 
Change in unrealized gains included in net income related to assets still held at September 30, 2022$— $— $— $1 $1 
Nine Months Ended September 30, 2021
Beginning balance at January 1, 2021$325 $2 $5 $60 $392 
Total gains:
Recognized in net income2 — — 17 19 
Recognized in accumulated other comprehensive loss4 — — — 4 
Purchases135 — — 11 146 
Sales(12)— — (4)(16)
Settlements(118)— (1)— (119)
Transfers out of Level III(2)(1)(2)— (5)
Ending balance at September 30, 2021$334 $1 $2 $84 $421 
Change in unrealized gains included in net income related to assets still held at September 30, 2021$— $— $— $17 $17 
There were no individually material transfers into or out of Level III during the three and nine months ended September 30, 2022 or 2021.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions,” we completed our acquisition of Integra in the second quarter of 2022 and the acquisitions of myNEXUS and MMM during the second quarter of 2021. The net assets acquired in our acquisitions of Integra, myNEXUS and MMM and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of assets acquired and liabilities assumed were recorded at their carrying values as of the respective date of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of Integra, myNEXUS and MMM were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisitions of Integra, myNEXUS and MMM described above, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the three and nine months ended September 30, 2022 or 2021.
Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows.
Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the three and nine months ended September 30, 2022 or 2021.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in our consolidated balance sheets.
Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.
The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.
The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value in our consolidated balance sheets:
Other invested assets: Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations and mortgage loans, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.
Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or, if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt—commercial paper: The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest rates at market value.
Long-term debt—senior unsecured notes and surplus notes: The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt—convertible debentures: The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade.
A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at September 30, 2022 and December 31, 2021 is as follows:
 Carrying
Value		Estimated Fair Value
 Level ILevel IILevel IIITotal
September 30, 2022
Assets:
Other invested assets$5,367 $— $— $5,367 $5,367 
Liabilities:
Debt:
Short-term borrowings265 — 265 — 265 
Commercial paper675 — 675 — 675 
Notes22,747 — 20,163 — 20,163 
Convertible debentures86 — 554 — 554 
December 31, 2021
Assets:
Other invested assets$5,087 $— $— $5,087 $5,087 
Liabilities:
Debt:
Short-term borrowings275 — 275 — 275 
Commercial paper300 — 300 — 300 
Notes22,384 — 25,150 — 25,150 
Convertible debentures72 — 687 — 687 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
During the three months ended September 30, 2022 and 2021, we recognized income tax expense of $533 and $494, respectively, which represent effective income tax rates of 24.8% and 24.7%, respectively.
During the nine months ended September 30, 2022 and 2021, we recognized income tax expense of $1,557 and $1,555, respectively, which represent effective income tax rates of 23.5% and 23.8%, respectively. The decrease in our effective tax rate from the nine months ended September 30, 2021 was primarily related to the tax impact of expected geographic changes in our mix of 2022 earnings.
Income taxes receivable totaled $214 and $173 at September 30, 2022 and December 31, 2021, respectively. We recognized the income taxes receivable as an asset under the caption “Other current assets” in our consolidated balance sheets.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Medical Claims Payable
 9 Months Ended
Sep. 30, 2022
Liability for Claims and Claims Adjustment Expense [Abstract]  
Medical Claims payable Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2022 is as follows:
Commercial
& Specialty
Business		Government
Business		OtherTotal
Gross medical claims payable, beginning of period$3,847 $9,157 $278 $13,282 
Ceded medical claims payable, beginning of period(13)(8)— (21)
Net medical claims payable, beginning of period3,834 9,149 278 13,261 
Business combinations and purchase adjustments3 130 — 133 
Net incurred medical claims:
Current period22,049 60,971 1,157 84,177 
Prior periods redundancies(183)(639)(79)(901)
Total net incurred medical claims21,866 60,332 1,078 83,276 
Net payments attributable to:
Current period medical claims18,604 50,950 899 70,453 
Prior periods medical claims3,181 7,854 184 11,219 
Total net payments21,785 58,804 1,083 81,672 
Net medical claims payable, end of period3,918 10,807 273 14,998 
Ceded medical claims payable, end of period3 — — 3 
Gross medical claims payable, end of period$3,921 $10,807 $273 $15,001 
At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Commercial & Specialty Business was $81, $388 and $3,449 for the claim years 2020 and prior, 2021 and 2022, respectively.
At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Government Business was $148, $508 and $10,151 for the claim years 2020 and prior, 2021 and 2022, respectively.
At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for Other was $2, $14 and $257 for the claim years 2020 and prior, 2021 and 2022, respectively.
A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2021 is as follows:
Commercial
& Specialty
Business		Government
Business		OtherTotal
Gross medical claims payable, beginning of period$3,294 $7,646 $195 $11,135 
Ceded medical claims payable, beginning of period(13)(33)— (46)
Net medical claims payable, beginning of period3,281 7,613 195 11,089 
Business combinations and purchase adjustments— 375 45 420 
Net incurred medical claims:
Current period20,499 52,422 1,176 74,097 
Prior periods redundancies(496)(1,309)(17)(1,822)
Total net incurred medical claims20,003 51,113 1,159 72,275 
Net payments attributable to:
Current period medical claims16,985 44,160 978 62,123 
Prior periods medical claims2,450 5,781 169 8,400 
Total net payments19,435 49,941 1,147 70,523 
Net medical claims payable, end of period3,849 9,160 252 13,261 
Ceded medical claims payable, end of period15 23 — 38 
Gross medical claims payable, end of period$3,864 $9,183 $252 $13,299 
The favorable development recognized in the nine months ended September 30, 2022 and 2021 resulted primarily from trend factors in late 2021 and late 2020, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter parts of 2020 developing faster than expected also contributed to the favorable development in the nine months ended September 30, 2021. The impact from COVID-19 on healthcare utilization and medical claims submission patterns continues to provide increased estimation uncertainty on our incurred but not reported liability at September 30, 2022.
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2022 is as follows:
Three Months EndedNine Months Ended September 30, 2022
March 31, 2022June 30, 2022September 30, 2022
Net incurred medical claims:
Commercial & Specialty Business$6,834 $7,522 $7,510 $21,866 
Government Business19,943 19,788 20,601 60,332 
Other354 324 400 1,078 
Total net incurred medical claims27,131 27,634 28,511 83,276 
Quality improvement and other claims expense1,084 1,143 893 3,120 
Benefit expense$28,215 $28,777 $29,404 $86,396 
During the three months ended September 30, 2022, based on recent regulatory clarification, we realigned certain quality improvement costs from benefit expense to administrative expense that were previously allocated to benefit expense during the three months ended March 31, 2022 and the three months ended June 30, 2022.
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2021 is as follows:
Three Months EndedNine Months Ended September 30, 2021
March 31, 2021June 30, 2021September 30, 2021
Net incurred medical claims:
Commercial & Specialty Business$6,072 $6,718 $7,213 $20,003 
Government Business16,319 16,723 18,071 51,113 
Other336 403 420 1,159 
Total net incurred medical claims22,727 23,844 25,704 72,275 
Quality improvement and other claims expense972 919 941 2,832 
Benefit expense$23,699 $24,763 $26,645 $75,107 
The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of September 30, 2022, is as follows:
Commercial
& Specialty
Business		Government
Business		OtherTotal
Net medical claims payable, end of period$3,918 $10,807 $273 $14,998 
Ceded medical claims payable, end of period3 — — 3 
Insurance lines other than short duration— 241 — 241 
Gross medical claims payable, end of period$3,921 $11,048 $273 $15,242 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Debt Debt
We generally issue senior unsecured notes for long-term borrowing purposes. At September 30, 2022 and December 31, 2021, we had $22,722 and $22,359, respectively, outstanding under these notes.
On May 16, 2022, we repaid, at maturity, the $850 outstanding balance of our 3.125% senior unsecured notes.
On April 29, 2022, we issued $600 aggregate principal amount of 4.100% Notes due 2032 (the “2032 Notes”) and $700 aggregate principal amount of 4.550% Notes due 2052 (the “2052 Notes”) under our shelf registration statement. Interest on the 2032 Notes and 2052 Notes is payable semi-annually in arrears on May 15 and November 15 of each year, commencing November 15, 2022. We used the net proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.
We have an unsecured surplus note with an outstanding principal balance of $25 at both September 30, 2022 and December 31, 2021.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. On April 18, 2022, we amended and restated the credit agreement for the 5-Year Facility to, among other things, extend the maturity date of the 5-Year Facility from June 2024 to April 2027 and increase the amount of credit available under the 5-Year Facility from $2,500 to $4,000. Also on April 18, 2022, concurrently with the amendment and restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which was scheduled to mature in June 2022 (the “2021 364-Day Facility”). In June 2021, we terminated our 364-day senior revolving credit facility (the “prior 364-Day Facility”), which was scheduled to mature in June 2021, and entered into the 2021 364-Day Facility with a group of lenders for general corporate purposes. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. As of September 30, 2022, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.7%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As
of September 30, 2022, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility, the 2021 364-Day Facility or the prior 364-Day Facility at any time during the nine months ended September 30, 2022 or the year ended December 31, 2021.
Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit of up to $200. At September 30, 2022 and December 31, 2021, there were no amounts outstanding under our Subsidiary Credit Facilities.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. In July 2022, we increased the amount available under the commercial paper program from $3,500 to $4,000. At September 30, 2022 and December 31, 2021, we had $675 and $300, respectively, outstanding under this program.
We have outstanding senior unsecured convertible debentures due 2042 (the “Debentures”), which are governed by an indenture (the “indenture”) between us and The Bank of New York Mellon Trust Company, N.A., as trustee. We accounted for the Debentures in accordance with the FASB cash conversion guidance for debt with conversion and other options at the time of issue. As a result, the value of the embedded conversion option (net of deferred taxes and equity issuance costs) was bifurcated from its debt host and recorded as a component of additional paid-in capital in our consolidated balance sheets. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease of our deferred tax liabilities of $8 and a corresponding cumulative-effect reduction to our opening retained earnings of $23, eliminating the bifurcation of the embedded conversion option. During the three and nine months ended September 30, 2022, $4 and $19 of aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of the indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments during the three and nine months ended September 30, 2022 of $25 and $132, respectively.
The following table summarizes at September 30, 2022 the related balances, conversion rate and conversion price of the Debentures:
Outstanding principal amount$86 
Net debt carrying amount$86 
Conversion rate (shares of common stock per $1,000 of principal amount)14.2967 
Effective conversion price (per $1,000 of principal amount)$69.9462 
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $265 and $275 of outstanding short-term borrowings from the FHLBs at September 30, 2022 and December 31, 2021, respectively.
All debt is a direct obligation of Elevance Health, Inc., except for the surplus note, the FHLB borrowings, and the Subsidiary Credit Facilities.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments And Contingencies
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments And Contingencies Commitments and Contingencies
Litigation and Regulatory Proceedings
In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to
income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss.
With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves is, in the aggregate, from $0 to approximately $250 at September 30, 2022. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.
Blue Cross Blue Shield Antitrust Litigation
We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the “Blue plans”) across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation that is pending in the U.S. District Court for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard® and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.

In April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, determining that the defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.
The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the “Subscriber Settlement Agreement”), which agreement required the Court’s approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-monetary obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan.
In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the July 2021 opt-out deadline. In excess of eight thousand claims were submitted by the November 2021 claims submission deadline. A fairness hearing was held in October 2021 and the Court took the request for final approval under advisement and requested supplemental briefing that was submitted. In February 2022, the Court ordered the issuance of a supplemental notice to self-funded account class members, which notice process was completed in March 2022. The deadline for objections to the supplemental notice along with opt-outs was in May 2022.
In August 2022, the Court issued a final approval order for the Subscriber Settlement Agreement. The Court amended its final approval order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In September 2022, an objector filed a motion to amend the final approval order, which the Court
denied. In compliance with the Subscriber Settlement Agreement, the Company paid its remaining $506 portion of the settlement fund into an escrow account in September 2022, for an aggregate settlement payment by the Company of $596.
Four notices of appeal of the final approval order were filed by the September 2022 deadline. Those appeals will proceed in the United States Court of Appeals for the Eleventh Circuit. In October 2022, the subscriber plaintiffs filed a motion to consolidate and expedite the four appeals. After all appellate rights have been exhausted in a manner that affirms the Court’s final order and judgment, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective.
In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determines the standard of review applicable to providers’ claims. In May 2021, the defendants and provider plaintiffs filed renewed standard of review motions. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued (i) an order granting certain defendants’ motion for partial summary judgment against provider plaintiffs who had previously released claims against such defendants, and (ii) an order granting provider plaintiffs’ motion for partial summary judgment, holding that Ohio v. American Express Co. does not affect the standard of review in this case. In August 2022, the Court issued (i) an order granting in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the “national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation conspiracy claims, and (ii) an order denying the provider plaintiffs’ motion for partial summary judgment on the standard of review, reaffirming its prior holding that the providers’ group boycott claims are subject to the rule of reason. We intend to continue to vigorously defend the provider litigation, which we believe is without merit; however, its ultimate outcome cannot be presently determined.
A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are: Alaska Air Group, Inc., et al. v. Anthem, Inc., et al., No. 2:21-cv-01209-AMM (N.D. Ala.); JetBlue Airways Corp., et al. v. Anthem, Inc., et al., No. 2:22-cv-00558-GMB (N.D. Ala.); Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al., No. 2:22-cv-00265-RDP (N.D. Ala.); Bed Bath & Beyond Inc. v. Anthem, Inc., No. 2:22-cv-01256-SGC (N.D. Ala.); Hoover, et al. v. Blue Cross Blue Shield Association, et al., No. 2:22-cv-00261-RDP (N.D. Ala.); and VHS Liquidating Trust v. Blue Cross of California, et al., No. RG21106600 (Cal. Super.). We intend to continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined.

Blue Cross of California Taxation Litigation
In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (“BCC”) was named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court (the “Superior Court”) captioned Michael D. Myers v. State Board of Equalization, et al. This action was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an “insurer” for purposes of taxation despite acknowledging it is not an “insurer” under regulatory law. At the time, under California law, “insurers” were required to pay a gross premiums tax (“GPT”) calculated as 2.35% on gross premiums. As a licensed Health Care Service Plan, BCC has paid the California Corporate Franchise Tax (“CFT”), the tax paid by California businesses generally. Plaintiff contends that BCC must pay the GPT rather than the CFT, and seeks a writ of mandate directing the taxing agencies to collect the GPT and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the complaint.
Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax periods at issue in the litigation.
In March 2018, the Superior Court denied BCC’s motion for judgment on the pleadings and similar motions brought by other entities. BCC filed a motion for summary judgment with the Superior Court, which was heard in October 2020. In December 2020, the Superior Court granted BCC’s motion for summary judgment, dismissing the plaintiff’s lawsuit. In
November 2021, the plaintiff appealed the order granting BCC's motion for summary judgment. BCC’s responding brief was filed in March 2022. Plaintiff’s reply was filed in May 2022. We estimate that the appeal will be heard in the winter of 2022. We intend to vigorously defend the appeal of this lawsuit.
Express Scripts, Inc. Pharmacy Benefit Management Litigation
In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for PBM services, captioned Anthem, Inc. v. Express Scripts, Inc., in the U.S. District Court for the Southern District of New York (the “District Court”). The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the “ESI PBM Agreement”), over $158 in damages related to operational breaches, as well as various declarations under the ESI PBM Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to us through the term of the ESI PBM Agreement; (iii) has breached the ESI PBM Agreement; and (iv) is required under the ESI PBM Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination.
Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI PBM Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI PBM Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have been unjustly enriched by its payment of $4,675 at the time we entered into the ESI PBM Agreement. In March 2017, the District Court granted our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such action, the only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In March 2022, the District Court granted in part and denied in part Express Scripts’ motion for summary judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Quarterly Report on Form 10-Q are (i) our operational breach claim based on Express Scripts’ prior authorization processes and (ii) Express Scripts’ counterclaim for breach of the market check provision of the ESI PBM Agreement. Express Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims, which we opposed in July 2022. We intend to appeal the earlier summary judgment decision at the appropriate time, vigorously pursue our claims and defend against counterclaims, which we believe are without merit; however, the ultimate outcome of this litigation cannot be presently determined.
Medicare Risk Adjustment Litigation
In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. (f/k/a Anthem, Inc.) in the U.S. District Court for the Southern District of New York (the “New York District Court”) in a case captioned United States v. Anthem, Inc. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint. In an opinion and order issued October 3, 2022, the New York District Court denied our motions, and the case will now proceed in such court. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.

Investigations of CareMore and HealthSun
With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data submitted to CMS (unrelated to our retrospective chart review program) at CareMore Health Plans, Inc. (“CareMore”), one of our California subsidiaries, and HealthSun Health Plans, Inc. (“HealthSun”), one of our Florida subsidiaries. Our CareMore investigation has resulted in the termination of CareMore’s relationship with one contracted provider in California. Our
HealthSun investigation has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to CMS and the Criminal and Civil Divisions of the DOJ. We are cooperating with the ongoing investigations of the Criminal and Civil Divisions of the DOJ related to these risk adjustment practices, and have entered into a tolling agreement with the Civil Division of the DOJ related to its investigation. We are analyzing the scope of potential data corrections to be submitted to CMS and have begun to submit data corrections to CMS. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for, among other things, breach of healthcare and financial representation provisions, based on the conduct discovered during our investigation. While certain elements of the escrow claims were resolved in the fourth quarter of 2021, litigation in the Delaware Court of Chancery related to the remaining indemnity claims for escrowed funds remains ongoing.
Other Contingencies
From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (“HMOs”) and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.
In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.
Contractual Obligations and Commitments
In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through June 2025. The new agreement supersedes certain prior agreements for such services and includes provisions for additional services not provided under those agreements. Our remaining commitment under this agreement at September 30, 2022 is approximately $830. We will have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination fees.
In the second quarter of 2019, we began using our pharmacy benefits manager IngenioRx to market and offer PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. The comprehensive PBM services portfolio includes, but is not limited to, formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities. IngenioRx delegates certain PBM administrative functions, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement. With IngenioRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Capital Stock
 9 Months Ended
Sep. 30, 2022
Banking Regulation, Total Capital [Abstract]  
Capital Stock Capital Stock
Use of Capital – Dividends and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
A summary of our cash dividend activity for the nine months ended September 30, 2022 and 2021 is as follows: 
Declaration DateRecord DatePayment Date
Cash
Dividend
per Share
Total
Nine Months Ended September 30, 2022
January 25, 2022March 10, 2022March 25, 2022$1.28$309 
April 19, 2022June 10, 2022June 24, 2022$1.28$309 
July 19, 2022September 9, 2022September 23, 2022$1.28$306 
Nine Months Ended September 30, 2021
January 26, 2021March 10, 2021March 25, 2021$1.13$277 
April 20, 2021June 10, 2021June 25, 2021$1.13$278 
July 20, 2021September 10, 2021September 24, 2021$1.13$276 
On October 18, 2022, our Audit Committee declared a fourth quarter 2022 dividend to shareholders of $1.28 per share, payable on December 21, 2022 to shareholders of record at the close of business on December 5, 2022.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 26, 2021, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to the common stock repurchase program. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are effected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.
A summary of common stock repurchases for the nine months ended September 30, 2022 and 2021 is as follows:
Nine Months Ended September 30
 20222021
Shares repurchased3.7 3.9 
Average price per share$473.36 $356.43 
Aggregate cost$1,748 $1,378 
Authorization remaining at the end of the period$2,444 $4,714 
For additional information regarding the use of capital for debt security repurchases, see Note 10, “Debt,” included in this Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K.
Stock Incentive Plans
A summary of stock option activity for the nine months ended September 30, 2022 is as follows:
Number of
Shares		Weighted-
Average
Option Price
per Share		Weighted-
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding at January 1, 20222.9 $255.50 
Granted0.5 452.34 
Exercised(0.4)243.39 
Forfeited or expired(0.1)339.52 
Outstanding at September 30, 20222.9 291.95 6.56$477 
Exercisable at September 30, 20221.7 239.27 5.35$370 
A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the nine months ended September 30, 2022 is as follows:
Restricted
Stock Shares
and Units		Weighted-
Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 20221.3 $299.65 
Granted0.6 453.16 
Vested(0.6)301.44 
Forfeited(0.1)345.25 
Nonvested at September 30, 20221.2 356.33 
During the nine months ended September 30, 2022, we granted approximately 0.2 restricted stock units that are contingent upon us achieving earnings targets over the three year period from 2022 to 2024. These grants have been included in the activity shown above, but will be subject to adjustment at the end of 2024 based on results in the three year period.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed discussion of our stock incentive plan fair value methodology, see Note 15, “Capital Stock,” to our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K.
The following weighted-average assumptions were used to estimate the fair values of options granted during the nine months ended September 30, 2022 and 2021:
Nine Months Ended September 30
20222021
Risk-free interest rate1.97 %1.44 %
Volatility factor29.00 %30.00 %
Quarterly dividend yield0.282 %0.360 %
Weighted-average expected life (years)5.105.50
The following weighted-average fair values per option or share were determined for the nine months ended September 30, 2022 and 2021: 
Nine Months Ended September 30
20222021
Options granted during the period$116.85 $79.51 
Restricted stock awards granted during the period453.16 315.54 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accumulated Other Comprehensive Loss
 9 Months Ended
Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss A reconciliation of the components of accumulated other comprehensive loss at September 30, 2022 and 2021 is as follows:
Three Months Ended
September 30		Nine Months Ended
September 30
2022202120222021
Net unrealized investment (losses) gains:
Beginning of period balance$(1,489)$762 $494 $949 
Other comprehensive loss before reclassifications, net of tax benefit of $220, $25, $896 and $71, respectively
(719)(80)(2,914)(203)
Amounts reclassified from accumulated other comprehensive loss, net of tax (expense) benefit of $(21), $5, $(75) and $21, respectively
80 (17)284 (81)
Other comprehensive loss(639)(97)(2,630)(284)
Other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(1), $0, $(4) and $(1), respectively
3 1 11 1 
End of period balance(2,125)666 (2,125)666 
Non-credit components of impairments on investments:
Beginning of period balance(2)— — (2)
Other comprehensive (loss) income, net of tax benefit (expense) of $0, $0, $1 and $(1), respectively
(1)(1)(3)1 
End of period balance(3)(1)(3)(1)
Net cash flow hedges:
Beginning of period balance(233)(244)(239)(250)
Other comprehensive income, net of tax expense of $0, $0, $(2) and $(2), respectively
2 4 8 10 
End of period balance(231)(240)(231)(240)
Pension and other postretirement benefits:
Beginning of period balance(413)(534)(429)(552)
Other comprehensive income, net of tax expense of $(3), $(4), $(9) and $(10), respectively
7 8 23 26 
End of period balance(406)(526)(406)(526)
Foreign currency translation adjustments:
Beginning of period balance(12)(1)(4)5 
Other comprehensive loss, net of tax benefit of $2, $1, $4 and $2, respectively
(7)(1)(15)(7)
End of period balance(19)(2)(19)(2)
Total:
Total beginning of period accumulated other comprehensive (loss)(2,149)(17)(178)150 
Total other comprehensive loss, net of tax benefit of $198, $27, $815 and $81, respectively
(638)(87)(2,617)(254)
Total other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(1), $0, $(4) and $(1), respectively
3 1 11 1 
Total end of period accumulated other comprehensive loss$(2,784)$(103)$(2,784)$(103)
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Earnings Per Share Earnings per Share
The denominator for basic and diluted earnings per share for the three and nine months ended September 30, 2022 and 2021 is as follows:
 Three Months Ended 
 September 30		Nine Months Ended 
 September 30
 2022202120222021
Denominator for basic earnings per share – weighted-average shares
239.6 243.4 240.5 244.3 
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures
2.6 2.6 2.8 2.9 
Denominator for diluted earnings per share
242.2 246.0 243.3 247.2 
During the three months ended September 30, 2022 and 2021, weighted-average shares related to certain stock options of 0.5 and 0.0, respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive. During the nine months ended September 30, 2022 and 2021, weighted-average shares related to certain stock options of 0.4 and 0.3, respectively, were excluded from each of the denominators for diluted earnings per share because the stock options were anti-dilutive.
During the three and nine months ended September 30, 2022, we issued approximately 0.0 and 0.6 restricted stock units under our stock incentive plans, 0.0 and 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three year period of 2022 through 2024. During the three and nine months ended September 30, 2021, we issued approximately 0.1 and 1.0 restricted stock units under our stock incentive plans, 0.0 and 0.3 of which vesting is contingent upon us meeting specified annual earnings targets for the three year period of 2021 through 2023. The contingent restricted stock units have been excluded from the denominators for diluted earnings per share and will be included only if and when the contingency is met.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Segment Information Segment Information
As discussed in Note 1 “Organization”, we will be organizing our brand portfolio into three core go-to-market brands over the next several years. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner, and given this evolution we are in the process of reviewing and modifying how we will manage our businesses in the future. Currently, there are no changes to our segments associated with this branding strategy. The results of our operations continue to be described through four reportable segments: Commercial & Specialty Business, Government Business, IngenioRx and Other.
Our Commercial & Specialty Business segment offers plans and services to our Individual, Group risk-based, Group fee-based and BlueCard® members. The Commercial & Specialty Business segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as dental, vision, life, disability and supplemental health insurance benefits.
Our Government Business segment includes our Medicare and Medicaid businesses, National Government Services, and services provided to the federal government in connection with the FEHB program.
Our IngenioRx segment includes our PBM business. IngenioRx markets and offers PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. IngenioRx has a comprehensive PBM services portfolio, which includes services such as formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities.
Our Other segment includes our Diversified Business Group, now known as Carelon, which is our health services business focused on lowering the cost and improving the quality of healthcare by enabling and creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic conditions. This segment also includes certain eliminations and corporate expenses not allocated to our other reportable segments.
We define operating revenues to include premium income, product revenue and administrative fees and other revenues. Operating revenues are derived from premiums and fees received, primarily from the sale and administration of health benefits and pharmacy products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative expense.
Affiliated revenues represent revenues or cost for services provided to our subsidiaries by IngenioRx and Carelon, formerly known as our Diversified Business Group, as well as certain back-office services provided by our international businesses, and are recorded at cost or management’s estimate of fair market value. These affiliated revenues are eliminated in consolidation.
Financial data by reportable segment for the three and nine months ended September 30, 2022 and 2021 is as follows:
Commercial
& Specialty
Business		Government
Business		IngenioRxOtherEliminationsTotal
Three Months Ended September 30, 2022
Operating revenue - unaffiliated$10,494 $24,571 $3,971 $589 $— $39,625 
Operating revenue - affiliated— — 3,278 2,776 (6,054)— 
Operating gain785 868 516 101 — 2,270 
Three Months Ended September 30, 2021
Operating revenue - unaffiliated$9,863 $21,658 $3,369 $658 $— $35,548 
Operating revenue - affiliated— — 3,180 2,012 (5,192)— 
Operating gain620 967 445 27 — 2,059 
Nine Months Ended September 30, 2022
Operating revenue - unaffiliated$31,324 $72,164 $10,838 $1,667 $— $115,993 
Operating revenue - affiliated— — 10,165 8,217 (18,382)— 
Operating gain2,673 2,653 1,393 365 — 7,084 
Nine Months Ended September 30, 2021
Operating revenue - unaffiliated$28,904 $61,007 $9,131 $1,883 $— $100,925 
Operating revenue - affiliated— — 9,499 5,674 (15,173)— 
Operating gain2,679 2,313 1,257 52 — 6,301 
The major product revenues for each of the reportable segments for the three and nine months ended September 30, 2022 and 2021 are as follows:
Three Months Ended 
 September 30		Nine Months Ended 
 September 30
2022202120222021
Commercial & Specialty Business
Managed care products
$8,478 $8,005 $25,500 $23,481 
Managed care services
1,610 1,489 4,618 4,291 
Dental/Vision products and services
360 342 1,075 1,013 
Other
46 27 131 119 
Total Commercial & Specialty Business
10,494 9,863 31,324 28,904 
Government Business
Managed care products
24,456 21,565 71,823 60,711 
Managed care services
115 93 341 296 
Total Government Business
24,571 21,658 72,164 61,007 
IngenioRx
Pharmacy products and services7,249 6,549 21,003 18,630 
Other
Integrated health services3,153 2,506 9,083 7,121 
Other
212 164 801 436 
Total Other3,365 2,670 9,884 7,557 
Eliminations
Eliminations
(6,054)(5,192)(18,382)(15,173)
Total product revenues
$39,625 $35,548 $115,993 $100,925 
The classification between managed care products and managed care services in the above table primarily distinguishes between the levels of risk assumed. Managed care products represent insurance products where we bear the insurance risk, whereas managed care services represent product offerings where we provide claims adjudication and other administrative services to the customer, but the customer principally bears the insurance risk. 
A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and nine months ended September 30, 2022 and 2021 is as follows:
 Three Months Ended 
 September 30		Nine Months Ended 
 September 30
 2022202120222021
Reportable segments’ operating revenue$39,625 $35,548 $115,993 $100,925 
Net investment income371 335 1,112 1,026 
Net (losses) gains on financial instruments(57)(61)(439)107 
Total revenues$39,939 $35,822 $116,666 $102,058 
A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three and nine months ended September 30, 2022 and 2021 is as follows:
 Three Months Ended 
 September 30		Nine Months Ended 
 September 30
 2022202120222021
Income before income tax expense$2,146 $1,996 $6,615 $6,525 
Net investment income(371)(335)(1,112)(1,026)
Net losses (gains) on financial instruments57 61 439 (107)
Interest expense213 201 622 598 
Amortization of other intangible assets225 136 520 306 
Loss on extinguishment of debt— — — 5 
Reportable segments’ operating gain$2,270 $2,059 $7,084 $6,301 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases
 9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Leases Leases
We lease office space and certain computer and related equipment using noncancellable operating leases. Our leases have remaining lease terms of 1 year to 12 years.
The information related to our leases is as follows:
Balance Sheet LocationSeptember 30, 2022December 31, 2021
Operating Leases
Right-of-use assetsOther noncurrent assets$600 $628 
Lease liabilities, currentOther current liabilities182 133 
Lease liabilities, noncurrentOther noncurrent liabilities739 864 
Three Months Ended 
 September 30		Nine Months Ended 
 September 30
2022202120222021
Lease Expense
Operating lease expense$35 $37 $100 $100 
Short-term lease expense11 10 35 34 
Sublease income(1)(1)(3)(3)
Total lease expense$45 $46 $132 $131 
Other information
 Operating cash paid for amounts included in the measurement of lease liabilities, operating leases$53 $53 $158 $141 
Right-of-use assets obtained in exchange for new lease liabilities, operating leases$23 $32 $62 $192 
As of September 30, 2022 and December 31, 2021, the weighted average remaining lease term of our operating leases was 7 years for each period. The lease liabilities reflect a weighted average discount rate of 2.79% at September 30, 2022 and 2.69% at December 31, 2021.
Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows:
2022 (excluding the nine months ended September 30, 2022)$54 
2023207 
2024179 
2025142 
2026105 
Thereafter345 
Total future minimum payments 1,032 
Less imputed interest(111)
Total lease liabilities$921 
As of September 30, 2022, we have no new leases which will commence during the fourth quarter of 2022.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Other Intangible Assets
 9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Other Intangible Assets
A summary of the change in the carrying amount of goodwill for our segments (see Note 15, “Segment Information”) for 2022 and 2021 is as follows:
Commercial
& Specialty
Business		Government
Business		IngenioRxOtherTotal
Balance as of January 1, 2021$11,593 $8,331 $48 $1,719 $21,691 
Acquisitions and adjustments— 2,018 11 508 2,537 
Balance as of December 31, 202111,593 10,349 59 2,227 24,228 
Acquisitions and adjustments18 126 — 9 153 
Balance as of September 30, 2022$11,611 $10,475 $59 $2,236 $24,381 
Accumulated impairment as of September 30, 2022$— $— $— $— $— 
The components of other intangible assets as of September 30, 2022 and December 31, 2021 are as follows:
 September 30, 2022December 31, 2021
Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount
Intangible assets with finite lives:
Customer relationships$5,791 $(3,580)$2,211 $5,598 $(3,236)$2,362 
Provider and hospital relationships326 (142)184 324 (129)195 
Other920 (310)610 610 (141)469 
Total7,037 (4,032)3,005 6,532 (3,506)3,026 
Intangible assets with indefinite lives:
Blue Cross and Blue Shield and other trademarks5,991 — 5,991 6,299 — 6,299 
State Medicaid licenses1,540 — 1,540 1,290 — 1,290 
Total7,531 — 7,531 7,589 — 7,589 
Other intangible assets$14,568 $(4,032)$10,536 $14,121 $(3,506)$10,615 
During the nine months ended September 30, 2022, we recorded intangible assets related to Integra and also reclassified $308 of trademarks with indefinite lives to intangible assets with finite lives - Other, which relates to our new branding strategy. In addition, the amortization period of certain intangible assets was shortened to align with the anticipated dates the new branding will take place.
Intangible assets, along with the related accumulated amortization, are removed from the table above at the end of the fiscal year in which they become fully amortized.
As of September 30, 2022, the estimated amortization expense for the year ending December 31, 2022 and each of the five succeeding years is as follows: 2022, $748; 2023, $735; 2024, $370; 2025, $311; 2026, $258; and 2027, $219.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our 2021 Annual Report on Form 10-K, unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and nine months ended September 30, 2022 and 2021 have been recorded. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2022, or any other period. The seasonal nature of portions of our health care and related benefits business, competitive and other market conditions, as well as COVID-19 related impacts, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K.
Foreign Currency Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Cash and Cash Equivalents Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $291 and $173 at September 30, 2022 and December 31, 2021, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investment, Policy
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the
securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption “Other invested assets” in our consolidated balance sheets.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” in our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities” in our consolidated balance sheets. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
Receivable
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $140 and $142 at September 30, 2022 and December 31, 2021, respectively.
Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $82 and $50 at September 30, 2022 and December 31, 2021, respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income, and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $709 and $648 at September 30, 2022 and December 31, 2021, respectively.
Revenue Recognition Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at September 30, 2022. For the three and nine months ended September 30, 2022 and 2021, revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
New Accounting Pronouncements
Recently Adopted Accounting Guidance: In January 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2021-01, Reference Rate Reform (Topic 848) (“ASU 2021-01”). The amendments in ASU 2021-01 provide optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of the reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
In October 2020, the FASB issued Accounting Standards Update No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other Costs (“ASU 2020-08”). The amendments in ASU 2020-08 clarify when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting periods beginning after December 15, 2020. The amendments were to be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted earnings per share calculation and expand disclosure requirements. The amendments became effective for our annual and interim reporting periods beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease to our deferred tax liabilities of $8, and a corresponding cumulative-effect reduction to our opening retained earnings of $23; these amounts are not material to our overall consolidated financial position. The adoption of ASU 2020-06 did not have an impact on our results of operations or our consolidated cash flows. Use of the if-converted method did not have an impact on our overall earnings per share calculation.
In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
Recent Accounting Guidance Not Yet Adopted: In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments
for market risk benefits are to be applied retrospectively. We do not believe the adoption of ASU 2020-11 and ASU 2018-12 will have a material impact on our consolidated financial position, results of operations, cash flows, and related disclosures.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Optimization Initiatives (Tables)
 9 Months Ended
Sep. 30, 2022
Business Optimization Initiatives [Abstract]  
Business Optimization Initiatives
Provided below is a summary of the activity, by reportable segment, related to the liability for employee termination costs previously incurred in connection with our enterprise-wide business optimization initiatives introduced in 2020.
Commercial & Specialty BusinessGovernment BusinessIngenioRxOtherTotal
2020 Business Optimization Initiatives
Employee termination costs:
Liability for employee termination costs at January 1, 2022$61 $57 $1 $3 $122 
Payments(16)(14)— — (30)
Liability for employee termination costs at September 30, 2022
$45 $43 $1 $3 $92 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments (Tables)
 9 Months Ended
Sep. 30, 2022
Investments [Abstract]  
Current and Long-Term Investments, Available-For-Sale
A summary of current and long-term fixed maturity securities, available-for-sale, at September 30, 2022 and December 31, 2021 is as follows:
Cost or Amortized CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Allowance
For Credit
Losses		Estimated
Fair Value
 
September 30, 2022
Fixed maturity securities:
United States Government securities$1,673 $— $(125)$— $1,548 
Government sponsored securities65 — (4)— 61 
Foreign government securities322 — (70)(1)251 
States, municipalities and political subdivisions4,431 5 (355)— 4,081 
Corporate securities13,766 9 (1,560)(7)12,208 
Residential mortgage-backed securities4,748 7 (506)(2)4,247 
Commercial mortgage-backed securities77 — (7)— 70 
Other securities3,895 37 (250)— 3,682 
Total fixed maturity securities$28,977 $58 $(2,877)$(10)$26,148 
December 31, 2021
Fixed maturity securities:
United States Government securities$1,443 $7 $(18)$— $1,432 
Government sponsored securities65 4 (1)— 68 
Foreign government securities353 7 (13)— 347 
States, municipalities and political subdivisions5,321 310 (10)— 5,621 
Corporate securities12,044 401 (78)(4)12,363 
Residential mortgage-backed securities4,059 75 (35)(2)4,097 
Commercial mortgage-backed securities65 2 (3)— 64 
Other securities2,907 24 (24)— 2,907 
Total fixed maturity securities$26,257 $830 $(182)$(6)$26,899 
Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position
For fixed maturity securities in an unrealized loss position at September 30, 2022 and December 31, 2021, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position: 
 Less than 12 Months12 Months or Greater
(Securities are whole amounts)Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss		Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss
September 30, 2022
Fixed maturity securities:
United States Government securities65 $911 $(77)29 $303 $(48)
Government sponsored securities40 61 (4)1 — — 
Foreign government securities
225 169 (34)151 81 (36)
States, municipalities and political subdivisions
1,964 3,602 (314)139 200 (41)
Corporate securities4,322 10,228 (1,165)1,318 1,679 (395)
Residential mortgage-backed securities2,035 2,949 (294)530 1,182 (212)
Commercial mortgage-backed securities34 56 (3)7 13 (4)
Other securities921 2,535 (165)269 670 (85)
Total fixed maturity securities9,606 $20,511 $(2,056)2,444 $4,128 $(821)
December 31, 2021
Fixed maturity securities:
United States Government securities
51 $990 $(11)27 $176 $(7)
Government sponsored securities
— — — 1 1 (1)
Foreign government securities
188 143 (8)68 41 (5)
States, municipalities and political subdivisions
281 634 (9)8 16 (1)
Corporate securities
1,846 3,310 (57)403 485 (21)
Residential mortgage-backed securities
692 1,967 (26)125 173 (9)
Commercial mortgage-backed securities
2 4 (1)4 8 (2)
Other securities
511 1,707 (19)50 85 (5)
Total fixed maturity securities3,571 $8,755 $(131)686 $985 $(51)
Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity
The amortized cost and fair value of fixed maturity securities at September 30, 2022, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.
Amortized
Cost		Estimated
Fair Value
Due in one year or less$911 $901 
Due after one year through five years7,364 6,871 
Due after five years through ten years9,535 8,467 
Due after ten years6,342 5,592 
Mortgage-backed securities4,825 4,317 
Total fixed maturity securities$28,977 $26,148 
Investments In Equity Securities
A summary of marketable equity securities at September 30, 2022 and December 31, 2021 is as follows:
 September 30, 2022December 31, 2021
Equity securities:
Exchange traded funds$1,403 $1,750 
Common equity securities5 42 
Private equity securities95 89 
Total$1,503 $1,881 
Net Investment Gains (Losses)
Net investment (losses) gains for the three and nine months ended September 30, 2022 and 2021 are as follows:
Three Months Ended
September 30		Nine Months Ended
September 30
2022202120222021
Net (losses) gains:
Fixed maturity securities:
Gross realized gains from sales$8 $30 $44 $133 
Gross realized losses from sales(99)(8)(353)(32)
Impairment (losses) recoveries recognized in income(5)— (25)1 
Net realized (losses) gains from sales of fixed maturity securities(96)22 (334)102 
Equity securities:
Unrealized (losses) gains recognized on equity securities still held at the end of the period(43)(4)(192)4 
Net realized gains (losses) recognized on equity securities sold during the period4 (1)(20)(57)
Net losses on equity securities(39)(5)(212)(53)
Other investments:
Gross gains95 2 126 9 
Gross losses(2)(93)(45)(5)
Impairment (losses) recoveries recognized in income(12)1 (17)(5)
Net losses (gains) on other investments81 (90)64 (1)
Net (losses) gains on investments$(54)$(73)$(482)$48 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value (Tables)
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at September 30, 2022 and December 31, 2021 is as follows:
Level ILevel IILevel IIITotal
September 30, 2022
Assets:
Cash equivalents$5,794 $— $— $5,794 
Fixed maturity securities, available-for-sale:
United States Government securities— 1,548 — 1,548 
Government sponsored securities— 61 — 61 
Foreign government securities— 251 — 251 
States, municipalities and political subdivisions, tax-exempt— 4,081 — 4,081 
Corporate securities— 12,079 129 12,208 
Residential mortgage-backed securities— 4,247 — 4,247 
Commercial mortgage-backed securities— 70 — 70 
Other securities— 3,371 311 3,682 
Total fixed maturity securities, available-for-sale— 25,708 440 26,148 
Equity securities:
Exchange traded funds1,403 — — 1,403 
Common equity securities6 (1)— 5 
Private equity securities— — 95 95 
Total equity securities1,409 (1)95 1,503 
Other invested assets - common equity securities149 — — 149 
Securities lending collateral— 2,841 — 2,841 
Derivatives - other assets— 25 — 25 
Total assets$7,352 $28,573 $535 $36,460 
Liabilities:
Derivatives - other liabilities$— $(70)$— $(70)
Total liabilities$— $(70)$— $(70)
December 31, 2021
Assets:
Cash equivalents$2,415 $— $— $2,415 
Fixed maturity securities, available-for-sale:
United States Government securities— 1,432 — 1,432 
Government sponsored securities— 68 — 68 
Foreign government securities— 347 — 347 
States, municipalities and political subdivisions, tax-exempt— 5,621 — 5,621 
Corporate securities— 12,027 336 12,363 
Residential mortgage-backed securities— 4,092 5 4,097 
Commercial mortgage-backed securities— 64 — 64 
Other securities— 2,888 19 2,907 
Total fixed maturity securities, available-for-sale— 26,539 360 26,899 
Equity securities:
Exchange traded funds1,750 — — 1,750 
Common equity securities8 34 — 42 
Private equity securities— — 89 89 
Total equity securities1,758 34 89 1,881 
Other invested assets - common equity securities138 — — 138 
Securities lending collateral— 2,155 — 2,155 
Derivatives - other assets— 19 — 19 
Total assets$4,311 $28,747 $449 $33,507 
Liabilities:
Derivatives - other liabilities$— $(1)$— $(1)
Total liabilities$— $(1)$— $(1)
Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs
A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended September 30, 2022 and 2021 is as follows:
Corporate
Securities		Residential
Mortgage-
backed
Securities		Other 
Securities		Equity
Securities		Total
Three Months Ended September 30, 2022
Beginning balance at July 1, 2022$155 $— $218 $94 $467 
Total losses:
Recognized in net income— — — — — 
Recognized in accumulated other comprehensive loss1 — 17 — 18 
Purchases15 — 77 3 95 
Sales(26)— (1)(2)(29)
Settlements(10)— — — (10)
Transfers out of Level III(6)— — — (6)
Ending balance at September 30, 2022$129 $— $311 $95 $535 
Change in unrealized losses included in net income related to assets still held at September 30, 2022$— $— $— $— $— 
Three Months Ended September 30, 2021
Beginning balance at July 1, 2021$351 $2 $7 $77 $437 
Total gains:
Recognized in net income1 — — 5 6 
Recognized in accumulated other comprehensive loss(1)— — — (1)
Purchases34 — — 3 37 
Sales— — — (1)(1)
Settlements(47)— — — (47)
Transfers out of Level III(4)(1)(5)— (10)
Ending balance at September 30, 2021$334 $1 $2 $84 $421 
Change in unrealized gains included in net income related to assets still held at September 30, 2021$— $— $— $5 $5 
A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the nine months ended September 30, 2022 and 2021 is as follows:
Corporate
Securities		Residential
Mortgage-
backed
Securities		Other 
Securities		Equity
Securities		Total
Nine Months Ended September 30, 2022
Beginning balance at January 1, 2022$336 $5 $19 $89 $449 
Total losses:
Recognized in net income— — — 1 1 
Recognized in accumulated other comprehensive loss(1)— 17 — 16 
Purchases40 — 281 24 345 
Sales(201)— (1)(19)(221)
Settlements(42)— — — (42)
Transfers into Level III9 — — — 9 
Transfers out of Level III(12)(5)(5)— (22)
Ending balance at September 30, 2022$129 $— $311 $95 $535 
Change in unrealized gains included in net income related to assets still held at September 30, 2022$— $— $— $1 $1 
Nine Months Ended September 30, 2021
Beginning balance at January 1, 2021$325 $2 $5 $60 $392 
Total gains:
Recognized in net income2 — — 17 19 
Recognized in accumulated other comprehensive loss4 — — — 4 
Purchases135 — — 11 146 
Sales(12)— — (4)(16)
Settlements(118)— (1)— (119)
Transfers out of Level III(2)(1)(2)— (5)
Ending balance at September 30, 2021$334 $1 $2 $84 $421 
Change in unrealized gains included in net income related to assets still held at September 30, 2021$— $— $— $17 $17 
Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet
A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at September 30, 2022 and December 31, 2021 is as follows:
 Carrying
Value		Estimated Fair Value
 Level ILevel IILevel IIITotal
September 30, 2022
Assets:
Other invested assets$5,367 $— $— $5,367 $5,367 
Liabilities:
Debt:
Short-term borrowings265 — 265 — 265 
Commercial paper675 — 675 — 675 
Notes22,747 — 20,163 — 20,163 
Convertible debentures86 — 554 — 554 
December 31, 2021
Assets:
Other invested assets$5,087 $— $— $5,087 $5,087 
Liabilities:
Debt:
Short-term borrowings275 — 275 — 275 
Commercial paper300 — 300 — 300 
Notes22,384 — 25,150 — 25,150 
Convertible debentures72 — 687 — 687 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Medical Claims Payable (Tables)
 9 Months Ended
Sep. 30, 2022
Liability for Claims and Claims Adjustment Expense [Abstract]  
Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2022 is as follows:
Commercial
& Specialty
Business		Government
Business		OtherTotal
Gross medical claims payable, beginning of period$3,847 $9,157 $278 $13,282 
Ceded medical claims payable, beginning of period(13)(8)— (21)
Net medical claims payable, beginning of period3,834 9,149 278 13,261 
Business combinations and purchase adjustments3 130 — 133 
Net incurred medical claims:
Current period22,049 60,971 1,157 84,177 
Prior periods redundancies(183)(639)(79)(901)
Total net incurred medical claims21,866 60,332 1,078 83,276 
Net payments attributable to:
Current period medical claims18,604 50,950 899 70,453 
Prior periods medical claims3,181 7,854 184 11,219 
Total net payments21,785 58,804 1,083 81,672 
Net medical claims payable, end of period3,918 10,807 273 14,998 
Ceded medical claims payable, end of period3 — — 3 
Gross medical claims payable, end of period$3,921 $10,807 $273 $15,001 
At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Commercial & Specialty Business was $81, $388 and $3,449 for the claim years 2020 and prior, 2021 and 2022, respectively.
At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Government Business was $148, $508 and $10,151 for the claim years 2020 and prior, 2021 and 2022, respectively.
At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for Other was $2, $14 and $257 for the claim years 2020 and prior, 2021 and 2022, respectively.
A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2021 is as follows:
Commercial
& Specialty
Business		Government
Business		OtherTotal
Gross medical claims payable, beginning of period$3,294 $7,646 $195 $11,135 
Ceded medical claims payable, beginning of period(13)(33)— (46)
Net medical claims payable, beginning of period3,281 7,613 195 11,089 
Business combinations and purchase adjustments— 375 45 420 
Net incurred medical claims:
Current period20,499 52,422 1,176 74,097 
Prior periods redundancies(496)(1,309)(17)(1,822)
Total net incurred medical claims20,003 51,113 1,159 72,275 
Net payments attributable to:
Current period medical claims16,985 44,160 978 62,123 
Prior periods medical claims2,450 5,781 169 8,400 
Total net payments19,435 49,941 1,147 70,523 
Net medical claims payable, end of period3,849 9,160 252 13,261 
Ceded medical claims payable, end of period15 23 — 38 
Gross medical claims payable, end of period$3,864 $9,183 $252 $13,299 
The favorable development recognized in the nine months ended September 30, 2022 and 2021 resulted primarily from trend factors in late 2021 and late 2020, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter parts of 2020 developing faster than expected also contributed to the favorable development in the nine months ended September 30, 2021. The impact from COVID-19 on healthcare utilization and medical claims submission patterns continues to provide increased estimation uncertainty on our incurred but not reported liability at September 30, 2022.
Reconciliation of Net Incurred Medical Claims to Benefit Expense
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2022 is as follows:
Three Months EndedNine Months Ended September 30, 2022
March 31, 2022June 30, 2022September 30, 2022
Net incurred medical claims:
Commercial & Specialty Business$6,834 $7,522 $7,510 $21,866 
Government Business19,943 19,788 20,601 60,332 
Other354 324 400 1,078 
Total net incurred medical claims27,131 27,634 28,511 83,276 
Quality improvement and other claims expense1,084 1,143 893 3,120 
Benefit expense$28,215 $28,777 $29,404 $86,396 
During the three months ended September 30, 2022, based on recent regulatory clarification, we realigned certain quality improvement costs from benefit expense to administrative expense that were previously allocated to benefit expense during the three months ended March 31, 2022 and the three months ended June 30, 2022.
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2021 is as follows:
Three Months EndedNine Months Ended September 30, 2021
March 31, 2021June 30, 2021September 30, 2021
Net incurred medical claims:
Commercial & Specialty Business$6,072 $6,718 $7,213 $20,003 
Government Business16,319 16,723 18,071 51,113 
Other336 403 420 1,159 
Total net incurred medical claims22,727 23,844 25,704 72,275 
Quality improvement and other claims expense972 919 941 2,832 
Benefit expense$23,699 $24,763 $26,645 $75,107 
Reconciliation of Short Duration Medical Claims Payable to the Consolidated Medical Claims Payable
The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of September 30, 2022, is as follows:
Commercial
& Specialty
Business		Government
Business		OtherTotal
Net medical claims payable, end of period$3,918 $10,807 $273 $14,998 
Ceded medical claims payable, end of period3 — — 3 
Insurance lines other than short duration— 241 — 241 
Gross medical claims payable, end of period$3,921 $11,048 $273 $15,242 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt (Tables)
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Convertible Debenture Terms
The following table summarizes at September 30, 2022 the related balances, conversion rate and conversion price of the Debentures:
Outstanding principal amount$86 
Net debt carrying amount$86 
Conversion rate (shares of common stock per $1,000 of principal amount)14.2967 
Effective conversion price (per $1,000 of principal amount)$69.9462 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Capital Stock (Tables)
 9 Months Ended
Sep. 30, 2022
Banking Regulation, Total Capital [Abstract]  
Summary of Cash Dividend Activity
A summary of our cash dividend activity for the nine months ended September 30, 2022 and 2021 is as follows: 
Declaration DateRecord DatePayment Date
Cash
Dividend
per Share
Total
Nine Months Ended September 30, 2022
January 25, 2022March 10, 2022March 25, 2022$1.28$309 
April 19, 2022June 10, 2022June 24, 2022$1.28$309 
July 19, 2022September 9, 2022September 23, 2022$1.28$306 
Nine Months Ended September 30, 2021
January 26, 2021March 10, 2021March 25, 2021$1.13$277 
April 20, 2021June 10, 2021June 25, 2021$1.13$278 
July 20, 2021September 10, 2021September 24, 2021$1.13$276 
Summary of Share Repurchases
A summary of common stock repurchases for the nine months ended September 30, 2022 and 2021 is as follows:
Nine Months Ended September 30
 20222021
Shares repurchased3.7 3.9 
Average price per share$473.36 $356.43 
Aggregate cost$1,748 $1,378 
Authorization remaining at the end of the period$2,444 $4,714 
Summary of Stock Option Activity
A summary of stock option activity for the nine months ended September 30, 2022 is as follows:
Number of
Shares		Weighted-
Average
Option Price
per Share		Weighted-
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding at January 1, 20222.9 $255.50 
Granted0.5 452.34 
Exercised(0.4)243.39 
Forfeited or expired(0.1)339.52 
Outstanding at September 30, 20222.9 291.95 6.56$477 
Exercisable at September 30, 20221.7 239.27 5.35$370 
Summary of Nonvested Restricted Stock Activity Including Restricted Stock Units
A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the nine months ended September 30, 2022 is as follows:
Restricted
Stock Shares
and Units		Weighted-
Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 20221.3 $299.65 
Granted0.6 453.16 
Vested(0.6)301.44 
Forfeited(0.1)345.25 
Nonvested at September 30, 20221.2 356.33 
Summary of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted During the Periods
The following weighted-average assumptions were used to estimate the fair values of options granted during the nine months ended September 30, 2022 and 2021:
Nine Months Ended September 30
20222021
Risk-free interest rate1.97 %1.44 %
Volatility factor29.00 %30.00 %
Quarterly dividend yield0.282 %0.360 %
Weighted-average expected life (years)5.105.50
Schedule of Weighted-Average Fair Values Determined for the Periods
The following weighted-average fair values per option or share were determined for the nine months ended September 30, 2022 and 2021: 
Nine Months Ended September 30
20222021
Options granted during the period$116.85 $79.51 
Restricted stock awards granted during the period453.16 315.54 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accumulated Other Comprehensive Loss (Tables)
 9 Months Ended
Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Reconciliation Of Components Of Accumulated Other Comprehensive Loss A reconciliation of the components of accumulated other comprehensive loss at September 30, 2022 and 2021 is as follows:
Three Months Ended
September 30		Nine Months Ended
September 30
2022202120222021
Net unrealized investment (losses) gains:
Beginning of period balance$(1,489)$762 $494 $949 
Other comprehensive loss before reclassifications, net of tax benefit of $220, $25, $896 and $71, respectively
(719)(80)(2,914)(203)
Amounts reclassified from accumulated other comprehensive loss, net of tax (expense) benefit of $(21), $5, $(75) and $21, respectively
80 (17)284 (81)
Other comprehensive loss(639)(97)(2,630)(284)
Other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(1), $0, $(4) and $(1), respectively
3 1 11 1 
End of period balance(2,125)666 (2,125)666 
Non-credit components of impairments on investments:
Beginning of period balance(2)— — (2)
Other comprehensive (loss) income, net of tax benefit (expense) of $0, $0, $1 and $(1), respectively
(1)(1)(3)1 
End of period balance(3)(1)(3)(1)
Net cash flow hedges:
Beginning of period balance(233)(244)(239)(250)
Other comprehensive income, net of tax expense of $0, $0, $(2) and $(2), respectively
2 4 8 10 
End of period balance(231)(240)(231)(240)
Pension and other postretirement benefits:
Beginning of period balance(413)(534)(429)(552)
Other comprehensive income, net of tax expense of $(3), $(4), $(9) and $(10), respectively
7 8 23 26 
End of period balance(406)(526)(406)(526)
Foreign currency translation adjustments:
Beginning of period balance(12)(1)(4)5 
Other comprehensive loss, net of tax benefit of $2, $1, $4 and $2, respectively
(7)(1)(15)(7)
End of period balance(19)(2)(19)(2)
Total:
Total beginning of period accumulated other comprehensive (loss)(2,149)(17)(178)150 
Total other comprehensive loss, net of tax benefit of $198, $27, $815 and $81, respectively
(638)(87)(2,617)(254)
Total other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(1), $0, $(4) and $(1), respectively
3 1 11 1 
Total end of period accumulated other comprehensive loss$(2,784)$(103)$(2,784)$(103)
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share (Tables)
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Denominator for Basic and Diluted Earnings Per Share
The denominator for basic and diluted earnings per share for the three and nine months ended September 30, 2022 and 2021 is as follows:
 Three Months Ended 
 September 30		Nine Months Ended 
 September 30
 2022202120222021
Denominator for basic earnings per share – weighted-average shares
239.6 243.4 240.5 244.3 
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures
2.6 2.6 2.8 2.9 
Denominator for diluted earnings per share
242.2 246.0 243.3 247.2 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Financial Data By Reportable Segment
Financial data by reportable segment for the three and nine months ended September 30, 2022 and 2021 is as follows:
Commercial
& Specialty
Business		Government
Business		IngenioRxOtherEliminationsTotal
Three Months Ended September 30, 2022
Operating revenue - unaffiliated$10,494 $24,571 $3,971 $589 $— $39,625 
Operating revenue - affiliated— — 3,278 2,776 (6,054)— 
Operating gain785 868 516 101 — 2,270 
Three Months Ended September 30, 2021
Operating revenue - unaffiliated$9,863 $21,658 $3,369 $658 $— $35,548 
Operating revenue - affiliated— — 3,180 2,012 (5,192)— 
Operating gain620 967 445 27 — 2,059 
Nine Months Ended September 30, 2022
Operating revenue - unaffiliated$31,324 $72,164 $10,838 $1,667 $— $115,993 
Operating revenue - affiliated— — 10,165 8,217 (18,382)— 
Operating gain2,673 2,653 1,393 365 — 7,084 
Nine Months Ended September 30, 2021
Operating revenue - unaffiliated$28,904 $61,007 $9,131 $1,883 $— $100,925 
Operating revenue - affiliated— — 9,499 5,674 (15,173)— 
Operating gain2,679 2,313 1,257 52 — 6,301 
Major Product Revenue by Segment
The major product revenues for each of the reportable segments for the three and nine months ended September 30, 2022 and 2021 are as follows:
Three Months Ended 
 September 30		Nine Months Ended 
 September 30
2022202120222021
Commercial & Specialty Business
Managed care products
$8,478 $8,005 $25,500 $23,481 
Managed care services
1,610 1,489 4,618 4,291 
Dental/Vision products and services
360 342 1,075 1,013 
Other
46 27 131 119 
Total Commercial & Specialty Business
10,494 9,863 31,324 28,904 
Government Business
Managed care products
24,456 21,565 71,823 60,711 
Managed care services
115 93 341 296 
Total Government Business
24,571 21,658 72,164 61,007 
IngenioRx
Pharmacy products and services7,249 6,549 21,003 18,630 
Other
Integrated health services3,153 2,506 9,083 7,121 
Other
212 164 801 436 
Total Other3,365 2,670 9,884 7,557 
Eliminations
Eliminations
(6,054)(5,192)(18,382)(15,173)
Total product revenues
$39,625 $35,548 $115,993 $100,925 
Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income
A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and nine months ended September 30, 2022 and 2021 is as follows:
 Three Months Ended 
 September 30		Nine Months Ended 
 September 30
 2022202120222021
Reportable segments’ operating revenue$39,625 $35,548 $115,993 $100,925 
Net investment income371 335 1,112 1,026 
Net (losses) gains on financial instruments(57)(61)(439)107 
Total revenues$39,939 $35,822 $116,666 $102,058 
Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income
A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three and nine months ended September 30, 2022 and 2021 is as follows:
 Three Months Ended 
 September 30		Nine Months Ended 
 September 30
 2022202120222021
Income before income tax expense$2,146 $1,996 $6,615 $6,525 
Net investment income(371)(335)(1,112)(1,026)
Net losses (gains) on financial instruments57 61 439 (107)
Interest expense213 201 622 598 
Amortization of other intangible assets225 136 520 306 
Loss on extinguishment of debt— — — 5 
Reportable segments’ operating gain$2,270 $2,059 $7,084 $6,301 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Tables)
 9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Lessee, Operating Lease, Disclosure [Table Text Block]
The information related to our leases is as follows:
Balance Sheet LocationSeptember 30, 2022December 31, 2021
Operating Leases
Right-of-use assetsOther noncurrent assets$600 $628 
Lease liabilities, currentOther current liabilities182 133 
Lease liabilities, noncurrentOther noncurrent liabilities739 864 
Three Months Ended 
 September 30		Nine Months Ended 
 September 30
2022202120222021
Lease Expense
Operating lease expense$35 $37 $100 $100 
Short-term lease expense11 10 35 34 
Sublease income(1)(1)(3)(3)
Total lease expense$45 $46 $132 $131 
Other information
 Operating cash paid for amounts included in the measurement of lease liabilities, operating leases$53 $53 $158 $141 
Right-of-use assets obtained in exchange for new lease liabilities, operating leases$23 $32 $62 $192 
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows:
2022 (excluding the nine months ended September 30, 2022)$54 
2023207 
2024179 
2025142 
2026105 
Thereafter345 
Total future minimum payments 1,032 
Less imputed interest(111)
Total lease liabilities$921 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Other Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment
A summary of the change in the carrying amount of goodwill for our segments (see Note 15, “Segment Information”) for 2022 and 2021 is as follows:
Commercial
& Specialty
Business		Government
Business		IngenioRxOtherTotal
Balance as of January 1, 2021$11,593 $8,331 $48 $1,719 $21,691 
Acquisitions and adjustments— 2,018 11 508 2,537 
Balance as of December 31, 202111,593 10,349 59 2,227 24,228 
Acquisitions and adjustments18 126 — 9 153 
Balance as of September 30, 2022$11,611 $10,475 $59 $2,236 $24,381 
Accumulated impairment as of September 30, 2022$— $— $— $— $— 
Components Of Other Intangible Assets
The components of other intangible assets as of September 30, 2022 and December 31, 2021 are as follows:
 September 30, 2022December 31, 2021
Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount
Intangible assets with finite lives:
Customer relationships$5,791 $(3,580)$2,211 $5,598 $(3,236)$2,362 
Provider and hospital relationships326 (142)184 324 (129)195 
Other920 (310)610 610 (141)469 
Total7,037 (4,032)3,005 6,532 (3,506)3,026 
Intangible assets with indefinite lives:
Blue Cross and Blue Shield and other trademarks5,991 — 5,991 6,299 — 6,299 
State Medicaid licenses1,540 — 1,540 1,290 — 1,290 
Total7,531 — 7,531 7,589 — 7,589 
Other intangible assets$14,568 $(4,032)$10,536 $14,121 $(3,506)$10,615 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization (Details)
medical_member in Millions
Sep. 30, 2022
medical_member
county
states
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of Medical Members | medical_member 47
Number of counties in the Kansas City area the Company does not serve | county 30
Number of states in which the Company is licensed to conduct insurance operations | states 50
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Signficant Accounting Policies Basis of Presentation and Significant Acconting Policies (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Accounting Policies [Line Items]              
Customer funds and cash and cash equivalents on deposit for regulatory requirements $ 291     $ 173      
Securities lending transactions, initial collateral percentage value 102.00%            
Premium receivable, allowance for doubtful accounts $ 140     142      
Self-funded receivables, allowance for doubtful accounts 82     50      
Allowance for doubtful accounts, other receivables 709     648      
Stockholders' equity attributable to parent 35,991     36,060 $ 35,808    
Retained Earnings [Member]              
Accounting Policies [Line Items]              
Stockholders' equity attributable to parent $ 29,604 $ 28,825 $ 28,058 27,088 $ 26,700 $ 25,874 $ 24,793
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 [Member] | Retained Earnings [Member]              
Accounting Policies [Line Items]              
Long-term Debt       31      
Deferred Tax and Other Liabilities, Noncurrent       (8)      
Stockholders' equity attributable to parent       $ (23)      
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Acquisitions Business Acquisition (Assets Liabilities Acquired) (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Dec. 31, 2020
Business Acquisition [Line Items]      
Finite-lived Intangible Assets Acquired $ 1,577    
Indefinite-lived Intangible Assets Acquired 20    
Goodwill, Acquired During Period 2,531    
Goodwill 24,381 $ 24,228 $ 21,691
Integra Managed Care [Member]      
Business Acquisition [Line Items]      
Finite-lived Intangible Assets Acquired 89    
Indefinite-lived Intangible Assets Acquired 250    
Goodwill, Purchase Accounting Adjustments 13    
Goodwill $ 123    
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Optimization Initiatives (Employee Termination Costs) (Details) - Employee Severance [Member]
$ in Millions
 9 Months Ended
Sep. 30, 2022
USD ($)
Business Optimization Initiatives [Line Items]  
Liability for employee terminations costs, beginning $ 122
Payments (30)
Liability for employee terminations costs, ending 92
IngenioRx Segment [Member]  
Business Optimization Initiatives [Line Items]  
Liability for employee terminations costs, beginning 1
Payments 0
Liability for employee terminations costs, ending 1
Other Segment [Member]  
Business Optimization Initiatives [Line Items]  
Liability for employee terminations costs, beginning 3
Payments 0
Liability for employee terminations costs, ending 3
Government Business Segment [Member]  
Business Optimization Initiatives [Line Items]  
Liability for employee terminations costs, beginning 57
Payments (14)
Liability for employee terminations costs, ending 43
Commercial & Specialty Business Segment [Member]  
Business Optimization Initiatives [Line Items]  
Liability for employee terminations costs, beginning 61
Payments (16)
Liability for employee terminations costs, ending $ 45
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments (Current And Long-Term Fixed Maturity Securities, Available-For-Sale) (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost $ 28,977 $ 26,257
Gross Unrealized Gains 58 830
Gross Unrealized Losses (2,877) (182)
Fixed maturities, allowance for credit loss (10) (6)
Available-for-sale Securities 26,148 26,899
United States Government Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 1,673 1,443
Gross Unrealized Gains 0 7
Gross Unrealized Losses (125) (18)
Fixed maturities, allowance for credit loss 0 0
Available-for-sale Securities 1,548 1,432
Government Sponsored Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 65 65
Gross Unrealized Gains 0 4
Gross Unrealized Losses (4) (1)
Fixed maturities, allowance for credit loss 0 0
Available-for-sale Securities 61 68
Foreign Government Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 322 353
Gross Unrealized Gains 0 7
Gross Unrealized Losses (70) (13)
Fixed maturities, allowance for credit loss (1) 0
Available-for-sale Securities 251 347
States, Municipalities And Political Subdivisions [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 4,431 5,321
Gross Unrealized Gains 5 310
Gross Unrealized Losses (355) (10)
Fixed maturities, allowance for credit loss 0 0
Available-for-sale Securities 4,081 5,621
Corporate Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 13,766 12,044
Gross Unrealized Gains 9 401
Gross Unrealized Losses (1,560) (78)
Fixed maturities, allowance for credit loss (7) (4)
Available-for-sale Securities 12,208 12,363
Residential Mortgage-Backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 4,748 4,059
Gross Unrealized Gains 7 75
Gross Unrealized Losses (506) (35)
Fixed maturities, allowance for credit loss (2) (2)
Available-for-sale Securities 4,247 4,097
Commercial Mortgage-Backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 77 65
Gross Unrealized Gains 0 2
Gross Unrealized Losses (7) (3)
Fixed maturities, allowance for credit loss 0 0
Available-for-sale Securities 70 64
Other Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 3,895 2,907
Gross Unrealized Gains 37 24
Gross Unrealized Losses (250) (24)
Fixed maturities, allowance for credit loss 0 0
Available-for-sale Securities $ 3,682 $ 2,907
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details) - Fixed Maturities [Member]
$ in Millions
Sep. 30, 2022
USD ($)
securities
Dec. 31, 2021
USD ($)
securities
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 9,606 3,571
Estimated fair value, less than 12 months $ 20,511 $ 8,755
Gross unrealized loss, less than 12 months $ (2,056) $ (131)
Number of securities, 12 months or greater | securities 2,444 686
Estimated fair value, 12 months or greater $ 4,128 $ 985
Gross unrealized loss, 12 months or greater $ (821) $ (51)
United States Government Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 65 51
Estimated fair value, less than 12 months $ 911 $ 990
Gross unrealized loss, less than 12 months $ (77) $ (11)
Number of securities, 12 months or greater | securities 29 27
Estimated fair value, 12 months or greater $ 303 $ 176
Gross unrealized loss, 12 months or greater $ (48) $ (7)
Government Sponsored Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 40 0
Estimated fair value, less than 12 months $ 61 $ 0
Gross unrealized loss, less than 12 months $ (4) $ 0
Number of securities, 12 months or greater | securities 1 1
Estimated fair value, 12 months or greater $ 0 $ 1
Gross unrealized loss, 12 months or greater $ 0 $ (1)
Foreign Government Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 225 188
Estimated fair value, less than 12 months $ 169 $ 143
Gross unrealized loss, less than 12 months $ (34) $ (8)
Number of securities, 12 months or greater | securities 151 68
Estimated fair value, 12 months or greater $ 81 $ 41
Gross unrealized loss, 12 months or greater $ (36) $ (5)
States, Municipalities And Political Subdivisions [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 1,964 281
Estimated fair value, less than 12 months $ 3,602 $ 634
Gross unrealized loss, less than 12 months $ (314) $ (9)
Number of securities, 12 months or greater | securities 139 8
Estimated fair value, 12 months or greater $ 200 $ 16
Gross unrealized loss, 12 months or greater $ (41) $ (1)
Corporate Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 4,322 1,846
Estimated fair value, less than 12 months $ 10,228 $ 3,310
Gross unrealized loss, less than 12 months $ (1,165) $ (57)
Number of securities, 12 months or greater | securities 1,318 403
Estimated fair value, 12 months or greater $ 1,679 $ 485
Gross unrealized loss, 12 months or greater $ (395) $ (21)
Residential Mortgage-Backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 2,035 692
Estimated fair value, less than 12 months $ 2,949 $ 1,967
Gross unrealized loss, less than 12 months $ (294) $ (26)
Number of securities, 12 months or greater | securities 530 125
Estimated fair value, 12 months or greater $ 1,182 $ 173
Gross unrealized loss, 12 months or greater $ (212) $ (9)
Commercial Mortgage-Backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 34 2
Estimated fair value, less than 12 months $ 56 $ 4
Gross unrealized loss, less than 12 months $ (3) $ (1)
Number of securities, 12 months or greater | securities 7 4
Estimated fair value, 12 months or greater $ 13 $ 8
Gross unrealized loss, 12 months or greater $ (4) $ (2)
Other Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | securities 921 511
Estimated fair value, less than 12 months $ 2,535 $ 1,707
Gross unrealized loss, less than 12 months $ (165) $ (19)
Number of securities, 12 months or greater | securities 269 50
Estimated fair value, 12 months or greater $ 670 $ 85
Gross unrealized loss, 12 months or greater $ (85) $ (5)
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]    
Due in one year or less, Amortized Cost $ 911  
Due after one year through five years, Amortized Cost 7,364  
Due after five years through ten years, Amortized Cost 9,535  
Due after ten years, Amortized Cost 6,342  
Mortgage-backed securities, Amortized Cost 4,825  
Available-for-sale securities, Amortized Cost 28,977 $ 26,257
Due in one year or less, Estimated Fair Value 901  
Due after one year through five years, Estimated Fair Value 6,871  
Due after five years through ten years, Estimated Fair Value 8,467  
Due after ten years, Estimated Fair Value 5,592  
Mortgage-backed securities, Estimated Fair Value 4,317  
Available-for-sale securities, Estimated Fair Value $ 26,148 $ 26,899
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments (Current Equity Securities) (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Equity Securities [Line Items]    
Equity securities $ 1,503 $ 1,881
Exchange Traded Funds [Member]    
Equity Securities [Line Items]    
Equity securities 1,403 1,750
Common Equity Securities [Member]    
Equity Securities [Line Items]    
Equity securities 5 42
Private Equity Funds [Member]    
Equity Securities [Line Items]    
Equity securities $ 95 $ 89
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments (Net Investment Gains/Losses) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Investment [Line Items]        
Net (losses) gains on investments $ (54) $ (73) $ (482) $ 48
Fixed Maturities [Member]        
Investment [Line Items]        
Debt Securities, Available-for-sale, Realized Gain 8 30 44 133
Debt Securities, Available-for-sale, Realized Loss (99) (8) (353) (32)
Impairment (losses) recoveries recognized in income (5) 0 (25) 1
Debt Securities, Available-for-sale, Realized Gain (Loss) (96) 22 (334) 102
Equity Securities [Member]        
Investment [Line Items]        
Unrealized (losses) gains recognized on equity securities still held at the end of the period (43) (4) (192) 4
Net realized gains (losses) recognized on equity securities sold during the period 4 (1) (20) (57)
Net losses on equity securities (39) (5) (212) (53)
Other Investments [Member]        
Investment [Line Items]        
Gross gains 95 2 126 9
Gross losses (2) (93) (45) (5)
Impairment (losses) recoveries recognized in income (12) 1 (17) (5)
Net losses (gains) on other investments $ 81 $ (90) $ 64 $ (1)
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Schedule of Investments [Line Items]          
Accrued investment income receivable $ 228   $ 228   $ 205
Fair value of collateral received at time of securities lending transactions $ 2,841   $ 2,841   $ 2,155
Securities lending transactions ratio of fair value of collateral held to fair value of securities loaned 102.00%   102.00%   102.00%
Fixed maturities, allowance for credit losses $ (10)   $ (10)   $ (6)
United States Government Securities [Member]          
Schedule of Investments [Line Items]          
Fixed maturities, allowance for credit losses 0   0   0
Other Securities [Member]          
Schedule of Investments [Line Items]          
Fixed maturities, allowance for credit losses 0   0   0
Fixed Maturities [Member]          
Schedule of Investments [Line Items]          
Proceeds from Sale of Available-for-sale Securities 5,281 $ 2,620 15,953 $ 8,570  
Overnight and Continuous [Member] | Cash [Member]          
Schedule of Investments [Line Items]          
Collateral received for securities loaned, at carrying value 2,636   2,636   1,874
Overnight and Continuous [Member] | United States Government Securities [Member]          
Schedule of Investments [Line Items]          
Collateral received for securities loaned, at carrying value 180   180   281
Overnight and Continuous [Member] | Other Securities [Member]          
Schedule of Investments [Line Items]          
Collateral received for securities loaned, at carrying value $ 25   $ 25   $ 0
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Derivative Financial Instruments (Financial Statement Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosures [Line Items]          
Derivative, Gain (Loss) Recognized $ (3) $ 12 $ 43 $ 59  
Cash Flow Hedging [Member]          
Derivative Instruments and Hedging Activities Disclosures [Line Items]          
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax $ (231)   $ (231)   $ (239)
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents $ 5,794 $ 2,415
Available-for-sale Securities 26,148 26,899
Other invested assets 5,516 5,225
Securities lending collateral 2,841 2,155
Total assets 36,460 33,507
Total liabilities (70) (1)
United States Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 1,548 1,432
Government Sponsored Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 61 68
Foreign Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 251 347
States, Municipalities And Political Subdivisions [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 4,081 5,621
Corporate Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 12,208 12,363
Residential Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 4,247 4,097
Commercial Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 70 64
Other Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 3,682 2,907
Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 1,503 1,881
Equity Securities [Member] | Exchange Traded Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 1,403 1,750
Equity Securities [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 5 42
Equity Securities [Member] | Private Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 95 89
Other Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 5,367 5,087
Other Investments [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 149 138
Derivatives [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 25 19
Derivative liabilities (70) (1)
Level I [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 5,794 2,415
Available-for-sale Securities 0 0
Securities lending collateral 0 0
Total assets 7,352 4,311
Total liabilities 0 0
Level I [Member] | United States Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | Government Sponsored Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | Foreign Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | States, Municipalities And Political Subdivisions [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | Corporate Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | Residential Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | Commercial Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | Other Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level I [Member] | Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 1,409 1,758
Level I [Member] | Equity Securities [Member] | Exchange Traded Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 1,403 1,750
Level I [Member] | Equity Securities [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 6 8
Level I [Member] | Equity Securities [Member] | Private Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 0 0
Level I [Member] | Other Investments [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 149 138
Level I [Member] | Derivatives [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 0 0
Derivative liabilities 0 0
Level II [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Available-for-sale Securities 25,708 26,539
Securities lending collateral 2,841 2,155
Total assets 28,573 28,747
Total liabilities (70) (1)
Level II [Member] | United States Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 1,548 1,432
Level II [Member] | Government Sponsored Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 61 68
Level II [Member] | Foreign Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 251 347
Level II [Member] | States, Municipalities And Political Subdivisions [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 4,081 5,621
Level II [Member] | Corporate Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 12,079 12,027
Level II [Member] | Residential Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 4,247 4,092
Level II [Member] | Commercial Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 70 64
Level II [Member] | Other Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 3,371 2,888
Level II [Member] | Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities (1) 34
Level II [Member] | Equity Securities [Member] | Exchange Traded Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 0 0
Level II [Member] | Equity Securities [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities (1) 34
Level II [Member] | Equity Securities [Member] | Private Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 0 0
Level II [Member] | Other Investments [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 0 0
Level II [Member] | Derivatives [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 25 19
Derivative liabilities (70) (1)
Level III [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 0 0
Available-for-sale Securities 440 360
Securities lending collateral 0 0
Total assets 535 449
Total liabilities 0 0
Level III [Member] | United States Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level III [Member] | Government Sponsored Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level III [Member] | Foreign Government Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level III [Member] | States, Municipalities And Political Subdivisions [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level III [Member] | Corporate Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 129 336
Level III [Member] | Residential Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 5
Level III [Member] | Commercial Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 0 0
Level III [Member] | Other Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Available-for-sale Securities 311 19
Level III [Member] | Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 95 89
Level III [Member] | Equity Securities [Member] | Exchange Traded Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 0 0
Level III [Member] | Equity Securities [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 0 0
Level III [Member] | Equity Securities [Member] | Private Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity Securities 95 89
Level III [Member] | Other Investments [Member] | Common Equity Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 0 0
Level III [Member] | Derivatives [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 0 0
Derivative liabilities $ 0 $ 0
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning balance $ 467 $ 437 $ 449 $ 392
Total gains (losses) recognized in net income 0 6 1 19
Total gains (losses) recognized in accumulated other comprehensive loss 18 (1) 16 4
Purchases 95 37 345 146
Sales (29) (1) (221) (16)
Settlements (10) (47) (42) (119)
Transfers into Level III     9  
Transfers out of Level III (6) (10) (22) (5)
Ending balance 535 421 535 421
Change in unrealized gains (losses) included in net income related to assets still held 0 5 1 17
Corporate Securities [Member]        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning balance 155 351 336 325
Total gains (losses) recognized in net income 0 1 0 2
Total gains (losses) recognized in accumulated other comprehensive loss 1 (1) (1) 4
Purchases 15 34 40 135
Sales (26) 0 (201) (12)
Settlements (10) (47) (42) (118)
Transfers into Level III     9  
Transfers out of Level III (6) (4) (12) (2)
Ending balance 129 334 129 334
Change in unrealized gains (losses) included in net income related to assets still held 0 0 0 0
Residential Mortgage-Backed Securities [Member]        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning balance 0 2 5 2
Total gains (losses) recognized in net income 0 0 0 0
Total gains (losses) recognized in accumulated other comprehensive loss 0 0 0 0
Purchases 0 0 0 0
Sales 0 0 0 0
Settlements 0 0 0 0
Transfers into Level III     0  
Transfers out of Level III 0 (1) (5) (1)
Ending balance 0 1 0 1
Change in unrealized gains (losses) included in net income related to assets still held 0 0 0 0
Other Securities [Member]        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning balance 218 7 19 5
Total gains (losses) recognized in net income 0 0 0 0
Total gains (losses) recognized in accumulated other comprehensive loss 17 0 17 0
Purchases 77 0 281 0
Sales (1) 0 (1) 0
Settlements 0 0 0 (1)
Transfers into Level III     0  
Transfers out of Level III 0 (5) (5) (2)
Ending balance 311 2 311 2
Change in unrealized gains (losses) included in net income related to assets still held 0 0 0 0
Equity Securities [Member]        
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning balance 94 77 89 60
Total gains (losses) recognized in net income 0 5 1 17
Total gains (losses) recognized in accumulated other comprehensive loss 0 0 0 0
Purchases 3 3 24 11
Sales (2) (1) (19) (4)
Settlements 0 0 0 0
Transfers into Level III     0  
Transfers out of Level III 0 0 0 0
Ending balance 95 84 95 84
Change in unrealized gains (losses) included in net income related to assets still held $ 0 $ 5 $ 1 $ 17
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value (Carrying And Estimated Fair Values by Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets $ 5,516 $ 5,225
Short-term borrowings 265 275
Commercial paper 675 300
Notes 20,163 25,150
Convertible debentures 554 687
Fair Value, Recurring [Member] | Level III [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term borrowings 0 0
Commercial paper 0 0
Notes 0 0
Convertible debentures 0 0
Fair Value, Recurring [Member] | Level II [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term borrowings 265 275
Commercial paper 675 300
Notes 20,163 25,150
Convertible debentures 554 687
Fair Value, Recurring [Member] | Level I [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term borrowings 0 0
Commercial paper 0 0
Notes 0 0
Convertible debentures 0 0
Fair Value, Nonrecurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 5,367 5,087
Short-term borrowings 265 275
Commercial paper 675 300
Notes 22,747 22,384
Convertible debentures 86 72
Other Investments [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 5,367 5,087
Other Investments [Member] | Fair Value, Recurring [Member] | Level III [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 5,367 5,087
Other Investments [Member] | Fair Value, Recurring [Member] | Level II [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets 0 0
Other Investments [Member] | Fair Value, Recurring [Member] | Level I [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Other invested assets $ 0 $ 0
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Income Tax Disclosure [Abstract]          
Income tax expense $ 533 $ 494 $ 1,557 $ 1,555  
Effective tax rate 24.80% 24.70% 23.50% 23.80%  
Income taxes receivable $ 214   $ 214   $ 173
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable By Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Medical Claims Payable [Line Items]                
Gross medical claims payable, beginning of period     $ 13,282     $ 11,135 $ 13,282 $ 11,135
Ceded medical claims payable, beginning of period     (21)     (46) (21) (46)
Net medical claims payable, beginning of period     13,261     11,089 13,261 11,089
Business combinations and purchase adjustments $ 133     $ 420     133 420
Current period net incurred medical claims             84,177 74,097
Prior periods redundancies             (901) (1,822)
Total net incurred medical claims 28,511 $ 27,634 27,131 25,704 $ 23,844 22,727 83,276 72,275
Net payments attributable to current period medical claims             70,453 62,123
Net payments attributable to prior periods medical claims             11,219 8,400
Total net payments             81,672 70,523
Net medical claims payable, end of period 14,998     13,261     14,998 13,261
Ceded medical claims payable, end of period 3     38     3 38
Gross medical claims payable, end of period 15,001     13,299     15,001 13,299
Commercial & Specialty Business Segment [Member]                
Medical Claims Payable [Line Items]                
Gross medical claims payable, beginning of period     3,847     3,294 3,847 3,294
Ceded medical claims payable, beginning of period     (13)     (13) (13) (13)
Net medical claims payable, beginning of period     3,834     3,281 3,834 3,281
Business combinations and purchase adjustments 3     0     3 0
Current period net incurred medical claims             22,049 20,499
Prior periods redundancies             (183) (496)
Total net incurred medical claims 7,510 7,522 6,834 7,213 6,718 6,072 21,866 20,003
Net payments attributable to current period medical claims             18,604 16,985
Net payments attributable to prior periods medical claims             3,181 2,450
Total net payments             21,785 19,435
Net medical claims payable, end of period 3,918     3,849     3,918 3,849
Ceded medical claims payable, end of period 3     15     3 15
Gross medical claims payable, end of period 3,921     3,864     3,921 3,864
Government Business Segment [Member]                
Medical Claims Payable [Line Items]                
Gross medical claims payable, beginning of period     9,157     7,646 9,157 7,646
Ceded medical claims payable, beginning of period     (8)     (33) (8) (33)
Net medical claims payable, beginning of period     9,149     7,613 9,149 7,613
Business combinations and purchase adjustments 130     375     130 375
Current period net incurred medical claims             60,971 52,422
Prior periods redundancies             (639) (1,309)
Total net incurred medical claims 20,601 19,788 19,943 18,071 16,723 16,319 60,332 51,113
Net payments attributable to current period medical claims             50,950 44,160
Net payments attributable to prior periods medical claims             7,854 5,781
Total net payments             58,804 49,941
Net medical claims payable, end of period 10,807     9,160     10,807 9,160
Ceded medical claims payable, end of period 0     23     0 23
Gross medical claims payable, end of period 10,807     9,183     10,807 9,183
Other Segment [Member]                
Medical Claims Payable [Line Items]                
Gross medical claims payable, beginning of period     278     195 278 195
Ceded medical claims payable, beginning of period     0     0 0 0
Net medical claims payable, beginning of period     278     195 278 195
Business combinations and purchase adjustments 0     45     0 45
Current period net incurred medical claims             1,157 1,176
Prior periods redundancies             (79) (17)
Total net incurred medical claims 400 $ 324 $ 354 420 $ 403 $ 336 1,078 1,159
Net payments attributable to current period medical claims             899 978
Net payments attributable to prior periods medical claims             184 169
Total net payments             1,083 1,147
Net medical claims payable, end of period 273     252     273 252
Ceded medical claims payable, end of period 0     0     0 0
Gross medical claims payable, end of period $ 273     $ 252     $ 273 $ 252
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Medical Claims Payable (Reconciliation Of Net Incurred Medical Claims To Benefit Expense) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Reconciliation of net incurred medical claims to benefit expense [Line Items]                
Total net incurred medical claims $ 28,511 $ 27,634 $ 27,131 $ 25,704 $ 23,844 $ 22,727 $ 83,276 $ 72,275
Quality improvement and other claims expense 893 1,143 1,084 941 919 972 3,120 2,832
Benefit expense 29,404 28,777 28,215 26,645 24,763 23,699 86,396 75,107
Commercial & Specialty Business Segment [Member]                
Reconciliation of net incurred medical claims to benefit expense [Line Items]                
Total net incurred medical claims 7,510 7,522 6,834 7,213 6,718 6,072 21,866 20,003
Government Business Segment [Member]                
Reconciliation of net incurred medical claims to benefit expense [Line Items]                
Total net incurred medical claims 20,601 19,788 19,943 18,071 16,723 16,319 60,332 51,113
Other Segment [Member]                
Reconciliation of net incurred medical claims to benefit expense [Line Items]                
Total net incurred medical claims $ 400 $ 324 $ 354 $ 420 $ 403 $ 336 $ 1,078 $ 1,159
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Medical Claims Payable Medical Claims Payable (Reconciliation of the Claims Development to the Claims Liability) (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Sep. 30, 2021
Dec. 31, 2020
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]        
Net medical claims payable, end of period $ 14,998 $ 13,261   $ 11,089
Ceded medical claims payable end of period 3 21 $ 38 46
Insurance lines other than short duration 241      
Gross medical claims payable, end of period 15,242 13,518    
Commercial & Specialty Business Segment [Member]        
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]        
Net medical claims payable, end of period 3,918 3,834   3,281
Ceded medical claims payable end of period 3 13 15 13
Insurance lines other than short duration 0      
Gross medical claims payable, end of period 3,921      
Government Business Segment [Member]        
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]        
Net medical claims payable, end of period 10,807 9,149   7,613
Ceded medical claims payable end of period 0 8 23 33
Insurance lines other than short duration 241      
Gross medical claims payable, end of period 11,048      
Other Segment [Member]        
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]        
Net medical claims payable, end of period 273 278   195
Ceded medical claims payable end of period 0 $ 0 $ 0 $ 0
Insurance lines other than short duration 0      
Gross medical claims payable, end of period $ 273      
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Medical Claims Payable (Narrative) (Details)
$ in Millions
Sep. 30, 2022
USD ($)
Short-Duration Insurance Contract, Accident Year 2020 [Member] | Commercial & Specialty Business Segment [Member]  
Claims Development [Line Items]  
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net $ 81
Short-Duration Insurance Contract, Accident Year 2020 [Member] | Government Business Segment [Member]  
Claims Development [Line Items]  
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 148
Short-Duration Insurance Contract, Accident Year 2020 [Member] | Other Segment [Member]  
Claims Development [Line Items]  
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 2
Short-Duration Insurance Contract, Accident Year 2021 [Member] | Commercial & Specialty Business Segment [Member]  
Claims Development [Line Items]  
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 388
Short-Duration Insurance Contract, Accident Year 2021 [Member] | Government Business Segment [Member]  
Claims Development [Line Items]  
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 508
Short-Duration Insurance Contract, Accident Year 2021 [Member] | Other Segment [Member]  
Claims Development [Line Items]  
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 14
Short-Duration Insurance Contract, Accident Year 2022 [Member] | Commercial & Specialty Business Segment [Member]  
Claims Development [Line Items]  
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 3,449
Short-Duration Insurance Contract, Accident Year 2022 [Member] | Government Business Segment [Member]  
Claims Development [Line Items]  
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net 10,151
Short-Duration Insurance Contract, Accident Year 2022 [Member] | Other Segment [Member]  
Claims Development [Line Items]  
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net $ 257
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt (Convertible Debenture Details) (Details)
$ / shares in Units, $ in Millions
 9 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
Debt Instrument [Line Items]    
Net debt carrying amount $ 554 $ 687
Convertible Debt [Member]    
Debt Instrument [Line Items]    
Outstanding principal amount 86  
Net debt carrying amount $ 86  
Conversion rate (shares of common stock per $1,000 of principal) 14.2967  
Effective conversion price (per $1,000 of principal amount) per share | $ / shares $ 69.9462  
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Apr. 18, 2022
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
May 16, 2022
Apr. 29, 2022
Mar. 31, 2022
Dec. 31, 2021
Jun. 30, 2021
Mar. 31, 2021
Debt Instrument [Line Items]                        
Loss on extinguishment of debt   $ 0 $ 0 $ 0 $ 5              
Commercial paper   675   675           $ 300    
Stockholders' equity attributable to parent   35,991 35,808 35,991 35,808         36,060    
Repayments of Long-term Debt       982 954              
Short-term borrowings   265   265           275    
Retained Earnings [Member]                        
Debt Instrument [Line Items]                        
Stockholders' equity attributable to parent   29,604 $ 26,700 $ 29,604 $ 26,700 $ 28,825     $ 28,058 27,088 $ 25,874 $ 24,793
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 [Member] | Retained Earnings [Member]                        
Debt Instrument [Line Items]                        
Long-term Debt                   31    
Deferred Tax and Other Liabilities, Noncurrent                   (8)    
Stockholders' equity attributable to parent                   (23)    
Senior Revolving Credit Facility [Member]                        
Debt Instrument [Line Items]                        
Covenant description       Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility.                
Covenant compliance       As of September 30, 2022, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.7%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of September 30, 2022, we were in compliance with all of our debt covenants under the 5-Year Facility.                
Convertible Debt [Member]                        
Debt Instrument [Line Items]                        
Debt Conversion Debt Principal Amount   4   $ 19                
Repayments of Long-term Debt   25   132                
Subsidiary Credit Facilities [Member]                        
Debt Instrument [Line Items]                        
Maximum borrowing capacity   200   200                
Federal Home Loan Bank Advances [Member]                        
Debt Instrument [Line Items]                        
Federal Home Loan Bank, advances, short-term   265   265           275    
Surplus Notes [Member]                        
Debt Instrument [Line Items]                        
Long-term Debt   25   25           25    
Senior Unsecured Notes [Member]                        
Debt Instrument [Line Items]                        
Long-term Debt   22,722   22,722           22,359    
Senior Unsecured Notes [Member] | Four Point One Zero Percent Due Two Thousand Thirty Two [Member]                        
Debt Instrument [Line Items]                        
Debt instrument interest rate               4.10%        
Debt Instrument, Face Amount               $ 600        
Senior Unsecured Notes [Member] | Four Point Five Five Zero Due Two Thousand Fifty Two [Member]                        
Debt Instrument [Line Items]                        
Debt instrument interest rate               4.55%        
Debt Instrument, Face Amount               $ 700        
Senior Unsecured Notes [Member] | Three Point One Two Five Percent Due Two Thousand Twenty Two [Member]                        
Debt Instrument [Line Items]                        
Debt instruments, repurchased face amount             $ 850          
Debt instrument interest rate             3.125%          
Commercial Paper Program                        
Debt Instrument [Line Items]                        
Commercial paper authorized   4,000   4,000   $ 3,500            
Commercial paper   $ 675   $ 675           $ 300    
2021 364-Day Facility [Member]                        
Debt Instrument [Line Items]                        
Line of Credit Facility, Description Also on April 18, 2022, concurrently with the amendment and restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which was scheduled to mature in June 2022                      
2021 364-Day Facility [Member] | Senior Revolving Credit Facility [Member]                        
Debt Instrument [Line Items]                        
Maximum borrowing capacity                 1,000      
5-Year Facility [Member] | Senior Revolving Credit Facility [Member]                        
Debt Instrument [Line Items]                        
Maximum borrowing capacity $ 4,000               $ 2,500      
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments And Contingencies (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2022
USD ($)
Commitments And Contingencies [Line Items]  
Aggregate settlement amount $ 596
Loss Contingency Accrual, Payments $ 506
Gross premium tax rate, state of California 2.35%
Long-term purchase commitment, amount $ 830
Minimum [Member]  
Commitments And Contingencies [Line Items]  
Aggregate settlement amount 0
Maximum [Member]  
Commitments And Contingencies [Line Items]  
Aggregate settlement amount $ 250
BCBS Antitrust Litigation [Member]  
Commitments And Contingencies [Line Items]  
Loss Contingency, Pending Claims, Number 8,000
Anthem, Inc. v. Express Scripts, Inc. [Member]  
Commitments And Contingencies [Line Items]  
Proceeds originally received at time of divestiture $ 4,675
Anthem, Inc. v. Express Scripts, Inc. [Member] | Damages for Pharmacy Pricing [Member]  
Commitments And Contingencies [Line Items]  
Approximate amount of damages sought for breaches 14,800
Anthem, Inc. v. Express Scripts, Inc. [Member] | Damages for Operational Breaches [Member]  
Commitments And Contingencies [Line Items]  
Approximate amount of damages sought for breaches $ 158
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
Capital Stock (Summary of Cash Dividend Activity) (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Banking Regulation, Total Capital [Abstract]                
Declaration date Jul. 19, 2022 Apr. 19, 2022 Jan. 25, 2022 Jul. 20, 2021 Apr. 20, 2021 Jan. 26, 2021    
Record date Sep. 09, 2022 Jun. 10, 2022 Mar. 10, 2022 Sep. 10, 2021 Jun. 10, 2021 Mar. 10, 2021    
Payment date Sep. 23, 2022 Jun. 24, 2022 Mar. 25, 2022 Sep. 24, 2021 Jun. 25, 2021 Mar. 25, 2021    
Cash dividends per share $ 1.28 $ 1.28 $ 1.28 $ 1.13 $ 1.13 $ 1.13    
Total payment $ 306 $ 309 $ 309 $ 276 $ 278 $ 277 $ 924 $ 831
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
Capital Stock (Summary of Share Repurchases) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Equity, Class of Treasury Stock [Line Items]                
Shares repurchased             3.7 3.9
Average price per share             $ 473.36 $ 356.43
Aggregate cost $ 579 $ 624 $ 545 $ 451 $ 480 $ 447 $ 1,748 $ 1,378
Authorization remaining at the end of the period $ 2,444     $ 4,714     $ 2,444 $ 4,714
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.22.2.2
Capital Stock (Summary of Stock Option Activity) (Details)
$ / shares in Units, shares in Millions, $ in Millions
 9 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Number of Shares [Roll Forward]  
Outstanding at beginning of period, Number of Shares | shares 2.9
Granted, Number of Shares | shares 0.5
Exercised, Number of Shares | shares (0.4)
Forfeited or expired, Number of Shares | shares (0.1)
Outstanding at end of period, Number of Shares | shares 2.9
Exercisable at end of period, Number of Shares | shares 1.7
Weighted-Average Option Price Per Share [Roll Forward]  
Outstanding at beginning of period, Weighted-Average Option Price per Share | $ / shares $ 255.50
Granted, Weighted-Average Option Price per Share | $ / shares 452.34
Exercised, Weighted-Average Option Price per Share | $ / shares 243.39
Forfeited or expired, Weighted-Average Option Price per Share | $ / shares 339.52
Outstanding at end of period, Weighted-Average Option Price per Share | $ / shares 291.95
Exercisable at end of period, Weighted-Average Option Price per Share | $ / shares $ 239.27
Outstanding at end of period, Weighted-Average Remaining Contractual Life 6 years 6 months 21 days
Exercisable at end of period, Weighted-Average Remaining Contractual Life 5 years 4 months 6 days
Outstanding at end of period, Aggregate Intrinsic Value | $ $ 477
Exercisable at end of period, Aggregate Intrinsic Value | $ $ 370
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.22.2.2
Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details) - $ / shares
shares in Millions
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Restricted Stock Shares and Units [Roll Forward]    
Nonvested at Beginning Balance, Restricted Stock Shares and Units 1.3  
Granted, Restricted Stock Shares and Units 0.6  
Vested, Restricted Stock Shares And Units (0.6)  
Forfeited, Restricted Stock Shares And Units (0.1)  
Nonvested at Ending Balance, Restricted Stock Shares and Units 1.2  
Weighted-Average Grant Date Fair Value Per Share [Roll Forward]    
Nonvested at Beginning Balance, Weighted-Average Grant Date Fair Value per Share $ 299.65  
Granted, Weighted-Average Grant Date Fair Value per Share 453.16 $ 315.54
Vested, Weighted-Average Grant Date Fair Value per Share 301.44  
Forfeited, Weighted-Average Grant Date Fair Value per Share 345.25  
Nonvested at Ending Balance, Weighted-Average Grant Date Fair Value per Share $ 356.33  
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.22.2.2
Capital Stock (Fair Values of Options Granted During The Period Estimated Using Weighted-Average Assumptions) (Details)
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Banking Regulation, Total Capital [Abstract]    
Risk-free interest rate 1.97% 1.44%
Volatility factor 29.00% 30.00%
Quarterly dividend yield 0.282% 0.36%
Weighted-average expected life (years) 5 years 1 month 6 days 5 years 6 months
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.22.2.2
Capital Stock (Schedule Of Weighted-Average Fair Values Determined For The Periods) (Details) - $ / shares
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Banking Regulation, Total Capital [Abstract]    
Options granted during the period $ 116.85 $ 79.51
Restricted stock awards granted during the period $ 453.16 $ 315.54
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.22.2.2
Capital Stock (Narrative) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Oct. 18, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Jan. 26, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]                  
Dividends Payable, Date to be Paid   Sep. 23, 2022 Jun. 24, 2022 Mar. 25, 2022 Sep. 24, 2021 Jun. 25, 2021 Mar. 25, 2021    
Dividends Payable, Date of Record   Sep. 09, 2022 Jun. 10, 2022 Mar. 10, 2022 Sep. 10, 2021 Jun. 10, 2021 Mar. 10, 2021    
Increase In Stock Repurchase Program Authorization                 $ 5,000
Subsequent Event [Member]                  
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]                  
Dividends Payable, Amount Per Share $ 1.28                
Dividends Payable, Date to be Paid Dec. 21, 2022                
Dividends Payable, Date of Record Dec. 05, 2022                
2022 to 2024 | Restricted Stock Units (RSUs) [Member]                  
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross               0.2  
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.22.2.2
Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Accumulated Other Comprehensive Loss, Beginning Balance $ (2,149)   $ (178) $ (17)   $ 150 $ (178) $ 150
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax (639)     (97)     (2,630) (284)
Other comprehensive loss attributable to noncontrolling interests 3     1     11 1
Cash flow hedges, holding gain (loss), net of tax 2     4     8 10
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax (7)     (8)     (23) (26)
Foreign currency translation adjustment, net of tax (7)     (1)     (15) (7)
Other Comprehensive Income (Loss), Net of Tax (638) $ (916) (1,063) (87) $ 180 (347) (2,617) (254)
Accumulated Other Comprehensive Loss, Ending Balance (2,784) (2,149)   (103) (17)   (2,784) (103)
Other Comprehensive Income (Loss), Tax (Expense) Benefit, Portion Attributable to Parent 198     27     815 81
Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest (1)     0     (4) (1)
Net unrealized investment (losses) gains                
AOCI, Debt Securities, Beginning Balance (1,489)   494 762   949 494 949
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax (719)     (80)     (2,914) (203)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax 80     (17)     284 (81)
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax (639)     (97)     (2,630) (284)
Other comprehensive loss attributable to noncontrolling interests 3     1     11 1
AOCI, Debt Securities, Ending Balance (2,125) (1,489)   666 762   (2,125) 666
Net holding gain (loss) on investment securities arising during the period, tax (expense) benefit 220     25     896 71
Reclassification adjustment for net realized loss (gain) on investment securities, tax (benefit) expense (21)     5     (75) 21
Non-credit components of impairments on investments [Member]                
Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Debt Securities (2)   0 0   (2) 0 (2)
Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Available-for-sale Securities (1)     (1)     (3) 1
AOCI, Other than Temporary Impairment, Not Credit Loss, Ending Balance (3) (2)   (1) 0   (3) (1)
Tax (expense) benefit of non credit impairment on available-for-sale securities recognized in other comprehensive income (loss) 0     0     1 (1)
Net cash flow hedges                
AOCI, Cash Flow Hedge, Beginning Balance (233)   (239) (244)   (250) (239) (250)
Cash flow hedges, holding gain (loss), net of tax 2     4     8 10
AOCI, Cash Flow Hedge, Ending Balance (231) (233)   (240) (244)   (231) (240)
Cash flow hedges, holding gain (loss), tax (expense) benefit 0     0     (2) (2)
Pension and other postretirement benefits                
AOCI, Defined Benefit Plan, Beginning Balance (413)   (429) (534)   (552) (429) (552)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax 7     8     23 26
AOCI, Defined Benefit Plan, Ending Balance (406) (413)   (526) (534)   (406) (526)
Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, tax expense (3)     (4)     (9) (10)
Foreign currency translation adjustments                
AOCI, Foreign Currency Translation Adjustment, Net of Tax, Beginning Balance (12)   $ (4) (1)   $ 5 (4) 5
Foreign currency translation adjustment, net of tax (7)     (1)     (15) (7)
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax, Ending Balance (19) $ (12)   (2) $ (1)   (19) (2)
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax (Expense) Benefit $ 2     $ 1     $ 4 $ 2
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details) - shares
shares in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Earnings Per Share [Abstract]        
Denominator for basic earnings per share - weighted-average shares 239.6 243.4 240.5 244.3
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures 2.6 2.6 2.8 2.9
Denominator for diluted earnings per share 242.2 246.0 243.3 247.2
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share (Narrative) (Details) - shares
shares in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Earnings Per Share [Abstract]        
Weighted average shares excluded from denominator for diluted earnings per share because the stock options were anti-dilutive 0.5 0.0 0.4 0.3
Restricted stock units issued under stock incentive plan     0.6  
2022 to 2024 [Member]        
Restricted stock units issued under stock incentive plan 0.0   0.6  
Restricted stock units excluded from the denominator for diluted earnings per share 0.0   0.2  
2021 to 2023 [Member]        
Restricted stock units issued under stock incentive plan   0.1   1.0
Restricted stock units excluded from the denominator for diluted earnings per share   0.0   0.3
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Financial Data By Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting Information [Line Items]        
Reportable segments operating revenues $ 39,625 $ 35,548 $ 115,993 $ 100,925
Operating gain (loss) 2,270 2,059 7,084 6,301
Commercial & Specialty [Member]        
Segment Reporting Information [Line Items]        
Operating gain (loss) 785 620 2,673 2,679
Government Business [Member]        
Segment Reporting Information [Line Items]        
Operating gain (loss) 868 967 2,653 2,313
IngenioRx Segment [Member]        
Segment Reporting Information [Line Items]        
Operating gain (loss) 516 445 1,393 1,257
Other [Member]        
Segment Reporting Information [Line Items]        
Operating gain (loss) 101 27 365 52
Intersegment Eliminations [Member]        
Segment Reporting Information [Line Items]        
Reportable segments operating revenues (6,054) (5,192) (18,382) (15,173)
Unaffiliated        
Segment Reporting Information [Line Items]        
Reportable segments operating revenues 39,625 35,548 115,993 100,925
Unaffiliated | Commercial & Specialty [Member]        
Segment Reporting Information [Line Items]        
Reportable segments operating revenues 10,494 9,863 31,324 28,904
Unaffiliated | Government Business [Member]        
Segment Reporting Information [Line Items]        
Reportable segments operating revenues 24,571 21,658 72,164 61,007
Unaffiliated | IngenioRx Segment [Member]        
Segment Reporting Information [Line Items]        
Reportable segments operating revenues 3,971 3,369 10,838 9,131
Unaffiliated | Other [Member]        
Segment Reporting Information [Line Items]        
Reportable segments operating revenues 589 658 1,667 1,883
Affiliated [Member]        
Segment Reporting Information [Line Items]        
Reportable segments operating revenues 0 0 0 0
Affiliated [Member] | Commercial & Specialty [Member]        
Segment Reporting Information [Line Items]        
Reportable segments operating revenues   0 0 0
Affiliated [Member] | Government Business [Member]        
Segment Reporting Information [Line Items]        
Reportable segments operating revenues   0 0 0
Affiliated [Member] | IngenioRx Segment [Member]        
Segment Reporting Information [Line Items]        
Reportable segments operating revenues 3,278 3,180 10,165 9,499
Affiliated [Member] | Other [Member]        
Segment Reporting Information [Line Items]        
Reportable segments operating revenues $ 2,776 $ 2,012 $ 8,217 $ 5,674
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information Segment Information (Major Product Revenues for Each Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Major Product Revenue By Segment [Line Items]        
Insurance Services Revenue $ 39,625 $ 35,548 $ 115,993 $ 100,925
Commercial & Specialty Business Segment [Member]        
Major Product Revenue By Segment [Line Items]        
Insurance Services Revenue 10,494 9,863 31,324 28,904
Government Business Segment [Member]        
Major Product Revenue By Segment [Line Items]        
Insurance Services Revenue 24,571 21,658 72,164 61,007
Other Segment [Member]        
Major Product Revenue By Segment [Line Items]        
Insurance Services Revenue 3,365 2,670 9,884 7,557
Segment Eliminations [Member]        
Major Product Revenue By Segment [Line Items]        
Insurance Services Revenue (6,054) (5,192) (18,382) (15,173)
Managed Care Products [Member] | Commercial & Specialty Business Segment [Member]        
Major Product Revenue By Segment [Line Items]        
Insurance Services Revenue 8,478 8,005 25,500 23,481
Managed Care Products [Member] | Government Business Segment [Member]        
Major Product Revenue By Segment [Line Items]        
Insurance Services Revenue 24,456 21,565 71,823 60,711
Managed Care Services [Member] | Commercial & Specialty Business Segment [Member]        
Major Product Revenue By Segment [Line Items]        
Insurance Services Revenue 1,610 1,489 4,618 4,291
Managed Care Services [Member] | Government Business Segment [Member]        
Major Product Revenue By Segment [Line Items]        
Insurance Services Revenue 115 93 341 296
Dental Vision Products And Services [Member] | Commercial & Specialty Business Segment [Member]        
Major Product Revenue By Segment [Line Items]        
Insurance Services Revenue 360 342 1,075 1,013
Other Products [Member] | Commercial & Specialty Business Segment [Member]        
Major Product Revenue By Segment [Line Items]        
Insurance Services Revenue 46 27 131 119
Other Products [Member] | Other Segment [Member]        
Major Product Revenue By Segment [Line Items]        
Insurance Services Revenue 212 164 801 436
Pharmacy products and services [Member] | IngenioRx Segment [Member]        
Major Product Revenue By Segment [Line Items]        
Insurance Services Revenue 7,249 6,549 21,003 18,630
Integrated health services | Other Segment [Member]        
Major Product Revenue By Segment [Line Items]        
Insurance Services Revenue $ 3,153 $ 2,506 $ 9,083 $ 7,121
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting [Abstract]        
Reportable segments operating revenues $ 39,625 $ 35,548 $ 115,993 $ 100,925
Net investment income 371 335 1,112 1,026
Net (losses) gains on financial instruments (57) (61) (439) 107
Total revenues $ 39,939 $ 35,822 $ 116,666 $ 102,058
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information (Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting [Abstract]        
Income before income tax expense $ 2,146 $ 1,996 $ 6,615 $ 6,525
Net investment income (371) (335) (1,112) (1,026)
Net losses (gains) on financial instruments 57 61 439 (107)
Interest expense 213 201 622 598
Amortization of other intangible assets 225 136 520 306
Loss on extinguishment of debt 0 0 0 5
Reportable segments operating gain $ 2,270 $ 2,059 $ 7,084 $ 6,301
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Information Segment Information (Narrative) (Details)
 9 Months Ended
Sep. 30, 2022
segment
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]  
Number of Reportable Segments 4
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Lease and Other Information) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Operating Lease, Right-of-Use Asset $ 600   $ 600   $ 628
Operating Lease, Liability, Current 182   182   133
Operating Lease, Liability, Noncurrent 739   739   $ 864
Operating Lease, Cost 35 $ 37 100 $ 100  
Short-term Lease, Cost 11 10 35 34  
Sublease Income (1) (1) (3) (3)  
Lease, Cost 45 46 132 131  
Operating Lease, Payments 53 53 158 141  
Right-of-use assets obtained in exchange for new operating lease liabilities $ 23 $ 32 $ 62 $ 192  
Balance sheet location of operating lease right-of-use assets Other noncurrent assets   Other noncurrent assets   Other noncurrent assets
Balance sheet location of current operating lease liabilities Other current liabilities   Other current liabilities   Other current liabilities
Balance sheet location of noncurrent operating lease liabilities Other noncurrent liabilities   Other noncurrent liabilities   Other noncurrent liabilities
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details)
$ in Millions
Sep. 30, 2022
USD ($)
Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) [Abstract]  
Operating lease payments, 2022; excluding the nine months ended September 30, 2022 $ 54
Operating lease payments, 2023 207
Operating lease payments, 2024 179
Operating lease payments, 2025 142
Operating lease payments, 2026 105
Operating lease payments, Thereafter 345
Total future minimum payments 1,032
Imputed Interest, Leases (111)
Operating Lease Liabilities $ 921
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Narrative) (Details)
Sep. 30, 2022
Dec. 31, 2021
Lessee, Lease, Description [Line Items]    
Operating Lease, Weighted Average Remaining Lease Term 7 years 7 years
Weighted Average Discount Rate, Percent 2.79% 2.69%
Minimum [Member]    
Lessee, Lease, Description [Line Items]    
Lessee, Operating Lease, Term of Contract 1 year  
Maximum [Member]    
Lessee, Lease, Description [Line Items]    
Lessee, Operating Lease, Term of Contract 12 years  
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill And Other Intangible Assets (Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2021
Sep. 30, 2022
Dec. 31, 2021
Goodwill [Roll Forward]      
Goodwill, Beginning Balance $ 21,691 $ 24,228 $ 21,691
Goodwill, Period Increase (Decrease)   153 2,537
Goodwill, Ending Balance   24,381 24,228
Goodwill, Impaired, Accumulated Impairment Loss as of September 30, 2022   0  
Commercial & Specialty Business Segment [Member]      
Goodwill [Roll Forward]      
Goodwill, Beginning Balance 11,593 11,593 11,593
Goodwill, Period Increase (Decrease) 0 18  
Goodwill, Ending Balance   11,611 11,593
Goodwill, Impaired, Accumulated Impairment Loss as of September 30, 2022   0  
Government Business Segment [Member]      
Goodwill [Roll Forward]      
Goodwill, Beginning Balance 8,331 10,349 8,331
Goodwill, Period Increase (Decrease)   126 2,018
Goodwill, Ending Balance   10,475 10,349
Goodwill, Impaired, Accumulated Impairment Loss as of September 30, 2022   0  
IngenioRx Segment [Member]      
Goodwill [Roll Forward]      
Goodwill, Beginning Balance 48 59 48
Goodwill, Period Increase (Decrease)   0 11
Goodwill, Ending Balance   59 59
Goodwill, Impaired, Accumulated Impairment Loss as of September 30, 2022   0  
Other Segment [Member]      
Goodwill [Roll Forward]      
Goodwill, Beginning Balance $ 1,719 2,227 1,719
Goodwill, Period Increase (Decrease)   9 508
Goodwill, Ending Balance   2,236 $ 2,227
Goodwill, Impaired, Accumulated Impairment Loss as of September 30, 2022   $ 0  
XML 89 R78.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill And Other Intangible Assets (Components Of Other Intangible Assets) (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Intangible Assets [Line Items]    
Gross Carrying Amount, Finite Lived Intangibles $ 7,037 $ 6,532
Accumulated Amortization, Finite-Lived Intangible Assets (4,032) (3,506)
Net Carrying Amount, Finite-Lived Intangible Assets 3,005 3,026
Gross Carrying Amount, Indefinite-Lived Intangible Assets 7,531 7,589
Net Carrying Amount, Indefinite-Lived Intangible Assets 7,531 7,589
Gross Carrying Amount, Total Intangible Assets 14,568 14,121
Accumulated Amortization, Total Intangible Assets (4,032) (3,506)
Net Carrying Amount, Total Intangible Assets 10,536 10,615
Blue Cross And Blue Shield And Other Trademarks [Member]    
Intangible Assets [Line Items]    
Gross Carrying Amount, Indefinite-Lived Intangible Assets 5,991 6,299
Net Carrying Amount, Indefinite-Lived Intangible Assets 5,991 6,299
State Medicaid Licenses [Member]    
Intangible Assets [Line Items]    
Gross Carrying Amount, Indefinite-Lived Intangible Assets 1,540 1,290
Net Carrying Amount, Indefinite-Lived Intangible Assets 1,540 1,290
Customer Relationships [Member]    
Intangible Assets [Line Items]    
Gross Carrying Amount, Finite Lived Intangibles 5,791 5,598
Accumulated Amortization, Finite-Lived Intangible Assets (3,580) (3,236)
Net Carrying Amount, Finite-Lived Intangible Assets 2,211 2,362
Provider And Hospital Relationships [Member]    
Intangible Assets [Line Items]    
Gross Carrying Amount, Finite Lived Intangibles 326 324
Accumulated Amortization, Finite-Lived Intangible Assets (142) (129)
Net Carrying Amount, Finite-Lived Intangible Assets 184 195
Other [Member]    
Intangible Assets [Line Items]    
Gross Carrying Amount, Finite Lived Intangibles 920 610
Accumulated Amortization, Finite-Lived Intangible Assets (310) (141)
Net Carrying Amount, Finite-Lived Intangible Assets $ 610 $ 469
XML 90 R79.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill And Other Intangible Assets (Narrative) (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2022
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Finite-Lived Intangible Assets, Period Increase $ 308
Indefinite-Lived Intangible Assets, Period Decrease 308
Finite-Lived Intangible Asset, Expected Amortization, 2022 748
Finite-Lived Intangible Asset, Expected Amortization, 2023 735
Finite-Lived Intangible Asset, Expected Amortization, 2024 370
Finite-Lived Intangible Asset, Expected Amortization, 2025 311
Finite-Lived Intangible Asset, Expected Amortization, 2026 258
Finite-Lived Intangible Asset, Expected Amortization, 2027 $ 219
XML 91 elv-20220930_htm.xml IDEA: XBRL DOCUMENT 0001156039 2022-01-01 2022-09-30 0001156039 2022-10-12 0001156039 2022-09-30 0001156039 2021-12-31 0001156039 2022-07-01 2022-09-30 0001156039 2021-07-01 2021-09-30 0001156039 2021-01-01 2021-09-30 0001156039 2020-12-31 0001156039 2021-09-30 0001156039 us-gaap:CommonStockMember 2021-12-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001156039 us-gaap:RetainedEarningsMember 2021-12-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001156039 us-gaap:NoncontrollingInterestMember 2021-12-31 0001156039 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate202006Member us-gaap:RetainedEarningsMember 2021-12-31 0001156039 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate202006Member 2021-12-31 0001156039 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:RetainedEarningsMember 2021-12-31 0001156039 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2021-12-31 0001156039 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001156039 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001156039 2022-01-01 2022-03-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001156039 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001156039 us-gaap:CommonStockMember 2022-03-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001156039 us-gaap:RetainedEarningsMember 2022-03-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001156039 us-gaap:NoncontrollingInterestMember 2022-03-31 0001156039 2022-03-31 0001156039 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001156039 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001156039 2022-04-01 2022-06-30 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001156039 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001156039 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001156039 us-gaap:CommonStockMember 2022-06-30 0001156039 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001156039 us-gaap:RetainedEarningsMember 2022-06-30 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001156039 us-gaap:NoncontrollingInterestMember 2022-06-30 0001156039 2022-06-30 0001156039 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001156039 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001156039 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001156039 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001156039 us-gaap:CommonStockMember 2022-09-30 0001156039 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001156039 us-gaap:RetainedEarningsMember 2022-09-30 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001156039 us-gaap:NoncontrollingInterestMember 2022-09-30 0001156039 us-gaap:CommonStockMember 2020-12-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001156039 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:RetainedEarningsMember 2020-12-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001156039 us-gaap:NoncontrollingInterestMember 2020-12-31 0001156039 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2020-12-31 0001156039 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001156039 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001156039 2021-01-01 2021-03-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001156039 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001156039 us-gaap:CommonStockMember 2021-03-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001156039 us-gaap:RetainedEarningsMember 2021-03-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001156039 us-gaap:NoncontrollingInterestMember 2021-03-31 0001156039 2021-03-31 0001156039 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001156039 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001156039 2021-04-01 2021-06-30 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001156039 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001156039 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001156039 us-gaap:CommonStockMember 2021-06-30 0001156039 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001156039 us-gaap:RetainedEarningsMember 2021-06-30 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001156039 us-gaap:NoncontrollingInterestMember 2021-06-30 0001156039 2021-06-30 0001156039 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001156039 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001156039 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001156039 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001156039 us-gaap:CommonStockMember 2021-09-30 0001156039 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001156039 us-gaap:RetainedEarningsMember 2021-09-30 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001156039 us-gaap:NoncontrollingInterestMember 2021-09-30 0001156039 elv:IntegraManagedCareMember 2022-01-01 2022-09-30 0001156039 elv:IntegraManagedCareMember 2022-09-30 0001156039 us-gaap:EmployeeSeveranceMember elv:CommercialSpecialtyBusinessSegmentMember 2021-12-31 0001156039 us-gaap:EmployeeSeveranceMember elv:GovernmentBusinessSegmentMember 2021-12-31 0001156039 us-gaap:EmployeeSeveranceMember elv:IngenioRxSegmentMember 2021-12-31 0001156039 us-gaap:EmployeeSeveranceMember elv:OtherSegmentMember 2021-12-31 0001156039 us-gaap:EmployeeSeveranceMember 2021-12-31 0001156039 us-gaap:EmployeeSeveranceMember elv:CommercialSpecialtyBusinessSegmentMember 2022-01-01 2022-09-30 0001156039 us-gaap:EmployeeSeveranceMember elv:GovernmentBusinessSegmentMember 2022-01-01 2022-09-30 0001156039 us-gaap:EmployeeSeveranceMember elv:IngenioRxSegmentMember 2022-01-01 2022-09-30 0001156039 us-gaap:EmployeeSeveranceMember elv:OtherSegmentMember 2022-01-01 2022-09-30 0001156039 us-gaap:EmployeeSeveranceMember 2022-01-01 2022-09-30 0001156039 us-gaap:EmployeeSeveranceMember elv:CommercialSpecialtyBusinessSegmentMember 2022-09-30 0001156039 us-gaap:EmployeeSeveranceMember elv:GovernmentBusinessSegmentMember 2022-09-30 0001156039 us-gaap:EmployeeSeveranceMember elv:IngenioRxSegmentMember 2022-09-30 0001156039 us-gaap:EmployeeSeveranceMember elv:OtherSegmentMember 2022-09-30 0001156039 us-gaap:EmployeeSeveranceMember 2022-09-30 0001156039 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:ForeignGovernmentDebtMember 2022-09-30 0001156039 us-gaap:USStatesAndPoliticalSubdivisionsMember 2022-09-30 0001156039 us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-09-30 0001156039 us-gaap:CommercialMortgageBackedSecuritiesMember 2022-09-30 0001156039 us-gaap:OtherAggregatedInvestmentsMember 2022-09-30 0001156039 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:ForeignGovernmentDebtMember 2021-12-31 0001156039 us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0001156039 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-12-31 0001156039 us-gaap:CommercialMortgageBackedSecuritiesMember 2021-12-31 0001156039 us-gaap:OtherAggregatedInvestmentsMember 2021-12-31 0001156039 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FixedMaturitiesMember 2022-09-30 0001156039 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FixedMaturitiesMember 2022-09-30 0001156039 us-gaap:ForeignGovernmentDebtMember us-gaap:FixedMaturitiesMember 2022-09-30 0001156039 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FixedMaturitiesMember 2022-09-30 0001156039 us-gaap:CorporateDebtSecuritiesMember us-gaap:FixedMaturitiesMember 2022-09-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember us-gaap:FixedMaturitiesMember 2022-09-30 0001156039 us-gaap:CommercialMortgageBackedSecuritiesMember us-gaap:FixedMaturitiesMember 2022-09-30 0001156039 us-gaap:OtherAggregatedInvestmentsMember us-gaap:FixedMaturitiesMember 2022-09-30 0001156039 us-gaap:FixedMaturitiesMember 2022-09-30 0001156039 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FixedMaturitiesMember 2021-12-31 0001156039 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FixedMaturitiesMember 2021-12-31 0001156039 us-gaap:ForeignGovernmentDebtMember us-gaap:FixedMaturitiesMember 2021-12-31 0001156039 us-gaap:USStatesAndPoliticalSubdivisionsMember us-gaap:FixedMaturitiesMember 2021-12-31 0001156039 us-gaap:CorporateDebtSecuritiesMember us-gaap:FixedMaturitiesMember 2021-12-31 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember us-gaap:FixedMaturitiesMember 2021-12-31 0001156039 us-gaap:CommercialMortgageBackedSecuritiesMember us-gaap:FixedMaturitiesMember 2021-12-31 0001156039 us-gaap:OtherAggregatedInvestmentsMember us-gaap:FixedMaturitiesMember 2021-12-31 0001156039 us-gaap:FixedMaturitiesMember 2021-12-31 0001156039 us-gaap:FixedMaturitiesMember 2022-07-01 2022-09-30 0001156039 us-gaap:FixedMaturitiesMember 2022-01-01 2022-09-30 0001156039 us-gaap:FixedMaturitiesMember 2021-07-01 2021-09-30 0001156039 us-gaap:FixedMaturitiesMember 2021-01-01 2021-09-30 0001156039 us-gaap:ExchangeTradedFundsMember 2022-09-30 0001156039 us-gaap:ExchangeTradedFundsMember 2021-12-31 0001156039 elv:CommonEquitySecuritiesMember 2022-09-30 0001156039 elv:CommonEquitySecuritiesMember 2021-12-31 0001156039 us-gaap:PrivateEquityFundsMember 2022-09-30 0001156039 us-gaap:PrivateEquityFundsMember 2021-12-31 0001156039 us-gaap:EquitySecuritiesMember 2022-07-01 2022-09-30 0001156039 us-gaap:EquitySecuritiesMember 2021-07-01 2021-09-30 0001156039 us-gaap:EquitySecuritiesMember 2022-01-01 2022-09-30 0001156039 us-gaap:EquitySecuritiesMember 2021-01-01 2021-09-30 0001156039 us-gaap:OtherInvestmentsMember 2022-07-01 2022-09-30 0001156039 us-gaap:OtherInvestmentsMember 2021-07-01 2021-09-30 0001156039 us-gaap:OtherInvestmentsMember 2022-01-01 2022-09-30 0001156039 us-gaap:OtherInvestmentsMember 2021-01-01 2021-09-30 0001156039 us-gaap:MaturityOvernightMember us-gaap:CashMember 2022-09-30 0001156039 us-gaap:MaturityOvernightMember us-gaap:CashMember 2021-12-31 0001156039 us-gaap:MaturityOvernightMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:MaturityOvernightMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:MaturityOvernightMember us-gaap:OtherAggregatedInvestmentsMember 2022-09-30 0001156039 us-gaap:MaturityOvernightMember us-gaap:OtherAggregatedInvestmentsMember 2021-12-31 0001156039 us-gaap:CashFlowHedgingMember 2022-09-30 0001156039 us-gaap:CashFlowHedgingMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignGovernmentDebtMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignGovernmentDebtMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignGovernmentDebtMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialMortgageBackedSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialMortgageBackedSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialMortgageBackedSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:OtherDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:OtherDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:OtherDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:OtherDebtSecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2022-09-30 0001156039 elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:DerivativeMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeMember 2022-09-30 0001156039 us-gaap:DerivativeMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignGovernmentDebtMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignGovernmentDebtMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignGovernmentDebtMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialMortgageBackedSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialMortgageBackedSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialMortgageBackedSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:OtherDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:OtherDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:OtherDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:OtherDebtSecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2021-12-31 0001156039 elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:DerivativeMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeMember 2021-12-31 0001156039 us-gaap:DerivativeMember 2021-12-31 0001156039 us-gaap:CorporateDebtSecuritiesMember 2022-06-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-06-30 0001156039 us-gaap:OtherDebtSecuritiesMember 2022-06-30 0001156039 us-gaap:EquitySecuritiesMember 2022-06-30 0001156039 us-gaap:CorporateDebtSecuritiesMember 2022-07-01 2022-09-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-07-01 2022-09-30 0001156039 us-gaap:OtherDebtSecuritiesMember 2022-07-01 2022-09-30 0001156039 us-gaap:EquitySecuritiesMember 2022-07-01 2022-09-30 0001156039 us-gaap:EquitySecuritiesMember 2022-09-30 0001156039 us-gaap:CorporateDebtSecuritiesMember 2021-06-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-06-30 0001156039 us-gaap:OtherDebtSecuritiesMember 2021-06-30 0001156039 us-gaap:EquitySecuritiesMember 2021-06-30 0001156039 us-gaap:CorporateDebtSecuritiesMember 2021-07-01 2021-09-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-07-01 2021-09-30 0001156039 us-gaap:OtherDebtSecuritiesMember 2021-07-01 2021-09-30 0001156039 us-gaap:EquitySecuritiesMember 2021-07-01 2021-09-30 0001156039 us-gaap:CorporateDebtSecuritiesMember 2021-09-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-09-30 0001156039 us-gaap:OtherDebtSecuritiesMember 2021-09-30 0001156039 us-gaap:EquitySecuritiesMember 2021-09-30 0001156039 us-gaap:EquitySecuritiesMember 2021-12-31 0001156039 us-gaap:CorporateDebtSecuritiesMember 2022-01-01 2022-09-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2022-01-01 2022-09-30 0001156039 us-gaap:OtherDebtSecuritiesMember 2022-01-01 2022-09-30 0001156039 us-gaap:EquitySecuritiesMember 2022-01-01 2022-09-30 0001156039 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2020-12-31 0001156039 us-gaap:OtherDebtSecuritiesMember 2020-12-31 0001156039 us-gaap:EquitySecuritiesMember 2020-12-31 0001156039 us-gaap:CorporateDebtSecuritiesMember 2021-01-01 2021-09-30 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2021-01-01 2021-09-30 0001156039 us-gaap:OtherDebtSecuritiesMember 2021-01-01 2021-09-30 0001156039 us-gaap:EquitySecuritiesMember 2021-01-01 2021-09-30 0001156039 us-gaap:FairValueMeasurementsNonrecurringMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherInvestmentsMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherInvestmentsMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherInvestmentsMember 2022-09-30 0001156039 us-gaap:OtherInvestmentsMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001156039 us-gaap:FairValueMeasurementsNonrecurringMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherInvestmentsMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherInvestmentsMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherInvestmentsMember 2021-12-31 0001156039 us-gaap:OtherInvestmentsMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001156039 elv:CommercialSpecialtyBusinessSegmentMember 2021-12-31 0001156039 elv:GovernmentBusinessSegmentMember 2021-12-31 0001156039 elv:OtherSegmentMember 2021-12-31 0001156039 elv:CommercialSpecialtyBusinessSegmentMember 2022-09-30 0001156039 elv:GovernmentBusinessSegmentMember 2022-09-30 0001156039 elv:OtherSegmentMember 2022-09-30 0001156039 elv:CommercialSpecialtyBusinessSegmentMember 2022-01-01 2022-09-30 0001156039 elv:GovernmentBusinessSegmentMember 2022-01-01 2022-09-30 0001156039 elv:OtherSegmentMember 2022-01-01 2022-09-30 0001156039 us-gaap:ShortDurationInsuranceContractAccidentYear2020Member elv:CommercialSpecialtyBusinessSegmentMember 2022-09-30 0001156039 us-gaap:ShortDurationInsuranceContractAccidentYear2021Member elv:CommercialSpecialtyBusinessSegmentMember 2022-09-30 0001156039 us-gaap:ShortDurationInsuranceContractAccidentYear2022Member elv:CommercialSpecialtyBusinessSegmentMember 2022-09-30 0001156039 us-gaap:ShortDurationInsuranceContractAccidentYear2020Member elv:GovernmentBusinessSegmentMember 2022-09-30 0001156039 us-gaap:ShortDurationInsuranceContractAccidentYear2021Member elv:GovernmentBusinessSegmentMember 2022-09-30 0001156039 us-gaap:ShortDurationInsuranceContractAccidentYear2022Member elv:GovernmentBusinessSegmentMember 2022-09-30 0001156039 us-gaap:ShortDurationInsuranceContractAccidentYear2020Member elv:OtherSegmentMember 2022-09-30 0001156039 us-gaap:ShortDurationInsuranceContractAccidentYear2021Member elv:OtherSegmentMember 2022-09-30 0001156039 us-gaap:ShortDurationInsuranceContractAccidentYear2022Member elv:OtherSegmentMember 2022-09-30 0001156039 elv:CommercialSpecialtyBusinessSegmentMember 2020-12-31 0001156039 elv:GovernmentBusinessSegmentMember 2020-12-31 0001156039 elv:OtherSegmentMember 2020-12-31 0001156039 elv:CommercialSpecialtyBusinessSegmentMember 2021-09-30 0001156039 elv:GovernmentBusinessSegmentMember 2021-09-30 0001156039 elv:OtherSegmentMember 2021-09-30 0001156039 elv:CommercialSpecialtyBusinessSegmentMember 2021-01-01 2021-09-30 0001156039 elv:GovernmentBusinessSegmentMember 2021-01-01 2021-09-30 0001156039 elv:OtherSegmentMember 2021-01-01 2021-09-30 0001156039 elv:CommercialSpecialtyBusinessSegmentMember 2022-01-01 2022-03-31 0001156039 elv:CommercialSpecialtyBusinessSegmentMember 2022-04-01 2022-06-30 0001156039 elv:CommercialSpecialtyBusinessSegmentMember 2022-07-01 2022-09-30 0001156039 elv:GovernmentBusinessSegmentMember 2022-01-01 2022-03-31 0001156039 elv:GovernmentBusinessSegmentMember 2022-04-01 2022-06-30 0001156039 elv:GovernmentBusinessSegmentMember 2022-07-01 2022-09-30 0001156039 elv:OtherSegmentMember 2022-01-01 2022-03-31 0001156039 elv:OtherSegmentMember 2022-04-01 2022-06-30 0001156039 elv:OtherSegmentMember 2022-07-01 2022-09-30 0001156039 elv:CommercialSpecialtyBusinessSegmentMember 2021-01-01 2021-03-31 0001156039 elv:CommercialSpecialtyBusinessSegmentMember 2021-04-01 2021-06-30 0001156039 elv:CommercialSpecialtyBusinessSegmentMember 2021-07-01 2021-09-30 0001156039 elv:GovernmentBusinessSegmentMember 2021-01-01 2021-03-31 0001156039 elv:GovernmentBusinessSegmentMember 2021-04-01 2021-06-30 0001156039 elv:GovernmentBusinessSegmentMember 2021-07-01 2021-09-30 0001156039 elv:OtherSegmentMember 2021-01-01 2021-03-31 0001156039 elv:OtherSegmentMember 2021-04-01 2021-06-30 0001156039 elv:OtherSegmentMember 2021-07-01 2021-09-30 0001156039 elv:SeniorUnsecuredNotesMember 2022-09-30 0001156039 elv:SeniorUnsecuredNotesMember 2021-12-31 0001156039 elv:ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember elv:SeniorUnsecuredNotesMember 2022-05-16 0001156039 elv:FourPointOneZeroPercentDueTwoThousandThirtyTwoMember elv:SeniorUnsecuredNotesMember 2022-04-29 0001156039 elv:FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember elv:SeniorUnsecuredNotesMember 2022-04-29 0001156039 elv:SurplusNotesMember 2021-12-31 0001156039 elv:SurplusNotesMember 2022-09-30 0001156039 elv:A5YearFacilityMember us-gaap:RevolvingCreditFacilityMember 2022-03-31 0001156039 elv:A5YearFacilityMember us-gaap:RevolvingCreditFacilityMember 2022-04-18 0001156039 elv:A2021364DayFacilityMember 2022-04-18 2022-04-18 0001156039 elv:A2021364DayFacilityMember us-gaap:RevolvingCreditFacilityMember 2022-03-31 0001156039 us-gaap:RevolvingCreditFacilityMember 2022-01-01 2022-09-30 0001156039 us-gaap:LineOfCreditMember 2022-09-30 0001156039 us-gaap:CommercialPaperMember 2022-09-30 0001156039 us-gaap:CommercialPaperMember 2022-06-30 0001156039 us-gaap:CommercialPaperMember 2021-12-31 0001156039 us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-30 0001156039 us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0001156039 us-gaap:ConvertibleDebtMember 2022-09-30 0001156039 us-gaap:FederalHomeLoanBankAdvancesMember 2022-09-30 0001156039 us-gaap:FederalHomeLoanBankAdvancesMember 2021-12-31 0001156039 srt:MinimumMember 2022-09-30 0001156039 srt:MaximumMember 2022-09-30 0001156039 elv:BCBSAntitrustLitigationMember 2022-09-30 0001156039 elv:AnthemInc.v.ExpressScriptsInc.Member elv:PharmacypricingMember 2022-01-01 2022-09-30 0001156039 elv:AnthemInc.v.ExpressScriptsInc.Member elv:OperationalMember 2022-01-01 2022-09-30 0001156039 elv:AnthemInc.v.ExpressScriptsInc.Member 2022-01-01 2022-09-30 0001156039 us-gaap:SubsequentEventMember 2022-10-18 0001156039 us-gaap:SubsequentEventMember 2022-10-18 2022-10-18 0001156039 2021-01-26 0001156039 us-gaap:RestrictedStockUnitsRSUMember elv:A2022To2024Member 2022-01-01 2022-09-30 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-07-01 2022-09-30 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2021-07-01 2021-09-30 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-09-30 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-09-30 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-09-30 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2021-09-30 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2022-06-30 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2021-06-30 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2021-12-31 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2020-12-31 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2022-07-01 2022-09-30 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2021-07-01 2021-09-30 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2022-01-01 2022-09-30 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2021-01-01 2021-09-30 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2022-09-30 0001156039 elv:NonCreditComponentsOfImpairmentsOnInvestmentsMember 2021-09-30 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-06-30 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2021-06-30 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2021-12-31 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-12-31 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-07-01 2022-09-30 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2021-07-01 2021-09-30 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-01-01 2022-09-30 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2021-01-01 2021-09-30 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-09-30 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2021-09-30 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-07-01 2022-09-30 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-07-01 2021-09-30 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-09-30 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-09-30 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-09-30 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-09-30 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-06-30 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-12-31 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-07-01 2022-09-30 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-07-01 2021-09-30 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-01 2022-09-30 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-01-01 2021-09-30 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-09-30 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2021-09-30 0001156039 elv:A2022To2024Member 2022-07-01 2022-09-30 0001156039 elv:A2022To2024Member 2022-01-01 2022-09-30 0001156039 elv:A2021To2023Member 2021-07-01 2021-09-30 0001156039 elv:A2021To2023Member 2021-01-01 2021-09-30 0001156039 elv:UnaffiliatedMember elv:CommercialSpecialtyMember 2022-07-01 2022-09-30 0001156039 elv:UnaffiliatedMember elv:GovernmentBusinessSegmentMember 2022-07-01 2022-09-30 0001156039 elv:UnaffiliatedMember elv:IngenioRxSegmentMember 2022-07-01 2022-09-30 0001156039 elv:UnaffiliatedMember elv:OtherSegmentMember 2022-07-01 2022-09-30 0001156039 elv:UnaffiliatedMember 2022-07-01 2022-09-30 0001156039 elv:IngenioRxSegmentMember elv:AffiliatedMember 2022-07-01 2022-09-30 0001156039 elv:OtherSegmentMember elv:AffiliatedMember 2022-07-01 2022-09-30 0001156039 us-gaap:IntersegmentEliminationMember 2022-07-01 2022-09-30 0001156039 elv:AffiliatedMember 2022-07-01 2022-09-30 0001156039 elv:CommercialSpecialtyMember 2022-07-01 2022-09-30 0001156039 elv:GovernmentBusinessSegmentMember 2022-07-01 2022-09-30 0001156039 elv:IngenioRxSegmentMember 2022-07-01 2022-09-30 0001156039 elv:OtherSegmentMember 2022-07-01 2022-09-30 0001156039 elv:UnaffiliatedMember elv:CommercialSpecialtyMember 2021-07-01 2021-09-30 0001156039 elv:UnaffiliatedMember elv:GovernmentBusinessSegmentMember 2021-07-01 2021-09-30 0001156039 elv:UnaffiliatedMember elv:IngenioRxSegmentMember 2021-07-01 2021-09-30 0001156039 elv:UnaffiliatedMember elv:OtherSegmentMember 2021-07-01 2021-09-30 0001156039 elv:UnaffiliatedMember 2021-07-01 2021-09-30 0001156039 elv:CommercialSpecialtyMember elv:AffiliatedMember 2021-07-01 2021-09-30 0001156039 elv:GovernmentBusinessSegmentMember elv:AffiliatedMember 2021-07-01 2021-09-30 0001156039 elv:IngenioRxSegmentMember elv:AffiliatedMember 2021-07-01 2021-09-30 0001156039 elv:OtherSegmentMember elv:AffiliatedMember 2021-07-01 2021-09-30 0001156039 us-gaap:IntersegmentEliminationMember 2021-07-01 2021-09-30 0001156039 elv:AffiliatedMember 2021-07-01 2021-09-30 0001156039 elv:CommercialSpecialtyMember 2021-07-01 2021-09-30 0001156039 elv:GovernmentBusinessSegmentMember 2021-07-01 2021-09-30 0001156039 elv:IngenioRxSegmentMember 2021-07-01 2021-09-30 0001156039 elv:OtherSegmentMember 2021-07-01 2021-09-30 0001156039 elv:UnaffiliatedMember elv:CommercialSpecialtyMember 2022-01-01 2022-09-30 0001156039 elv:UnaffiliatedMember elv:GovernmentBusinessSegmentMember 2022-01-01 2022-09-30 0001156039 elv:UnaffiliatedMember elv:IngenioRxSegmentMember 2022-01-01 2022-09-30 0001156039 elv:UnaffiliatedMember elv:OtherSegmentMember 2022-01-01 2022-09-30 0001156039 elv:UnaffiliatedMember 2022-01-01 2022-09-30 0001156039 elv:CommercialSpecialtyMember elv:AffiliatedMember 2022-01-01 2022-09-30 0001156039 elv:GovernmentBusinessSegmentMember elv:AffiliatedMember 2022-01-01 2022-09-30 0001156039 elv:IngenioRxSegmentMember elv:AffiliatedMember 2022-01-01 2022-09-30 0001156039 elv:OtherSegmentMember elv:AffiliatedMember 2022-01-01 2022-09-30 0001156039 us-gaap:IntersegmentEliminationMember 2022-01-01 2022-09-30 0001156039 elv:AffiliatedMember 2022-01-01 2022-09-30 0001156039 elv:CommercialSpecialtyMember 2022-01-01 2022-09-30 0001156039 elv:GovernmentBusinessSegmentMember 2022-01-01 2022-09-30 0001156039 elv:IngenioRxSegmentMember 2022-01-01 2022-09-30 0001156039 elv:OtherSegmentMember 2022-01-01 2022-09-30 0001156039 elv:UnaffiliatedMember elv:CommercialSpecialtyMember 2021-01-01 2021-09-30 0001156039 elv:UnaffiliatedMember elv:GovernmentBusinessSegmentMember 2021-01-01 2021-09-30 0001156039 elv:UnaffiliatedMember elv:IngenioRxSegmentMember 2021-01-01 2021-09-30 0001156039 elv:UnaffiliatedMember elv:OtherSegmentMember 2021-01-01 2021-09-30 0001156039 elv:UnaffiliatedMember 2021-01-01 2021-09-30 0001156039 elv:CommercialSpecialtyMember elv:AffiliatedMember 2021-01-01 2021-09-30 0001156039 elv:GovernmentBusinessSegmentMember elv:AffiliatedMember 2021-01-01 2021-09-30 0001156039 elv:IngenioRxSegmentMember elv:AffiliatedMember 2021-01-01 2021-09-30 0001156039 elv:OtherSegmentMember elv:AffiliatedMember 2021-01-01 2021-09-30 0001156039 us-gaap:IntersegmentEliminationMember 2021-01-01 2021-09-30 0001156039 elv:AffiliatedMember 2021-01-01 2021-09-30 0001156039 elv:CommercialSpecialtyMember 2021-01-01 2021-09-30 0001156039 elv:GovernmentBusinessSegmentMember 2021-01-01 2021-09-30 0001156039 elv:IngenioRxSegmentMember 2021-01-01 2021-09-30 0001156039 elv:OtherSegmentMember 2021-01-01 2021-09-30 0001156039 elv:ManagedCareProductsMember elv:CommercialSpecialtyBusinessSegmentMember 2022-07-01 2022-09-30 0001156039 elv:ManagedCareProductsMember elv:CommercialSpecialtyBusinessSegmentMember 2021-07-01 2021-09-30 0001156039 elv:ManagedCareProductsMember elv:CommercialSpecialtyBusinessSegmentMember 2022-01-01 2022-09-30 0001156039 elv:ManagedCareProductsMember elv:CommercialSpecialtyBusinessSegmentMember 2021-01-01 2021-09-30 0001156039 elv:ManagedCareServicesMember elv:CommercialSpecialtyBusinessSegmentMember 2022-07-01 2022-09-30 0001156039 elv:ManagedCareServicesMember elv:CommercialSpecialtyBusinessSegmentMember 2021-07-01 2021-09-30 0001156039 elv:ManagedCareServicesMember elv:CommercialSpecialtyBusinessSegmentMember 2022-01-01 2022-09-30 0001156039 elv:ManagedCareServicesMember elv:CommercialSpecialtyBusinessSegmentMember 2021-01-01 2021-09-30 0001156039 elv:DentalVisionProductsAndServicesMember elv:CommercialSpecialtyBusinessSegmentMember 2022-07-01 2022-09-30 0001156039 elv:DentalVisionProductsAndServicesMember elv:CommercialSpecialtyBusinessSegmentMember 2021-07-01 2021-09-30 0001156039 elv:DentalVisionProductsAndServicesMember elv:CommercialSpecialtyBusinessSegmentMember 2022-01-01 2022-09-30 0001156039 elv:DentalVisionProductsAndServicesMember elv:CommercialSpecialtyBusinessSegmentMember 2021-01-01 2021-09-30 0001156039 elv:OtherProductsMember elv:CommercialSpecialtyBusinessSegmentMember 2022-07-01 2022-09-30 0001156039 elv:OtherProductsMember elv:CommercialSpecialtyBusinessSegmentMember 2021-07-01 2021-09-30 0001156039 elv:OtherProductsMember elv:CommercialSpecialtyBusinessSegmentMember 2022-01-01 2022-09-30 0001156039 elv:OtherProductsMember elv:CommercialSpecialtyBusinessSegmentMember 2021-01-01 2021-09-30 0001156039 elv:ManagedCareProductsMember elv:GovernmentBusinessSegmentMember 2022-07-01 2022-09-30 0001156039 elv:ManagedCareProductsMember elv:GovernmentBusinessSegmentMember 2021-07-01 2021-09-30 0001156039 elv:ManagedCareProductsMember elv:GovernmentBusinessSegmentMember 2022-01-01 2022-09-30 0001156039 elv:ManagedCareProductsMember elv:GovernmentBusinessSegmentMember 2021-01-01 2021-09-30 0001156039 elv:ManagedCareServicesMember elv:GovernmentBusinessSegmentMember 2022-07-01 2022-09-30 0001156039 elv:ManagedCareServicesMember elv:GovernmentBusinessSegmentMember 2021-07-01 2021-09-30 0001156039 elv:ManagedCareServicesMember elv:GovernmentBusinessSegmentMember 2022-01-01 2022-09-30 0001156039 elv:ManagedCareServicesMember elv:GovernmentBusinessSegmentMember 2021-01-01 2021-09-30 0001156039 elv:PharmacyproductsandservicesMember elv:IngenioRxSegmentMember 2022-07-01 2022-09-30 0001156039 elv:PharmacyproductsandservicesMember elv:IngenioRxSegmentMember 2021-07-01 2021-09-30 0001156039 elv:PharmacyproductsandservicesMember elv:IngenioRxSegmentMember 2022-01-01 2022-09-30 0001156039 elv:PharmacyproductsandservicesMember elv:IngenioRxSegmentMember 2021-01-01 2021-09-30 0001156039 elv:IntegratedHealthServicesMember elv:OtherSegmentMember 2022-07-01 2022-09-30 0001156039 elv:IntegratedHealthServicesMember elv:OtherSegmentMember 2021-07-01 2021-09-30 0001156039 elv:IntegratedHealthServicesMember elv:OtherSegmentMember 2022-01-01 2022-09-30 0001156039 elv:IntegratedHealthServicesMember elv:OtherSegmentMember 2021-01-01 2021-09-30 0001156039 elv:OtherProductsMember elv:OtherSegmentMember 2022-07-01 2022-09-30 0001156039 elv:OtherProductsMember elv:OtherSegmentMember 2021-07-01 2021-09-30 0001156039 elv:OtherProductsMember elv:OtherSegmentMember 2022-01-01 2022-09-30 0001156039 elv:OtherProductsMember elv:OtherSegmentMember 2021-01-01 2021-09-30 0001156039 elv:SegmentEliminationsMember 2022-07-01 2022-09-30 0001156039 elv:SegmentEliminationsMember 2021-07-01 2021-09-30 0001156039 elv:SegmentEliminationsMember 2022-01-01 2022-09-30 0001156039 elv:SegmentEliminationsMember 2021-01-01 2021-09-30 0001156039 elv:IngenioRxSegmentMember 2020-12-31 0001156039 elv:GovernmentBusinessSegmentMember 2021-01-01 2021-12-31 0001156039 elv:IngenioRxSegmentMember 2021-01-01 2021-12-31 0001156039 elv:OtherSegmentMember 2021-01-01 2021-12-31 0001156039 2021-01-01 2021-12-31 0001156039 elv:IngenioRxSegmentMember 2021-12-31 0001156039 elv:IngenioRxSegmentMember 2022-01-01 2022-09-30 0001156039 elv:IngenioRxSegmentMember 2022-09-30 0001156039 us-gaap:CustomerRelationshipsMember 2022-09-30 0001156039 us-gaap:CustomerRelationshipsMember 2021-12-31 0001156039 us-gaap:ContractualRightsMember 2022-09-30 0001156039 us-gaap:ContractualRightsMember 2021-12-31 0001156039 us-gaap:OtherIntangibleAssetsMember 2022-09-30 0001156039 us-gaap:OtherIntangibleAssetsMember 2021-12-31 0001156039 us-gaap:TrademarksMember 2022-09-30 0001156039 us-gaap:TrademarksMember 2021-12-31 0001156039 us-gaap:LicensingAgreementsMember 2022-09-30 0001156039 us-gaap:LicensingAgreementsMember 2021-12-31 shares iso4217:USD iso4217:USD shares elv:medical_member elv:county elv:states pure elv:securities elv:segment false 2022 Q3 0001156039 --12-31 28306000000 25641000000 10000000 6000000 671000000 616000000 0 0 0 0 100000000 100000000 0 0 0 0 0.01 0.01 900000000 900000000 238974624 241770746 238974624 241770746 http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent 10-Q true 2022-09-30 false 001-16751 ELEVANCE HEALTH, INC. IN 35-2145715 220 Virginia Avenue Indianapolis IN 46204 833 401-1577 Common Stock, $0.01 par value ELV NYSE Yes Yes Large Accelerated Filer false false false 238827582 8872000000 4880000000 28306000000 25641000000 10000000 6000000 25526000000 26267000000 1503000000 1881000000 6682000000 5681000000 3873000000 4010000000 3651000000 3749000000 5496000000 4654000000 55603000000 51122000000 671000000 616000000 0 0 622000000 632000000 5516000000 5225000000 4197000000 3919000000 24381000000 24228000000 10536000000 10615000000 2171000000 1719000000 103026000000 97460000000 15242000000 13518000000 5482000000 5521000000 3702000000 1153000000 4963000000 4970000000 265000000 275000000 2249000000 1599000000 9384000000 7849000000 41287000000 34885000000 21258000000 21157000000 825000000 802000000 1825000000 2805000000 1788000000 1683000000 66983000000 61332000000 100000000 0 0 0 0.01 900000000 238974624 241770746 2000000 2000000 9169000000 9148000000 29604000000 27088000000 -2784000000 -178000000 35991000000 36060000000 52000000 68000000 36043000000 36128000000 103026000000 97460000000 33722000000 30395000000 99583000000 86604000000 3972000000 3353000000 10841000000 9132000000 1931000000 1800000000 5569000000 5189000000 39625000000 35548000000 115993000000 100925000000 371000000 335000000 1112000000 1026000000 -57000000 -61000000 -439000000 107000000 39939000000 35822000000 116666000000 102058000000 29404000000 26645000000 86396000000 75107000000 3437000000 2898000000 9389000000 7825000000 4514000000 3946000000 13124000000 11692000000 213000000 201000000 622000000 598000000 225000000 136000000 520000000 306000000 0 0 0 -5000000 37793000000 33826000000 110051000000 95533000000 2146000000 1996000000 6615000000 6525000000 533000000 494000000 1557000000 1555000000 1613000000 1502000000 5058000000 4970000000 -5000000 -7000000 -18000000 3000000 1618000000 1509000000 5076000000 4967000000 6.75 6.20 21.11 20.33 6.68 6.13 20.86 20.09 1.28 1.13 3.84 3.39 1613000000 1502000000 5058000000 4970000000 -639000000 -97000000 -2630000000 -284000000 -1000000 -1000000 -3000000 1000000 2000000 4000000 8000000 10000000 -7000000 -8000000 -23000000 -26000000 -7000000 -1000000 -15000000 -7000000 -638000000 -87000000 -2617000000 -254000000 -5000000 -7000000 -18000000 3000000 -3000000 -1000000 -11000000 -1000000 983000000 1423000000 2470000000 4714000000 5058000000 4970000000 -439000000 107000000 304000000 437000000 1202000000 942000000 -170000000 114000000 191000000 196000000 678000000 1751000000 -46000000 56000000 474000000 470000000 1537000000 2328000000 2548000000 -308000000 598000000 1093000000 -41000000 168000000 35000000 -10000000 9917000000 6692000000 19612000000 15130000000 9402000000 8339000000 7606000000 3388000000 677000000 1030000000 623000000 3442000000 854000000 747000000 91000000 50000000 -4849000000 -8672000000 375000000 -150000000 1286000000 3462000000 982000000 954000000 1365000000 175000000 1375000000 0 685000000 1030000000 181000000 316000000 1748000000 1378000000 924000000 831000000 152000000 161000000 91000000 101000000 16000000 8000000 -1060000000 1738000000 -16000000 -9000000 3992000000 -251000000 4880000000 5741000000 8872000000 5490000000 241800000 2000000 9148000000 27088000000 -178000000 68000000 36128000000 -23000000 -23000000 241800000 2000000 9148000000 27065000000 -178000000 68000000 36105000000 1805000000 -10000000 1795000000 -1058000000 -5000000 -1063000000 3000000 3000000 1200000 45000000 500000000 545000000 312000000 312000000 500000 39000000 39000000 9000000 9000000 241100000 2000000 9151000000 28058000000 -1236000000 56000000 36031000000 1653000000 -3000000 1650000000 -913000000 -3000000 -916000000 5000000 5000000 1300000 48000000 576000000 624000000 310000000 310000000 200000 111000000 111000000 -80000000 -80000000 240000000.0 2000000 9134000000 28825000000 -2149000000 55000000 35867000000 1618000000 -5000000 1613000000 -635000000 -3000000 -638000000 5000000 5000000 1200000 47000000 532000000 579000000 307000000 307000000 200000 103000000 103000000 -21000000 -21000000 239000000.0 2000000 9169000000 29604000000 -2784000000 52000000 36043000000 245400000 3000000 9244000000 23802000000 150000000 0 33199000000 1665000000 2000000 1667000000 -345000000 -2000000 -347000000 65000000 65000000 1400000 1000000 53000000 393000000 447000000 281000000 281000000 900000 62000000 62000000 244900000 2000000 9253000000 24793000000 -195000000 65000000 33918000000 1793000000 8000000 1801000000 178000000 2000000 180000000 3000000 3000000 1300000 0 47000000 433000000 480000000 279000000 279000000 300000 119000000 119000000 -216000000 -216000000 243900000 2000000 9109000000 25874000000 -17000000 78000000 35046000000 1509000000 -7000000 1502000000 -86000000 -1000000 -87000000 1000000 1000000 1200000 0 44000000 407000000 451000000 276000000 276000000 100000 75000000 75000000 -2000000 -2000000 242800000 2000000 9138000000 26700000000 -103000000 71000000 35808000000 Organization<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 18, 2022, our shareholders approved a proposal to amend our amended and restated articles of incorporation to change our name from Anthem, Inc. to Elevance Health, Inc. This amendment and name change went into effect on June 27, 2022. We began operating as Elevance Health, Inc. and trading under our new ticker symbol “ELV” on June 28, 2022. References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context otherwise requires.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevance Health is a health company with the purpose of improving the health of humanity. We are the largest health insurer in the United States in terms of medical membership, serving over 47 million medical members through our affiliated health plans as of September 30, 2022. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management and wellness programs, actuarial services and other administrative services. We also provide services to the federal government in connection with our Federal Health Products &amp; Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to our subsidiary health plans and also unaffiliated health plans, including pharmacy benefits management (“PBM”) services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. In addition, we conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, Integra Managed Care, MMM, Optimum HealthCare, Simply Healthcare, and/or UniCare. We offer PBM services through our IngenioRx, Inc. (“IngenioRx”) subsidiary. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our name change to Elevance Health, on June 15, 2022 we announced that over the next several years we will organize our brand portfolio into the following core go-to-market brands:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Wellpoint — we intend to unite select non-BCBSA licensed Medicare, Medicaid and Commercial plans under the Wellpoint name; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Carelon — this brand will bring together our healthcare brands and capabilities, including our Diversified Business Group and IngenioRx business under a single brand name. We now refer to our Diversified Business Group as Carelon. In January 2023, IngenioRx will become CarelonRx.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are currently no segment changes associated with this branding strategy. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner, and given this evolution we are in the process of reviewing and modifying how we will manage our businesses in the future.</span></div> 47000000 30 50 Basis of Presentation and Significant Accounting Policies<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our 2021 Annual Report on Form 10-K, unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and nine months ended September 30, 2022 and 2021 have been recorded. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2022, or any other period. The seasonal nature of portions of our health care and related benefits business, competitive and other market conditions, as well as COVID-19 related impacts, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $291 and $173 at September 30, 2022 and December 31, 2021, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption “Other invested assets” in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” in our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities” in our consolidated balance sheets. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premium receivables include the uncollected amounts from risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $140 and $142 at September 30, 2022 and December 31, 2021, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $82 and $50 at September 30, 2022 and December 31, 2021, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income, and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $709 and $648 at September 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at September 30, 2022. For the three and nine months ended September 30, 2022 and 2021, revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Guidance: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2021-01”). The amendments in ASU 2021-01 provide optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of the reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued Accounting Standards Update No. 2020-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-08”). The amendments in ASU 2020-08 clarify when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting periods beginning after December 15, 2020. The amendments were to be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued Accounting Standards Update No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-06”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted earnings per share calculation and expand disclosure requirements. The amendments became effective for our annual and interim reporting periods beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease to our deferred tax liabilities of $8, and a corresponding cumulative-effect reduction to our opening retained earnings of $23; these amounts are not material to our overall consolidated financial position. The adoption of ASU 2020-06 did not have an impact on our results of operations or our consolidated cash flows. Use of the if-converted method did not have an impact on our overall earnings per share calculation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2019-12”). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance Not Yet Adopted: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the FASB issued Accounting Standards Update No. 2020-11,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Services—Insurance (Topic 944): Effective Date and Early Application </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for market risk benefits are to be applied retrospectively. We do not believe the adoption of ASU 2020-11 and ASU 2018-12 will have a material impact on our consolidated financial position, results of operations, cash flows, and related disclosures.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other new accounting pronouncements that were issued or became effective since the issuance of our 2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our 2021 Annual Report on Form 10-K, unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three and nine months ended September 30, 2022 and 2021 have been recorded. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2022, or any other period. The seasonal nature of portions of our health care and related benefits business, competitive and other market conditions, as well as COVID-19 related impacts, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K.</span> Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $291 and $173 at September 30, 2022 and December 31, 2021, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.</span> 291000000 173000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption “Other invested assets” in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” in our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities” in our consolidated balance sheets. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.</span></div> 1.02 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Premium receivables include the uncollected amounts from risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $140 and $142 at September 30, 2022 and December 31, 2021, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $82 and $50 at September 30, 2022 and December 31, 2021, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income, and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $709 and $648 at September 30, 2022 and December 31, 2021, respectively.</span></div> 140000000 142000000 82000000 50000000 709000000 648000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at September 30, 2022. For the three and nine months ended September 30, 2022 and 2021, revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at September 30, 2022. For the three and nine months ended September 30, 2022 and 2021, revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.</span> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Guidance: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2021-01”). The amendments in ASU 2021-01 provide optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of the reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued Accounting Standards Update No. 2020-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-08”). The amendments in ASU 2020-08 clarify when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting periods beginning after December 15, 2020. The amendments were to be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued Accounting Standards Update No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-06”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted earnings per share calculation and expand disclosure requirements. The amendments became effective for our annual and interim reporting periods beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease to our deferred tax liabilities of $8, and a corresponding cumulative-effect reduction to our opening retained earnings of $23; these amounts are not material to our overall consolidated financial position. The adoption of ASU 2020-06 did not have an impact on our results of operations or our consolidated cash flows. Use of the if-converted method did not have an impact on our overall earnings per share calculation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2019-12”). The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance Not Yet Adopted: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the FASB issued Accounting Standards Update No. 2020-11,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Services—Insurance (Topic 944): Effective Date and Early Application </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments </span></div>for market risk benefits are to be applied retrospectively. We do not believe the adoption of ASU 2020-11 and ASU 2018-12 will have a material impact on our consolidated financial position, results of operations, cash flows, and related disclosures. 31000000 -8000000 -23000000 Business Acquisitions<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Completed Acquisitions </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2022, we completed our acquisition of Integra Managed Care (“Integra”) from Personal Touch Holding Corporation. Integra is a managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and disabilities to live safely and independently in their own homes. The purchase price was allocated to the tangible and intangible net assets acquired based on management’s initial estimates of their fair values, of which $89 has been allocated to finite-lived intangible assets, $250 to indefinite-lived intangible assets, and $123 to goodwill, including measurement period adjustments to goodwill of $13 during the quarter ended September 30, 2022. The majority of goodwill is deductible for income tax purposes. As of September 30, 2022, the initial accounting for the acquisition had not been finalized. Any subsequent adjustments made to the assets acquired or liabilities assumed during the measurement period will be recorded as an adjustment to goodwill. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.</span></div>Acquisitions completed during the year ended December 31, 2021, for which the initial accounting was finalized during the three months ended June 30, 2022 included myNEXUS, Inc. (“myNEXUS”), a comprehensive home-based nursing management company for payors, and MMM Holdings, LLC (“MMM”), including its Medicare Advantage plan, Medicaid plan and other affiliated companies. As of September 30, 2022, the purchase price of each transaction was allocated to the tangible and intangible net assets acquired based on management’s final estimates of their fair values, of which $1,577 has been allocated to finite-lived intangible assets, $20 to indefinite-lived intangible assets, and $2,531 to goodwill. The majority of goodwill is not deductible for income tax purposes. 89000000 250000000 123000000 13000000 1577000000 20000000 2531000000 Business Optimization Initiatives<div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provided below is a summary of the activity, by reportable segment, related to the liability for employee termination costs previously incurred in connection with our enterprise-wide business optimization initiatives introduced in 2020.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">IngenioRx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Business Optimization Initiatives</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee termination costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for employee termination costs at January 1, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for employee termination costs at September 30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provided below is a summary of the activity, by reportable segment, related to the liability for employee termination costs previously incurred in connection with our enterprise-wide business optimization initiatives introduced in 2020.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">IngenioRx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Business Optimization Initiatives</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee termination costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for employee termination costs at January 1, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for employee termination costs at September 30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 61000000 57000000 1000000 3000000 122000000 16000000 14000000 0 0 30000000 45000000 43000000 1000000 3000000 92000000 Investments <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fixed Maturity Securities</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. We have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value may occur and additional material impairment losses for credit losses on investments may be recorded in future periods.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of current and long-term fixed maturity securities, available-for-sale, at September 30, 2022 and December 31, 2021 is as follows:</span></div><div style="margin-bottom:4pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost or Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance <br/>For Credit <br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,673 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,766 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,977 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,877)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,363 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,097 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,257 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,899 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fixed maturity securities in an unrealized loss position at September 30, 2022 and December 31, 2021, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Securities are whole amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,322 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,511 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(821)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,571 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,755 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although not material to our consolidated results of operations, during the nine months ended September 30, 2022, we recorded a combination of credit losses, losses on sales of fixed maturity securities and impairments related to our exposure resulting from investments in Russia and Ukraine. At September 30, 2022, our remaining holdings of Russia and Ukraine fixed maturity securities were not material.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses on our securities shown in the table above have not been recognized into income because, as of September 30, 2022, we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior to their maturity or anticipated recovery. The declines in fair values are largely due to increasing interest rates driven by the high rate of inflation and other market conditions and not by unfavorable changes in the credit quality characteristics that impact our assessment on collectability of principal and interest. We have evaluated qualitative and quantitative factors for indications of credit losses on our securities, including factors such as credit rating, foreign political conflicts, uncertainties around future ability to collect payment, significant declines in fair value and industry conditions, market data, and notifications of maturity and coupon default, and have recorded an allowance for credit losses in the amount of $10 and $6 at September 30, 2022 and December 31, 2021, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of fixed maturity securities at September 30, 2022, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.782%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,977 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,148 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $5,281 and $15,953, respectively. During the three and nine months ended September 30, 2021, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $2,620 and $8,570, respectively.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities </span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of marketable equity securities at September 30, 2022 and December 31, 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:68.211%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Invested Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, mortgage loans and the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Financial information for certain of these investments are reported on a one or three month lag due to the timing of when we receive financial information from the companies.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Gains and Losses</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment (losses) gains for the three and nine months ended September 30, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized gains from sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized losses from sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment (losses) recoveries recognized in income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized (losses) gains from sales of fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains recognized on equity securities still held at the end of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains (losses) recognized on equity securities sold during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment (losses) recoveries recognized in income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) on other investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(482)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Investment Income</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022 and December 31, 2021, accrued investment income totaled $228 and $205, respectively. We recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Lending Programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. The fair value of the collateral received at the time of the transactions amounted to $2,841 and $2,155 at September 30, 2022 and December 31, 2021, respectively. The value of the collateral represented 102% of the market value of the securities on loan at each of September 30, 2022 and December 31, 2021. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022 and December 31, 2021, the remaining contractual maturity of our securities lending agreements included overnight and continuous transactions of cash for $2,636 and $1,874, respectively, of United States Government securities for $180 and $281, respectively, and of Other securities for $25 and $0, respectively.</span></div> <div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of current and long-term fixed maturity securities, available-for-sale, at September 30, 2022 and December 31, 2021 is as follows:</span></div><div style="margin-bottom:4pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost or Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance <br/>For Credit <br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,673 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,766 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,977 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,877)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,363 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,097 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,257 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,899 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 1673000000 0 125000000 0 1548000000 65000000 0 4000000 0 61000000 322000000 0 70000000 -1000000 251000000 4431000000 5000000 355000000 0 4081000000 13766000000 9000000 1560000000 -7000000 12208000000 4748000000 7000000 506000000 -2000000 4247000000 77000000 0 7000000 0 70000000 3895000000 37000000 250000000 0 3682000000 28977000000 58000000 2877000000 -10000000 26148000000 1443000000 7000000 18000000 0 1432000000 65000000 4000000 1000000 0 68000000 353000000 7000000 13000000 0 347000000 5321000000 310000000 10000000 0 5621000000 12044000000 401000000 78000000 -4000000 12363000000 4059000000 75000000 35000000 -2000000 4097000000 65000000 2000000 3000000 0 64000000 2907000000 24000000 24000000 0 2907000000 26257000000 830000000 182000000 -6000000 26899000000 <div style="margin-bottom:3pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fixed maturity securities in an unrealized loss position at September 30, 2022 and December 31, 2021, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Securities are whole amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,322 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,511 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(821)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,571 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,755 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 65 911000000 77000000 29 303000000 48000000 40 61000000 4000000 1 0 0 225 169000000 34000000 151 81000000 36000000 1964 3602000000 314000000 139 200000000 41000000 4322 10228000000 1165000000 1318 1679000000 395000000 2035 2949000000 294000000 530 1182000000 212000000 34 56000000 3000000 7 13000000 4000000 921 2535000000 165000000 269 670000000 85000000 9606 20511000000 2056000000 2444 4128000000 821000000 51 990000000 11000000 27 176000000 7000000 0 0 0 1 1000000 1000000 188 143000000 8000000 68 41000000 5000000 281 634000000 9000000 8 16000000 1000000 1846 3310000000 57000000 403 485000000 21000000 692 1967000000 26000000 125 173000000 9000000 2 4000000 1000000 4 8000000 2000000 511 1707000000 19000000 50 85000000 5000000 3571 8755000000 131000000 686 985000000 51000000 -10000000 -6000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of fixed maturity securities at September 30, 2022, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.782%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,977 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,148 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 911000000 901000000 7364000000 6871000000 9535000000 8467000000 6342000000 5592000000 4825000000 4317000000 28977000000 26148000000 5281000000 15953000000 2620000000 8570000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of marketable equity securities at September 30, 2022 and December 31, 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:68.211%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1403000000 1750000000 5000000 42000000 95000000 89000000 1503000000 1881000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment (losses) gains for the three and nine months ended September 30, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized gains from sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized losses from sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment (losses) recoveries recognized in income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized (losses) gains from sales of fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains recognized on equity securities still held at the end of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized gains (losses) recognized on equity securities sold during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment (losses) recoveries recognized in income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) on other investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(482)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 8000000 30000000 44000000 133000000 -99000000 -8000000 -353000000 -32000000 5000000 0 25000000 -1000000 -96000000 22000000 -334000000 102000000 -43000000 -4000000 -192000000 4000000 4000000 -1000000 -20000000 -57000000 -39000000 -5000000 -212000000 -53000000 95000000 2000000 126000000 9000000 2000000 93000000 45000000 5000000 12000000 -1000000 17000000 5000000 81000000 -90000000 64000000 -1000000 -54000000 -73000000 -482000000 48000000 228000000 205000000 2841000000 2155000000 1.02 1.02 2636000000 1874000000 180000000 281000000 25000000 0 Derivative Financial Instruments<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIBOR or the Secured Overnight Financing Rate (“SOFR”). Any amounts recognized for changes in fair value of these derivatives are included in the captions “Other current assets,” “Other noncurrent assets,” “Other current liabilities” or “Other noncurrent liabilities” in our consolidated balance sheets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $231 and $239 at September 30, 2022 and December 31, 2021, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">three and nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we recognized net (losses) gains on non-hedging derivatives of $(3) and $43, respectively. During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">three and nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we recognized net gains on non-hedging derivatives of $12 and $59, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information relating to the fair value of our derivative assets and liabilities, see Note 7, “Fair Value,” of this Form 10-Q.</span></div> -231000000 -239000000 -3000000 43000000 12000000 59000000 Fair Value<div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:8.317%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.736%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Level Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Input Definition</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level III</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in our consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash equivalents:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed maturity securities, available-for-sale:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities, United States government securities, foreign government securities, and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily corporate debt securities, which are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity securities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities lending collateral:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate observable market inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by counterparty.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at September 30, 2022 and December 31, 2021 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level III</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,079 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,708 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,841 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,841 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,352 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,573 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,460 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,363 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,899 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,311 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,747 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,507 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended September 30, 2022 and 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Residential<br/>Mortgage-<br/>backed<br/>Securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other <br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at July 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total losses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at September 30, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-5.4pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized losses included in net income related to assets still held at September 30, 2022</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at July 1, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gains:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at September 30, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-5.4pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gains included in net income related to assets still held at September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the nine months ended September 30, 2022 and 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Residential<br/>Mortgage-<br/>backed<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other <br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total losses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at September 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gains included in net income related to assets still held at September 30, 2022</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gains:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gains included in net income related to assets still held at September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no individually material transfers into or out of Level III during the three and nine months ended September 30, 2022 or 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions,” we completed our acquisition of Integra in the second quarter of 2022 and the acquisitions of myNEXUS and MMM during the second quarter of 2021. The net assets acquired in our acquisitions of Integra, myNEXUS and MMM and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of assets acquired and liabilities assumed were recorded at their carrying values as of the respective date of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of Integra, myNEXUS and MMM were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisitions of Integra, myNEXUS and MMM described above, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the three and nine months ended September 30, 2022 or 2021.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the three and nine months ended September 30, 2022 or 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value in our consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other invested assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations and mortgage loans, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term borrowings:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or, if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term debt—commercial paper:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest rates at market value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term debt—senior unsecured notes and surplus notes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term debt—convertible debentures:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at September 30, 2022 and December 31, 2021 is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level III</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debentures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,384 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debentures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at September 30, 2022 and December 31, 2021 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level III</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,079 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,247 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,708 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,841 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,841 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,352 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,573 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,460 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,363 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,092 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,899 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,311 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,747 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,507 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 5794000000 0 0 5794000000 0 1548000000 0 1548000000 0 61000000 0 61000000 0 251000000 0 251000000 0 4081000000 0 4081000000 0 12079000000 129000000 12208000000 0 4247000000 0 4247000000 0 70000000 0 70000000 0 3371000000 311000000 3682000000 0 25708000000 440000000 26148000000 1403000000 0 0 1403000000 6000000 -1000000 0 5000000 0 0 95000000 95000000 1409000000 -1000000 95000000 1503000000 149000000 0 0 149000000 0 2841000000 0 2841000000 0 25000000 0 25000000 7352000000 28573000000 535000000 36460000000 0 70000000 0 70000000 0 70000000 0 70000000 2415000000 0 0 2415000000 0 1432000000 0 1432000000 0 68000000 0 68000000 0 347000000 0 347000000 0 5621000000 0 5621000000 0 12027000000 336000000 12363000000 0 4092000000 5000000 4097000000 0 64000000 0 64000000 0 2888000000 19000000 2907000000 0 26539000000 360000000 26899000000 1750000000 0 0 1750000000 8000000 34000000 0 42000000 0 0 89000000 89000000 1758000000 34000000 89000000 1881000000 138000000 0 0 138000000 0 2155000000 0 2155000000 0 19000000 0 19000000 4311000000 28747000000 449000000 33507000000 0 1000000 0 1000000 0 1000000 0 1000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended September 30, 2022 and 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Residential<br/>Mortgage-<br/>backed<br/>Securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other <br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at July 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total losses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at September 30, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-5.4pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized losses included in net income related to assets still held at September 30, 2022</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at July 1, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gains:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at September 30, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-5.4pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gains included in net income related to assets still held at September 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the nine months ended September 30, 2022 and 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Residential<br/>Mortgage-<br/>backed<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other <br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total losses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers into Level III</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at September 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gains included in net income related to assets still held at September 30, 2022</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance at January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gains:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized in accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers out of Level III</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance at September 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gains included in net income related to assets still held at September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 155000000 0 218000000 94000000 467000000 0 0 0 0 0 1000000 0 17000000 0 18000000 15000000 0 77000000 3000000 95000000 26000000 0 1000000 2000000 29000000 10000000 0 0 0 10000000 6000000 0 0 0 6000000 129000000 0 311000000 95000000 535000000 0 0 0 0 0 351000000 2000000 7000000 77000000 437000000 1000000 0 0 5000000 6000000 -1000000 0 0 0 -1000000 34000000 0 0 3000000 37000000 0 0 0 1000000 1000000 47000000 0 0 0 47000000 4000000 1000000 5000000 0 10000000 334000000 1000000 2000000 84000000 421000000 0 0 0 5000000 5000000 336000000 5000000 19000000 89000000 449000000 0 0 0 1000000 1000000 -1000000 0 17000000 0 16000000 40000000 0 281000000 24000000 345000000 201000000 0 1000000 19000000 221000000 42000000 0 0 0 42000000 9000000 0 0 0 9000000 12000000 5000000 5000000 0 22000000 129000000 0 311000000 95000000 535000000 0 0 0 1000000 1000000 325000000 2000000 5000000 60000000 392000000 2000000 0 0 17000000 19000000 4000000 0 0 0 4000000 135000000 0 0 11000000 146000000 12000000 0 0 4000000 16000000 118000000 0 1000000 0 119000000 2000000 1000000 2000000 0 5000000 334000000 1000000 2000000 84000000 421000000 0 0 0 17000000 17000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at September 30, 2022 and December 31, 2021 is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level III</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debentures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,384 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debentures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5367000000 0 0 5367000000 5367000000 265000000 0 265000000 0 265000000 675000000 0 675000000 0 675000000 22747000000 0 20163000000 0 20163000000 86000000 0 554000000 0 554000000 5087000000 0 0 5087000000 5087000000 275000000 0 275000000 0 275000000 300000000 0 300000000 0 300000000 22384000000 0 25150000000 0 25150000000 72000000 0 687000000 0 687000000 Income Taxes<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2021, we recognized income tax expense of $533 and $494, respectively, which represent effective income tax rates of 24.8% and 24.7%, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2021, we recognized income tax expense of $1,557 and $1,555, respectively, which represent effective income tax rates of 23.5% and 23.8%, respectively. The decrease in our effective tax rate from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was primarily related to the tax impact of expected geographic changes in our mix of 2022 earnings.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes receivable totaled $214 and $173 at September 30, 2022 and December 31, 2021, respectively. We recognized the income taxes receivable as an asset under the caption “Other current assets” in our consolidated balance sheets.</span></div> 533000000 494000000 0.248 0.247 1557000000 1555000000 0.235 0.238 214000000 173000000 Medical Claims Payable<div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,157 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,834 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business combinations and purchase adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,049 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods redundancies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,866 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,332 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,276 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period medical claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods medical claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,854 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,785 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,804 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,672 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,921 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,807 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,001 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Commercial &amp; Specialty Business was $81, $388 and $3,449 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Government Business was $148, $508 and $10,151 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for Other was $2, $14 and $257 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2021 is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,613 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,089 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business combinations and purchase adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods redundancies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,003 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,113 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,275 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period medical claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods medical claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,435 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,941 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,523 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,849 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,160 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,183 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,299 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable development recognized in the nine months ended September 30, 2022 and 2021 resulted primarily from trend factors in late 2021 and late 2020, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter parts of 2020 developing faster than expected also contributed to the favorable development in the nine months ended September 30, 2021. The impact from COVID-19 on healthcare utilization and medical claims submission patterns continues to provide increased estimation uncertainty on our incurred but not reported liability at September 30, 2022.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2022 is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.825%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial &amp; Specialty Business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,834 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,522 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,510 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,866 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,943 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,634 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,511 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,276 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality improvement and other claims expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,120 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,215 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,777 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,404 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,396 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three months ended September 30, 2022, based on recent regulatory clarification, we realigned certain quality improvement costs from benefit expense to administrative expense that were previously allocated to benefit expense during the three months ended March 31, 2022 and the three months ended June 30, 2022.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,072 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,718 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,213 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,003 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Business</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,727 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,844 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality improvement and other claims expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,832 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,699 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,763 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,645 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,107 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of September 30, 2022, is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,921 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,048 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,242 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,157 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,834 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business combinations and purchase adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,049 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods redundancies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,866 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,332 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,276 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period medical claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,453 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods medical claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,854 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,219 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,785 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,804 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,672 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,921 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,807 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,001 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Commercial &amp; Specialty Business was $81, $388 and $3,449 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Government Business was $148, $508 and $10,151 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the total of net incurred but not reported liabilities plus expected development on reported claims for Other was $2, $14 and $257 for the claim years 2020 and prior, 2021 and 2022, respectively.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the nine months ended September 30, 2021 is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,613 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,089 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business combinations and purchase adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,422 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods redundancies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,003 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,113 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,275 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period medical claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods medical claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,435 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,941 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,523 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,849 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,160 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,864 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,183 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,299 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable development recognized in the nine months ended September 30, 2022 and 2021 resulted primarily from trend factors in late 2021 and late 2020, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter parts of 2020 developing faster than expected also contributed to the favorable development in the nine months ended September 30, 2021. The impact from COVID-19 on healthcare utilization and medical claims submission patterns continues to provide increased estimation uncertainty on our incurred but not reported liability at September 30, 2022.</span></div> 3847000000 9157000000 278000000 13282000000 13000000 8000000 0 21000000 3834000000 9149000000 278000000 13261000000 3000000 130000000 0 133000000 22049000000 60971000000 1157000000 84177000000 183000000 639000000 79000000 901000000 21866000000 60332000000 1078000000 83276000000 18604000000 50950000000 899000000 70453000000 3181000000 7854000000 184000000 11219000000 21785000000 58804000000 1083000000 81672000000 3918000000 10807000000 273000000 14998000000 3000000 0 0 3000000 3921000000 10807000000 273000000 15001000000 81000000 388000000 3449000000 148000000 508000000 10151000000 2000000 14000000 257000000 3294000000 7646000000 195000000 11135000000 13000000 33000000 0 46000000 3281000000 7613000000 195000000 11089000000 0 375000000 45000000 420000000 20499000000 52422000000 1176000000 74097000000 496000000 1309000000 17000000 1822000000 20003000000 51113000000 1159000000 72275000000 16985000000 44160000000 978000000 62123000000 2450000000 5781000000 169000000 8400000000 19435000000 49941000000 1147000000 70523000000 3849000000 9160000000 252000000 13261000000 15000000 23000000 0 38000000 3864000000 9183000000 252000000 13299000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2022 is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.825%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial &amp; Specialty Business</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,834 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,522 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,510 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,866 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,943 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,634 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,511 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,276 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality improvement and other claims expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,120 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,215 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,777 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,404 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,396 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three months ended September 30, 2022, based on recent regulatory clarification, we realigned certain quality improvement costs from benefit expense to administrative expense that were previously allocated to benefit expense during the three months ended March 31, 2022 and the three months ended June 30, 2022.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,072 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,718 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,213 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,003 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government Business</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,319 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,727 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,844 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality improvement and other claims expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,832 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,699 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,763 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,645 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,107 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6834000000 7522000000 7510000000 21866000000 19943000000 19788000000 20601000000 60332000000 354000000 324000000 400000000 1078000000 27131000000 27634000000 28511000000 83276000000 1084000000 1143000000 893000000 3120000000 28215000000 28777000000 29404000000 86396000000 6072000000 6718000000 7213000000 20003000000 16319000000 16723000000 18071000000 51113000000 336000000 403000000 420000000 1159000000 22727000000 23844000000 25704000000 72275000000 972000000 919000000 941000000 2832000000 23699000000 24763000000 26645000000 75107000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of September 30, 2022, is as follows:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,998 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,921 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,048 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,242 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3918000000 10807000000 273000000 14998000000 3000000 0 0 3000000 0 241000000 0 241000000 3921000000 11048000000 273000000 15242000000 Debt<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally issue senior unsecured notes for long-term borrowing purposes. At September 30, 2022 and December 31, 2021, we had $22,722 and $22,359, respectively, outstanding under these notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2022, we repaid, at maturity, the $850 outstanding balance of our 3.125% senior unsecured notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2022, we issued $600 aggregate principal amount of 4.100% Notes due 2032 (the “2032 Notes”) and $700 aggregate principal amount of 4.550% Notes due 2052 (the “2052 Notes”) under our shelf registration statement. Interest on the 2032 Notes and 2052 Notes is payable semi-annually in arrears on May 15 and November 15 of each year, commencing November 15, 2022. We used the net proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an unsecured surplus note with an outstanding principal balance of $25 at both September 30, 2022 and December 31, 2021. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. On April 18, 2022, we amended and restated the credit agreement for the 5-Year Facility to, among other things, extend the maturity date of the 5-Year Facility from June 2024 to April 2027 and increase the amount of credit available under the 5-Year Facility from $2,500 to $4,000. Also on April 18, 2022, concurrently with the amendment and restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which was scheduled to mature in June 2022 (the “2021 364-Day Facility”). In June 2021, we terminated our 364-day senior revolving credit facility (the “prior 364-Day Facility”), which was scheduled to mature in June 2021, and entered into the 2021 364-Day Facility with a group of lenders for general corporate purposes. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. As of September 30, 2022, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.7%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of September 30, 2022, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility, the 2021 364-Day Facility or the prior 364-Day Facility at any time during the nine months ended September 30, 2022 or the year ended December 31, 2021. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit of up to $200. At September 30, 2022 and December 31, 2021, there were no amounts outstanding under our Subsidiary Credit Facilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. In July 2022, we increased the amount available under the commercial paper program from $3,500 to $4,000. At September 30, 2022 and December 31, 2021, we had $675 and $300, respectively, outstanding under this program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have outstanding senior unsecured convertible debentures due 2042 (the “Debentures”), which are governed by an indenture (the “indenture”) between us and The Bank of New York Mellon Trust Company, N.A., as trustee. We accounted for the Debentures in accordance with the FASB cash conversion guidance for debt with conversion and other options at the time of issue. As a result, the value of the embedded conversion option (net of deferred taxes and equity issuance costs) was bifurcated from its debt host and recorded as a component of additional paid-in capital in our consolidated balance sheets. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease of our deferred tax liabilities of $8 and a corresponding cumulative-effect reduction to our opening retained earnings of $23, eliminating the bifurcation of the embedded conversion option. During the three and nine months ended September 30, 2022, $4 and $19 of aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of the indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments during the three and nine months ended September 30, 2022 of $25 and $132, respectively.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes at September 30, 2022 the related balances, conversion rate and conversion price of the Debentures:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net debt carrying amount</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion rate (shares of common stock per $1,000 of principal amount)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective conversion price (per $1,000 of principal amount)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.9462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $265 and $275 of outstanding short-term borrowings from the FHLBs at September 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All debt is a direct obligation of Elevance Health, Inc., except for the surplus note, the FHLB borrowings, and the Subsidiary Credit Facilities.</span></div> 22722000000 22359000000 850000000 0.03125 600000000 0.04100 700000000 0.04550 25000000 25000000 2500000000 4000000000 Also on April 18, 2022, concurrently with the amendment and restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which was scheduled to mature in June 2022 1000000000 Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. As of September 30, 2022, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.7%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of September 30, 2022, we were in compliance with all of our debt covenants under the 5-Year Facility. 200000000 4000000000 3500000000 675000000 300000000 31000000 -8000000 -23000000 4000000 19000000 25000000 132000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes at September 30, 2022 the related balances, conversion rate and conversion price of the Debentures:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net debt carrying amount</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion rate (shares of common stock per $1,000 of principal amount)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective conversion price (per $1,000 of principal amount)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.9462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 86000000 86000000 14.2967 69.9462 265000000 275000000 Commitments and Contingencies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Proceedings </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss. </span></div><div style="margin-bottom:9pt;padding-right:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves is, in the aggregate, from $0 to approximately $250 at September 30, 2022. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Blue Cross Blue Shield Antitrust Litigation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the “Blue plans”) across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Blue Cross Blue Shield Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that is pending in the U.S. District Court for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, determining that the defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the “Subscriber Settlement Agreement”), which agreement required the Court’s approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-monetary obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the July 2021 opt-out deadline. In excess of eight thousand claims were submitted by the November 2021 claims submission deadline. A fairness hearing was held in October 2021 and the Court took the request for final approval under advisement and requested supplemental briefing that was submitted. In February 2022, the Court ordered the issuance of a supplemental notice to self-funded account class members, which notice process was completed in March 2022. The deadline for objections to the supplemental notice along with opt-outs was in May 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Court issued a final approval order for the Subscriber Settlement Agreement. The Court amended its final approval order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In September 2022, an objector filed a motion to amend the final approval order, which the Court </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">denied. In compliance with the Subscriber Settlement Agreement, the Company paid its remaining $506 portion of the settlement fund into an escrow account in September 2022, for an aggregate settlement payment by the Company of $596.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Four notices of appeal of the final approval order were filed by the September 2022 deadline. Those appeals will proceed in the United States Court of Appeals for the Eleventh Circuit. In October 2022, the subscriber plaintiffs filed a motion to consolidate and expedite the four appeals. After all appellate rights have been exhausted in a manner that affirms the Court’s final order and judgment, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determines the standard of review applicable to providers’ claims. In May 2021, the defendants and provider plaintiffs filed renewed standard of review motions. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued (i) an order granting certain defendants’ motion for partial summary judgment against provider plaintiffs who had previously released claims against such defendants, and (ii) an order granting provider plaintiffs’ motion for partial summary judgment, holding that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ohio v. American Express Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. does not affect the standard of review in this case. In August 2022, the Court issued (i) an order granting in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the “national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation conspiracy claims, and (ii) an order denying the provider plaintiffs’ motion for partial summary judgment on the standard of review, reaffirming its prior holding that the providers’ group boycott claims are subject to the rule of reason. We intend to continue to vigorously defend the provider litigation, which we believe is without merit; however, its ultimate outcome cannot be presently determined.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alaska Air Group, Inc., et al. v. Anthem, Inc., et al.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No. 2:21-cv-01209-AMM (N.D. Ala.); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">JetBlue Airways Corp., et al. v. Anthem, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-00558-GMB (N.D. Ala.); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-00265-RDP (N.D. Ala.); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bed Bath &amp; Beyond Inc. v. Anthem, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-01256-SGC (N.D. Ala.);</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Hoover, et al. v. Blue Cross Blue Shield Association, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-00261-RDP (N.D. Ala.); and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VHS Liquidating Trust v. Blue Cross of California, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. RG21106600 (Cal. Super.). We intend to continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Blue Cross of California Taxation Litigation</span></div><div style="margin-bottom:9pt;padding-right:6.75pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (“BCC”) was named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court (the “Superior Court”) captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Michael D. Myers v. State Board of Equalization, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This action was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an “insurer” for purposes of taxation despite acknowledging it is not an “insurer” under regulatory law. At the time, under California law, “insurers” were required to pay a gross premiums tax (“GPT”) calculated as 2.35% on gross premiums. As a licensed Health Care Service Plan, BCC has paid the California Corporate Franchise Tax (“CFT”), the tax paid by California businesses generally. Plaintiff contends that BCC must pay the GPT rather than the CFT, and seeks a writ of mandate directing the taxing agencies to collect the GPT and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the complaint.</span></div><div style="margin-bottom:9pt;padding-right:6.75pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax periods at issue in the litigation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, the Superior Court denied BCC’s motion for judgment on the pleadings and similar motions brought by other entities. BCC filed a motion for summary judgment with the Superior Court, which was heard in October 2020. In December 2020, the Superior Court granted BCC’s motion for summary judgment, dismissing the plaintiff’s lawsuit. In </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2021, the plaintiff appealed the order granting BCC's motion for summary judgment. BCC’s responding brief was filed in March 2022. Plaintiff’s reply was filed in May 2022. We estimate that the appeal will be heard in the winter of 2022. We intend to vigorously defend the appeal of this lawsuit.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Express Scripts, Inc. Pharmacy Benefit Management Litigation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for PBM services, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anthem, Inc. v. Express Scripts, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. District Court for the Southern District of New York (the “District Court”). The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the “ESI PBM Agreement”), over $158 in damages related to operational breaches, as well as various declarations under the ESI PBM Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to us through the term of the ESI PBM Agreement; (iii) has breached the ESI PBM Agreement; and (iv) is required under the ESI PBM Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI PBM Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI PBM Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have been unjustly enriched by its payment of $4,675 at the time we entered into the ESI PBM Agreement. In March 2017, the District Court granted our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such action, the only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In March 2022, the District Court granted in part and denied in part Express Scripts’ motion for summary judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Quarterly Report on Form 10-Q are (i) our operational breach claim based on Express Scripts’ prior authorization processes and (ii) Express Scripts’ counterclaim for breach of the market check provision of the ESI PBM Agreement. Express Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims, which we opposed in July 2022. We intend to appeal the earlier summary judgment decision at the appropriate time, vigorously pursue our claims and defend against counterclaims, which we believe are without merit; however, the ultimate outcome of this litigation cannot be presently determined.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Risk Adjustment Litigation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. (f/k/a Anthem, Inc.) in the U.S. District Court for the Southern District of New York (the “New York District Court”) in a case captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States v. Anthem, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint. In an opinion and order issued October 3, 2022, the New York District Court denied our motions, and the case will now proceed in such court. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investigations of CareMore and HealthSun</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data submitted to CMS (unrelated to our retrospective chart review program) at CareMore Health Plans, Inc. (“CareMore”), one of our California subsidiaries, and HealthSun Health Plans, Inc. (“HealthSun”), one of our Florida subsidiaries. Our CareMore investigation has resulted in the termination of CareMore’s relationship with one contracted provider in California. Our </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HealthSun investigation has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to CMS and the Criminal and Civil Divisions of the DOJ. We are cooperating with the ongoing investigations of the Criminal and Civil Divisions of the DOJ related to these risk adjustment practices, and have entered into a tolling agreement with the Civil Division of the DOJ related to its investigation. We are analyzing the scope of potential data corrections to be submitted to CMS and have begun to submit data corrections to CMS. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for, among other things, breach of healthcare and financial representation provisions, based on the conduct discovered during our investigation. While certain elements of the escrow claims were resolved in the fourth quarter of 2021, litigation in the Delaware Court of Chancery related to the remaining indemnity claims for escrowed funds remains ongoing.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Other Contingencies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (“HMOs”) and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through June 2025. The new agreement supersedes certain prior agreements for such services and includes provisions for additional services not provided under those agreements. Our remaining commitment under this agreement at September 30, 2022 is approximately $830. We will have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination fees.</span></div>In the second quarter of 2019, we began using our pharmacy benefits manager IngenioRx to market and offer PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. The comprehensive PBM services portfolio includes, but is not limited to, formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities. IngenioRx delegates certain PBM administrative functions, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement. With IngenioRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy. 0 250000000 8000 506000000 596000000 0.0235 14800000000 158000000 4675000000 830000000 Capital Stock<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Capital – Dividends and Stock Repurchase Program</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors. </span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash dividend activity for the nine months ended September 30, 2022 and 2021 is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:40.006%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.918%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Declaration Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Record Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Payment Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 25, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 19, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 24, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 19, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 9, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 23, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 26, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 25, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 20, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 10, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 24, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2022, our Audit Committee declared a fourth quarter 2022 dividend to shareholders of $1.28 per share, payable on December 21, 2022 to shareholders of record at the close of business on December 5, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 26, 2021, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to the common stock repurchase program. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are effected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings. </span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock repurchases for the nine months ended September 30, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorization remaining at the end of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding the use of capital for debt security repurchases, see Note 10, “Debt,” included in this Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the nine months ended September 30, 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:44.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.887%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Option Price<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the nine months ended September 30, 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:72.183%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock Shares<br/>and Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301.44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, we granted approximately 0.2 restricted stock units that are contingent upon us achieving earnings targets over the three year period from 2022 to 2024. These grants have been included in the activity shown above, but will be subject to adjustment at the end of 2024 based on results in the three year period.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed discussion of our stock incentive plan fair value methodology, see Note 15, “Capital Stock,” to our audited consolidated financial statements as of and for the year ended December 31, 2021 included in our 2021 Annual Report on Form 10-K. </span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used to estimate the fair values of options granted during the nine months ended September 30, 2022 and 2021:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:72.183%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility factor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarterly dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50</span></td></tr></table></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average fair values per option or share were determined for the nine months ended September 30, 2022 and 2021:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:72.183%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards granted during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash dividend activity for the nine months ended September 30, 2022 and 2021 is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:40.006%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.918%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Declaration Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Record Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Payment Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 25, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 19, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 24, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 19, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 9, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 23, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 26, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 25, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 20, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 10, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 24, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2022-01-25 2022-03-10 2022-03-25 1.28 309000000 2022-04-19 2022-06-10 2022-06-24 1.28 309000000 2022-07-19 2022-09-09 2022-09-23 1.28 306000000 2021-01-26 2021-03-10 2021-03-25 1.13 277000000 2021-04-20 2021-06-10 2021-06-25 1.13 278000000 2021-07-20 2021-09-10 2021-09-24 1.13 276000000 1.28 2022-12-21 2022-12-05 5000000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock repurchases for the nine months ended September 30, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorization remaining at the end of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3700000 3900000 473.36 356.43 1748000000 1378000000 2444000000 4714000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the nine months ended September 30, 2022 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:44.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.887%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Option Price<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2900000 255.50 500000 452.34 400000 243.39 100000 339.52 2900000 291.95 P6Y6M21D 477000000 1700000 239.27 P5Y4M6D 370000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the nine months ended September 30, 2022 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:72.183%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock Shares<br/>and Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301.44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1300000 299.65 600000 453.16 600000 301.44 100000 345.25 1200000 356.33 200000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used to estimate the fair values of options granted during the nine months ended September 30, 2022 and 2021:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:72.183%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility factor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarterly dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50</span></td></tr></table></div> 0.0197 0.0144 0.2900 0.3000 0.00282 0.00360 P5Y1M6D P5Y6M <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average fair values per option or share were determined for the nine months ended September 30, 2022 and 2021:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:72.183%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards granted during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315.54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 116.85 79.51 453.16 315.54 Accumulated Other Comprehensive Loss <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the components of accumulated other comprehensive loss at September 30, 2022 and 2021 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net unrealized investment (losses) gains:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications, net of tax benefit of $220, $25, $896 and $71, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,914)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss, net of tax (expense) benefit of $(21), $5, $(75) and $21, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(639)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(284)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(1), $0, $(4) and $(1), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,125)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,125)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-credit components of impairments on investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax benefit (expense) of $0, $0, $1 and $(1), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax expense of $0, $0, $(2) and $(2), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension and other postretirement benefits:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax expense of $(3), $(4), $(9) and $(10), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax benefit of $2, $1, $4 and $2, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total beginning of period accumulated other comprehensive (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive loss, net of tax benefit of $198, $27, $815 and $81, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,617)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(1), $0, $(4) and $(1), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total end of period accumulated other comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,784)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,784)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the components of accumulated other comprehensive loss at September 30, 2022 and 2021 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/>September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net unrealized investment (losses) gains:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications, net of tax benefit of $220, $25, $896 and $71, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,914)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss, net of tax (expense) benefit of $(21), $5, $(75) and $21, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(639)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(284)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(1), $0, $(4) and $(1), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,125)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,125)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-credit components of impairments on investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax benefit (expense) of $0, $0, $1 and $(1), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax expense of $0, $0, $(2) and $(2), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension and other postretirement benefits:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax expense of $(3), $(4), $(9) and $(10), respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax benefit of $2, $1, $4 and $2, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total beginning of period accumulated other comprehensive (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive loss, net of tax benefit of $198, $27, $815 and $81, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,617)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(1), $0, $(4) and $(1), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total end of period accumulated other comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,784)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,784)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> -1489000000 762000000 494000000 949000000 220000000 25000000 896000000 71000000 -719000000 -80000000 -2914000000 -203000000 21000000 -5000000 75000000 -21000000 80000000 -17000000 284000000 -81000000 -639000000 -97000000 -2630000000 -284000000 -1000000 0 -4000000 -1000000 -3000000 -1000000 -11000000 -1000000 -2125000000 666000000 -2125000000 666000000 -2000000 0 0 -2000000 0 0 1000000 -1000000 -1000000 -1000000 -3000000 1000000 -3000000 -1000000 -3000000 -1000000 -233000000 -244000000 -239000000 -250000000 0 0 -2000000 -2000000 2000000 4000000 8000000 10000000 -231000000 -240000000 -231000000 -240000000 413000000 534000000 429000000 552000000 -3000000 -4000000 -9000000 -10000000 7000000 8000000 23000000 26000000 406000000 526000000 406000000 526000000 -12000000 -1000000 -4000000 5000000 2000000 1000000 4000000 2000000 -7000000 -1000000 -15000000 -7000000 -19000000 -2000000 -19000000 -2000000 -2149000000 -17000000 -178000000 150000000 198000000 27000000 815000000 81000000 -638000000 -87000000 -2617000000 -254000000 -1000000 0 -4000000 -1000000 -3000000 -1000000 -11000000 -1000000 -2784000000 -103000000 -2784000000 -103000000 Earnings per Share<div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The denominator for basic and diluted earnings per share for the three and nine months ended September 30, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.084%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended <br/> September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic earnings per share – weighted-average shares</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for diluted earnings per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the three months ended September 30, 2022 and 2021, weighted-average shares related to certain stock options of 0.5 and 0.0, respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive. During the nine months ended September 30, 2022 and 2021, weighted-average shares related to certain stock options of 0.4 and 0.3, respectively, were excluded from each of the denominators for diluted earnings per share because the stock options were anti-dilutive.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022, we issued approximately 0.0 and 0.6 restricted stock units under our stock incentive plans, 0.0 and 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three year period of 2022 through 2024. During the three and nine months ended September 30, 2021, we issued approximately 0.1 and 1.0 restricted stock units under our stock incentive plans, 0.0 and 0.3 of which vesting is contingent upon us meeting specified annual earnings targets for the three year period of 2021 through 2023. The contingent restricted stock units have been excluded from the denominators for diluted earnings per share and will be included only if and when the contingency is met.</span></div> <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The denominator for basic and diluted earnings per share for the three and nine months ended September 30, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.084%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended <br/> September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic earnings per share – weighted-average shares</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for diluted earnings per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 239600000 243400000 240500000 244300000 2600000 2600000 2800000 2900000 242200000 246000000.0 243300000 247200000 500000 0.0 400000 300000 0.0 600000 0.0 200000 100000 1000000.0 0.0 300000 Segment Information<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1 “Organization”, we will be organizing our brand portfolio into three core go-to-market brands over the next several years. Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner, and given this evolution we are in the process of reviewing and modifying how we will manage our businesses in the future. Currently, there are no changes to our segments associated with this branding strategy. The results of our operations continue to be described through four reportable segments: Commercial &amp; Specialty Business, Government Business, IngenioRx and Other.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Commercial &amp; Specialty Business segment offers plans and services to our Individual, Group risk-based, Group fee-based and BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> members. The Commercial &amp; Specialty Business segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as dental, vision, life, disability and supplemental health insurance benefits.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Government Business segment includes our Medicare and Medicaid businesses, National Government Services, and services provided to the federal government in connection with the FEHB program. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our IngenioRx segment includes our PBM business. IngenioRx markets and offers PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. IngenioRx has a comprehensive PBM services portfolio, which includes services such as formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Other segment includes our Diversified Business Group, now known as Carelon, which is our health services business focused on lowering the cost and improving the quality of healthcare by enabling and creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic conditions. This segment also includes certain eliminations and corporate expenses not allocated to our other reportable segments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define operating revenues to include premium income, product revenue and administrative fees and other revenues. Operating revenues are derived from premiums and fees received, primarily from the sale and administration of health benefits and pharmacy products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative expense.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affiliated revenues represent revenues or cost for services provided to our subsidiaries by IngenioRx and Carelon, formerly known as our Diversified Business Group, as well as certain back-office services provided by our international businesses, and are recorded at cost or management’s estimate of fair market value. These affiliated revenues are eliminated in consolidation.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial data by reportable segment for the three and nine months ended September 30, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">IngenioRx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,054)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,863 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major product revenues for each of the reportable segments for the three and nine months ended September 30, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended <br/> September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care services</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,618 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dental/Vision products and services</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Commercial &amp; Specialty Business</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,863 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,324 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,904 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care products</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,565 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care services</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Government Business</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,571 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,658 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,164 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,007 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IngenioRx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy products and services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,249 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,549 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,003 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,630 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated health services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,365 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,884 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,557 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eliminations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,054)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,625 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,548 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,993 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,925 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classification between managed care products and managed care services in the above table primarily distinguishes between the levels of risk assumed. Managed care products represent insurance products where we bear the insurance risk, whereas managed care services represent product offerings where we provide claims adjudication and other administrative services to the customer, but the customer principally bears the insurance risk. </span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and nine months ended September 30, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended <br/> September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments’ operating revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,548 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,993 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,939 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,822 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,666 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,058 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three and nine months ended September 30, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended <br/> September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,146 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,615 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,026)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments’ operating gain</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,270 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,084 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,301 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4 <div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial data by reportable segment for the three and nine months ended September 30, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial<br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">IngenioRx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,054)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,863 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10494000000 24571000000 3971000000 589000000 39625000000 3278000000 2776000000 -6054000000 0 785000000 868000000 516000000 101000000 2270000000 9863000000 21658000000 3369000000 658000000 35548000000 0 0 3180000000 2012000000 -5192000000 0 620000000 967000000 445000000 27000000 2059000000 31324000000 72164000000 10838000000 1667000000 115993000000 0 0 10165000000 8217000000 -18382000000 0 2673000000 2653000000 1393000000 365000000 7084000000 28904000000 61007000000 9131000000 1883000000 100925000000 0 0 9499000000 5674000000 -15173000000 0 2679000000 2313000000 1257000000 52000000 6301000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major product revenues for each of the reportable segments for the three and nine months ended September 30, 2022 and 2021 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended <br/> September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commercial &amp; Specialty Business</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care products</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care services</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,618 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dental/Vision products and services</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Commercial &amp; Specialty Business</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,863 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,324 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,904 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Government Business</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care products</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,565 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care services</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Government Business</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,571 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,658 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,164 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,007 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IngenioRx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy products and services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,249 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,549 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,003 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,630 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integrated health services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,365 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,884 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,557 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eliminations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eliminations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,054)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,625 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,548 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,993 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,925 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 8478000000 8005000000 25500000000 23481000000 1610000000 1489000000 4618000000 4291000000 360000000 342000000 1075000000 1013000000 46000000 27000000 131000000 119000000 10494000000 9863000000 31324000000 28904000000 24456000000 21565000000 71823000000 60711000000 115000000 93000000 341000000 296000000 24571000000 21658000000 72164000000 61007000000 7249000000 6549000000 21003000000 18630000000 3153000000 2506000000 9083000000 7121000000 212000000 164000000 801000000 436000000 3365000000 2670000000 9884000000 7557000000 -6054000000 -5192000000 -18382000000 -15173000000 39625000000 35548000000 115993000000 100925000000 <div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three and nine months ended September 30, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended <br/> September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments’ operating revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,548 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,993 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,939 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,822 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,666 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,058 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 39625000000 35548000000 115993000000 100925000000 371000000 335000000 1112000000 1026000000 -57000000 -61000000 -439000000 107000000 39939000000 35822000000 116666000000 102058000000 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three and nine months ended September 30, 2022 and 2021 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended <br/> September 30</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,146 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,615 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,026)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments’ operating gain</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,270 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,084 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,301 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2146000000 1996000000 6615000000 6525000000 371000000 335000000 1112000000 1026000000 -57000000 -61000000 -439000000 107000000 213000000 201000000 622000000 598000000 225000000 136000000 520000000 306000000 0 0 0 -5000000 2270000000 2059000000 7084000000 6301000000 Leases<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office space and certain computer and related equipment using noncancellable operating leases. Our leases have remaining lease terms of 1 year to 12 years.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information related to our leases is as follows:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:44.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE4NmUwNTE4NzhmZTQyMTk5NzBlZmM3MmE5ZmNkYWQ0L3NlYzoxODZlMDUxODc4ZmU0MjE5OTcwZWZjNzJhOWZjZGFkNF85MS9mcmFnOmE5MGUyM2YyMWM5YjQ2NTBiZDY5ZjhiZWEwMzI4ZGZkL3RhYmxlOmFjOWNjYmViMmMyZDQ1Yzc4ZGYxMWJmNDhkZTQ3Yjk2L3RhYmxlcmFuZ2U6YWM5Y2NiZWIyYzJkNDVjNzhkZjExYmY0OGRlNDdiOTZfMi0xLTEtMS03NzQ3Mg_35223446-da43-4885-b1af-792d126f0d02"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE4NmUwNTE4NzhmZTQyMTk5NzBlZmM3MmE5ZmNkYWQ0L3NlYzoxODZlMDUxODc4ZmU0MjE5OTcwZWZjNzJhOWZjZGFkNF85MS9mcmFnOmE5MGUyM2YyMWM5YjQ2NTBiZDY5ZjhiZWEwMzI4ZGZkL3RhYmxlOmFjOWNjYmViMmMyZDQ1Yzc4ZGYxMWJmNDhkZTQ3Yjk2L3RhYmxlcmFuZ2U6YWM5Y2NiZWIyYzJkNDVjNzhkZjExYmY0OGRlNDdiOTZfMi0xLTEtMS03NzQ3Mg_9be99ce3-7827-4188-b28e-80ce38a6cc7e">Other noncurrent assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE4NmUwNTE4NzhmZTQyMTk5NzBlZmM3MmE5ZmNkYWQ0L3NlYzoxODZlMDUxODc4ZmU0MjE5OTcwZWZjNzJhOWZjZGFkNF85MS9mcmFnOmE5MGUyM2YyMWM5YjQ2NTBiZDY5ZjhiZWEwMzI4ZGZkL3RhYmxlOmFjOWNjYmViMmMyZDQ1Yzc4ZGYxMWJmNDhkZTQ3Yjk2L3RhYmxlcmFuZ2U6YWM5Y2NiZWIyYzJkNDVjNzhkZjExYmY0OGRlNDdiOTZfMy0xLTEtMS03NzQ4MQ_3f09f4af-f1d9-4a52-8c2e-e79a525ccc59"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE4NmUwNTE4NzhmZTQyMTk5NzBlZmM3MmE5ZmNkYWQ0L3NlYzoxODZlMDUxODc4ZmU0MjE5OTcwZWZjNzJhOWZjZGFkNF85MS9mcmFnOmE5MGUyM2YyMWM5YjQ2NTBiZDY5ZjhiZWEwMzI4ZGZkL3RhYmxlOmFjOWNjYmViMmMyZDQ1Yzc4ZGYxMWJmNDhkZTQ3Yjk2L3RhYmxlcmFuZ2U6YWM5Y2NiZWIyYzJkNDVjNzhkZjExYmY0OGRlNDdiOTZfMy0xLTEtMS03NzQ4MQ_ce213197-b1dc-4b00-96f5-82a38cd1810f">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE4NmUwNTE4NzhmZTQyMTk5NzBlZmM3MmE5ZmNkYWQ0L3NlYzoxODZlMDUxODc4ZmU0MjE5OTcwZWZjNzJhOWZjZGFkNF85MS9mcmFnOmE5MGUyM2YyMWM5YjQ2NTBiZDY5ZjhiZWEwMzI4ZGZkL3RhYmxlOmFjOWNjYmViMmMyZDQ1Yzc4ZGYxMWJmNDhkZTQ3Yjk2L3RhYmxlcmFuZ2U6YWM5Y2NiZWIyYzJkNDVjNzhkZjExYmY0OGRlNDdiOTZfNC0xLTEtMS03NzQ5OQ_3538eea0-82a4-4a60-af7e-b84b7a69ca57"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE4NmUwNTE4NzhmZTQyMTk5NzBlZmM3MmE5ZmNkYWQ0L3NlYzoxODZlMDUxODc4ZmU0MjE5OTcwZWZjNzJhOWZjZGFkNF85MS9mcmFnOmE5MGUyM2YyMWM5YjQ2NTBiZDY5ZjhiZWEwMzI4ZGZkL3RhYmxlOmFjOWNjYmViMmMyZDQ1Yzc4ZGYxMWJmNDhkZTQ3Yjk2L3RhYmxlcmFuZ2U6YWM5Y2NiZWIyYzJkNDVjNzhkZjExYmY0OGRlNDdiOTZfNC0xLTEtMS03NzQ5OQ_3bcb0bf3-e902-449c-94d0-fd8995ada510">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended <br/> September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 17.5pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Operating cash paid for amounts included in the measurement of lease liabilities, operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 17.5pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease liabilities, operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the weighted average remaining lease term of our operating leases was 7 years for each period. The lease liabilities reflect a weighted average discount rate of 2.79% at September 30, 2022 and 2.69% at December 31, 2021.</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the nine months ended September 30, 2022)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we have no new leases which will commence during the fourth quarter of 2022.</span></div> P1Y P12Y <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information related to our leases is as follows:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:44.027%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE4NmUwNTE4NzhmZTQyMTk5NzBlZmM3MmE5ZmNkYWQ0L3NlYzoxODZlMDUxODc4ZmU0MjE5OTcwZWZjNzJhOWZjZGFkNF85MS9mcmFnOmE5MGUyM2YyMWM5YjQ2NTBiZDY5ZjhiZWEwMzI4ZGZkL3RhYmxlOmFjOWNjYmViMmMyZDQ1Yzc4ZGYxMWJmNDhkZTQ3Yjk2L3RhYmxlcmFuZ2U6YWM5Y2NiZWIyYzJkNDVjNzhkZjExYmY0OGRlNDdiOTZfMi0xLTEtMS03NzQ3Mg_35223446-da43-4885-b1af-792d126f0d02"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE4NmUwNTE4NzhmZTQyMTk5NzBlZmM3MmE5ZmNkYWQ0L3NlYzoxODZlMDUxODc4ZmU0MjE5OTcwZWZjNzJhOWZjZGFkNF85MS9mcmFnOmE5MGUyM2YyMWM5YjQ2NTBiZDY5ZjhiZWEwMzI4ZGZkL3RhYmxlOmFjOWNjYmViMmMyZDQ1Yzc4ZGYxMWJmNDhkZTQ3Yjk2L3RhYmxlcmFuZ2U6YWM5Y2NiZWIyYzJkNDVjNzhkZjExYmY0OGRlNDdiOTZfMi0xLTEtMS03NzQ3Mg_9be99ce3-7827-4188-b28e-80ce38a6cc7e">Other noncurrent assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE4NmUwNTE4NzhmZTQyMTk5NzBlZmM3MmE5ZmNkYWQ0L3NlYzoxODZlMDUxODc4ZmU0MjE5OTcwZWZjNzJhOWZjZGFkNF85MS9mcmFnOmE5MGUyM2YyMWM5YjQ2NTBiZDY5ZjhiZWEwMzI4ZGZkL3RhYmxlOmFjOWNjYmViMmMyZDQ1Yzc4ZGYxMWJmNDhkZTQ3Yjk2L3RhYmxlcmFuZ2U6YWM5Y2NiZWIyYzJkNDVjNzhkZjExYmY0OGRlNDdiOTZfMy0xLTEtMS03NzQ4MQ_3f09f4af-f1d9-4a52-8c2e-e79a525ccc59"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE4NmUwNTE4NzhmZTQyMTk5NzBlZmM3MmE5ZmNkYWQ0L3NlYzoxODZlMDUxODc4ZmU0MjE5OTcwZWZjNzJhOWZjZGFkNF85MS9mcmFnOmE5MGUyM2YyMWM5YjQ2NTBiZDY5ZjhiZWEwMzI4ZGZkL3RhYmxlOmFjOWNjYmViMmMyZDQ1Yzc4ZGYxMWJmNDhkZTQ3Yjk2L3RhYmxlcmFuZ2U6YWM5Y2NiZWIyYzJkNDVjNzhkZjExYmY0OGRlNDdiOTZfMy0xLTEtMS03NzQ4MQ_ce213197-b1dc-4b00-96f5-82a38cd1810f">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE4NmUwNTE4NzhmZTQyMTk5NzBlZmM3MmE5ZmNkYWQ0L3NlYzoxODZlMDUxODc4ZmU0MjE5OTcwZWZjNzJhOWZjZGFkNF85MS9mcmFnOmE5MGUyM2YyMWM5YjQ2NTBiZDY5ZjhiZWEwMzI4ZGZkL3RhYmxlOmFjOWNjYmViMmMyZDQ1Yzc4ZGYxMWJmNDhkZTQ3Yjk2L3RhYmxlcmFuZ2U6YWM5Y2NiZWIyYzJkNDVjNzhkZjExYmY0OGRlNDdiOTZfNC0xLTEtMS03NzQ5OQ_3538eea0-82a4-4a60-af7e-b84b7a69ca57"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE4NmUwNTE4NzhmZTQyMTk5NzBlZmM3MmE5ZmNkYWQ0L3NlYzoxODZlMDUxODc4ZmU0MjE5OTcwZWZjNzJhOWZjZGFkNF85MS9mcmFnOmE5MGUyM2YyMWM5YjQ2NTBiZDY5ZjhiZWEwMzI4ZGZkL3RhYmxlOmFjOWNjYmViMmMyZDQ1Yzc4ZGYxMWJmNDhkZTQ3Yjk2L3RhYmxlcmFuZ2U6YWM5Y2NiZWIyYzJkNDVjNzhkZjExYmY0OGRlNDdiOTZfNC0xLTEtMS03NzQ5OQ_3bcb0bf3-e902-449c-94d0-fd8995ada510">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> September 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended <br/> September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Expense</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="6" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 17.5pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Operating cash paid for amounts included in the measurement of lease liabilities, operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 17.5pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease liabilities, operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 600000000 628000000 182000000 133000000 739000000 864000000 35000000 37000000 100000000 100000000 11000000 10000000 35000000 34000000 1000000 1000000 3000000 3000000 45000000 46000000 132000000 131000000 53000000 53000000 158000000 141000000 23000000 32000000 62000000 192000000 P7Y P7Y 0.0279 0.0269 <div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the nine months ended September 30, 2022)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 54000000 207000000 179000000 142000000 105000000 345000000 1032000000 111000000 921000000 Goodwill and Other Intangible Assets <div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the change in the carrying amount of goodwill for our segments (see Note 15, “Segment Information”) for 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.161%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial <br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">IngenioRx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,593 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,331 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,691 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions and adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,593 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions and adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,475 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,236 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment as of September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of other intangible assets as of September 30, 2022 and December 31, 2021 are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:29pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with finite lives:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider and hospital relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,037 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,032)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,532 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,506)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Cross and Blue Shield and other trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,991 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,991 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State Medicaid licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,531 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,531 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,568 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,032)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,536 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,121 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,506)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,615 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, we recorded intangible assets related to Integra and also reclassified $308 of trademarks with indefinite lives to intangible assets with finite lives - Other, which relates to our new branding strategy. In addition, the amortization period of certain intangible assets was shortened to align with the anticipated dates the new branding will take place. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, along with the related accumulated amortization, are removed from the table above at the end of the fiscal year in which they become fully amortized.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the estimated amortization expense for the year ending December 31, 2022 and each of the five succeeding years is as follows: 2022, $748; 2023, $735; 2024, $370; 2025, $311; 2026, $258; and 2027, $219.</span></div> <div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the change in the carrying amount of goodwill for our segments (see Note 15, “Segment Information”) for 2022 and 2021 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.161%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commercial <br/>&amp; Specialty<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government<br/>Business</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">IngenioRx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,593 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,331 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,691 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions and adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,593 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions and adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,475 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,236 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated impairment as of September 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 11593000000 8331000000 48000000 1719000000 21691000000 0 2018000000 11000000 508000000 2537000000 11593000000 10349000000 59000000 2227000000 24228000000 18000000 126000000 0 9000000 153000000 11611000000 10475000000 59000000 2236000000 24381000000 0 0 0 0 0 <div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of other intangible assets as of September 30, 2022 and December 31, 2021 are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:29pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with finite lives:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider and hospital relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,037 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,032)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,532 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,506)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Cross and Blue Shield and other trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,991 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,991 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State Medicaid licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,531 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,531 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,589 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,568 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,032)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,536 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,121 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,506)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,615 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5791000000 3580000000 2211000000 5598000000 3236000000 2362000000 326000000 142000000 184000000 324000000 129000000 195000000 920000000 310000000 610000000 610000000 141000000 469000000 7037000000 4032000000 3005000000 6532000000 3506000000 3026000000 5991000000 5991000000 6299000000 6299000000 1540000000 1540000000 1290000000 1290000000 7531000000 7531000000 7589000000 7589000000 14568000000 4032000000 10536000000 14121000000 3506000000 10615000000 308000000 308000000 748000000 735000000 370000000 311000000 258000000 219000000 EXCEL 92 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 93 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 94 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 95 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 569 418 1 false 92 0 false 9 false false R1.htm 0001001 - Document - Document And Entity Information Document Sheet http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument Document And Entity Information Document Cover 1 false false R2.htm 1001002 - Statement - Consolidated Balance Sheets Sheet http://www.elevancehealth.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Consolidated Statements Of Income Sheet http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome Consolidated Statements Of Income Statements 4 false false R5.htm 1004005 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 1005006 - Statement - Consolidated Statements Of Cash Flows Sheet http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements Of Cash Flows Statements 6 false false R7.htm 1006007 - Statement - Consolidated Statements Of Changes in Equity Sheet http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity Consolidated Statements Of Changes in Equity Statements 7 false false R8.htm 2101101 - Disclosure - Organization Sheet http://www.elevancehealth.com/role/Organization Organization Notes 8 false false R9.htm 2103102 - Disclosure - Basis Of Presentation and Significant Accounting Policies Sheet http://www.elevancehealth.com/role/BasisOfPresentationandSignificantAccountingPolicies Basis Of Presentation and Significant Accounting Policies Notes 9 false false R10.htm 2106103 - Disclosure - Business Acquisitions Sheet http://www.elevancehealth.com/role/BusinessAcquisitions Business Acquisitions Notes 10 false false R11.htm 2108104 - Disclosure - Business Optimization Initiatives Sheet http://www.elevancehealth.com/role/BusinessOptimizationInitiatives Business Optimization Initiatives Notes 11 false false R12.htm 2111105 - Disclosure - Investments Sheet http://www.elevancehealth.com/role/Investments Investments Notes 12 false false R13.htm 2119106 - Disclosure - Derivative Financial Instruments Sheet http://www.elevancehealth.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 13 false false R14.htm 2121107 - Disclosure - Fair Value Sheet http://www.elevancehealth.com/role/FairValue Fair Value Notes 14 false false R15.htm 2127108 - Disclosure - Income Taxes Sheet http://www.elevancehealth.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 2129109 - Disclosure - Medical Claims Payable Sheet http://www.elevancehealth.com/role/MedicalClaimsPayable Medical Claims Payable Notes 16 false false R17.htm 2135110 - Disclosure - Debt Sheet http://www.elevancehealth.com/role/Debt Debt Notes 17 false false R18.htm 2139111 - Disclosure - Commitments And Contingencies Sheet http://www.elevancehealth.com/role/CommitmentsAndContingencies Commitments And Contingencies Notes 18 false false R19.htm 2141112 - Disclosure - Capital Stock Sheet http://www.elevancehealth.com/role/CapitalStock Capital Stock Notes 19 false false R20.htm 2150113 - Disclosure - Accumulated Other Comprehensive Loss Sheet http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLoss Accumulated Other Comprehensive Loss Notes 20 false false R21.htm 2153114 - Disclosure - Earnings Per Share Sheet http://www.elevancehealth.com/role/EarningsPerShare Earnings Per Share Notes 21 false false R22.htm 2157115 - Disclosure - Segment Information Sheet http://www.elevancehealth.com/role/SegmentInformation Segment Information Notes 22 false false R23.htm 2164116 - Disclosure - Leases Sheet http://www.elevancehealth.com/role/Leases Leases Notes 23 false false R24.htm 2169117 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.elevancehealth.com/role/GoodwillandOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 24 false false R25.htm 2204201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://www.elevancehealth.com/role/BasisOfPresentationandSignificantAccountingPolicies 25 false false R26.htm 2309301 - Disclosure - Business Optimization Initiatives (Tables) Sheet http://www.elevancehealth.com/role/BusinessOptimizationInitiativesTables Business Optimization Initiatives (Tables) Tables http://www.elevancehealth.com/role/BusinessOptimizationInitiatives 26 false false R27.htm 2312302 - Disclosure - Investments (Tables) Sheet http://www.elevancehealth.com/role/InvestmentsTables Investments (Tables) Tables http://www.elevancehealth.com/role/Investments 27 false false R28.htm 2322303 - Disclosure - Fair Value (Tables) Sheet http://www.elevancehealth.com/role/FairValueTables Fair Value (Tables) Tables http://www.elevancehealth.com/role/FairValue 28 false false R29.htm 2330304 - Disclosure - Medical Claims Payable (Tables) Sheet http://www.elevancehealth.com/role/MedicalClaimsPayableTables Medical Claims Payable (Tables) Tables http://www.elevancehealth.com/role/MedicalClaimsPayable 29 false false R30.htm 2336305 - Disclosure - Debt (Tables) Sheet http://www.elevancehealth.com/role/DebtTables Debt (Tables) Tables http://www.elevancehealth.com/role/Debt 30 false false R31.htm 2342306 - Disclosure - Capital Stock (Tables) Sheet http://www.elevancehealth.com/role/CapitalStockTables Capital Stock (Tables) Tables http://www.elevancehealth.com/role/CapitalStock 31 false false R32.htm 2351307 - Disclosure - Accumulated Other Comprehensive Loss (Tables) Sheet http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Tables) Tables http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLoss 32 false false R33.htm 2354308 - Disclosure - Earnings Per Share (Tables) Sheet http://www.elevancehealth.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.elevancehealth.com/role/EarningsPerShare 33 false false R34.htm 2358309 - Disclosure - Segment Information (Tables) Sheet http://www.elevancehealth.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.elevancehealth.com/role/SegmentInformation 34 false false R35.htm 2365310 - Disclosure - Leases (Tables) Sheet http://www.elevancehealth.com/role/LeasesTables Leases (Tables) Tables http://www.elevancehealth.com/role/Leases 35 false false R36.htm 2370311 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://www.elevancehealth.com/role/GoodwillandOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://www.elevancehealth.com/role/GoodwillandOtherIntangibleAssets 36 false false R37.htm 2402401 - Disclosure - Organization (Details) Sheet http://www.elevancehealth.com/role/OrganizationDetails Organization (Details) Details http://www.elevancehealth.com/role/Organization 37 false false R38.htm 2405402 - Disclosure - Basis of Presentation and Signficant Accounting Policies Basis of Presentation and Significant Acconting Policies (Details) Sheet http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails Basis of Presentation and Signficant Accounting Policies Basis of Presentation and Significant Acconting Policies (Details) Details 38 false false R39.htm 2407403 - Disclosure - Business Acquisitions Business Acquisition (Assets Liabilities Acquired) (Details) Sheet http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails Business Acquisitions Business Acquisition (Assets Liabilities Acquired) (Details) Details 39 false false R40.htm 2410404 - Disclosure - Business Optimization Initiatives (Employee Termination Costs) (Details) Sheet http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails Business Optimization Initiatives (Employee Termination Costs) (Details) Details http://www.elevancehealth.com/role/BusinessOptimizationInitiativesTables 40 false false R41.htm 2413405 - Disclosure - Investments (Current And Long-Term Fixed Maturity Securities, Available-For-Sale) (Details) Sheet http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails Investments (Current And Long-Term Fixed Maturity Securities, Available-For-Sale) (Details) Details http://www.elevancehealth.com/role/InvestmentsTables 41 false false R42.htm 2414406 - Disclosure - Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details) Sheet http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details) Details http://www.elevancehealth.com/role/InvestmentsTables 42 false false R43.htm 2415407 - Disclosure - Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details) Sheet http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details) Details http://www.elevancehealth.com/role/InvestmentsTables 43 false false R44.htm 2416408 - Disclosure - Investments (Current Equity Securities) (Details) Sheet http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails Investments (Current Equity Securities) (Details) Details http://www.elevancehealth.com/role/InvestmentsTables 44 false false R45.htm 2417409 - Disclosure - Investments (Net Investment Gains/Losses) (Details) Sheet http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails Investments (Net Investment Gains/Losses) (Details) Details http://www.elevancehealth.com/role/InvestmentsTables 45 false false R46.htm 2418410 - Disclosure - Investments (Narrative) (Details) Sheet http://www.elevancehealth.com/role/InvestmentsNarrativeDetails Investments (Narrative) (Details) Details http://www.elevancehealth.com/role/InvestmentsTables 46 false false R47.htm 2420411 - Disclosure - Derivative Financial Instruments (Financial Statement Narrative) (Details) Sheet http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails Derivative Financial Instruments (Financial Statement Narrative) (Details) Details http://www.elevancehealth.com/role/DerivativeFinancialInstruments 47 false false R48.htm 2423412 - Disclosure - Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details) Sheet http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details) Details http://www.elevancehealth.com/role/FairValueTables 48 false false R49.htm 2424413 - Disclosure - Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details) Sheet http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details) Details http://www.elevancehealth.com/role/FairValueTables 49 false false R50.htm 2425414 - Disclosure - Fair Value (Carrying And Estimated Fair Values by Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details) Sheet http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails Fair Value (Carrying And Estimated Fair Values by Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details) Details http://www.elevancehealth.com/role/FairValueTables 50 false false R51.htm 2428416 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) Details http://www.elevancehealth.com/role/IncomeTaxes 51 false false R52.htm 2431417 - Disclosure - Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable By Segment) (Details) Sheet http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable By Segment) (Details) Details http://www.elevancehealth.com/role/MedicalClaimsPayableTables 52 false false R53.htm 2432418 - Disclosure - Medical Claims Payable (Reconciliation Of Net Incurred Medical Claims To Benefit Expense) (Details) Sheet http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails Medical Claims Payable (Reconciliation Of Net Incurred Medical Claims To Benefit Expense) (Details) Details http://www.elevancehealth.com/role/MedicalClaimsPayableTables 53 false false R54.htm 2433419 - Disclosure - Medical Claims Payable Medical Claims Payable (Reconciliation of the Claims Development to the Claims Liability) (Details) Sheet http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails Medical Claims Payable Medical Claims Payable (Reconciliation of the Claims Development to the Claims Liability) (Details) Details 54 false false R55.htm 2434420 - Disclosure - Medical Claims Payable (Narrative) (Details) Sheet http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails Medical Claims Payable (Narrative) (Details) Details http://www.elevancehealth.com/role/MedicalClaimsPayableTables 55 false false R56.htm 2437421 - Disclosure - Debt (Convertible Debenture Details) (Details) Sheet http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails Debt (Convertible Debenture Details) (Details) Details http://www.elevancehealth.com/role/DebtTables 56 false false R57.htm 2438422 - Disclosure - Debt (Narrative) (Details) Sheet http://www.elevancehealth.com/role/DebtNarrativeDetails Debt (Narrative) (Details) Details http://www.elevancehealth.com/role/DebtTables 57 false false R58.htm 2440423 - Disclosure - Commitments And Contingencies (Details) Sheet http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails Commitments And Contingencies (Details) Details http://www.elevancehealth.com/role/CommitmentsAndContingencies 58 false false R59.htm 2443424 - Disclosure - Capital Stock (Summary of Cash Dividend Activity) (Details) Sheet http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails Capital Stock (Summary of Cash Dividend Activity) (Details) Details http://www.elevancehealth.com/role/CapitalStockTables 59 false false R60.htm 2444425 - Disclosure - Capital Stock (Summary of Share Repurchases) (Details) Sheet http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails Capital Stock (Summary of Share Repurchases) (Details) Details http://www.elevancehealth.com/role/CapitalStockTables 60 false false R61.htm 2445426 - Disclosure - Capital Stock (Summary of Stock Option Activity) (Details) Sheet http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails Capital Stock (Summary of Stock Option Activity) (Details) Details http://www.elevancehealth.com/role/CapitalStockTables 61 false false R62.htm 2446427 - Disclosure - Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details) Sheet http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details) Details http://www.elevancehealth.com/role/CapitalStockTables 62 false false R63.htm 2447428 - Disclosure - Capital Stock (Fair Values of Options Granted During The Period Estimated Using Weighted-Average Assumptions) (Details) Sheet http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringThePeriodEstimatedUsingWeightedAverageAssumptionsDetails Capital Stock (Fair Values of Options Granted During The Period Estimated Using Weighted-Average Assumptions) (Details) Details http://www.elevancehealth.com/role/CapitalStockTables 63 false false R64.htm 2448429 - Disclosure - Capital Stock (Schedule Of Weighted-Average Fair Values Determined For The Periods) (Details) Sheet http://www.elevancehealth.com/role/CapitalStockScheduleOfWeightedAverageFairValuesDeterminedForThePeriodsDetails Capital Stock (Schedule Of Weighted-Average Fair Values Determined For The Periods) (Details) Details http://www.elevancehealth.com/role/CapitalStockTables 64 false false R65.htm 2449430 - Disclosure - Capital Stock (Narrative) (Details) Sheet http://www.elevancehealth.com/role/CapitalStockNarrativeDetails Capital Stock (Narrative) (Details) Details http://www.elevancehealth.com/role/CapitalStockTables 65 false false R66.htm 2452431 - Disclosure - Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details) Sheet http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details) Details http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossTables 66 false false R67.htm 2455432 - Disclosure - Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details) Sheet http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details) Details http://www.elevancehealth.com/role/EarningsPerShareTables 67 false false R68.htm 2456433 - Disclosure - Earnings Per Share (Narrative) (Details) Sheet http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails Earnings Per Share (Narrative) (Details) Details http://www.elevancehealth.com/role/EarningsPerShareTables 68 false false R69.htm 2459434 - Disclosure - Segment Information (Financial Data By Reportable Segment) (Details) Sheet http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails Segment Information (Financial Data By Reportable Segment) (Details) Details http://www.elevancehealth.com/role/SegmentInformationTables 69 false false R70.htm 2460435 - Disclosure - Segment Information Segment Information (Major Product Revenues for Each Reportable Segment) (Details) Sheet http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails Segment Information Segment Information (Major Product Revenues for Each Reportable Segment) (Details) Details 70 false false R71.htm 2461436 - Disclosure - Segment Information (Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income) (Details) Sheet http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentsOperatingRevenuesToTotalRevenuesReportedInTheConsolidatedStatementsOfIncomeDetails Segment Information (Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income) (Details) Details http://www.elevancehealth.com/role/SegmentInformationTables 71 false false R72.htm 2462437 - Disclosure - Segment Information (Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income) (Details) Sheet http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails Segment Information (Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income) (Details) Details http://www.elevancehealth.com/role/SegmentInformationTables 72 false false R73.htm 2463438 - Disclosure - Segment Information Segment Information (Narrative) (Details) Sheet http://www.elevancehealth.com/role/SegmentInformationSegmentInformationNarrativeDetails Segment Information Segment Information (Narrative) (Details) Details 73 false false R74.htm 2466439 - Disclosure - Leases (Lease and Other Information) (Details) Sheet http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails Leases (Lease and Other Information) (Details) Details http://www.elevancehealth.com/role/LeasesTables 74 false false R75.htm 2467440 - Disclosure - Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details) Sheet http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details) Details http://www.elevancehealth.com/role/LeasesTables 75 false false R76.htm 2468441 - Disclosure - Leases (Narrative) (Details) Sheet http://www.elevancehealth.com/role/LeasesNarrativeDetails Leases (Narrative) (Details) Details http://www.elevancehealth.com/role/LeasesTables 76 false false R77.htm 2471442 - Disclosure - Goodwill And Other Intangible Assets (Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment) (Details) Sheet http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails Goodwill And Other Intangible Assets (Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment) (Details) Details 77 false false R78.htm 2472443 - Disclosure - Goodwill And Other Intangible Assets (Components Of Other Intangible Assets) (Details) Sheet http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails Goodwill And Other Intangible Assets (Components Of Other Intangible Assets) (Details) Details 78 false false R79.htm 2473444 - Disclosure - Goodwill And Other Intangible Assets (Narrative) (Details) Sheet http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails Goodwill And Other Intangible Assets (Narrative) (Details) Details 79 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 24 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent, us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent, us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent, us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding - elv-20220930.htm 4 elv-20220930.htm elv-20220930.xsd elv-20220930_cal.xml elv-20220930_def.xml elv-20220930_lab.xml elv-20220930_pre.xml exhibit311-20220930q32022.htm exhibit312-20220930q32022.htm exhibit321-20220930q32022.htm exhibit322-20220930q32022.htm elv-20220930_g1.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 98 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "elv-20220930.htm": { "axisCustom": 1, "axisStandard": 27, "contextCount": 569, "dts": { "calculationLink": { "local": [ "elv-20220930_cal.xml" ] }, "definitionLink": { "local": [ "elv-20220930_def.xml" ] }, "inline": { "local": [ "elv-20220930.htm" ] }, "labelLink": { "local": [ "elv-20220930_lab.xml" ] }, "presentationLink": { "local": [ "elv-20220930_pre.xml" ] }, "schema": { "local": [ "elv-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 683, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 30, "http://xbrl.sec.gov/dei/2022": 5, "total": 35 }, "keyCustom": 34, "keyStandard": 384, "memberCustom": 30, "memberStandard": 54, "nsprefix": "elv", "nsuri": "http://www.elevancehealth.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document And Entity Information Document", "role": "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument", "shortName": "Document And Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106103 - Disclosure - Business Acquisitions", "role": "http://www.elevancehealth.com/role/BusinessAcquisitions", "shortName": "Business Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108104 - Disclosure - Business Optimization Initiatives", "role": "http://www.elevancehealth.com/role/BusinessOptimizationInitiatives", "shortName": "Business Optimization Initiatives", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111105 - Disclosure - Investments", "role": "http://www.elevancehealth.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119106 - Disclosure - Derivative Financial Instruments", "role": "http://www.elevancehealth.com/role/DerivativeFinancialInstruments", "shortName": "Derivative Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121107 - Disclosure - Fair Value", "role": "http://www.elevancehealth.com/role/FairValue", "shortName": "Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127108 - Disclosure - Income Taxes", "role": "http://www.elevancehealth.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129109 - Disclosure - Medical Claims Payable", "role": "http://www.elevancehealth.com/role/MedicalClaimsPayable", "shortName": "Medical Claims Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135110 - Disclosure - Debt", "role": "http://www.elevancehealth.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139111 - Disclosure - Commitments And Contingencies", "role": "http://www.elevancehealth.com/role/CommitmentsAndContingencies", "shortName": "Commitments And Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2141112 - Disclosure - Capital Stock", "role": "http://www.elevancehealth.com/role/CapitalStock", "shortName": "Capital Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Consolidated Balance Sheets", "role": "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2150113 - Disclosure - Accumulated Other Comprehensive Loss", "role": "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLoss", "shortName": "Accumulated Other Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2153114 - Disclosure - Earnings Per Share", "role": "http://www.elevancehealth.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2157115 - Disclosure - Segment Information", "role": "http://www.elevancehealth.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2164116 - Disclosure - Leases", "role": "http://www.elevancehealth.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2169117 - Disclosure - Goodwill and Other Intangible Assets", "role": "http://www.elevancehealth.com/role/GoodwillandOtherIntangibleAssets", "shortName": "Goodwill and Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)", "role": "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Business Optimization Initiatives (Tables)", "role": "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesTables", "shortName": "Business Optimization Initiatives (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312302 - Disclosure - Investments (Tables)", "role": "http://www.elevancehealth.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322303 - Disclosure - Fair Value (Tables)", "role": "http://www.elevancehealth.com/role/FairValueTables", "shortName": "Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330304 - Disclosure - Medical Claims Payable (Tables)", "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableTables", "shortName": "Medical Claims Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2336305 - Disclosure - Debt (Tables)", "role": "http://www.elevancehealth.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2342306 - Disclosure - Capital Stock (Tables)", "role": "http://www.elevancehealth.com/role/CapitalStockTables", "shortName": "Capital Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2351307 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "role": "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossTables", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2354308 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.elevancehealth.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2358309 - Disclosure - Segment Information (Tables)", "role": "http://www.elevancehealth.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2365310 - Disclosure - Leases (Tables)", "role": "http://www.elevancehealth.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2370311 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "role": "http://www.elevancehealth.com/role/GoodwillandOtherIntangibleAssetsTables", "shortName": "Goodwill and Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "elv:NumberOfMedicalMembersServed", "reportCount": 1, "unique": true, "unitRef": "medical_member", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Organization (Details)", "role": "http://www.elevancehealth.com/role/OrganizationDetails", "shortName": "Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "elv:NumberOfMedicalMembersServed", "reportCount": 1, "unique": true, "unitRef": "medical_member", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashAndInvestmentsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Basis of Presentation and Signficant Accounting Policies Basis of Presentation and Significant Acconting Policies (Details)", "role": "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails", "shortName": "Basis of Presentation and Signficant Accounting Policies Basis of Presentation and Significant Acconting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashAndInvestmentsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Business Acquisitions Business Acquisition (Assets Liabilities Acquired) (Details)", "role": "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails", "shortName": "Business Acquisitions Business Acquisition (Assets Liabilities Acquired) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PremiumsEarnedNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Consolidated Statements Of Income", "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "shortName": "Consolidated Statements Of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PremiumsEarnedNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i3ce8730226514909b48e611420368522_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Business Optimization Initiatives (Employee Termination Costs) (Details)", "role": "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails", "shortName": "Business Optimization Initiatives (Employee Termination Costs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i3ce8730226514909b48e611420368522_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - Investments (Current And Long-Term Fixed Maturity Securities, Available-For-Sale) (Details)", "role": "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "shortName": "Investments (Current And Long-Term Fixed Maturity Securities, Available-For-Sale) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "ic06c4cd0bfbf4349bb38d37c2a08f1d5_I20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "securities", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details)", "role": "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "shortName": "Investments (Aggregate Fair Value And Gross Unrealized Loss Of Fixed Maturity Securities In An Unrealized Loss Position) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "ic06c4cd0bfbf4349bb38d37c2a08f1d5_I20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "securities", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415407 - Disclosure - Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details)", "role": "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "shortName": "Investments (Amortized Cost And Fair Value Of Fixed Maturity Securities, By Contractual Maturity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416408 - Disclosure - Investments (Current Equity Securities) (Details)", "role": "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails", "shortName": "Investments (Current Equity Securities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "elv:InvestmentsinequitysecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i4fddf0df137b450988ab2a4425925e2c_I20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "elv:InvestmentGainsLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417409 - Disclosure - Investments (Net Investment Gains/Losses) (Details)", "role": "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails", "shortName": "Investments (Net Investment Gains/Losses) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "elv:InvestmentGainsLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccruedInvestmentIncomeReceivable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418410 - Disclosure - Investments (Narrative) (Details)", "role": "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails", "shortName": "Investments (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "if060cd6ed5574a068397b3bc9ec5ac0c_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AccruedInvestmentIncomeReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420411 - Disclosure - Derivative Financial Instruments (Financial Statement Narrative) (Details)", "role": "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails", "shortName": "Derivative Financial Instruments (Financial Statement Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423412 - Disclosure - Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details)", "role": "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "shortName": "Fair Value (Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "ia0a535c1ffe84e6da717792a25f25e09_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424413 - Disclosure - Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details)", "role": "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails", "shortName": "Fair Value (Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "ia0a535c1ffe84e6da717792a25f25e09_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "elv:Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherLongTermInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425414 - Disclosure - Fair Value (Carrying And Estimated Fair Values by Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details)", "role": "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "shortName": "Fair Value (Carrying And Estimated Fair Values by Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "elv:CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428416 - Disclosure - Income Taxes (Narrative) (Details)", "role": "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "if060cd6ed5574a068397b3bc9ec5ac0c_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431417 - Disclosure - Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable By Segment) (Details)", "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails", "shortName": "Medical Claims Payable (Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable By Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "elv:ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432418 - Disclosure - Medical Claims Payable (Reconciliation Of Net Incurred Medical Claims To Benefit Expense) (Details)", "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails", "shortName": "Medical Claims Payable (Reconciliation Of Net Incurred Medical Claims To Benefit Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "elv:ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:SupplementaryInsuranceInformationOtherOperatingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433419 - Disclosure - Medical Claims Payable Medical Claims Payable (Reconciliation of the Claims Development to the Claims Liability) (Details)", "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "shortName": "Medical Claims Payable Medical Claims Payable (Reconciliation of the Claims Development to the Claims Liability) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "ic61874748541445bb5346014604b1e2f_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434420 - Disclosure - Medical Claims Payable (Narrative) (Details)", "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails", "shortName": "Medical Claims Payable (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "ic61874748541445bb5346014604b1e2f_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "elv:CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437421 - Disclosure - Debt (Convertible Debenture Details) (Details)", "role": "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails", "shortName": "Debt (Convertible Debenture Details) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id074490de8a844b3947b679412d173b1_I20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438422 - Disclosure - Debt (Narrative) (Details)", "role": "http://www.elevancehealth.com/role/DebtNarrativeDetails", "shortName": "Debt (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i8956e0659bb44abdac0434240d851087_D20220101-20220930", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentCovenantDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyEstimateOfPossibleLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440423 - Disclosure - Commitments And Contingencies (Details)", "role": "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments And Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyEstimateOfPossibleLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsPayableDateDeclaredDayMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443424 - Disclosure - Capital Stock (Summary of Cash Dividend Activity) (Details)", "role": "http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails", "shortName": "Capital Stock (Summary of Cash Dividend Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsPayableDateDeclaredDayMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Consolidated Statements Of Cash Flows", "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements Of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444425 - Disclosure - Capital Stock (Summary of Share Repurchases) (Details)", "role": "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails", "shortName": "Capital Stock (Summary of Share Repurchases) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "2", "lang": "en-US", "name": "elv:StockRepurchasedAndRetiredDuringPeriodAveragePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "if060cd6ed5574a068397b3bc9ec5ac0c_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445426 - Disclosure - Capital Stock (Summary of Stock Option Activity) (Details)", "role": "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails", "shortName": "Capital Stock (Summary of Stock Option Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "if060cd6ed5574a068397b3bc9ec5ac0c_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "if060cd6ed5574a068397b3bc9ec5ac0c_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446427 - Disclosure - Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details)", "role": "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails", "shortName": "Capital Stock (Nonvested Restricted Stock Activity Including Restricted Stock Units) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "if060cd6ed5574a068397b3bc9ec5ac0c_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447428 - Disclosure - Capital Stock (Fair Values of Options Granted During The Period Estimated Using Weighted-Average Assumptions) (Details)", "role": "http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringThePeriodEstimatedUsingWeightedAverageAssumptionsDetails", "shortName": "Capital Stock (Fair Values of Options Granted During The Period Estimated Using Weighted-Average Assumptions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448429 - Disclosure - Capital Stock (Schedule Of Weighted-Average Fair Values Determined For The Periods) (Details)", "role": "http://www.elevancehealth.com/role/CapitalStockScheduleOfWeightedAverageFairValuesDeterminedForThePeriodsDetails", "shortName": "Capital Stock (Schedule Of Weighted-Average Fair Values Determined For The Periods) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendPayableDateToBePaidDayMonthAndYear", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449430 - Disclosure - Capital Stock (Narrative) (Details)", "role": "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "shortName": "Capital Stock (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i90083e53041c4397abce83d13efa37ae_I20210126", "decimals": "-6", "lang": "en-US", "name": "elv:IncreaseInStockRepurchaseProgramAuthorization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "ia0a535c1ffe84e6da717792a25f25e09_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452431 - Disclosure - Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details)", "role": "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "shortName": "Accumulated Other Comprehensive Loss (Reconciliation Of The Components Of Accumulated Other Comprehensive Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455432 - Disclosure - Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details)", "role": "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails", "shortName": "Earnings Per Share (Denominator For Basic And Diluted Earnings Per Share) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456433 - Disclosure - Earnings Per Share (Narrative) (Details)", "role": "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails", "shortName": "Earnings Per Share (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "elv:MajorProductRevenueBySegmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InsuranceServicesRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459434 - Disclosure - Segment Information (Financial Data By Reportable Segment) (Details)", "role": "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails", "shortName": "Segment Information (Financial Data By Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id8f86bdb8cf2469aa0b7d726398ab429_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9bcdceadaae34b568b184717c1feb64d_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Consolidated Statements Of Changes in Equity", "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "shortName": "Consolidated Statements Of Changes in Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i3fe61236f9a84e4fb0548f191cf989dd_D20210101-20210331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "elv:MajorProductRevenueBySegmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InsuranceServicesRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460435 - Disclosure - Segment Information Segment Information (Major Product Revenues for Each Reportable Segment) (Details)", "role": "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails", "shortName": "Segment Information Segment Information (Major Product Revenues for Each Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "elv:MajorProductRevenueBySegmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9adaeacf598a42c3b72b8540b126e10b_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:InsuranceServicesRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "elv:MajorProductRevenueBySegmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InsuranceServicesRevenue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461436 - Disclosure - Segment Information (Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income) (Details)", "role": "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentsOperatingRevenuesToTotalRevenuesReportedInTheConsolidatedStatementsOfIncomeDetails", "shortName": "Segment Information (Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "id7416b92a0f24b5285865ba00fcbd376_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462437 - Disclosure - Segment Information (Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income) (Details)", "role": "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails", "shortName": "Segment Information (Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R73": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463438 - Disclosure - Segment Information Segment Information (Narrative) (Details)", "role": "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationNarrativeDetails", "shortName": "Segment Information Segment Information (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2466439 - Disclosure - Leases (Lease and Other Information) (Details)", "role": "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails", "shortName": "Leases (Lease and Other Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "if060cd6ed5574a068397b3bc9ec5ac0c_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467440 - Disclosure - Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details)", "role": "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails", "shortName": "Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468441 - Disclosure - Leases (Narrative) (Details)", "role": "http://www.elevancehealth.com/role/LeasesNarrativeDetails", "shortName": "Leases (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9aceaf2b19bf4d5d916eb0f2039e41de_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2471442 - Disclosure - Goodwill And Other Intangible Assets (Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment) (Details)", "role": "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails", "shortName": "Goodwill And Other Intangible Assets (Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GoodwillPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PresentValueOfFutureInsuranceProfitsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2472443 - Disclosure - Goodwill And Other Intangible Assets (Components Of Other Intangible Assets) (Details)", "role": "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails", "shortName": "Goodwill And Other Intangible Assets (Components Of Other Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PresentValueOfFutureInsuranceProfitsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i578c5a2ae22d4fcf8e5f4f5f45ccf5f7_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2473444 - Disclosure - Goodwill And Other Intangible Assets (Narrative) (Details)", "role": "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails", "shortName": "Goodwill And Other Intangible Assets (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization", "role": "http://www.elevancehealth.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Basis Of Presentation and Significant Accounting Policies", "role": "http://www.elevancehealth.com/role/BasisOfPresentationandSignificantAccountingPolicies", "shortName": "Basis Of Presentation and Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elv-20220930.htm", "contextRef": "i9607c090bb1947fcbddd65a1fbc6aae4_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 92, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r802" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r803" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r800" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r800" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r800" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r812" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r800" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r800" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r800" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r800" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r799" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r801" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "elv_A2021364DayFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 364-Day Facility [Member]", "label": "2021 364-Day Facility [Member]", "terseLabel": "2021 364-Day Facility [Member]" } } }, "localname": "A2021364DayFacilityMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_A2021To2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 to 2023", "label": "2021 to 2023 [Member]", "terseLabel": "2021 to 2023 [Member]" } } }, "localname": "A2021To2023Member", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_A2022To2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 to 2024", "label": "2022 to 2024 [Member]", "terseLabel": "2022 to 2024", "verboseLabel": "2022 to 2024 [Member]" } } }, "localname": "A2022To2024Member", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_A5YearFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5-Year Facility [Member]", "label": "5-Year Facility [Member]", "terseLabel": "5-Year Facility [Member]" } } }, "localname": "A5YearFacilityMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_AccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies [Line Items]", "label": "Accounting Policies [Line Items]", "terseLabel": "Accounting Policies [Line Items]" } } }, "localname": "AccountingPoliciesLineItems", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails" ], "xbrltype": "stringItemType" }, "elv_AccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies", "label": "Accounting Policies [Table]", "terseLabel": "Accounting Policies [Table]" } } }, "localname": "AccountingPoliciesTable", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails" ], "xbrltype": "stringItemType" }, "elv_AffiliatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Affiliated [Member]", "label": "Affiliated [Member]", "terseLabel": "Affiliated [Member]" } } }, "localname": "AffiliatedMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_AnthemInc.v.ExpressScriptsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Anthem, Inc. v. Express Scripts, Inc. [Member]", "label": "Anthem, Inc. v. Express Scripts, Inc. [Member]", "terseLabel": "Anthem, Inc. v. Express Scripts, Inc. [Member]" } } }, "localname": "AnthemInc.v.ExpressScriptsInc.Member", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "elv_BCBSAntitrustLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BCBS Antitrust Litigation [Member]", "label": "BCBS Antitrust Litigation [Member]", "terseLabel": "BCBS Antitrust Litigation [Member]" } } }, "localname": "BCBSAntitrustLitigationMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "elv_BusinessOptimizationInitiativesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Optimization Initiatives", "label": "Business Optimization Initiatives [Abstract]" } } }, "localname": "BusinessOptimizationInitiativesAbstract", "nsuri": "http://www.elevancehealth.com/20220930", "xbrltype": "stringItemType" }, "elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet [Table Text Block]", "terseLabel": "Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet" } } }, "localname": "CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "elv_Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in non-credit component of impairment losses on investments, net of tax effect.", "label": "Change in non-credit component of impairment losses on investments net of tax", "terseLabel": "Change in non-credit component of impairment losses on investments" } } }, "localname": "Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "elv_CommercialPaperMaximumBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Commercial Paper, Maximum Borrowing Capacity", "label": "Commercial Paper Maximum Borrowing Capacity", "terseLabel": "Commercial paper authorized" } } }, "localname": "CommercialPaperMaximumBorrowingCapacity", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elv_CommercialSpecialtyBusinessSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial and Specialty Business Segment", "label": "Commercial & Specialty Business Segment [Member]", "terseLabel": "Commercial & Specialty Business Segment [Member]" } } }, "localname": "CommercialSpecialtyBusinessSegmentMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails", "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_CommercialSpecialtyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial & Specialty [Member]", "label": "Commercial Specialty [Member]", "verboseLabel": "Commercial & Specialty [Member]" } } }, "localname": "CommercialSpecialtyMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments And Contingencies [Line Items]", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "elv_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies [Table].", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "elv_CommonEquitySecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Equity Securities [Member]", "label": "Common Equity Securities [Member]", "terseLabel": "Common Equity Securities [Member]" } } }, "localname": "CommonEquitySecuritiesMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "xbrltype": "domainItemType" }, "elv_DebtConversionDebtPrincipalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate principal amount of the original debt instrument that was surrendered for conversion.", "label": "Debt Conversion Debt Principal Amount", "terseLabel": "Debt Conversion Debt Principal Amount" } } }, "localname": "DebtConversionDebtPrincipalAmount", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elv_DentalVisionProductsAndServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dental Vision Products And Services [Member]", "label": "Dental Vision Products And Services [Member]", "terseLabel": "Dental Vision Products And Services [Member]" } } }, "localname": "DentalVisionProductsAndServicesMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_EquitySecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investments in equity securities.", "label": "Equity Securities", "terseLabel": "Equity Securities" } } }, "localname": "EquitySecurities", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "elv_FiniteLivedIntangibleAssetExpectedAmortizationYearSix": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Asset, Expected Amortization, Year Six", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Six", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, 2027" } } }, "localname": "FiniteLivedIntangibleAssetExpectedAmortizationYearSix", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elv_FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Point Five Five Zero Due Two Thousand Fifty Two", "label": "Four Point Five Five Zero Due Two Thousand Fifty Two [Member]", "terseLabel": "Four Point Five Five Zero Due Two Thousand Fifty Two [Member]" } } }, "localname": "FourPointFiveFiveZeroDueTwoThousandFiftyTwoMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_FourPointOneZeroPercentDueTwoThousandThirtyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Point One Zero Percent Due Two Thousand Thirty Two", "label": "Four Point One Zero Percent Due Two Thousand Thirty Two [Member]", "terseLabel": "Four Point One Zero Percent Due Two Thousand Thirty Two [Member]" } } }, "localname": "FourPointOneZeroPercentDueTwoThousandThirtyTwoMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_GainsFromOtherInvestments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gains From Other Investments", "label": "Gains From Other Investments", "terseLabel": "Gross gains" } } }, "localname": "GainsFromOtherInvestments", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "elv_GovernmentBusinessSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government Business Segment", "label": "Government Business Segment [Member]", "terseLabel": "Government Business Segment [Member]", "verboseLabel": "Government Business [Member]" } } }, "localname": "GovernmentBusinessSegmentMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails", "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_GrossLossesFromOtherInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross Losses From Other Investments", "label": "Gross Losses From Other Investments", "negatedTerseLabel": "Gross losses" } } }, "localname": "GrossLossesFromOtherInvestments", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "elv_GrossPremiumTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross premium tax rate", "label": "Gross Premium Tax Rate", "terseLabel": "Gross premium tax rate, state of California" } } }, "localname": "GrossPremiumTaxRate", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "elv_Impairmentlossesreversalsoninvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total impairment (losses) reversals on investments, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Impairment (losses) reversals on investments", "negatedTerseLabel": "Impairment (losses) recoveries recognized in income" } } }, "localname": "Impairmentlossesreversalsoninvestments", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "elv_IncreaseInStockRepurchaseProgramAuthorization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an increase authorized by an entity's Board of Directors to a previously authorized stock repurchase program.", "label": "Increase In Stock Repurchase Program Authorization", "terseLabel": "Increase In Stock Repurchase Program Authorization" } } }, "localname": "IncreaseInStockRepurchaseProgramAuthorization", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elv_IngenioRxSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IngenioRx Segment [Member]", "label": "IngenioRx Segment [Member]", "terseLabel": "IngenioRx Segment [Member]" } } }, "localname": "IngenioRxSegmentMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails", "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Intangible Assets Accumulated Amortization Excluding Goodwill", "label": "Intangible Assets Accumulated Amortization Excluding Goodwill", "negatedTerseLabel": "Accumulated Amortization, Total Intangible Assets" } } }, "localname": "IntangibleAssetsAccumulatedAmortizationExcludingGoodwill", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "elv_IntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Assets", "label": "Intangible Assets [Line Items]", "terseLabel": "Intangible Assets [Line Items]" } } }, "localname": "IntangibleAssetsLineItems", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "elv_IntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Assets", "label": "Intangible Assets [Table]", "terseLabel": "Intangible Assets [Table]" } } }, "localname": "IntangibleAssetsTable", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "elv_IntegraManagedCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Integra Managed Care", "label": "Integra Managed Care [Member]", "terseLabel": "Integra Managed Care [Member]" } } }, "localname": "IntegraManagedCareMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "domainItemType" }, "elv_IntegratedHealthServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Integrated health services", "label": "Integrated health services [Member]", "terseLabel": "Integrated health services" } } }, "localname": "IntegratedHealthServicesMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_InvestmentGainsLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment Gains (Losses)", "label": "Investment Gains (Losses)", "verboseLabel": "Net (losses) gains on investments" } } }, "localname": "InvestmentGainsLosses", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "elv_InvestmentsinequitysecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments in equity securities [Table Text Block]", "label": "Investments in equity securities [Table Text Block]", "terseLabel": "Investments In Equity Securities" } } }, "localname": "InvestmentsinequitysecuritiesTableTextBlock", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "elv_LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reconciliation of future lease payments to total lease liabilities.", "label": "Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) [Abstract]", "terseLabel": "Leases (Reconciliation of Future Lease Payments to Total Lease Liabilities) [Abstract]" } } }, "localname": "LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesAbstract", "nsuri": "http://www.elevancehealth.com/20220930", "xbrltype": "stringItemType" }, "elv_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments", "label": "Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments", "terseLabel": "Business combinations and purchase adjustments" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "elv_MajorProductRevenueBySegmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Major Product Revenue By Segment [Table]", "label": "Major Product Revenue By Segment [Line Items]", "terseLabel": "Major Product Revenue By Segment [Line Items]" } } }, "localname": "MajorProductRevenueBySegmentLineItems", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "elv_MajorProductRevenueBySegmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Major Product Revenue By Segment [Table]", "label": "Major Product Revenue By Segment [Table]", "terseLabel": "Major Product Revenue By Segment [Table]" } } }, "localname": "MajorProductRevenueBySegmentTable", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "elv_MajorProductRevenueBySegmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Table Text Block] for Major Product Revenue By Segment [Table]", "label": "Major Product Revenue By Segment [Table Text Block]", "terseLabel": "Major Product Revenue by Segment" } } }, "localname": "MajorProductRevenueBySegmentTableTextBlock", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "elv_ManagedCareProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Managed Care Products [Member]", "label": "Managed Care Products [Member]", "terseLabel": "Managed Care Products [Member]" } } }, "localname": "ManagedCareProductsMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_ManagedCareServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Managed Care Services [Member]", "label": "Managed Care Services [Member]", "terseLabel": "Managed Care Services [Member]" } } }, "localname": "ManagedCareServicesMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) [Abstract]", "label": "Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) [Abstract]", "terseLabel": "Medical Claims Payable (Reconciliation of Net Incurred Medical Claims to Benefit Expense) [Abstract]" } } }, "localname": "MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseAbstract", "nsuri": "http://www.elevancehealth.com/20220930", "xbrltype": "stringItemType" }, "elv_NetLossesGainsOnFinancialInstruments": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net (losses) gains on financial instruments", "label": "Net (losses) gains on financial instruments", "negatedLabel": "Net losses (gains) on financial instruments", "negatedTerseLabel": "Net losses (gains) on financial instruments", "terseLabel": "Net (losses) gains on financial instruments" } } }, "localname": "NetLossesGainsOnFinancialInstruments", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentsOperatingRevenuesToTotalRevenuesReportedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "elv_NonCreditComponentsOfImpairmentsOnInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-credit components of impairments on investments", "label": "Non-credit components of impairments on investments [Member]", "terseLabel": "Non-credit components of impairments on investments [Member]" } } }, "localname": "NonCreditComponentsOfImpairmentsOnInvestmentsMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "elv_NoncontrollingInterestPeriodIncreaseDecrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest, Period Increase (Decrease)", "label": "Noncontrolling Interest, Period Increase (Decrease)", "terseLabel": "Noncontrolling interests adjustment" } } }, "localname": "NoncontrollingInterestPeriodIncreaseDecrease", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "elv_NumberOfCountiesInStateOfKansasCompanyDoesNotServe": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Counties In The State Of Kansas Company Does Not Serve", "label": "Number Of Counties In State Of Kansas Company Does Not Serve", "terseLabel": "Number of counties in the Kansas City area the Company does not serve" } } }, "localname": "NumberOfCountiesInStateOfKansasCompanyDoesNotServe", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/OrganizationDetails" ], "xbrltype": "integerItemType" }, "elv_NumberOfMedicalMembersServed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of medical members served", "label": "Number Of Medical Members Served", "verboseLabel": "Number of Medical Members" } } }, "localname": "NumberOfMedicalMembersServed", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/OrganizationDetails" ], "xbrltype": "decimalItemType" }, "elv_OperatingRevenue": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from insurance services and products sold.", "label": "Operating Revenue", "totalLabel": "Total operating revenue" } } }, "localname": "OperatingRevenue", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "elv_OperationalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operational [Member]", "label": "Operational [Member]", "terseLabel": "Damages for Operational Breaches [Member]" } } }, "localname": "OperationalMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "elv_OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense", "terseLabel": "Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, tax expense" } } }, "localname": "OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "elv_OtherProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Products [Member]", "label": "Other Products [Member]", "terseLabel": "Other Products [Member]" } } }, "localname": "OtherProductsMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_OtherSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other segment", "label": "Other Segment [Member]", "terseLabel": "Other Segment [Member]", "verboseLabel": "Other [Member]" } } }, "localname": "OtherSegmentMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails", "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_PerformanceMeasurementPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance measurement period [Domain]", "label": "Performance measurement period [Domain]", "terseLabel": "Performance measurement period [Domain]" } } }, "localname": "PerformanceMeasurementPeriodDomain", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_PerformancemeasurementperiodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance measurement period [Axis]", "label": "Performance measurement period [Axis]", "terseLabel": "Performance measurement period [Axis]" } } }, "localname": "PerformancemeasurementperiodAxis", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "elv_PharmacypricingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmacy pricing [Member]", "label": "Pharmacy pricing [Member]", "terseLabel": "Damages for Pharmacy Pricing [Member]" } } }, "localname": "PharmacypricingMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "elv_PharmacyproductsandservicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmacy products and services [Member]", "label": "Pharmacy products and services [Member]", "terseLabel": "Pharmacy products and services [Member]" } } }, "localname": "PharmacyproductsandservicesMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Potentially Dilutive Restricted Stock Units Contingent On Operating Results", "label": "Potentially Dilutive Restricted Stock Units Contingent On Operating Results", "terseLabel": "Restricted stock units excluded from the denominator for diluted earnings per share" } } }, "localname": "PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "elv_Proceedsfromsaleofequityandfixedmaturitysecurities": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of equity and fixed maturity securities.", "label": "Proceeds from sale of equity and fixed maturity securities", "terseLabel": "Proceeds from sale of investments" } } }, "localname": "Proceedsfromsaleofequityandfixedmaturitysecurities", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "elv_ProductRevenue": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "elv_OperatingRevenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold.", "label": "Product Revenue", "terseLabel": "Product revenue" } } }, "localname": "ProductRevenue", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "elv_ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reconciliation Of The Claims Development To The Claims Liability [Abstract]", "label": "Reconciliation Of The Claims Development To The Claims Liability [Abstract]", "terseLabel": "Reconciliation Of The Claims Development To The Claims Liability [Abstract]" } } }, "localname": "ReconciliationOfTheClaimsDevelopmentToTheClaimsLiabilityAbstract", "nsuri": "http://www.elevancehealth.com/20220930", "xbrltype": "stringItemType" }, "elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reconciliation of net incurred medical claims to benefit expense [Table]", "label": "Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table]", "terseLabel": "Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table]" } } }, "localname": "ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTable", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails" ], "xbrltype": "stringItemType" }, "elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular Disclosure For Reconciliation of Net Incurred Medical Claims to Benefit Expense.", "label": "Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table Text Block]", "terseLabel": "Reconciliation of Net Incurred Medical Claims to Benefit Expense" } } }, "localname": "ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableTables" ], "xbrltype": "textBlockItemType" }, "elv_ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Reconciliation of net incurred medical claims to benefit expense [Table]", "label": "reconciliation of net incurred medical claims to benefit expense [Line Items]", "terseLabel": "Reconciliation of net incurred medical claims to benefit expense [Line Items]" } } }, "localname": "ReconciliationofnetincurredmedicalclaimstobenefitexpenseLineItems", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails" ], "xbrltype": "stringItemType" }, "elv_SecuritiesLendingTransactionsInitialCollateralPercentageValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial minimum percentage of cash and/or securities collateral accepted as compared to the value of securities on loan in a securities lending transaction.", "label": "Securities Lending Transactions Initial Collateral Percentage Value", "terseLabel": "Securities lending transactions, initial collateral percentage value" } } }, "localname": "SecuritiesLendingTransactionsInitialCollateralPercentageValue", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails" ], "xbrltype": "percentItemType" }, "elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ratio of fair value of collateral held to fair value of securities loaned in securities lending transactions.", "label": "Securities Lending Transactions Ratio of Fair Value of Collateral Held To Securities On Loan", "terseLabel": "Securities lending transactions ratio of fair value of collateral held to fair value of securities loaned" } } }, "localname": "SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "elv_SegmentEliminationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Segment Eliminations [Member]", "label": "Segment Eliminations [Member]", "terseLabel": "Segment Eliminations [Member]" } } }, "localname": "SegmentEliminationsMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "elv_SelfFundedReceivablesNet": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount as of the balance sheet date due the entity from self-insured customers, net of the allowance for doubtful accounts.", "label": "Self-Funded Receivables, Net", "terseLabel": "Self-funded receivables" } } }, "localname": "SelfFundedReceivablesNet", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "elv_SelffundedReceivablesAllowanceForDoubtfulAccounts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross self-funded receivable to net realizable value.", "label": "Self-funded Receivables, Allowance For Doubtful Accounts", "terseLabel": "Self-funded receivables, allowance for doubtful accounts" } } }, "localname": "SelffundedReceivablesAllowanceForDoubtfulAccounts", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "elv_SeniorUnsecuredNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Unsecured Notes [Member]", "label": "Senior Unsecured Notes [Member]", "terseLabel": "Senior Unsecured Notes [Member]" } } }, "localname": "SeniorUnsecuredNotesMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount needed to reflect the estimated ultimate cost of settling short duration contract claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date for short duration.", "label": "Short Duration Contract Liability For Claims Adjustment Expense", "periodEndLabel": "Gross medical claims payable, end of period", "periodStartLabel": "Gross medical claims payable, beginning of period" } } }, "localname": "ShortDurationContractLiabilityForClaimsAdjustmentExpense", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Short duration contract liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for short duration contract claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid short duration contract claims.", "label": "Short duration contract liability for unpaid claims and adjustment expense, Net", "terseLabel": "Net medical claims payable, end of period" } } }, "localname": "ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "elv_StockRepurchasedAndRetiredDuringPeriodAveragePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Repurchased and Retired During Period Average Price", "label": "Stock Repurchased and Retired During Period Average Price", "terseLabel": "Average price per share" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodAveragePrice", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "perShareItemType" }, "elv_SurplusNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Surplus Notes [Member]", "label": "Surplus Notes [Member]", "terseLabel": "Surplus Notes [Member]" } } }, "localname": "SurplusNotesMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tax (expense) benefit of non-credit component of impairment loss on available-for-sale securities recognized in other comprehensive income", "label": "Tax (expense) benefit of non credit impairment on available-for-sale securities recognized in other comprehensive income (loss)", "terseLabel": "Tax (expense) benefit of non credit impairment on available-for-sale securities recognized in other comprehensive income (loss)" } } }, "localname": "Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "elv_ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point One Two Five Percent Due Two Thousand Twenty Two", "label": "Three Point One Two Five Percent Due Two Thousand Twenty Two [Member]", "terseLabel": "Three Point One Two Five Percent Due Two Thousand Twenty Two [Member]" } } }, "localname": "ThreePointOneTwoFivePercentDueTwoThousandTwentyTwoMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elv_UnaffiliatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unaffiliated [Member]", "label": "Unaffiliated [Member]", "terseLabel": "Unaffiliated" } } }, "localname": "UnaffiliatedMember", "nsuri": "http://www.elevancehealth.com/20220930", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r132", "r337", "r341", "r346", "r510", "r511", "r518", "r519", "r621", "r796" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r132", "r337", "r341", "r346", "r510", "r511", "r518", "r519", "r621", "r796" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": { "auth_ref": [ "r2", "r137", "r144", "r256", "r467", "r468", "r469", "r481", "r482", "r539", "r544", "r545", "r618" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r137", "r144", "r150", "r256", "r467", "r468", "r469", "r481", "r482", "r539", "r542", "r544", "r545", "r618" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r137", "r144", "r150", "r256", "r467", "r468", "r469", "r481", "r482", "r539", "r542", "r544", "r545", "r618" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r137", "r144", "r150", "r256", "r467", "r468", "r469", "r481", "r482", "r539", "r542", "r544", "r545", "r618" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r206", "r417", "r419", "r757" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r326", "r328", "r329", "r330", "r352", "r391", "r431", "r433", "r632", "r633", "r634", "r635", "r636", "r637", "r657", "r755", "r759", "r797", "r798" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails", "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r326", "r328", "r329", "r330", "r352", "r391", "r431", "r433", "r632", "r633", "r634", "r635", "r636", "r637", "r657", "r755", "r759", "r797", "r798" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails", "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r206", "r417", "r419", "r757" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r203", "r328", "r329", "r417", "r418", "r658", "r752", "r756" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r203", "r328", "r329", "r417", "r418", "r658", "r752", "r756" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r305", "r326", "r328", "r329", "r330", "r352", "r391", "r420", "r431", "r433", "r460", "r461", "r462", "r632", "r633", "r634", "r635", "r636", "r637", "r657", "r755", "r759", "r797", "r798" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails", "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r305", "r326", "r328", "r329", "r330", "r352", "r391", "r420", "r431", "r433", "r460", "r461", "r462", "r632", "r633", "r634", "r635", "r636", "r637", "r657", "r755", "r759", "r797", "r798" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails", "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "Accounting Standards Update 2020-06 [Member]" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedInvestmentIncomeReceivable": { "auth_ref": [ "r27", "r667", "r717" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.", "label": "Accrued Investment Income Receivable", "terseLabel": "Accrued investment income receivable" } } }, "localname": "AccruedInvestmentIncomeReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r60", "r66", "r75", "r76", "r77", "r517" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.", "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Pension and other postretirement benefits" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r54", "r66", "r75", "r76", "r77", "r517" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r66", "r75", "r76", "r77", "r516" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Net cash flow hedges" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r56", "r57", "r59", "r66", "r75", "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]", "terseLabel": "Net unrealized investment (losses) gains" } } }, "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r65" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax", "periodEndLabel": "AOCI, Debt Securities, Ending Balance", "periodStartLabel": "AOCI, Debt Securities, Beginning Balance" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r61", "r66", "r428" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "negatedPeriodEndLabel": "AOCI, Defined Benefit Plan, Ending Balance", "negatedPeriodStartLabel": "AOCI, Defined Benefit Plan, Beginning Balance" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r53", "r63", "r65", "r66", "r564" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "periodEndLabel": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax, Ending Balance", "periodStartLabel": "AOCI, Foreign Currency Translation Adjustment, Net of Tax, Beginning Balance" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r30", "r63", "r65", "r66", "r713", "r767", "r771" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Accumulated Other Comprehensive Loss, Ending Balance", "periodStartLabel": "Accumulated Other Comprehensive Loss, Beginning Balance", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities": { "auth_ref": [ "r66", "r222" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total of accumulated other comprehensive loss related to that portion of other than temporary impairment (OTTI) due to factors other than credit losses on debt securities categorized either as available-for-sale or held-to-maturity that an entity does not intend to sell and which it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis of the debt security. The amount represented by this item is net of tax, as applicable.", "label": "Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Debt Securities", "periodEndLabel": "AOCI, Other than Temporary Impairment, Not Credit Loss, Ending Balance", "periodStartLabel": "Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Debt Securities" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r62", "r66", "r75", "r76", "r77", "r134", "r135", "r136", "r517", "r620", "r762", "r763" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r28", "r624" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r134", "r135", "r136", "r467", "r468", "r469", "r544" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r138", "r139", "r140", "r141", "r150", "r216", "r217", "r253", "r254", "r255", "r256", "r257", "r258", "r467", "r468", "r469", "r479", "r480", "r481", "r482", "r501", "r502", "r503", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r586", "r587", "r594", "r595", "r596", "r597", "r615", "r616", "r617", "r618", "r619", "r620", "r660", "r661", "r662", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments", "terseLabel": "Convertible debenture repurchases, conversions and tax adjustments" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on receivable, classified as other and current.", "label": "Allowance for Credit Loss, Receivable, Other, Current", "terseLabel": "Allowance for doubtful accounts, other receivables" } } }, "localname": "AllowanceForDoubtfulOtherReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r112", "r290", "r298" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 5.0, "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of other intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Weighted average shares excluded from denominator for diluted earnings per share because the stock options were anti-dilutive" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "periodEndLabel": "AOCI, Cash Flow Hedge, Ending Balance", "periodStartLabel": "AOCI, Cash Flow Hedge, Beginning Balance", "terseLabel": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax" } } }, "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r17", "r126", "r185", "r192", "r199", "r252", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r510", "r518", "r565", "r622", "r624", "r668", "r709" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r35", "r126", "r252", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r510", "r518", "r565", "r622", "r624" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r549" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain": { "auth_ref": [ "r131", "r641" ], "lang": { "en-us": { "role": { "documentation": "Maturity period remaining for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements. Element name and standard label in Maturity [numeric lower end] to [numeric higher end] [date measure] [Member] or Maturity Greater Than [low end numeric value] [date measure] [Member] or Maturity Less Than [high end numeric value] [date measure] [Member] formats.", "label": "Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]", "terseLabel": "Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]" } } }, "localname": "AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis": { "auth_ref": [ "r131", "r641" ], "lang": { "en-us": { "role": { "documentation": "Information by maturity period remaining for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements. Element name and standard label in Maturity [numeric lower end] to [numeric higher end] [date measure] [Member] or Maturity Greater Than [low end numeric value] [date measure] [Member] or Maturity Less Than [high end numeric value] [date measure] [Member] formats.", "label": "Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]", "terseLabel": "Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]" } } }, "localname": "AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "verboseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r228" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r224", "r266" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Cost or Amortized Cost", "totalLabel": "Available-for-sale securities, Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "auth_ref": [ "r233" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "verboseLabel": "Due after five years through ten years, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r229", "r233", "r692" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "verboseLabel": "Due after five years through ten years, Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r232" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "verboseLabel": "Due after one year through five years, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r229", "r232", "r691" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "verboseLabel": "Due after one year through five years, Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": { "auth_ref": [ "r234" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10", "verboseLabel": "Due after ten years, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": { "auth_ref": [ "r229", "r234", "r693" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10", "verboseLabel": "Due after ten years, Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r231" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "verboseLabel": "Due in one year or less, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r229", "r231", "r690" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "verboseLabel": "Due in one year or less, Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost": { "auth_ref": [ "r235" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 5.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.", "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost", "verboseLabel": "Mortgage-backed securities, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": { "auth_ref": [ "r235", "r694" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": 5.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.", "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value", "verboseLabel": "Mortgage-backed securities, Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r219", "r225", "r266", "r674" ], "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Available-for-sale Securities", "totalLabel": "Available-for-sale securities, Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r221", "r266" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Fixed maturities, current" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r13", "r221", "r266" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-Sale, Noncurrent", "terseLabel": "Fixed maturities, long-term" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r434", "r435", "r436", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r453", "r454", "r456", "r457", "r459", "r460", "r461", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisOfPresentationandSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BenefitsLossesAndExpenses": { "auth_ref": [ "r739" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs.", "label": "Benefits, Losses and Expenses", "totalLabel": "Total expenses" } } }, "localname": "BenefitsLossesAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_BenefitsLossesAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Benefits, Losses and Expenses [Abstract]", "terseLabel": "Expenses" } } }, "localname": "BenefitsLossesAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r430", "r432", "r496" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r430", "r432", "r494", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Banking Regulation, Total Capital [Abstract]", "terseLabel": "Capital [Abstract]" } } }, "localname": "CapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r12", "r114" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r108", "r114", "r119" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r108", "r575" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash [Member]" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClaimsDevelopmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Claims Development [Line Items]", "terseLabel": "Claims Development [Line Items]" } } }, "localname": "ClaimsDevelopmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r24", "r25", "r26", "r123", "r126", "r153", "r154", "r155", "r157", "r159", "r167", "r168", "r169", "r252", "r337", "r341", "r342", "r343", "r346", "r347", "r389", "r390", "r393", "r397", "r404", "r565", "r804" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r412", "r413", "r414", "r415" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialMortgageBackedSecuritiesMember": { "auth_ref": [ "r235", "r421" ], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by commercial real estate mortgage loans.", "label": "Commercial Mortgage-Backed Securities [Member]", "terseLabel": "Commercial Mortgage-Backed Securities [Member]" } } }, "localname": "CommercialMortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaper": { "auth_ref": [ "r18", "r669", "r712" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.", "label": "Commercial Paper", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaper", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails", "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper", "verboseLabel": "Commercial Paper Program" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r47", "r677", "r719" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies \u2013 Note 11" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r321", "r322", "r323", "r332", "r795" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments And Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "verboseLabel": "Cash dividends per share" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "verboseLabel": "Dividends per share" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r134", "r135", "r544" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r26", "r404" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26", "r624" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $0.01, shares authorized \u2013 900,000,000; shares issued and outstanding \u2013 238,974,624 and 241,770,746" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r71", "r73", "r74", "r85", "r683", "r729" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total shareholders\u2019 comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r84", "r91", "r682", "r727" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractualRightsMember": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).", "label": "Contractual Rights [Member]", "terseLabel": "Provider And Hospital Relationships [Member]" } } }, "localname": "ContractualRightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r348", "r349", "r350", "r352", "r362", "r363", "r364", "r368", "r369", "r370", "r371", "r372", "r380", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Convertible debentures", "verboseLabel": "Net debt carrying amount" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails", "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Convertible Debenture Terms" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r421", "r429", "r774" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r87", "r658" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r122", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r366", "r373", "r374", "r376", "r387" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r20", "r22", "r23", "r125", "r132", "r349", "r350", "r351", "r352", "r353", "r354", "r356", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r380", "r381", "r382", "r383", "r592", "r670", "r671", "r706" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r23", "r377", "r671", "r706" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "verboseLabel": "Outstanding principal amount" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r351", "r379" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Effective conversion price (per $1,000 of principal amount) per share" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r44", "r351", "r405", "r406", "r408" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion rate (shares of common stock per $1,000 of principal)" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentCovenantCompliance": { "auth_ref": [ "r23", "r698" ], "lang": { "en-us": { "role": { "documentation": "States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.", "label": "Debt Instrument, Covenant Compliance", "terseLabel": "Covenant compliance" } } }, "localname": "DebtInstrumentCovenantCompliance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCovenantDescription": { "auth_ref": [ "r23", "r698" ], "lang": { "en-us": { "role": { "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.", "label": "Debt Instrument, Covenant Description", "terseLabel": "Covenant description" } } }, "localname": "DebtInstrumentCovenantDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r349", "r380", "r381", "r590", "r592", "r593" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r43", "r350" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r45", "r125", "r132", "r349", "r350", "r351", "r352", "r353", "r354", "r356", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r380", "r381", "r382", "r383", "r592" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r699" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r699" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of the original debt instrument that was repurchased.", "label": "Debt Instrument, Repurchased Face Amount", "terseLabel": "Debt instruments, repurchased face amount" } } }, "localname": "DebtInstrumentRepurchasedFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r45", "r125", "r132", "r349", "r350", "r351", "r352", "r353", "r354", "r356", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r375", "r380", "r381", "r382", "r383", "r405", "r407", "r408", "r409", "r589", "r590", "r592", "r593", "r700" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Instruments [Abstract]", "terseLabel": "Debt Instruments [Abstract]" } } }, "localname": "DebtInstrumentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r226", "r266", "r272", "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "terseLabel": "Fixed maturities, allowance for credit losses", "verboseLabel": "Fixed maturities, allowance for credit loss" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent": { "auth_ref": [ "r266" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Current", "terseLabel": "Fixed maturities, allowance for credit loss, current" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent": { "auth_ref": [ "r266" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Noncurrent", "terseLabel": "Fixed maturities, allowance for credit Loss, noncurrent" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": { "auth_ref": [ "r224", "r266" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current", "terseLabel": "Fixed maturities, amortized cost, current" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": { "auth_ref": [ "r224", "r266" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent", "verboseLabel": "Fixed Maturities, long-term, amortized cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r240", "r270", "r275" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "verboseLabel": "Estimated fair value, 12 months or greater" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r240", "r270" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "negatedLabel": "Gross unrealized loss, 12 months or greater" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions", "terseLabel": "Number of securities, 12 months or greater" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r240", "r270", "r275" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "verboseLabel": "Estimated fair value, less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r240", "r270" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "negatedLabel": "Gross unrealized loss, less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions", "terseLabel": "Number of securities, less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Gain", "terseLabel": "Debt Securities, Available-for-sale, Realized Gain" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "terseLabel": "Debt Securities, Available-for-sale, Realized Gain (Loss)" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": { "auth_ref": [ "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Loss", "terseLabel": "Debt Securities, Available-for-sale, Realized Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r112", "r127", "r478", "r485", "r486", "r487" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r471", "r472" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities, net" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.", "label": "Deferred Tax and Other Liabilities, Noncurrent", "terseLabel": "Deferred Tax and Other Liabilities, Noncurrent" } } }, "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue": { "auth_ref": [ "r776" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash received as security in return for loaning securities to another party.", "label": "Deposits Received for Securities Loaned, at Carrying Value", "terseLabel": "Collateral received for securities loaned, at carrying value" } } }, "localname": "DepositsReceivedForSecuritiesLoanedAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "auth_ref": [ "r112" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Depreciation, Amortization and Accretion, Net", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAmortizationAndAccretionNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement": { "auth_ref": [ "r50", "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.", "label": "Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement", "terseLabel": "Derivative assets" } } }, "localname": "DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r527" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Derivative, Gain (Loss) Recognized" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r52", "r526", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r533", "r548" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r525", "r526", "r529" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement": { "auth_ref": [ "r50", "r52" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.", "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement", "negatedTerseLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeMember": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender).", "label": "Derivative [Member]", "terseLabel": "Derivatives [Member]" } } }, "localname": "DerivativeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Date the declared dividend will be paid, in YYYY-MM-DD format.", "label": "Dividends Payable, Date to be Paid", "terseLabel": "Payment date", "verboseLabel": "Dividends Payable, Date to be Paid" } } }, "localname": "DividendPayableDateToBePaidDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r410", "r697" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Common Stock", "negatedLabel": "Dividends and dividend equivalents" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsDeclaredTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.", "label": "Dividends Declared [Table Text Block]", "terseLabel": "Summary of Cash Dividend Activity" } } }, "localname": "DividendsDeclaredTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPayableAmountPerShare": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.", "label": "Dividends Payable, Amount Per Share", "terseLabel": "Dividends Payable, Amount Per Share" } } }, "localname": "DividendsPayableAmountPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DividendsPayableDateDeclaredDayMonthAndYear": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Date the dividend to be paid was declared, in YYYY-MM-DD format.", "label": "Dividends Payable, Date Declared", "terseLabel": "Declaration date" } } }, "localname": "DividendsPayableDateDeclaredDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format.", "label": "Dividends Payable, Date of Record", "terseLabel": "Record date", "verboseLabel": "Dividends Payable, Date of Record" } } }, "localname": "DividendsPayableDateOfRecordDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails" ], "xbrltype": "dateItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "Shareholders\u2019 net income per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r86", "r142", "r143", "r144", "r145", "r146", "r151", "r153", "r157", "r158", "r159", "r163", "r164", "r545", "r546", "r684", "r730" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r86", "r142", "r143", "r144", "r145", "r146", "r153", "r157", "r158", "r159", "r163", "r164", "r545", "r546", "r684", "r730" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r160", "r161", "r162", "r165" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r575" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "verboseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee Severance [Member]" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r75", "r76", "r77", "r134", "r135", "r136", "r139", "r147", "r149", "r166", "r256", "r404", "r410", "r467", "r468", "r469", "r481", "r482", "r544", "r576", "r577", "r578", "r579", "r580", "r583", "r620", "r762", "r763", "r764" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r9", "r21", "r563" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r249" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "terseLabel": "Net losses on equity securities" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGain": { "auth_ref": [ "r249" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain", "terseLabel": "Unrealized (losses) gains recognized on equity securities still held at the end of the period" } } }, "localname": "EquitySecuritiesFvNiRealizedGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r249", "r732" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "terseLabel": "Net realized gains (losses) recognized on equity securities sold during the period" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedLoss": { "auth_ref": [ "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of realized loss from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Loss", "negatedTerseLabel": "Net realized gains (losses) recognized on equity securities sold during the period" } } }, "localname": "EquitySecuritiesFvNiRealizedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r249", "r732" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "terseLabel": "Unrealized (losses) gains recognized on equity securities still held at the end of the period" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r245", "r708", "r789", "r790", "r791" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity Securities [Member]" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExchangeTradedFundsMember": { "auth_ref": [ "r421", "r560" ], "lang": { "en-us": { "role": { "documentation": "Investment that follows an index, commodity or basket of assets that trades similar to a stock on an exchange.", "label": "Exchange Traded Funds [Member]", "terseLabel": "Exchange Traded Funds [Member]" } } }, "localname": "ExchangeTradedFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment of Debt [Axis]", "terseLabel": "Extinguishment of Debt [Axis]" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Type of debt extinguished.", "label": "Extinguishment of Debt, Type [Domain]", "terseLabel": "Extinguishment of Debt, Type [Domain]" } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r549", "r550", "r561" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "auth_ref": [ "r558" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.", "label": "Fair Value, Asset, Recurring Basis, Still Held, Unrealized Gain (Loss)", "terseLabel": "Change in unrealized gains (losses) included in net income related to assets still held" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r553", "r561" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r553", "r561" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Reconciliation Of The Beginning And Ending Balances Of Assets Measured At Fair Value On A Recurring Basis Using Level III Inputs" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r364", "r380", "r381", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r429", "r550", "r629", "r630", "r631" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r549", "r550", "r551", "r552", "r562" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r364", "r421", "r422", "r427", "r429", "r550", "r629" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level I [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r364", "r380", "r381", "r421", "r422", "r427", "r429", "r550", "r630" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level II [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r364", "r380", "r381", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r429", "r550", "r631" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level III [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "auth_ref": [ "r554" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "terseLabel": "Total gains (losses) recognized in net income" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": { "auth_ref": [ "r555" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)", "terseLabel": "Total gains (losses) recognized in accumulated other comprehensive loss" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "auth_ref": [ "r556" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "terseLabel": "Purchases" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": { "auth_ref": [ "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales", "negatedTerseLabel": "Sales" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": { "auth_ref": [ "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements", "negatedTerseLabel": "Settlements" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r557" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3", "terseLabel": "Transfers into Level III" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r557" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "negatedTerseLabel": "Transfers out of Level III" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r553" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r364", "r380", "r381", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r429", "r629", "r630", "r631" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "auth_ref": [ "r549", "r550", "r551", "r552", "r559", "r562" ], "lang": { "en-us": { "role": { "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.", "label": "Fair Value, Nonrecurring [Member]", "terseLabel": "Fair Value, Nonrecurring [Member]" } } }, "localname": "FairValueMeasurementsNonrecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r560", "r562" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueInNextRollingTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of advances from Federal Home Loan Bank (FHLBank) maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Federal Home Loan Bank, Advances, Maturities Summary, Due in Next Rolling 12 Months", "verboseLabel": "Federal Home Loan Bank, advances, short-term" } } }, "localname": "FederalHomeLoanBankAdvancesMaturitiesSummaryDueInNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FederalHomeLoanBankAdvancesMember": { "auth_ref": [ "r676" ], "lang": { "en-us": { "role": { "documentation": "Borrowings from the Federal Home Loan Bank, which are primarily used to cover shortages in the required reserve balance and also in times of liquidity shortages. The member institution executes a promissory note, which is generally collateralized by government securities to the Federal Reserve or loans.", "label": "Federal Home Loan Bank Advances [Member]", "terseLabel": "Federal Home Loan Bank Advances [Member]" } } }, "localname": "FederalHomeLoanBankAdvancesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r236", "r237", "r246", "r247", "r248", "r259", "r262", "r263", "r264", "r265", "r269", "r271", "r274", "r275", "r375", "r402", "r533", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r804", "r805", "r806", "r807", "r808", "r809", "r810" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "negatedTerseLabel": "Total liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r15", "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization, Finite-Lived Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, 2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r291", "r294", "r297", "r301", "r659", "r663" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r297", "r663" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount, Finite Lived Intangibles" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r291", "r296" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r297", "r659" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Net Carrying Amount, Finite-Lived Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Finite-Lived Intangible Assets, Period Increase" } } }, "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r292" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-Lived Intangible Assets Acquired", "terseLabel": "Finite-lived Intangible Assets Acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FixedMaturitiesMember": { "auth_ref": [ "r775" ], "lang": { "en-us": { "role": { "documentation": "This element provides types of investments that may be contained within the fixed maturity category which are securities having a stated final repayment date. Examples of items within this category may include bonds, including convertibles and bonds with warrants, and redeemable preferred stocks.", "label": "Fixed Maturities [Member]", "terseLabel": "Fixed Maturities [Member]" } } }, "localname": "FixedMaturitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails", "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r585" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignGovernmentDebtMember": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity.", "label": "Foreign Government Debt [Member]", "terseLabel": "Foreign Government Securities [Member]" } } }, "localname": "ForeignGovernmentDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainContingenciesByNatureAxis": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Information by nature of gain contingency.", "label": "Gain Contingencies, Nature [Axis]", "terseLabel": "Gain Contingency, Nature [Axis]" } } }, "localname": "GainContingenciesByNatureAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GainContingencyNatureDomain": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization.", "label": "Gain Contingency, Nature [Domain]", "terseLabel": "Gain Contingency, Nature [Domain]" } } }, "localname": "GainContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnInvestmentsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.", "label": "Gain (Loss) on Securities [Table Text Block]", "terseLabel": "Net Investment Gains (Losses)" } } }, "localname": "GainLossOnInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSaleOfOtherInvestments": { "auth_ref": [ "r112" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) included in earnings for investments classified as other.", "label": "Gain (Loss) on Sale of Other Investments", "terseLabel": "Net losses (gains) on other investments" } } }, "localname": "GainLossOnSaleOfOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r112", "r384", "r385" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 6.0, "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/DebtNarrativeDetails", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r14", "r276", "r277", "r284", "r288", "r624", "r666" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, Ending Balance", "periodStartLabel": "Goodwill, Beginning Balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails", "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r278", "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill, Acquired During Period" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillandOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r277", "r284", "r288" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Goodwill, Impaired, Accumulated Impairment Loss as of September 30, 2022" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Goodwill, Period Increase (Decrease)" } } }, "localname": "GoodwillPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r283", "r493" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Goodwill, Purchase Accounting Adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsFinancialStatementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r81", "r185", "r191", "r195", "r198", "r201", "r664", "r680", "r686", "r733" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income tax expense", "totalLabel": "Income before income tax expense" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r82", "r112", "r182", "r250", "r679", "r725" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Equity in net earnings of other invested assets" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r128", "r475", "r476", "r477", "r483", "r488", "r490", "r491", "r492" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r129", "r148", "r149", "r183", "r473", "r484", "r489", "r734" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r27", "r675", "r723" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Income taxes receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "auth_ref": [ "r111" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.", "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "terseLabel": "Accounts payable and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying amount of assets, which may include but are not limited to cash and investments, received as collateral pertaining to securities loaned to a counterparty to the transaction. Includes the change during the period in any unrealized gain or loss on such investments.", "label": "Increase (Decrease) in Collateral Held under Securities Lending", "negatedTerseLabel": "Changes in securities lending collateral" } } }, "localname": "IncreaseDecreaseInCollateralHeldUnderSecuritiesLending", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r111" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "verboseLabel": "Unearned income" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": { "auth_ref": [ "r111" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.", "label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable", "terseLabel": "Income taxes" } } }, "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInsuranceLiabilities": { "auth_ref": [ "r111" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in insurance liability balances during the period.", "label": "Increase (Decrease) in Insurance Liabilities", "terseLabel": "Policy liabilities" } } }, "localname": "IncreaseDecreaseInInsuranceLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r111" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r111" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities": { "auth_ref": [ "r115", "r116" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The change in cash during the period due to the net increase or decrease in outstanding checks, the liability that represents checks that have been issued but that have not cleared. The entity may classify these cash flows as financing or operating activities.", "label": "Increase (Decrease) in Outstanding Checks, Financing Activities", "terseLabel": "Changes in bank overdrafts" } } }, "localname": "IncreaseDecreaseInOutstandingChecksFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r111" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Receivables, net" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInSecuritiesLendingPayable": { "auth_ref": [], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying amount of the liability pertaining to obligations to return collateral that the entity received when it loaned securities to the counterparty to the transaction.", "label": "Increase (Decrease) in Securities Lending Payable", "terseLabel": "Changes in securities lending payable" } } }, "localname": "IncreaseDecreaseInSecuritiesLendingPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTradingSecurities": { "auth_ref": [ "r106", "r111" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of investment in debt and equity securities, measured at fair value with changes in fair value recognized in net income.", "label": "Increase (Decrease) in Debt Securities, Trading, and Equity Securities, FV-NI", "negatedLabel": "Other invested assets" } } }, "localname": "IncreaseDecreaseInTradingSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r293", "r300" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Net Carrying Amount, Indefinite-Lived Intangible Assets", "verboseLabel": "Gross Carrying Amount, Indefinite-Lived Intangible Assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r293", "r300" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Indefinite-Lived Intangible Assets, Period Decrease" } } }, "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.", "label": "Indefinite-Lived Intangible Assets Acquired", "terseLabel": "Indefinite-lived Intangible Assets Acquired" } } }, "localname": "IndefinitelivedIntangibleAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InsuranceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Insurance [Abstract]", "terseLabel": "Insurance [Abstract]" } } }, "localname": "InsuranceAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InsuranceServicesRevenue": { "auth_ref": [ "r735" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from insurance services, including net premiums earned, gain on sale of insurance block, agency management fees and insurance contract fees and commissions.", "label": "Insurance Services Revenue", "terseLabel": "Insurance Services Revenue", "verboseLabel": "Reportable segments operating revenues" } } }, "localname": "InsuranceServicesRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentsOperatingRevenuesToTotalRevenuesReportedInTheConsolidatedStatementsOfIncomeDetails", "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [ "r14" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Gross Carrying Amount, Total Intangible Assets" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r289", "r295" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other intangible assets", "verboseLabel": "Net Carrying Amount, Total Intangible Assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r79", "r179", "r588", "r591", "r685" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r177", "r190", "r191", "r192", "r193", "r195", "r197", "r201" ], "lang": { "en-us": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]", "terseLabel": "Intersegment Eliminations [Member]" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r251", "r731" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investment, Policy" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails", "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails", "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments [Abstract]", "terseLabel": "Investments [Abstract]" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r245", "r665", "r695", "r792", "r811" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r611", "r613" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Disclosure [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "verboseLabel": "Total future minimum payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Operating lease payments, Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Operating lease payments, 2022; excluding the nine months ended September 30, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "Operating lease payments, 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Operating lease payments, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Operating lease payments, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Operating lease payments, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Imputed Interest, Leases" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseNotYetCommencedDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Not yet Commenced, Description [Abstract]", "terseLabel": "Lessee, Operating Lease, Not yet Commenced, Description [Abstract]" } } }, "localname": "LesseeOperatingLeaseNotYetCommencedDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lessee, Operating Lease, Term of Contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r40", "r126", "r193", "r252", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r511", "r518", "r519", "r565", "r622", "r623" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r33", "r126", "r252", "r565", "r624", "r673", "r716" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r11", "r42", "r126", "r252", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r511", "r518", "r519", "r565", "r622", "r623", "r624" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r743", "r746" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.", "label": "Liability for Claims and Claims Adjustment Expense", "terseLabel": "Gross medical claims payable, end of period", "verboseLabel": "Medical claims payable" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liability for Claims and Claims Adjustment Expense [Abstract]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Abstract]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "terseLabel": "Medical Claims Payable [Line Items]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "terseLabel": "Medical Claims Payable" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForFuturePolicyBenefits": { "auth_ref": [ "r704", "r753", "r754", "r758", "r765" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.", "label": "Liability for Future Policy Benefit, before Reinsurance", "terseLabel": "Reserves for future policy benefits, noncurrent" } } }, "localname": "LiabilityForFuturePolicyBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": { "auth_ref": [ "r772" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.", "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]", "terseLabel": "Medical Claims payable" } } }, "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": { "auth_ref": [ "r745" ], "calculation": { "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails": { "order": 1.0, "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year", "terseLabel": "Net payments attributable to current period medical claims" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": { "auth_ref": [ "r745" ], "calculation": { "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails": { "order": 2.0, "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years", "terseLabel": "Net payments attributable to prior periods medical claims" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": { "auth_ref": [ "r744" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims", "terseLabel": "Total net incurred medical claims" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet": { "auth_ref": [ "r705", "r743", "r746" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Net", "periodStartLabel": "Net medical claims payable, beginning of period", "terseLabel": "Net medical claims payable, end of period" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "State Medicaid Licenses [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityDescription": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.", "label": "Line of Credit Facility, Description", "terseLabel": "Line of Credit Facility, Description" } } }, "localname": "LineOfCreditFacilityDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Subsidiary Credit Facilities [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r23", "r363", "r378", "r380", "r381", "r671", "r712" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Long-term Debt", "verboseLabel": "Senior revolving credit facility" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails", "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, less current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Investments [Abstract]", "terseLabel": "Long-term investments:" } } }, "localname": "LongTermInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-Term Purchase Commitment, Amount", "terseLabel": "Long-term purchase commitment, amount" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r45", "r336" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r324", "r325", "r326", "r327", "r328", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualPayments": { "auth_ref": [ "r324" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow reducing loss contingency liability.", "label": "Loss Contingency Accrual, Payments", "terseLabel": "Loss Contingency Accrual, Payments" } } }, "localname": "LossContingencyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r324", "r325", "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Approximate amount of damages sought for breaches" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "auth_ref": [ "r326", "r328", "r333" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.", "label": "Loss Contingency, Estimate of Possible Loss", "terseLabel": "Aggregate settlement amount" } } }, "localname": "LossContingencyEstimateOfPossibleLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r324", "r325", "r326", "r327", "r328", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r325", "r327" ], "lang": { "en-us": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Loss Contingency, Pending Claims, Number" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Marketable Securities [Line Items]", "terseLabel": "Equity Securities [Line Items]" } } }, "localname": "MarketableSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]", "terseLabel": "Equity Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MaturityOvernightMember": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Maturity period of the day after the reporting date for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements.", "label": "Maturity Overnight [Member]", "terseLabel": "Overnight and Continuous [Member]" } } }, "localname": "MaturityOvernightMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r7", "r504" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "Business Acquisitions" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r49", "r126", "r252", "r337", "r341", "r342", "r343", "r346", "r347", "r565", "r672", "r715" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "periodEndLabel": "Noncontrolling interests, Ending Balance", "periodStartLabel": "Noncontrolling interests, Beginning Balance", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r170", "r171" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Organization" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r108" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r108" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r108", "r110", "r113" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r6", "r69", "r72", "r77", "r83", "r113", "r126", "r138", "r142", "r143", "r144", "r145", "r148", "r149", "r156", "r185", "r191", "r195", "r198", "r201", "r252", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r546", "r565", "r681", "r726" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Shareholders' net income", "totalLabel": "Shareholders\u2019 net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r69", "r72", "r77", "r148", "r149", "r513", "r521" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedTerseLabel": "Net loss (income) attributable to noncontrolling interests", "terseLabel": "Net Income (Loss) Attributable to Noncontrolling Interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentIncome": { "auth_ref": [ "r728" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.", "label": "Net Investment Income", "negatedTerseLabel": "Net investment income", "terseLabel": "Net investment income" } } }, "localname": "NetInvestmentIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentsOperatingRevenuesToTotalRevenuesReportedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "auth_ref": [ "r411", "r509", "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "terseLabel": "Noncontrolling interests adjustment" } } }, "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r134", "r135", "r136", "r410", "r505" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r23", "r671", "r712" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "terseLabel": "Notes" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of states the entity operates in as of the balance sheet date.", "label": "Number of States in which Entity Operates", "terseLabel": "Number of states in which the Company is licensed to conduct insurance operations" } } }, "localname": "NumberOfStatesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/OrganizationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r185", "r191", "r195", "r198", "r201" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Reportable segments operating gain", "verboseLabel": "Operating gain (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfIncomeBeforeIncomeTaxExpenseToReportableSegmentsOperatingGainIncludedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r604", "r613" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r599" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating Lease Liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesReconciliationofFutureLeasePaymentstoTotalLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r599" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating Lease, Liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Balance sheet location of current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r599" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating Lease, Liability, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Balance sheet location of noncurrent operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r601", "r607" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r598" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Balance sheet location of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r610", "r613" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r609", "r613" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "auth_ref": [ "r388", "r531", "r532", "r534" ], "lang": { "en-us": { "role": { "documentation": "Information by type of options indexed to an issuer's equity.", "label": "Option Indexed to Issuer's Equity [Axis]", "terseLabel": "Option Indexed to Issuer's Equity [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityEquityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed to Issuer's Equity, Type [Domain]", "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAggregatedInvestmentsMember": { "auth_ref": [ "r778", "r781", "r784" ], "lang": { "en-us": { "role": { "documentation": "Other investments in debt and equity securities and other forms of securities that provide ownership interests.", "label": "Other Security Investments [Member]", "terseLabel": "Other Securities [Member]" } } }, "localname": "OtherAggregatedInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r34", "r624" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r56", "r57", "r63" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "verboseLabel": "Change in net unrealized losses/gains on investments" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax", "terseLabel": "Net holding gain (loss) on investment securities arising during the period, tax (expense) benefit" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r55", "r63" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Cash flow hedges, holding gain (loss), net of tax", "verboseLabel": "Change in net unrealized gains/losses on cash flow hedges" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "terseLabel": "Cash flow hedges, holding gain (loss), tax (expense) benefit" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r53" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment, net of tax", "verboseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "auth_ref": [ "r53", "r64", "r574", "r582" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax (Expense) Benefit" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r70", "r73", "r75", "r76", "r78", "r84", "r404", "r576", "r581", "r583", "r682", "r727" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive (loss) income, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r70", "r73", "r507", "r508", "r516" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "negatedTerseLabel": "Other comprehensive loss attributable to noncontrolling interests", "terseLabel": "Other Comprehensive (Loss) Income, Attributable to Noncontrolling Interest" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r70", "r73", "r507", "r508", "r516" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "verboseLabel": "Shareholders' other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r61", "r63" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Change in net periodic pension and postretirement costs", "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "auth_ref": [ "r63", "r67", "r68", "r244" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": { "auth_ref": [ "r64", "r244" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax", "negatedTerseLabel": "Reclassification adjustment for net realized loss (gain) on investment securities, tax (benefit) expense" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r507", "r508", "r516" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to noncontrolling interest.", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest", "terseLabel": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "auth_ref": [ "r507", "r508", "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "terseLabel": "Other Comprehensive Income (Loss), Tax (Expense) Benefit, Portion Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r56", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDebtSecuritiesMember": { "auth_ref": [ "r238", "r267", "r421", "r560" ], "lang": { "en-us": { "role": { "documentation": "Investments in debt securities classified as other.", "label": "Other Debt Obligations [Member]", "terseLabel": "Other Securities [Member]" } } }, "localname": "OtherDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r737" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "elv_OperatingRevenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Administrative fees and other revenue" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "terseLabel": "Other Investments [Member]" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r41", "r624" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermInvestments": { "auth_ref": [ "r13", "r721" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term investments classified as other.", "label": "Other Long-Term Investments", "terseLabel": "Other invested assets", "verboseLabel": "Other invested assets" } } }, "localname": "OtherLongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails", "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPolicyholderFunds": { "auth_ref": [ "r722" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount due to policyholders for funds held that are returnable under the terms of insurance contracts, classified as other.", "label": "Other Policyholder Funds", "terseLabel": "Other policyholder liabilities" } } }, "localname": "OtherPolicyholderFunds", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r27" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other Receivables", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities": { "auth_ref": [ "r58", "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other than temporary impairment (OTTI) loss on investment in available-for-sale debt security, recognized in other comprehensive loss.", "label": "Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Available-for-Sale Securities", "terseLabel": "Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Available-for-sale Securities" } } }, "localname": "OtherThanTemporaryImpairmentLossesInvestmentsPortionInOtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAvailableforsaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": { "auth_ref": [ "r109", "r745" ], "calculation": { "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid", "totalLabel": "Total net payments" } } }, "localname": "PaymentsForLossesAndLossAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r95", "r98" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r102" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase and retirement of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r105", "r308" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "Payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r102" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Cash dividends", "terseLabel": "Total payment" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r102" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Taxes paid through withholding of common stock under employee stock plans" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r96" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Purchases of subsidiaries, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r98" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r97" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet": { "auth_ref": [ "r701", "r738" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred.", "label": "Policyholder Benefits and Claims Incurred, Net", "terseLabel": "Benefit expense" } } }, "localname": "PolicyholderBenefitsAndClaimsIncurredNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PositionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by position taken for a security.", "label": "Position [Axis]", "terseLabel": "Position [Axis]" } } }, "localname": "PositionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PositionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates position taken for a security.", "label": "Position [Domain]", "terseLabel": "Position [Domain]" } } }, "localname": "PositionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r25", "r389" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r25", "r389" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r25", "r624" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, without par value, shares authorized \u2013 100,000,000; shares issued and outstanding \u2013 none" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PremiumsEarnedNet": { "auth_ref": [ "r678", "r724", "r741", "r773" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "elv_OperatingRevenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.", "label": "Premiums Earned, Net", "terseLabel": "Premiums" } } }, "localname": "PremiumsEarnedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts": { "auth_ref": [ "r208", "r210", "r260", "r261", "r707" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross premiums receivable to net realizable value.", "label": "Premium Receivable, Allowance for Credit Loss", "terseLabel": "Premium receivable, allowance for doubtful accounts" } } }, "localname": "PremiumsReceivableAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PremiumsReceivableAtCarryingValue": { "auth_ref": [ "r720" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount as of the balance sheet date due the entity from (a) agents and insureds, (b) uncollected premiums and (c) others, net of the allowance for doubtful accounts.", "label": "Premiums Receivable, Net", "terseLabel": "Premium receivables" } } }, "localname": "PremiumsReceivableAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PresentValueOfFutureInsuranceProfitsTableTextBlock": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of present value of future profits of insurance contract acquired in business combination.", "label": "Present Value of Future Insurance Profits [Table Text Block]", "terseLabel": "Components Of Other Intangible Assets" } } }, "localname": "PresentValueOfFutureInsuranceProfitsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PrivateEquityFundsMember": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Investments held in private equity funds.", "label": "Private Equity Funds [Member]", "terseLabel": "Private Equity Funds [Member]", "verboseLabel": "Private Equity Securities [Member]" } } }, "localname": "PrivateEquityFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "verboseLabel": "Proceeds originally received at time of divestiture" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r100" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from long-term borrowings" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r92", "r93", "r220" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "terseLabel": "Maturities, calls and redemptions from investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r101", "r104" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfCommercialPaper": { "auth_ref": [ "r100", "r103", "r116" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper.", "label": "Proceeds from (Repayments of) Commercial Paper", "terseLabel": "Net proceeds from (repayments of) commercial paper borrowings" } } }, "localname": "ProceedsFromRepaymentsOfCommercialPaper", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r92", "r93", "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from Sale of Available-for-sale Securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromShortTermDebt": { "auth_ref": [ "r100" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from Short-Term Debt", "terseLabel": "Proceeds from short-term borrowings" } } }, "localname": "ProceedsFromShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r99", "r466" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from issuance of common stock under employee stock plans" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r6", "r69", "r72", "r77", "r107", "r126", "r138", "r148", "r149", "r185", "r191", "r195", "r198", "r201", "r252", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r507", "r512", "r514", "r521", "r522", "r546", "r565", "r686" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r303", "r624", "r696", "r718" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r209", "r213", "r214", "r215" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r191", "r195" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "verboseLabel": "Reconciliation Of Income Before Income Tax Expense To Reportable Segments Operating Gain Included In The Consolidated Statements Of Income" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r190", "r195" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "verboseLabel": "Reconciliation Of Reportable Segments Operating Revenues To Total Revenues Reported In The Consolidated Statements Of Income" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments": { "auth_ref": [ "r702", "r742", "r743", "r746" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.", "label": "Reinsurance Recoverable for Unpaid Claims and Claims Adjustments", "negatedPeriodStartLabel": "Ceded medical claims payable, beginning of period", "periodEndLabel": "Ceded medical claims payable, end of period", "terseLabel": "Ceded medical claims payable end of period" } } }, "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r103" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedLabel": "Repayments of long-term borrowings", "terseLabel": "Repayments of Long-term Debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r103" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-Term Debt", "negatedLabel": "Repayments of short-term borrowings" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResidentialMortgageBackedSecuritiesMember": { "auth_ref": [ "r223", "r421" ], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by residential real estate mortgage loans.", "label": "Residential Mortgage-Backed Securities [Member]", "terseLabel": "Residential Mortgage-Backed Securities [Member]" } } }, "localname": "ResidentialMortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndInvestmentsCurrent": { "auth_ref": [ "r35", "r793", "r794" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.", "label": "Restricted Cash and Investments, Current", "terseLabel": "Customer funds and cash and cash equivalents on deposit for regulatory requirements" } } }, "localname": "RestrictedCashAndInvestmentsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r306", "r308", "r311", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Business Optimization Initiatives" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiatives" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r307", "r308", "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Business Optimization Initiatives by Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Business Optimization Initiatives [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r308", "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Liability for employee terminations costs, ending", "periodStartLabel": "Liability for employee terminations costs, beginning" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r410", "r624", "r714", "r766", "r771" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r134", "r135", "r136", "r139", "r147", "r149", "r256", "r467", "r468", "r469", "r481", "r482", "r544", "r762", "r764" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]", "verboseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r120", "r121" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r80", "r126", "r176", "r177", "r190", "r196", "r197", "r203", "r204", "r206", "r252", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r565", "r686" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationOfReportableSegmentsOperatingRevenuesToTotalRevenuesReportedInTheConsolidatedStatementsOfIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Senior Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r608", "r613" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]", "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]" } } }, "localname": "RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r66", "r581", "r583" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Reconciliation Of Components Of Accumulated Other Comprehensive Loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "verboseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Current and Long-Term Investments, Available-For-Sale" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r230", "r235", "r239", "r240", "r241", "r243", "r688", "r689" ], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-Sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsAmortizedCostAndFairValueOfFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r494", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Business Acquisitions [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsBusinessAcquisitionAssetsLiabilitiesAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Denominator for Basic and Diluted Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r464", "r470" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r549", "r550" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value Measurements By Level For Assets Measured At Fair Value On A Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Gain (Loss) on Securities [Line Items]", "terseLabel": "Investment [Line Items]" } } }, "localname": "ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGainLossOnInvestmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about realized and unrealized gain (loss) on investment in security.", "label": "Schedule of Gain (Loss) on Securities [Table]", "terseLabel": "Investment [Table]" } } }, "localname": "ScheduleOfGainLossOnInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentGainsLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Summary Of The Change In The Carrying Amount Of Goodwill By Reportable Segment" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillandOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": { "auth_ref": [ "r89", "r90", "r736" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.", "label": "Investment Income [Table]", "terseLabel": "Investment Income [Table]" } } }, "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Investments [Line Items]", "terseLabel": "Schedule of Investments [Line Items]" } } }, "localname": "ScheduleOfInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.", "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]", "terseLabel": "Reconciliation Of The Beginning And Ending Balances For Medical Claims Payable" } } }, "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r307", "r308", "r309", "r310", "r316", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Business Optimization Initiatives [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r312", "r313", "r315" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Business Optimization Initiatives" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r185", "r188", "r194", "r285" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r185", "r188", "r194", "r285" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Financial Data By Reportable Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r437", "r452", "r455" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted During the Periods" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "verboseLabel": "Summary of Nonvested Restricted Stock Activity Including Restricted Stock Units" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": { "auth_ref": [ "r412", "r413", "r414", "r415" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table Text Block]", "terseLabel": "Summary of Share Repurchases" } } }, "localname": "ScheduleOfTreasuryStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).", "label": "Schedule of Unrealized Loss on Investments [Table Text Block]", "terseLabel": "Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position" } } }, "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuritiesHeldAsCollateralAtFairValue": { "auth_ref": [ "r211" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount (fair value) as of the balance sheet date of securities held that had been pledged by counterparties under financing and lending arrangements, pursuant to which the entity has the right by agreement or custom to sell or re-pledge such securities.", "label": "Securities Held as Collateral, at Fair Value", "terseLabel": "Securities lending collateral" } } }, "localname": "SecuritiesHeldAsCollateralAtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuritiesLoanedFairValueOfCollateral": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of the securities pledged as collateral against securities loaned.", "label": "Securities Loaned, Fair Value of Collateral", "verboseLabel": "Fair value of collateral received at time of securities lending transactions" } } }, "localname": "SecuritiesLoanedFairValueOfCollateral", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r172", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r190", "r191", "r192", "r193", "r195", "r196", "r197", "r198", "r199", "r201", "r206", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r288", "r310", "r318", "r752" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails", "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]", "terseLabel": "Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]" } } }, "localname": "SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r172", "r174", "r175", "r185", "r189", "r195", "r199", "r200", "r201", "r202", "r203", "r205", "r206", "r207" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDataByReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r88" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r111" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited, Restricted Stock Shares And Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited, Weighted-Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted, Restricted Stock Shares and Units", "verboseLabel": "Restricted stock units issued under stock incentive plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails", "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Restricted stock awards granted during the period", "verboseLabel": "Granted, Weighted-Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails", "http://www.elevancehealth.com/role/CapitalStockScheduleOfWeightedAverageFairValuesDeterminedForThePeriodsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r446", "r447" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested at Ending Balance, Restricted Stock Shares and Units", "periodStartLabel": "Nonvested at Beginning Balance, Restricted Stock Shares and Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Stock Shares and Units [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r446", "r447" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested at Ending Balance, Weighted-Average Grant Date Fair Value per Share", "periodStartLabel": "Nonvested at Beginning Balance, Weighted-Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value Per Share [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested, Restricted Stock Shares And Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Vested, Weighted-Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Quarterly dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringThePeriodEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility factor" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringThePeriodEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringThePeriodEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of period, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of period, Weighted-Average Option Price per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Forfeited or expired, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "verboseLabel": "Forfeited or expired, Weighted-Average Option Price per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "verboseLabel": "Granted, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Options granted during the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockScheduleOfWeightedAverageFairValuesDeterminedForThePeriodsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "terseLabel": "Schedule of Weighted-Average Fair Values Determined for the Periods" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r465" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding at end of period, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r438", "r439" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period, Number of Shares", "periodStartLabel": "Outstanding at beginning of period, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r438", "r439" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period, Weighted-Average Option Price per Share", "periodStartLabel": "Outstanding at beginning of period, Weighted-Average Option Price per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Option Price Per Share [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r457" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "verboseLabel": "Exercisable at end of period, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r434", "r435", "r436", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r453", "r454", "r456", "r457", "r459", "r460", "r461", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Exercised, Weighted-Average Option Price per Share" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted, Weighted-Average Option Price per Share" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Weighted-average expected life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringThePeriodEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable at end of period, Weighted-Average Remaining Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding at end of period, Weighted-Average Remaining Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares), Ending", "periodStartLabel": "Balance (in shares), Beginning" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortDurationInsuranceContractAccidentYear2020Member": { "auth_ref": [ "r748" ], "lang": { "en-us": { "role": { "documentation": "Accident year 2020 in which covered event occurs under terms of short-duration insurance contract.", "label": "Short-Duration Insurance Contract, Accident Year 2020 [Member]", "terseLabel": "Short-Duration Insurance Contract, Accident Year 2020 [Member]" } } }, "localname": "ShortDurationInsuranceContractAccidentYear2020Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortDurationInsuranceContractAccidentYear2021Member": { "auth_ref": [ "r748" ], "lang": { "en-us": { "role": { "documentation": "Accident year 2021 in which covered event occurs under terms of short-duration insurance contract.", "label": "Short-Duration Insurance Contract, Accident Year 2021 [Member]", "terseLabel": "Short-Duration Insurance Contract, Accident Year 2021 [Member]" } } }, "localname": "ShortDurationInsuranceContractAccidentYear2021Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortDurationInsuranceContractAccidentYear2022Member": { "auth_ref": [ "r748" ], "lang": { "en-us": { "role": { "documentation": "Accident year 2022 in which covered event occurs under terms of short-duration insurance contract.", "label": "Short-Duration Insurance Contract, Accident Year 2022 [Member]", "terseLabel": "Short-Duration Insurance Contract, Accident Year 2022 [Member]" } } }, "localname": "ShortDurationInsuranceContractAccidentYear2022Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r19", "r624", "r670", "r711" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-Term Debt", "terseLabel": "Short-term borrowings", "verboseLabel": "Short-term borrowings" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/DebtNarrativeDetails", "http://www.elevancehealth.com/role/FairValueCarryingAndEstimatedFairValuesbyLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r605", "r613" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term Lease, Cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsAccidentYearAxis": { "auth_ref": [ "r748" ], "lang": { "en-us": { "role": { "documentation": "Information by accident year in which a covered event occurs under the terms of the short-duration insurance contract.", "label": "Short-Duration Insurance Contracts, Accident Year [Axis]", "terseLabel": "Short-duration Insurance Contracts, Claim Year [Axis]" } } }, "localname": "ShortdurationInsuranceContractsAccidentYearAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsAccidentYearDomain": { "auth_ref": [ "r748" ], "lang": { "en-us": { "role": { "documentation": "Accident year in which a covered event occurs under the terms of the short-duration insurance contract.", "label": "Short-Duration Insurance Contracts, Accident Year [Domain]", "terseLabel": "Short-duration Insurance Contracts, Claim Year [Domain]" } } }, "localname": "ShortdurationInsuranceContractsAccidentYearDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable": { "auth_ref": [ "r748" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about undiscounted information about claims development by accident year for short-duration insurance contracts.", "label": "Short-Duration Insurance Contracts, Claims Development [Table]", "terseLabel": "Short-duration Insurance Contracts, Claims Development [Table]" } } }, "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet": { "auth_ref": [ "r750", "r751" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Undiscounted amount, after reinsurance, of incurred-but-not-reported (IBNR) liabilities plus expected development on reported claims, for claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.", "label": "Short-Duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net", "terseLabel": "Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net" } } }, "localname": "ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem": { "auth_ref": [ "r749" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of reconciling item for the reconciliation of the liability in the disclosure of claims development (in excess of) less than the liability for unpaid claims and claims adjustment expense for short-duration insurance contracts, classified as other.", "label": "Short-Duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Other Reconciling Item", "terseLabel": "Insurance lines other than short duration" } } }, "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]", "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]" } } }, "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable": { "auth_ref": [ "r749" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.", "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]", "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]" } } }, "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock": { "auth_ref": [ "r749" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.", "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block]", "terseLabel": "Reconciliation of Short Duration Medical Claims Payable to the Consolidated Medical Claims Payable" } } }, "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r5", "r172", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r190", "r191", "r192", "r193", "r195", "r196", "r197", "r198", "r199", "r201", "r206", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r288", "r304", "r310", "r318", "r752" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails", "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfTheChangeInTheCarryingAmountOfGoodwillByReportableSegmentDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableMedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationSegmentInformationMajorProductRevenuesforEachReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r24", "r25", "r26", "r123", "r126", "r153", "r154", "r155", "r157", "r159", "r167", "r168", "r169", "r252", "r337", "r341", "r342", "r343", "r346", "r347", "r389", "r390", "r393", "r397", "r404", "r565", "r804" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r48", "r75", "r76", "r77", "r134", "r135", "r136", "r139", "r147", "r149", "r166", "r256", "r404", "r410", "r467", "r468", "r469", "r481", "r482", "r544", "r576", "r577", "r578", "r579", "r580", "r583", "r620", "r762", "r763", "r764" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Statement, Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails", "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r134", "r135", "r136", "r166", "r658" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossReconciliationOfTheComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/EarningsPerShareNarrativeDetails", "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r25", "r26", "r404", "r410" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock under employee stock plans, net of related tax benefits, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r25", "r26", "r404", "r410", "r443" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised, Number of Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r48", "r404", "r410" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock under employee stock plans, net of related tax benefits" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Authorization remaining at the end of the period" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r25", "r26", "r404", "r410" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Stock Repurchased and Retired During Period, Shares", "negatedTerseLabel": "Repurchase and retirement of common stock, shares", "verboseLabel": "Shares repurchased" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r25", "r26", "r404", "r410" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedTerseLabel": "Repurchase and retirement of common stock", "terseLabel": "Aggregate cost" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r26", "r31", "r32", "r126", "r212", "r252", "r565", "r624" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Total shareholders' equity, Ending Balance", "periodStartLabel": "Total shareholders' equity, Beginning Balance", "terseLabel": "Stockholders' equity attributable to parent", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails", "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r76", "r126", "r134", "r135", "r136", "r139", "r147", "r252", "r256", "r410", "r467", "r468", "r469", "r481", "r482", "r505", "r506", "r520", "r544", "r565", "r576", "r577", "r583", "r620", "r763", "r764" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Total equity, Ending Balance", "periodStartLabel": "Total equity, Beginning Balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r124", "r390", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r403", "r410", "r416", "r535" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Capital Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r606", "r613" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Sublease Income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/LeasesLeaseandOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r584", "r625" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r584", "r625" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r584", "r625" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r744" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.", "label": "Current Year Claims and Claims Adjustment Expense", "terseLabel": "Current period net incurred medical claims" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r744" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.", "label": "Prior Year Claims and Claims Adjustment Expense", "negatedLabel": "Prior periods redundancies" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfTheBeginningAndEndingBalancesForMedicalClaimsPayableBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementaryInsuranceInformationOtherOperatingExpense": { "auth_ref": [ "r740" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating expense classified as other, disclosed in supplementary insurance information.", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Other Operating Expense", "terseLabel": "Quality improvement and other claims expense" } } }, "localname": "SupplementaryInsuranceInformationOtherOperatingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationOfNetIncurredMedicalClaimsToBenefitExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Blue Cross And Blue Shield And Other Trademarks [Member]" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/GoodwillAndOtherIntangibleAssetsComponentsOfOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r236", "r237", "r246", "r247", "r248", "r375", "r402", "r533", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r804", "r805", "r806", "r807", "r808", "r809", "r810" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/FairValueReconciliationOfTheBeginningAndEndingBalancesOfAssetsMeasuredAtFairValueOnARecurringBasisUsingLevelIIIInputsDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r138", "r139", "r140", "r141", "r150", "r216", "r217", "r253", "r254", "r255", "r256", "r257", "r258", "r467", "r468", "r469", "r479", "r480", "r481", "r482", "r501", "r502", "r503", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r586", "r587", "r594", "r595", "r596", "r597", "r615", "r616", "r617", "r618", "r619", "r620", "r660", "r661", "r662", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignficantAccountingPoliciesBasisofPresentationandSignificantAccontingPoliciesDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsOfChangesinEquity", "http://www.elevancehealth.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r307", "r308", "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Business Optimization Initiatives by Type [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesEmployeeTerminationCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r131", "r421", "r687" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "United States Government Securities [Member]" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "auth_ref": [ "r421", "r687" ], "lang": { "en-us": { "role": { "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).", "label": "US Government-sponsored Enterprises Debt Securities [Member]", "terseLabel": "Government Sponsored Securities [Member]" } } }, "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USStatesAndPoliticalSubdivisionsMember": { "auth_ref": [ "r421", "r774" ], "lang": { "en-us": { "role": { "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.", "label": "US States and Political Subdivisions Debt Securities [Member]", "terseLabel": "States, Municipalities And Political Subdivisions [Member]" } } }, "localname": "USStatesAndPoliticalSubdivisionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/FairValueFairValueMeasurementsByLevelForAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueAndGrossUnrealizedLossOfFixedMaturitySecuritiesInAnUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentAndLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnearnedPremiums": { "auth_ref": [ "r710" ], "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date.", "label": "Unearned Premiums", "verboseLabel": "Unearned income" } } }, "localname": "UnearnedPremiums", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/DebtConvertibleDebentureDetailsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r159" ], "calculation": { "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Effect of dilutive securities \u2013 employee stock options, nonvested restricted stock awards and convertible debentures" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r152", "r159" ], "calculation": { "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Denominator for diluted earnings per share" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r151", "r159" ], "calculation": { "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Denominator for basic earnings per share - weighted-average shares" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.elevancehealth.com/role/EarningsPerShareDenominatorForBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3095-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3098-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5086-111524" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "35", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260725&loc=d3e25362-111560" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "9A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=SL6284427-111562" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r302": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org/topic&trid=2175745" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355" }, "r332": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631" }, "r387": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r416": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r492": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r504": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226013-175313" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126929950&loc=d3e34841-113949" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r548": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r585": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r614": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r665": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13(3)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(c))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(d)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803" }, "r695": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(g)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r7": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6824-158387" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=122135039&loc=d3e569990-122904" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(13)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(13)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(13)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),5)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.14)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.1,4)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.5)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.5,6,7)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column J))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574960-122915" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=99404803&loc=d3e21412-158489" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(cc)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671317-158438" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671321-158438" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "29E", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819541-158441" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r772": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/subtopic&trid=2560295" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(c)(3)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(11))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r792": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r799": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r800": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r801": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r802": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r803": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r804": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r805": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r806": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r807": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r808": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r809": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r810": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r811": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r812": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" } }, "version": "2.1" } ZIP 99 0001156039-22-000084-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001156039-22-000084-xbrl.zip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
  •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�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�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`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�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end